0001144204-14-009451.txt : 20140214 0001144204-14-009451.hdr.sgml : 20140214 20140214140525 ACCESSION NUMBER: 0001144204-14-009451 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20131231 FILED AS OF DATE: 20140214 DATE AS OF CHANGE: 20140214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOANALYTICAL SYSTEMS INC CENTRAL INDEX KEY: 0000720154 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 351345024 STATE OF INCORPORATION: IN FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23357 FILM NUMBER: 14614486 BUSINESS ADDRESS: STREET 1: 2701 KENT AVE CITY: WEST LAFAYETT STATE: IN ZIP: 47906-1382 BUSINESS PHONE: 3174634527 MAIL ADDRESS: STREET 1: 2701 KENT AVENUE CITY: WEST LAFAYETTE STATE: IN ZIP: 47906-1382 10-Q 1 v367799_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended December 31, 2013
     OR 
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________.

 

Commission File Number 000-23357

 

BIOANALYTICAL SYSTEMS, INC.

 

(Exact name of the registrant as specified in its charter)

 

INDIANA

(State or other jurisdiction of incorporation or
organization)

 

35-1345024

(I.R.S. Employer Identification No.)

     

2701 KENT AVENUE

WEST LAFAYETTE, INDIANA

(Address of principal executive offices)

 

47906

(Zip code)

 

(765) 463-4527

(Registrant's telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x        NO o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer o Accelerated filer o Non-accelerated filer o Smaller Reporting Company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES o NO x

 

As of February 11, 2014, 7,965,387 of the registrant's common shares were outstanding.

 

 
 

 

 TABLE OF CONTENTS

 

    Page
PART I FINANCIAL INFORMATION  
     
Item 1 Condensed Consolidated Financial Statements (Unaudited):  
     
  Condensed Consolidated Balance Sheets as of December 31, 2013 and September 30, 2013 3
     
  Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months Ended December 31, 2013 and 2012 4
     
  Condensed Consolidated Statements of Cash Flows for the Three Months Ended December 31, 2013 and 2012 5
     
  Notes to Condensed Consolidated Financial Statements 6
     
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
     
Item 3 Quantitative and Qualitative Disclosures about Market Risk 21
     
Item 4 Controls and Procedures 22
     
PART II OTHER INFORMATION  
     
Item 1A Risk Factors 22
     
Item 6 Exhibits 23
     
  Signatures 24

 

2
 

 

BIOANALYTICAL SYSTEMS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

 

   December 31,
2013
   September 30,
2013
 
   (Unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $841   $1,304 
Accounts receivable          
Trade, net of allowance $87 at December 31, 2013 and September 30, 2013, respectively   2,396    3,621 
Unbilled revenues and other   977    691 
Inventories   1,451    1,379 
Prepaid expenses   407    238 
Total current assets   6,072    7,233 
           
Property and equipment, net   16,564    16,913 
Goodwill   1,383    1,383 
Debt issue costs   55    21 
Other assets   45    47 
           
Total assets  $24,119   $25,597 
           
Liabilities and shareholders’ equity          
Current liabilities:          
Accounts payable  $3,215   $3,584 
Accrued expenses   1,538    1,689 
Customer advances   2,891    2,815 
Income tax accruals   16    30 
Revolving line of credit   168    1,415 
Fair value of warrant liability   1,573    612 
Current portion of capital lease obligation   272    268 
Current portion of long-term debt   5,205    613 
Total current liabilities   14,878    11,026 
           
Capital lease obligation, less current portion   401    471 
Long-term debt, less current portion       4,641 
Total liabilities   15,279    16,138 
           
Shareholders’ equity:          
Preferred shares, authorized 1,000,000 shares, no par value:
1,185 Series A shares at $1,000 stated value issued and outstanding at December 31, 2013 and 1,335 at September 30, 2013
   1,185    1,335 
Common shares, no par value:
Authorized 19,000,000 shares; 7,885,229 issued and outstanding at December 31, 2013 and 7,703,891 at September 30, 2013
   1,933    1,887 
Additional paid-in capital   20,098    19,925 
Accumulated deficit   (14,382)   (13,720)
Accumulated other comprehensive income   6    32 
           
Total shareholders’ equity   8,840    9,459 
           
Total liabilities and shareholders’ equity  $24,119   $25,597 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

3
 

 

BIOANALYTICAL SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME (LOSS)

(In thousands, except per share amounts)

(Unaudited)

 

   Three Months Ended
December 31,
 
   2013   2012 
         
Service revenue  $4,916   $4,670 
Product revenue   1,304    1,133 
Total revenue   6,220    5,803 
           
Cost of service revenue   3,323    3,382 
Cost of product revenue   752    566 
Total cost of revenue   4,075    3,948 
           
Gross profit   2,145    1,855 
Operating expenses:          
Selling   437    370 
Research and development   143    85 
General and administrative   1,103    1,098 
Total operating expenses   1,683    1,553 
           
Operating income   462    302 
           
Interest expense   (164)   (165)
Change in fair value of warrant liability – (increase) decrease   (961)   117 
Other income   1    2 
Income (loss) before income taxes   (662)   256 
           
Income taxes        
           
Net income (loss)  $(662)  $256 
           
Other comprehensive income (loss):          
Foreign currency translation adjustment   (26)   8 
           
Comprehensive income (loss)  $(688)  $264 
           
Basic net income (loss) per share  $(0.09)  $0.03 
Diluted net income (loss) per share  $(0.09)  $0.03 
           
Weighted common shares outstanding:          
Basic   7,735    7,639 
Diluted   7,735    8,406 

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

4
 

 

BIOANALYTICAL SYSTEMS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

   Three Months Ended December 31, 
   2013   2012 
         
Operating activities:          
Net income (loss)  $(662)  $256 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:          
Depreciation and amortization   402    473 
Change in fair value of warrant liability – increase (decrease)   961    (117)
Employee stock compensation expense   47    74 
Loss on sale of property and equipment       2 
Changes in operating assets and liabilities:          
Accounts receivable   939    1,387 
Inventories   (72)   (47)
Income tax accruals   (14)    
Prepaid expenses and other assets   (145)   74 
Accounts payable   (345)   82 
Accrued expenses   (151)   (782)
Customer advances   76    (685)
Net cash provided by operating activities   1,036    717 
           
Investing activities:          
Capital expenditures   (51)   (10)
Net cash used by investing activities   (51)   (10)
           
Financing activities:          
Payments of long-term debt   (49)   (166)
Payments of debt issuance costs   (60)   (15)
Payments on revolving line of credit   (7,619)   (6,118)
Borrowings on revolving line of credit   6,372    5,636 
Payments on capital lease obligations   (66)   (100)
Net cash used by financing activities   (1,422)   (763)
           
Effect of exchange rate changes   (26)   5 
           
Net decrease in cash and cash equivalents   (463)   (51)
Cash and cash equivalents at beginning of period   1,304    721 
Cash and cash equivalents at end of period  $841   $670 
           
Supplemental disclosure of non-cash financing activities:          
Preferred stock dividends paid in common shares  $(18)  $(20)

 

The accompanying notes are an integral part of the condensed consolidated financial statements.

 

5
 

 

BIOANALYTICAL SYSTEMS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Amounts in thousands except per share data or as otherwise indicated)

(Unaudited)

 

1.DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION

 

Bioanalytical Systems, Inc. and its subsidiaries (“We,” the “Company” or “BASi”) engage in contract laboratory research services and other services related to pharmaceutical development. We also manufacture scientific instruments for life sciences research, which we sell with related software for use in industrial, governmental and academic laboratories. Our customers are located throughout the world.

 

We have prepared the accompanying unaudited interim condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”), and therefore should be read in conjunction with our audited consolidated financial statements, and the notes thereto, included in the Company’s annual report on Form 10-K for the year ended September 30, 2013. In the opinion of management, the condensed consolidated financial statements for the three months ended December 31, 2013 and 2012 include all adjustments which are necessary for a fair presentation of the results of the interim periods and of our financial position at December 31, 2013. The results of operations for the three months ended December 31, 2013 are not necessarily indicative of the results for the year ending September 30, 2014.

 

2.STOCK-BASED COMPENSATION

 

The 2008 Stock Option Plan (“the Plan”) is used to promote our long-term interests by providing a means of attracting and retaining officers, directors and key employees and aligning their interests with those of our shareholders. The Plan is described more fully in Note 9 in the Notes to the Consolidated Financial Statements in our Form 10-K for the year ended September 30, 2013. All options granted under the Plan had an exercise price equal to the market value of the underlying common shares on the date of grant. We expense the estimated fair value of stock options over the vesting periods of the grants. We recognize expense for awards subject to graded vesting using the straight-line attribution method, reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment is recognized at that time. The Compensation Committee may also issue non-qualified stock option grants with vesting periods different from the 2008 Plan. As of December 31, 2013, there are 155 shares outstanding that were granted outside of the Plan. The assumptions used are detailed in Note 9 to the Consolidated Financial Statements in our Form 10-K for the year ended September 30, 2013. Stock based compensation expense for the three months ended December 31, 2013 and 2012 was $47 and $74, respectively.

 

A summary of our stock option activity for the three months ended December 31, 2013 is as follows (in thousands except for share prices):

 

   Options
(shares)
   Weighted-
Average
Exercise Price
   Weighted-
Average
Grant Date
Fair Value
 
             
Outstanding - October 1, 2013   479   $1.77   $1.35 
Exercised   -    -    - 
Granted   -    -    - 
Terminated   (40)   2.29      
Outstanding - December 31, 2013   439   $1.72   $1.32 

  

6
 

 

3.INCOME (LOSS) PER SHARE

 

We compute basic income (loss) per share using the weighted average number of common shares outstanding.

 

The Company has three categories of dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered direct offering, the Warrants issued in connection with the same offering in May 2011, and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method for preferred stock and the treasury stock method for stock options and warrants. Shares issuable upon exercise of options were not considered in computing diluted earnings per share for the quarters ended December 31, 2013 and 2012, respectively, because they were anti-dilutive. Warrants for 1,376,500 common shares were not considered in computing diluted earnings per share for the quarters ended December 31, 2012 because they were anti-dilutive. Warrants for 1,126,500 common shares and 660,902 common shares issuable upon conversion of preferred shares were not considered in computing diluted earnings per share for the quarter ended December 31, 2013 because they were also anti-dilutive.

 

The following table reconciles our computation of basic income (loss) per share to diluted income (loss) per share:

 

   Three Months Ended
December 31,
 
   2013   2012 
         
Basic net income (loss) per share:          
Net income (loss) applicable to common shareholders  $(662)  $256 
Weighted average common shares outstanding   7,735    7,639 
Basic net income (loss) per share  $(0.09)  $0.03 
           
Diluted net income (loss) per share:          
Diluted net income (loss) applicable to common shareholders  $(662)  $256 
           
Weighted average common shares outstanding   7,735    7,639 
Plus:  Incremental shares from assumed conversions          
Series A preferred shares       767 
Diluted weighted average common shares outstanding   7,735    8,406 
           
Diluted net income (loss) per share  $(0.09)  $0.03 

 

4.INVENTORIES

 

Inventories consisted of the following:

 

   December 31,
2013
   September 30,
2013
 
         
Raw materials  $1,281   $1,157 
Work in progress   235    322 
Finished goods   323    259 
   $1,839   $1,738 
Obsolescence reserve   (388)   (359)
   $1,451   $1,379 

 

5.SEGMENT INFORMATION

 

We operate in two principal segments - research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Our accounting policies in these segments are the same as those described in the summary of significant accounting policies found in Note 2 to Consolidated Financial Statements in our annual report on Form 10-K for the year ended September 30, 2013.

 

7
 

 

   Three Months Ended
December 31,
 
   2013   2012 
         
Revenue:          
Service  $4,916   $4,670 
Product   1,304    1,133 
   $6,220   $5,803 
           
Operating income:          
Service  $424   $199 
Product   38    103 
   $462   $302 
           
Interest Expense   (164)   (165)
Change in fair value of warrant liability – (increase) decrease   (961)   117 
Other income   1    2 
           
Income (loss) before income taxes  $(662)  $256 

 

6.INCOME TAXES

 

We use the asset and liability method of accounting for income taxes.  We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.

 

We recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. We measure the amount of the accrual for which an exposure exists as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position.

 

At December 31, 2013 and September 30, 2013, we had a $16 liability for uncertain income tax positions. The difference between the federal statutory rate of 34% and our effective rate of 0% is due to changes in our valuation allowance on our net deferred tax assets.

 

We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months.

 

We file income tax returns in the U.S., several U.S. States, and the United Kingdom. We remain subject to examination by taxing authorities in the jurisdictions in which we have filed returns for years after 2008.

 

8
 

 

7.DEBT

 

Mortgages and note payable

 

We have a term loan from Regions Bank (“Regions”) aggregating approximately $5,205 at December 31, 2013, which is secured by mortgages on our facilities in West Lafayette and Evansville, Indiana.

 

On November 9, 2012, we executed a sixth amendment with Regions which we further modified on December 21, 2012. In the sixth amendment, Regions agreed to extend the term loan and mortgage loan maturity dates to October 31, 2013. The unpaid principal on the notes was incorporated into a replacement note payable for $5,786 bearing interest at LIBOR plus 400 basis points (minimum of 6.0%) with monthly principal payments of approximately $47 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations. At September 30, 2013, the replacement note payable had a balance of $5,254.

 

On October 31, 2013, we executed a seventh amendment with Regions to extend the note payable maturity date to October 31, 2014.

  

Regions requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00 and a total liabilities to tangible net worth ratio of not greater than 2.10 to 1.00. Failure to comply with those covenants in future quarters would be a default under the Regions loans, requiring us to negotiate with Regions regarding loan modifications or waivers. If we are unable to obtain such modifications or waivers, Regions could accelerate the maturity of the loans and cause a cross default with our other lender.

 

The Regions loan agreements both contain cross-default provisions with each other and with the revolving line of credit with Entrepreneur Growth Capital LLC (“EGC”) described below.

 

The replacement note payable with Regions matures in the first quarter of fiscal 2015. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. We have listed for sale our 7.25 acres and 120,000 square foot facility at 2701 Kent Avenue, West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. We enlisted a new realtor in the third fiscal quarter of 2013 and changed the asking price to $10,800. We performed an impairment analysis on the building when we listed it for sale, but noted no impairment necessary. As of December 31, 2013, the net book value of the facility and land was $9,126.

 

We may be unsuccessful in renegotiating the terms of the debt or those terms may be unfavorable to us. For these reasons, if we are unsuccessful at refinancing our long-term debt, our operating results and financial condition could be adversely affected.

 

Revolving Line of Credit

 

At December 31, 2013, we had a $3,000 revolving line of credit agreement (“Credit Agreement”) with EGC. Pursuant to the terms of the Credit Agreement, the line of credit would have automatically renewed on January 31, 2014 unless either party gave a 60-day notice of intent to terminate or withdraw. On October 30, 2013, we informed EGC of our intent not to renew the line of credit on January 31, 2014. On January 31, 2014, we paid off the remaining balance on this line of credit.

 

At December 31, 2013, borrowings under the Credit Agreement bear interest at an annual rate equal to Citibank’s Prime Rate plus five percent (5%), or 8.25% as of December 31, 2013, with minimum monthly interest of $15. Interest is paid monthly. The line of credit also carries an annual facilities fee of 2% and a 0.2% collateral monitoring fee. Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. Borrowings are calculated based on 75% of eligible accounts receivable. Under the Credit Agreement, as amended, the Company has agreed to restrict advances to subsidiaries, limit additional indebtedness and capital expenditures and maintain a minimum tangible net worth of at least $8,000. The Credit Agreement also contains cross-default provisions with the Regions loan and any future EGC loans. At December 31, 2013, we had available borrowing capacity of $1,845 on this line, of which $168 was outstanding. At September 30, 2013, we had $1,415 outstanding on this line.

 

At December 31, 2013, we were not in compliance with the minimum tangible net worth covenant requirement mainly due to the increase in the warrant liability. On January 29, 2014, EGC waived our breach with this covenant.

 

9
 

  

We are actively pursuing alternatives to replace this line of credit. We are focused on growing our revenues and improving our cash flow from operations in fiscal 2014 to reduce our reliance on our line of credit.

 

8.RESTRUCTURING

 

In March 2012, we announced a plan to restructure our bioanalytical laboratory operations. We consolidated our laboratory in McMinnville, Oregon into our 120,000 square foot headquarters facility in West Lafayette, Indiana. This plan was implemented to reduce operating costs and strengthen our ability to meet clients’ needs by improving laboratory utilization. In the fourth fiscal quarter of 2012, we decided to initiate closure of our facility and bioanalytical laboratory in Warwickshire, United Kingdom after careful evaluation of its financial performance and analysis of our strategic alternatives. We will continue to sell our products globally while further consolidating delivery of our CRO services into our Indiana locations. As part of the overall evaluation of our business, personnel reductions in the Selling, R&D and General and Administrative functions were also implemented at both of our Indiana locations during the second half of fiscal 2012. In total, 74 employees were terminated as part of the restructuring activities in fiscal 2012.

 

We reserved for lease payments at the cease use date and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. In the first quarter of fiscal 2013, we began amortizing into general and administrative expense, equally through the cease use date, the estimated rent income of $200 when the reserve was originally established. We have been unsuccessful at subleasing the facility. Based on these, we have $898 reserved for UK lease related costs.

 

The following table sets forth the rollforward of the restructuring activity for the three months ended December 31, 2013.

 

   Balance,
September 30,
2013
   Total
Charges
   Cash
Payments
   Other   Balance,
December 31,
2013
 
One-time termination benefits  $-   $-   $-   $-   $- 
Lease related costs   877    -    -    21    898 
Equipment moving costs and method transfers   -    -    -    -    - 
Travel and relocation costs   -    -    -    -    - 
Loss on sale of equipment   (16)   -    -    8    (8)
Other costs   117    -    -    -    117 
Total  $978   $-   $-   $29   $1,007 

 

Other costs include legal and professional fees and other costs incurred in connection with transitioning services from sites being closed as well as costs incurred to remove improvements previously made to the UK facility. Other activity in the reserve rollforward primarily reflects a receivable for settlement of the capital lease in the UK.

 

9.FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

10
 

 

Level 1 – Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.
   
Level 2 – Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
   
Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

In May 2011, we issued Class A and B Warrants that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The assumptions used to compute the fair value of the warrants at December 31, 2013 and September 30, 2013:

 

   December 31, 2013   September 30, 2013 
   Warrant A   Warrant A 
         
Risk-free interest rate   0.52%   0.51%
Dividend yield   0.00%   0.00%
Volatility of the Company's common stock   72.83%   71.15%
Expected life of the options (years)   2.35    2.6 
           
Fair value per unit  $1.396   $0.444 

 

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The fair value of the revolving credit facility and certain long-term debt is equal to their carrying values due to the variable nature of their interest rates. Our long-term fixed rate debt was initiated in February 2011 and renewed on October 31, 2013.

 

10.MANAGEMENT’S PLAN

 

Our long-term strategic objective is to maximize the Company’s intrinsic value per share.   However, in response to our financial performance through the second quarter of fiscal 2012, we began to operate the business in a manner designed to place more emphasis on cash flow generation. Thus, our short-term tactical objective is to maximize free cash flow from operating activities.

 

During the first fiscal quarter of 2014, revenues improved 7.2% as did gross margin by 15.6% and operating income by 53.0% from the first fiscal quarter of 2013. We also generated $976 in cash from operations, maintained strict controls on expenditures and paid down our line of credit $1.2 million while meeting all of our other obligations.

 

We negotiated an amendment to our loans with Regions Bank, extending the maturity date to October 2014. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. We listed for sale our headquarters facility in West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations.

 

For the remainder of fiscal 2014, we will focus on growing our revenues and continue initiatives to control costs and improve productivity to further reduce our break-even point and achieve our financial objectives. We expect to see improvement in the volume of new bookings in fiscal 2014 along with the continued improvements in gross profit margins. We have debt service and lease obligations of approximately $1.7 million in fiscal 2014. Based on our expected revenue, the impact of the cost reductions implemented and restructuring activities during fiscal 2012, we project that we will have the liquidity required to meet our fiscal 2014 operations and debt obligations. Though our current line of credit expired on January 31, 2014, we were able to pay off the remaining balance while continuing to meet all other debt obligations and working capital requirements. Although management believes our cash flow from operations will generate sufficient cash flow for our debt obligations, working capital requirements and capital expenditures, we are pursuing alternatives to replace this line of credit.

 

11
 

 

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This report contains statements that constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those statements appear in a number of places in this Report and may include statements regarding our intent, belief or current expectations with respect to, but are not limited to (i) our strategic plans; (ii) trends in the demand for our products and services; (iii) trends in the industries that consume our products and services; (iv) our ability to develop new products and services; (v) our ability to make capital expenditures and finance operations; (vi) global economic conditions, especially as they impact our markets; (vii) our cash position; (viii) our ability to integrate a new sales and marketing team; (ix) our ability to refinance our outstanding indebtedness and (x) our expectations regarding the volume of new bookings, pricing, gross profit margins and liquidity. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in the forward looking statements as a result of various factors, many of which are beyond our control.

 

In addition, we have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, actual events may differ from those assumptions, and as a result, the forward-looking statements based upon those assumptions may not accurately project future events. The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included or incorporated by reference elsewhere in this Report. In addition to the historical information contained herein, the discussions in this Report may contain forward-looking statements that may be affected by risks and uncertainties, including those discussed in Item 1A, Risk Factors contained in our annual report on Form 10-K for the fiscal year ended September 30, 2013. Our actual results could differ materially from those discussed in the forward-looking statements.

 

The following amounts are in thousands, unless otherwise indicated.

 

General

 

We are an international contract research organization providing drug discovery and development services. Our clients and partners include pharmaceutical, biotechnology, academic and governmental organizations. We apply innovative technologies and products and a commitment to quality to help clients and partners accelerate the development of safe and effective therapeutics and maximize the returns on their research and development investments. We offer an efficient, variable-cost alternative to our clients' internal product development programs. Outsourcing development work to reduce overhead and speed drug approvals through the Food and Drug Administration ("FDA") is an established alternative to in-house development among pharmaceutical companies. We derive our revenues from sales of our research services and drug development tools, both of which are focused on determining drug safety and efficacy. The Company has been involved in the research of drugs to treat numerous therapeutic areas for over 35 years.

 

We support the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. We believe our scientists have the skills in analytical instrumentation development, chemistry, computer software development, physiology, medicine, analytical chemistry and toxicology to make the services and products we provide increasingly valuable to our current and potential clients. Our principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research at many of the small start-up biotechnology companies and the largest global pharmaceutical companies.

 

Our business is largely dependent on the level of pharmaceutical and biotechnology companies' efforts in new drug discovery and approval. Our services segment is a direct beneficiary of these efforts, through outsourcing by these companies of research work. Our products segment is an indirect beneficiary of these efforts, as increased drug development leads to capital expansion, providing opportunities to sell the equipment we produce and the consumable supplies we provide that support our products.

 

Developments within the industries we serve have a direct, and sometimes material, impact on our operations. Currently, many large pharmaceutical companies have major "block-buster" drugs that are nearing the end of their patent protections. This puts significant pressure on these companies both to develop new drugs with large market appeal, and to re-evaluate their cost structures and the time-to-market of their products. Contract research organizations ("CRO's") have benefited from these developments, as the pharmaceutical industry has turned to out-sourcing to both reduce fixed costs and to increase the speed of research and data development necessary for new drug applications. The number of significant drugs that have reached or are nearing the end of their patent protection has also benefited the generic drug industry. Generic drug companies provide a significant source of new business for CROs as they develop, test and manufacture their generic compounds.

 

12
 

 

A significant portion of innovation in the pharmaceutical industry is now being driven by biotech and small, venture capital funded, drug development companies. Many of these companies are "single-molecule" entities, whose success depends on one innovative compound. While several of the biotech companies have reached the status of major pharmaceuticals, the industry is still characterized by smaller entities. These developmental companies generally do not have the resources to perform much of the research within their organizations, and are therefore dependent on the CRO industry for both their research and for guidance in preparing their FDA submissions. These companies have provided significant new opportunities for the CRO industry, including us. They do, however, provide challenges in selling, as they frequently have only one product in development, which causes CROs to be unable to develop a flow of projects from a single company. These companies may expend all their available funds and cease operations prior to fully developing a product. Additionally, the funding of these companies is subject to investment market fluctuations, which changes as the risk profiles and appetite of investors change.

 

Research services are capital intensive. The investment in equipment and facilities to serve our markets is substantial and continuing. While our physical facilities are adequate to meet market needs for the near term, rapid changes in automation, precision, speed and technologies necessitate a constant investment in equipment and software to meet market demands. We are also impacted by the heightened regulatory environment and the need to improve our business infrastructure to support our increasingly diverse operations, which will necessitate additional capital investment. Our ability to generate capital to reinvest in our capabilities, both through operations and financial transactions, is critical to our success. While we are currently committed to fully utilizing recent additions to capacity, sustained growth will require additional investment in future periods. Our financial position could limit our ability to make such investments.

 

Patient Protection and Affordable Care Act

 

In March 2010, the Patient Protection and Affordable Care Act (the “Act”) was enacted by the U.S. Congress and signed into law by the President. The purpose of the legislation is to extend medical insurance coverage to a higher percentage of U.S. citizens. Many of the provisions in the Act have delayed effective dates over the next decade, and will require extensive regulatory guidance. Companies in our principal client industry, pharmaceuticals, will be required under the Act to provide additional discounts on medicines provided under Medicare and Medicaid to assist in the funding of the program; however, government estimates are that over 31 million additional citizens will eventually be covered by medical insurance as a result of the Act, which should expand the markets for their products. It is premature to accurately predict the impacts these and other competing forces will have on our basic client market, drug development. Additionally, the Act does not directly impact spiraling health care costs in the U.S., which could lead to additional legislation impacting our target markets in the future.

 

We maintain an optional health benefits package for all of our full-time employees, which is largely paid by our contributions with employees paying a portion of the cost, generally less than 20% of the total. Based on our current understanding of the Act, we do not anticipate significant changes to our programs or of their costs to the Company or our employees as a result of the Act. The provisions of the Act that have gone into effect have not significantly changed our plan or been a substantial driver of costs. As a Grandfathered Plan, there are certain provisions that our plan does not have to comply with at this time, and those changes, once implemented, are not expected to have a material financial impact on the Company.

 

We are exploring options in plan funding, delivery of benefits and employee wellness in our continuing effort to obtain maximum benefit for our health care expenditures, while maintaining quality programs for our employees. We do not expect these efforts to have a material financial impact on the Company.

 

Executive Overview

 

Our revenues are dependent on a relatively small number of industries and clients. As a result, we closely monitor the market for our services. In the first three months of fiscal 2014, we experienced an increase in the demand for our products and services as compared to the first three months of fiscal 2013 due to higher levels of new orders and product installations. We believe in the fundamentals of the market. For the remainder of fiscal 2014, we plan to focus on sales execution, operational excellence and building strategic partnerships with pharmaceutical and biotechnology companies, to differentiate our company and create value for our clients and shareholders.

 

13
 

 

We review various metrics to evaluate our financial performance, including revenue, margins and earnings. In the first three months of fiscal 2014, we had a 7.2% increase in revenues over the same period in fiscal 2013. Gross margin and operating income also increased in the current fiscal year compared to the prior fiscal year period by 15.6% and 53.0%, respectively. The improved margins and earnings were due to the revenue increase as well as dedication to cost monitoring. For a detailed discussion of our revenue, margins, earnings and other financial results for the three months ended December 31, 2013, see “Results of Operations” below.

 

As of December 31, 2013, we had $841 of cash and cash equivalents as compared to $1,304 of cash and cash equivalents at the end of fiscal 2013. In the first fiscal quarter of 2014, we generated $1,036 in cash from operations partially due to the higher operating income we reported in the first fiscal quarter of 2014. Total capital expenditures were only $51 in fiscal 2014, up slightly from $10 in fiscal 2013. We negotiated an amendment to our loans with Regions Bank, extending the maturity date to October 2014. We listed for sale our headquarters facility in West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. We successfully paid off our line of credit in January 2014. Further, we announced the launch of Culex® NxT, the latest generation of the Company’s proprietary in vivo automated sampling system in fiscal 2013. We are poised for increased capacity utilization and potential strategic growth in the remainder of fiscal 2014.

 

We believe that the development of innovative new drugs is going through an evolution, evidenced by the significant reduction of expenditures on research and development at several major international pharmaceutical companies, accompanied by increases in outsourcing and investments in smaller start-up companies that are performing the early development work on new compounds. Many of these smaller companies are funded by either venture capital or pharmaceutical investment, or both, and generally do not build internal staffs that possess the extensive scientific and regulatory capabilities to perform the various activities necessary to progress a drug candidate to the filing of an Investigative New Drug (“IND”) application with the FDA.

 

While continuing to maintain and develop our relationships with large pharmaceutical companies, we intend to aggressively promote our services to developing businesses, which will require us to expand our existing capabilities to provide services early in the drug development process, and to consult with clients on regulatory strategy and compliance leading to their FDA filings. We have recently launched our Enhanced Drug Discovery services as part of this strategy, utilizing our proprietary Culex® technology to provide early experiments in our laboratories that previously would have been conducted in the sponsor’s facilities. As we move forward, we must balance the demands of the large pharmaceutical companies with the personal touch needed by smaller biotechnology companies to develop a competitive advantage. We intend to accomplish this through the use of and expanding upon our existing project management skills, strategic partnerships and relationship management.

 

We are focused on continuing to improve our cash flow from operations in fiscal 2014 and pursuing alternatives to the expired line of credit. If we are unable to continue an increase in cash flow from operations in fiscal 2014, we may not have sufficient liquidity to continue our business.

 

Critical Accounting Policies

 

"Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Liquidity and Capital Resources" discuss the unaudited condensed consolidated financial statements of the Company, which have been prepared in accordance with accounting principles generally accepted in the United States. Preparation of these financial statements requires management to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosures of contingent assets and liabilities. Certain significant accounting policies applied in the preparation of the financial statements require management to make difficult, subjective or complex judgments, and are considered critical accounting policies. We have identified the following areas as critical accounting policies.

 

Revenue Recognition

 

The majority of our Bioanalytical and analytical research service contracts involve the development of analytical methods and the processing of bioanalytical samples for pharmaceutical companies and generally provide for a fixed fee for each sample processed. Revenue is recognized under the specific performance method of accounting and the related direct costs are recognized when services are performed. Our preclinical research service contracts generally consist of preclinical studies, and revenue is recognized under the proportional performance method of accounting. Revisions in profit estimates, if any, are reflected on a cumulative basis in the period in which such revisions become known. The establishment of contract prices and total contract costs involves estimates we make at the inception of the contract. These estimates could change during the term of the contract and impact the revenue and costs reported in the consolidated financial statements. Revisions to estimates have generally not been material. Research service contract fees received upon acceptance are deferred until earned, and classified within customer advances. Unbilled revenues represent revenues earned under contracts in advance of billings.

 

14
 

 

Product revenue from sales of equipment not requiring installation, testing or training is recognized upon shipment to customers. One product includes internally developed software and requires installation, testing and training, which occur concurrently. Revenue from these sales is recognized upon completion of the installation, testing and training when the services are bundled with the equipment sale.

 

Long-Lived Assets, Including Goodwill

 

Long-lived assets, such as property and equipment, and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

 

We carry goodwill at cost. Other intangible assets with definite lives are stated at cost and are amortized on a straight-line basis over their estimated useful lives. All intangible assets acquired that are obtained through contractual or legal right, or are capable of being separately sold, transferred, licensed, rented, or exchanged, are recognized as an asset apart from goodwill. Goodwill is not amortized.

 

Goodwill is tested annually for impairment and more frequently if events and circumstances indicate that the asset might be impaired. First, we can assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Then, we follow a two-step quantitative process. In the first step, we compare the fair value of each reporting unit, as computed primarily by present value cash flow calculations, to its book carrying value, including goodwill. We do not believe that market value is indicative of the true fair value of the Company mainly due to average daily trading volumes of less than 1%. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and we would then complete step 2 in order to measure the impairment loss. In step 2, the implied fair value is compared to the carrying amount of the goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, we would recognize an impairment loss equal to the difference. The implied fair value is calculated by allocating the fair value of the reporting unit (as determined in step 1) to all of its assets and liabilities (including unrecognized intangible assets) and any excess in fair value that is not assigned to the assets and liabilities is the implied fair value of goodwill.

 

The discount rate, gross margin and sales growth rates are the two material assumptions utilized in our calculations of the present value cash flows used to estimate the fair value of the reporting units when performing the annual goodwill impairment test. Our reporting units with goodwill at December 31, 2013 are Vetronics, which is included in our Products segment, bioanalytical services and preclinical services, which are both included in our Services segment, based on the discrete financial information available which is reviewed by management. We utilize a cash flow approach in estimating the fair value of the reporting units, where the discount rate reflects a weighted average cost of capital rate. The cash flow model used to derive fair value is sensitive to the discount rate and sales growth assumptions used.

 

Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows. Assumptions used in our impairment evaluations, such as forecasted sales growth rates and our cost of capital or discount rate, are based on the best available market information. Changes in these estimates or a continued decline in general economic conditions could change our conclusion regarding an impairment of goodwill and potentially result in a non-cash impairment loss in a future period. The assumptions used in our impairment testing could be adversely affected by certain of the risks discussed in “Risk Factors” in Item 1A of our 10-K for the fiscal year ended September 30, 2013. There have been no significant events since the timing of our impairment tests that have triggered additional impairment testing.

 

15
 

 

At December 31, 2013, remaining recorded goodwill was $1,383.

 

Stock-Based Compensation

 

We recognize the cost resulting from all share-based payment transactions in our financial statements using a fair-value-based method. We measure compensation cost for all share-based awards based on estimated fair values and recognize compensation over the vesting period for awards. We recognized stock-based compensation related to stock options of $47 and $74 during the three months ended December 31, 2013 and 2012, respectively.

  

We use the binomial option valuation model to determine the grant date fair value. The determination of fair value is affected by our stock price as well as assumptions regarding subjective and complex variables such as expected employee exercise behavior and our expected stock price volatility over the term of the award. Generally, our assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. We estimated the following key assumptions for the binomial valuation calculation:

 

Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant for the expected term of the option.

 

Expected volatility. We use our historical stock price volatility on our common stock for our expected volatility assumption.

 

Expected term. The expected term represents the weighted-average period the stock options are expected to remain outstanding. The expected term is determined based on historical exercise behavior, post-vesting termination patterns, options outstanding and future expected exercise behavior.

 

Expected dividends. We assumed that we will pay no dividends.

 

Employee stock-based compensation expense recognized in the first three months of fiscal 2014 and 2013 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment will be recognized at that time.

 

Changes to our underlying stock price, our assumptions used in the binomial option valuation calculation and our forfeiture rate as well as future grants of equity could significantly impact compensation expense to be recognized in fiscal 2014 and future periods.

 

Income Taxes

 

As described in Note 6 to the condensed consolidated financial statements, we use the asset and liability method of accounting for income taxes.  We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.

 

We recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. We measure the amount of the accrual for which an exposure exists as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position.

 

We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the accrued liability for uncertain tax positions would impact our effective tax rate. Over the next twelve months we do not anticipate changes to the carrying value of our reserve.  Interest and penalties are included in the reserve.

 

16
 

 

As of December 31, 2013 and September 30, 2013, we had a $16 liability for uncertain income tax positions.

 

We file income tax returns in the U.S., several U.S. states, and the foreign jurisdiction of the United Kingdom. We remain subject to examination by taxing authorities in the jurisdictions in which we have filed returns for years after 2008.

 

We have an accumulated net deficit in our UK subsidiary. Consequently, United States deferred tax assets on such earnings have not been recorded. Also, a valuation allowance was established in fiscal 2009 against the U.S. deferred income tax balance. We had previously recorded a valuation allowance on the UK subsidiary deferred income tax balance.

 

Inventories

 

Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) cost method of accounting. We evaluate inventories on a regular basis to identify inventory on hand that may be obsolete or in excess of current and future projected market demand. For inventory deemed to be obsolete, we provide a reserve for this inventory. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates the estimate of future demand.

 

Fair Value of Warrant Liability

 

In May 2011, we issued Class A and B Warrants that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 fair value measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The following table describes the changes in the fair value of the warrant liability since inception:

 

                       Change in 
   Fair Value per Share   Fair Value in $$   Fair Value 
Evaluation Date  Warrant A   Warrant B   Warrant A   Warrant B   Total   (Income) Expense 
5/11/2011  $1.433   $0.779   $1,973   $1,072   $3,045   $- 
6/30/2011   1.536    0.811    2,114    1,116    3,230    185 
9/30/2011   0.844    0.091    1,162    124    1,286    (1,944)
12/31/2011   0.901    0.074    1,240    102    1,342    56 
3/31/2012   0.933    0.001    1,284    2    1,286    (56)
6/30/2012   0.602    -    828    -    828    (458)
9/30/2012   0.881    -    1,213    -    1,213    385 
12/31/2012   0.796    -    1,096    -    1,096    (117)
3/31/2013   0.899    -    1,238    -    1,238    142 
6/30/2013   0.668    -    920    -    920    (318)
9/30/2013   0.444    -    612    -    612    (308)
12/31/2013   1.396    -    1,573    -    1,573    961 

  

17
 

 

Results of Operations

 

The following table summarizes the condensed consolidated statement of operations as a percentage of total revenues:

 

   Three Months Ended
December 31,
 
   2013   2012 
         
Service revenue   79.0%   80.5%
Product revenue   21.0    19.5 
Total revenue   100.0    100.0 
           
Cost of service revenue (a)   67.6    72.4 
Cost of product revenue (a)   57.7    49.9 
Total cost of revenue   65.5    68.0 
           
Gross profit   34.5    32.0 
           
Total operating expenses   27.1    26.8 
           
Operating income (loss)   7.4    5.2 
           
Other expense   (18.1)   (0.8)
           
Income (loss) before income taxes   (10.6)   4.4 
           
Income taxes        
           
Net income (loss)   (10.6)%   4.4%

 

(a)Percentage of service and product revenues, respectively

 

Three Months Ended December 31, 2013 Compared to Three Months Ended December 31, 2012

 

Service and Product Revenues

 

Revenues for the fiscal quarter ended December 31, 2013 increased 7.2% to $6,220 compared to $5,803 for the same period last year.

 

Our Service revenue increased 5.3% to $4,916 in the current quarter compared to $4,670 for the prior year period primarily as a result of higher toxicology and pharmaceutical analysis revenues offset slightly by lower bioanalytical analysis revenues. Toxicology and pharmaceutical analysis revenues increased due to an increase in new orders. Bioanalytical analysis revenues in our first fiscal quarter of 2014 were negatively impacted by cancellations by clients and a lower number of samples assayed as well as more time spent on method development and validations, which have lower revenues.

 

   Three Months Ended
December 31,
         
   2013   2012   Change   % 
Bioanalytical analysis  $1,947   $2,300   $(353)   -15.3%
Toxicology   2,162    1,897    265    14.0%
Other laboratory services   807    473    334    70.6%

 

Sales in our Products segment increased 15.1% in the current fiscal quarter from $1,133 to $1,304 when compared to the same period in the prior fiscal year. The majority of the increase stems from higher sales of our Culex automated in vivo sampling systems over the same period in prior fiscal year as we had new installations recognized in the current fiscal quarter as well as an increase in consumables.

 

   Three Months Ended
December 31,
         
   2013   2012   Change   % 
Culex®, in-vivo sampling systems  $652   $371   $281    75.7%
Analytical instruments   471    575    (104)   -18.1%
Other instruments   181    187    (6)   -3.2%

 

Cost of Revenues

 

Cost of revenues for the current quarter was $4,075 or 65.5% of revenue, compared to $3,948, or 68.0% of revenue for the prior year period.

 

Cost of Service revenue as a percentage of Service revenue decreased to 67.6% in the current quarter from 72.4% in the comparable period last year. The principal cause of this decrease was the increase in revenues which led to higher absorption of the fixed costs in our Service segment. A significant portion of our costs of productive capacity in the Service segment are fixed. Thus, increases in revenues lead to decreases in costs as a percentage of revenue.

 

Costs of Products revenue as a percentage of Product revenue in the current quarter increased to 57.7% from 49.9% in the comparable prior year period. This increase is mainly due to a change in the mix of products sold in the current quarter as well increases in material costs and in the inventory obsolescence reserve.

 

Operating Expenses

 

Selling expenses for the three months ended December 31, 2013 increased 18.1% to $437 from $370 for the comparable period last year. This increase stems mainly from hiring new sales employees in the second half of fiscal 2013.

 

Research and development expenses for the first quarter of fiscal 2013 increased 68.2% over the comparable period last year to $143 from $85. The increase was primarily due to new employees as well as increased utilization of outsourced professional engineering services in the current fiscal quarter.

 

18
 

 

General and administrative expenses for the current quarter increased 0.5% to $1,103 from $1,098 for the comparable prior year period.

 

Other Income (Expense)

 

Other expense for the current fiscal quarter increased to $1,124 from $46 for the same quarter of the prior fiscal year. The primary reason for the increase is the change in the fair value of the warrant liability.

 

Income Taxes

 

Our effective tax rate for the quarters ended December 31, 2013 and 2012 was 0.0%. No net benefits have been provided on taxable losses in the current fiscal year. We continue to maintain a full valuation allowance on our U.S. and UK subsidiary deferred income tax balances.

 

Restructuring Activities

 

In March 2012, we announced a plan to restructure our bioanalytical laboratory operations. We consolidated our laboratory in McMinnville, Oregon into our 120,000 square foot headquarters facility in West Lafayette, Indiana. This plan was implemented to reduce operating costs and strengthen our ability to meet clients’ needs by improving laboratory utilization. In the fourth fiscal quarter of 2012, we decided to initiate closure of our facility and bioanalytical laboratory in Warwickshire, United Kingdom after careful evaluation of its financial performance and analysis of our strategic alternatives. We will continue to sell our products globally while further consolidating delivery of our CRO services into our Indiana locations. As part of the overall evaluation of our business, personnel reductions in the Selling, R&D and General and Administrative functions were also implemented at both of our Indiana locations during the second half of fiscal 2012. In total, 74 employees were terminated as part of the restructuring activities in fiscal 2012.

 

We reserved for lease payments at the cease use date for our UK facility and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. In the first quarter of fiscal 2013, we began amortizing into general and administrative expense, equally through the cease use date, the estimated rent income of $200 when the reserve was originally established. We have been unsuccessful at subleasing the facility. Based on these, we have $898 reserved for UK lease related costs.

 

The following table sets forth the rollforward of the restructuring activity for the three months ended December 31, 2013.

 

   Balance,
September 30,
2013
   Total
Charges
   Cash
Payments
   Other   Balance,
December
31, 2013
 
One-time termination benefits  $-   $-   $-   $-   $- 
Lease related costs   877    -    -    21    898 
Equipment moving costs and method transfers   -    -    -    -    - 
Travel and relocation costs   -    -    -    -    - 
Loss on sale of equipment   (16)   -    -    8    (8)
Other costs   117    -    -    -    117 
Total  $978   $-   $-   $29   $1,007 

 

Other costs include legal and professional fees and other costs incurred in connection with transitioning services from sites being closed as well as costs incurred to remove improvements previously made to the UK facility. Other activity in the reserve rollforward primarily reflects a receivable for settlement of the capital lease in the UK.

 

19
 

 

Liquidity and Capital Resources

 

Comparative Cash Flow Analysis

 

At December 31, 2013, we had cash and cash equivalents of $841, compared to $1,304 at September 30, 2013.

 

Net cash provided by operating activities was $1,036 for the three months ended December 31, 2013 compared to $717 for the three months ended December 31, 2012. The increase in cash provided by operating activities in the current fiscal quarter partially results from higher operating income in the first fiscal quarter of 2014 versus the prior year period. Other contributing factors to our cash from operations were noncash charges of $402 for depreciation and amortization and a net decrease in accounts receivable of $939, offset slightly by a net increase in accounts payable of $345 and accrued expenses of $151 as well as an increase in prepaid and other assets of $205. Included in operating activities for the first fiscal quarter of 2013 are non-cash charges of $473 for depreciation and amortization, a reduction in accounts receivable of $1,387and an increase in accrued expenses of $782 and customer advances of $685. The impact on operating cash flow of other changes in working capital was not material.

 

Investing activities used $51 in the first quarter of fiscal 2014 due to capital expenditures as compared to $10 in the first three months of fiscal 2013. Our principal investments were for laboratory equipment as well as general building infrastructure.

 

Financing activities used $1,422 in the first three months of fiscal 2014 as compared to $763 used for the first three months of fiscal 2013. The main use of cash in the first quarter of fiscal 2014 was for long-term debt and capital lease payments of $115 as well as net payments on our line of credit of $1,247. In the first quarter of fiscal 2013, we had long-term debt and capital lease payments of $266, as well as net payments on our line of credit of $482.

 

Capital Resources

 

We have a term loan from Regions Bank (“Regions”) aggregating approximately $5,205 at December 31, 2013, which is secured by mortgages on our facilities in West Lafayette and Evansville, Indiana and a $3,000 line of credit with EGC. The EGC line of credit is subject to availability limitations that may substantially reduce or eliminate our borrowing capacity at any time.

 

On November 9, 2012, we executed a sixth amendment with Regions which we further modified on December 21, 2012. In the sixth amendment, Regions agreed to extend the term loan and mortgage loan maturity dates to October 31, 2013. The unpaid principal on the notes was incorporated into a replacement note payable for $5,786 bearing interest at LIBOR plus 400 basis points (minimum of 6.0%) with monthly principal payments of approximately $47 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations. The replacement note payable had a balance of $5,205 at December 31, 2013 and $5,254 at September 30, 2013.

 

On October 31, 2013, we executed a seventh amendment with Regions to extend the note payable maturity date to October 31, 2014.

  

Regions requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00 and a total liabilities to tangible net worth ratio of not greater than 2.10 to 1.00. At December 31, 2013, we were in compliance with the fixed charge coverage and the total liabilities to tangible net worth ratios in the Regions agreements. Failure to comply with those covenants in future quarters would be a default under the Regions loans, requiring us to negotiate with Regions regarding loan modifications or waivers. If we are unable to obtain such modifications or waivers, Regions could accelerate the maturity of the loans and cause a cross default with our other lender.

 

The Regions loan agreements both contain cross-default provisions with each other and with the revolving line of credit with EGC described below.

 

The replacement note payable with Regions matures in the first quarter of fiscal 2015. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. We have listed for sale our 7.25 acres and 120,000 square foot facility at 2701 Kent Avenue, West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. We enlisted a new realtor in the third quarter of fiscal 2013 and changed the asking price to $10,800. We performed an impairment analysis on the building when we listed it for sale, but noted no impairment. As of December 31, 2013, the net book value of the facility and land was $9,126.

 

20
 

 

We may be unsuccessful in renegotiating the terms of the Regions debt or they may be unfavorable to us. For these reasons, if we are unsuccessful at refinancing our long-term debt, our operating results and financial condition could be adversely affected.

 

Revolving Line of Credit

 

We have a $3,000 revolving line of credit agreement (“Credit Agreement”) with EGC. The term of the Credit Agreement expires on January 31, 2014. If we terminate prior to the expiration of the term, then we are subject to an early termination fee equal to the minimum interest charges of $15 for each of the months remaining until expiration.

 

Borrowings under the Credit Agreement bear interest at an annual rate equal to Citibank’s Prime Rate plus five percent (5%), or 8.25% as of September 30, 2013, with minimum monthly interest of $15. Interest is paid monthly. The line of credit also carries an annual facilities fee of 2% and a 0.2% collateral monitoring fee. Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. Borrowings are calculated based on 75% of eligible accounts receivable. Under the Credit Agreement, as amended, the Company has agreed to restrict advances to subsidiaries, limit additional indebtedness and capital expenditures and maintain a minimum tangible net worth of at least $8,000.

 

The Credit Agreement also contains cross-default provisions with the Regions loans and any future EGC loans. At December 31, 2013, we were not in compliance with the minimum tangible net worth covenant requirement mainly due to the increase in the warrant liability. On January 30, 2014, EGC waived our breach with this covenant.

 

Pursuant to the terms of the Credit Agreement, the line of credit would have automatically renewed on January 31, 2014 unless either party gave a 60-day notice of intent to terminate or withdraw. On October 30, 2013, we informed EGC of our intent not to renew the line of credit on January 31, 2014. On January 31, 2014, we paid off the remaining balance on this line of credit.

 

We are actively pursuing alternatives to replace this line of credit with more favorable terms. We are focused on growing our revenues and improving our cash flow from operations in fiscal 2014 to reduce our reliance on our line of credit. We may be unsuccessful in obtaining a new line of credit. If we are unable to continue to increase cash flow from operations in fiscal 2014 or obtain a new line of credit, we may not have sufficient liquidity to continue our business.

 

For the remainder of fiscal 2014, we expect to see continued improvement in the volume of new bookings with little improvement in pricing. We also expect to maintain improved gross profit margins due to cost controls implemented in fiscal 2013. We have debt service and lease obligations of approximately $1.7 million in fiscal 2014. Based on our expected revenue and the impact of the cost reductions implemented, we project that we will have the liquidity required to meet our fiscal 2014 operations and debt obligations.

 

Should operations materially fail to meet our expectations for the coming fiscal year, we may not be able to comply with all of our debt covenants, requiring that we obtain a waiver at that time. If that situation arises, we will be required to negotiate with our lenders again to obtain loan modifications or waivers as described above. We cannot predict whether our lenders will provide those waivers, if required, what the terms of any such waivers might be or what impact any such waivers will have on our liquidity, financial condition or results of operations.

 

ITEM 3 – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

A smaller reporting company is not required to provide the information required by this Item 3.

 

21
 

 

ITEM 4 - CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to provide reasonable assurance to our management and board of directors that information required to be disclosed in the reports we file or submit to the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on an evaluation conducted under the supervision and with the participation of the Company’s management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2013, we, including our Chief Executive Officer and Chief Financial Officer, determined that those controls and procedures were effective as of December 31, 2013.

 

Changes in Internal Controls

 

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the first three months of fiscal 2014 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

PART II

 

ITEM 1A - RISK FACTORS

 

You should carefully consider the risks described in our Annual Report on Form 10-K for the year ended September 30, 2013, including those under the heading “Risk Factors” appearing in Item 1A of Part I of the Form 10-K and other information contained in this Quarterly Report before investing in our securities. Realization of any of these risks could have a material adverse effect on our business, financial condition, cash flows and results of operations.

 

22
 

 

ITEM 6 - EXHIBITS

 

(a) Exhibits:

 

Number     Description of Exhibits
       
(10)   10.1 Seventh Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed and effective October 31, 2013 (incorporated by reference to Exhibit 10.1 for Form 8-K filed November 5, 2013).
       
    10.2 Notice of non-renewal to Entrepreneur Growth Capital LLC, dated October 30, 2013 (incorporated by reference to Exhibit 10.22 to Form 10-K for the fiscal year ended September 30, 2013).
       
    10.3 Severance Agreement between Lori D. Payne and Bioanalytical Systems, Inc., dated October 25, 2013 (filed herewith).
       
    10.4 Waiver letter, dated January 29, 2014 from Entrepreneur Growth Capital LLC (filed herewith).
       
(31)   31.1

Certification of Chief Executive Officer and Chief Financial Officer (filed herewith).

 

(32)   32.1 Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) (filed herewith)..
       
    101 XBRL data file (filed herewith).

 

23
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized:

 

  BIOANALYTICAL SYSTEMS, INC.
  (Registrant)
   
Date:   February 14, 2014 By:  /s/   Jacqueline M. Lemke
  Jacqueline M. Lemke
  President and Chief Executive Officer and Vice
President of Finance and Chief Financial Officer

 

24
 

 

EXHIBIT INDEX

 

Number     Description of Exhibits
       
(10)   10.1 Seventh Amendment to Loan Agreement between Bioanalytical Systems, Inc. and Regions Bank, executed and effective October 31, 2013 (incorporated by reference to Exhibit 10.1 for Form 8-K filed November 5, 2013).
       
    10.2 Notice of non-renewal to Entrepreneur Growth Capital LLC, dated October 30, 2013 (incorporated by reference to Exhibit 10.22 to Form 10-K for the fiscal year ended September 30, 2013).
       
    10.3 Severance Agreement between Lori D. Payne and Bioanalytical Systems, Inc., dated October 25, 2013 (filed herewith).
       
    10.4 Waiver letter, dated January 29, 2014 from Entrepreneur Growth Capital LLC (filed herewith).
       
(31)   31.1

Certification of Chief Executive Officer and Chief Financial Officer (filed herewith).

 

(32)   32.1 Written Statement of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) (filed herewith)..
       
    101 XBRL data file (filed herewith).

 

25

 

EX-10.3 2 v367799_ex10-3.htm EXHIBIT 10.3

 

 

 

October 25, 2013

 

 

VIA E-MAIL and HAND DELIVERY

 

Lori Payne, PhD. (Via Hand Delivery)

 

  Re: Severance Agreement and Release of All Claims

 

Dear Lori:

 

You have indicated that you intend to resign from your position as Vice President of Bioanalytical Services of Bioanalytical Systems, Inc. ("BASi" or "Company"). This letter will confirm certain agreements between you and the Company concerning the resolution of all contractual and other matters between the parties.

 

Upon your resignation, BASi is prepared to offer you a severance package with the terms detailed below. Although you will have the full time period spelled out in paragraph 16 below to consider this Agreement, your employment will end effective November 15, 2013. Thereafter, you will not be entitled to any additional compensation or to participate in any of BASi's benefit plans (except as otherwise specifically provided herein) from BASi other than what may be agreed to by the parties in the Agreement below.

 

Even if you do not sign this Agreement, BASi will (a) pay you at your normal weekly salary through November 15, 2013; (b) pay you for any accrued but unused vacation days in accordance with Company policy; and (c) reimburse you for previously incurred but unreimbursed business expenses in accordance with Company policy. Unless you notify BASi of a different bank account, your final pay will be deposited in the bank account that you have previously designated for direct deposit. Similarly, even if you do not sign this Agreement, you will be offered benefits to which you are entitled under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), as modified below.

 

A.Terms

 

1.Definitions. The terms “you” and “your” and “Payne” mean Lori Payne, and anyone who has or obtains any legal right or claims through her. “BASi” and “Company” mean Bioanalytical Systems, Inc. and include its past and present officers, directors, employees, agents, related corporations and entities, affiliates, principals, insurers, shareholders, attorneys, trustees, subsidiaries, predecessors, successors and assigns, any and all employee benefit plans (and any fiduciary of such plans) sponsored by BASi. “Agreement” means this letter agreement which contains the terms of the severance package and which includes a release of all claims arising out of Payne's employment relationship with BASi and the termination of the employment relationship. “The Parties” means Payne and BASi.

 

 
 

 

2.Resignation. Pursuant to this Agreement, Payne will be deemed to have resigned her employment with BASi effective November 15, 2013 (the Effective Date).

 

3.Payments and Benefits to be Provided to Payne. In exchange for and in consideration of Payne's agreement to release all claims against BASi as described in paragraph 4 and in consideration of the other promises contained in this Agreement, BASi agrees as follows:

 

a.BASi agrees to pay you a severance benefit in the form of salary continuation through the payroll period ending January 15, 2014 ("Severance Period"), in the amount of $13,333.33 per month. Unless you notify BASi’s payroll department of a different bank account, this amount will be deposited in the bank account that you have previously designated for direct deposit;

 

b.Additionally, following the Release Effective Date, if you are eligible for and timely elect to continue health insurance coverage under BASi's group health care program pursuant to the federal law known as COBRA, then, BASi will reimburse you through January 15, 2014, for the amount of COBRA premiums paid by you to maintain such coverage upon presentation by you to the Company of evidence that you have made such payments. Any month for which you receive such reimbursement from BASi will count toward the eighteen (18) month COBRA continuation period.

 

c.After the period referenced in paragraph 3(b) ends, you and your family will have the option of continuing to participate in BASi’s group health care program pursuant to COBRA for any remaining period of COBRA continuation coverage to the extent required under COBRA, but you will be responsible for the entire premium.

 

d.Payne agrees that all of her stock options, including vested and unvested stock options, shall be irrevocably terminated and of no further effect as of the termination date. Payne further agrees that she will not be eligible for any bonuses, commissions, or other incentive compensation paid by BASi following her termination date with the exception of bonuses earned under the Annual Incentive Bonus Program before the termination date.

 

 
 

 

4.Claims released by Payne. By signing this Agreement, Payne unconditionally and fully releases and forever discharges BASi from (a) any and all possible claims, known or unknown, arising out of or from her employment with BASi under any and all possible legal, equitable, tort, contract or statutory theories, including but not limited to any claims for constructive or wrongful discharge or breach of contract, except for any claims relating to accrued and vested rights under a retirement plan; (b) any and all claims arising on or before the date Payne signs this Agreement, including but not limited to any charges, claims, demands or actions under Title VII of the Civil Rights Act of 1964 and the Equal Pay Act, 42 U.S.C. § 2000e et seq., Section 1981 of the Civil Rights Act of 1866, 42 U.S.C. § 1981, the Age Discrimination in Employment Act, the Older Workers’ Benefit Protection Act, the Americans with Disabilities Act, 42 U.S.C. § 12101 et seq., the Indiana Civil Rights Law, the Employee Retirement Income Security Act, 29 U.S.C. § 1001 et seq., the United States Constitution, the Indiana Constitution, any and all amendments to said statutes, and any other federal, state or local statute or law, ordinance or regulation, dealing in any way with employment or employment-related benefits and all claims for costs and attorneys’ fees; and (c) all claims Payne may have against BASi arising out of Payne's employment and/or termination of employment with BASi, including any claims arising out of her Employment Agreement dated March 15, 2012. Payne agrees and understands that any claims she may have under the aforementioned laws, statutes or any other federal, state or local law, ordinance, rule or regulation are effectively waived by this Agreement. Payne understands that the signing of this Agreement prevents her from making any further claims against BASi in connection with her employment and the termination of her employment with BASi. Payne agrees to give up, release and waive all claims against BASi and not to bring any lawsuits against BASi relating to the claims she has given up, released and waived, nor will she allow any suit to be brought on her behalf. BASi represents that it is not aware of the existence of any claims it may have against Payne and has not discussed the possibility of litigation against her. BASi affirms and acknowledges that it is unaware of any potential claims it may have against Payne and has no present intention of asserting any such claims against her once the agreement is signed.

 

5.No Admission of Liability; Waiver. This Agreement shall not in any way be construed as an admission by BASi that it has acted wrongfully with respect to Payne or any other person, or that Payne has any rights whatsoever against BASi. Payne waives any right or claim of reinstatement to employment with BASi and agrees not to seek further employment with BASi. If Payne does seek employment with BASi, BASi is under no obligation to consider her for employment.

 

6.Acknowledgement. Payne acknowledges that she is not entitled to any of the payments and benefits listed in paragraph 3(a)-(b) of this Agreement unless she signs this Agreement and does not revoke it within the revocation period stated in paragraph 16 below.

  

 
 

 

7.Non-Disparagement. In consideration of the promises made in this Agreement, Payne and BASi each agrees not to make any false, negative or disparaging remarks or comments to any person and/or entity about the other party to this Agreement, nor shall Payne or BASi make any statement that may subject the other party to potential embarrassment, humiliation or any other negative consequence. In addition, Payne agrees that she shall not make any public statement, including but not limited to, any statement to the media or to BASi employees, regarding the termination of her employment with BASi with the exception of stating that she has resigned to pursue other opportunities.

 

8.Consultation with Attorney. Payne agrees that she has read this Agreement and the releases contained herein, that she understands all of the terms hereof, that she has not been coerced, threatened or intimidated into signing this Agreement, and that she executes this Agreement voluntarily and with full knowledge of its meaning and consequences and that she has had sufficient opportunity to consult with her attorney regarding this Agreement. Payne further acknowledges that BASi hereby advises her that she should consult with an attorney before executing this Agreement.

 

9.Violation of Agreement and Severability. Payne agrees that if she breaches any obligation set forth in this Agreement, BASi shall cease all payments to her, as described in this Agreement, and it shall also cease providing all benefits to her, as described in this Agreement. Payne also understands and agrees that in the event that this Agreement is ever held to be invalid or unenforceable, in whole or in part, as to any particular type of claim or charge or as to any particular circumstances, this Agreement shall remain fully valid and enforceable as to all other claims, charges and circumstances.

 

10.Confidentiality and Non-Solicitation. Payne agrees and understands that she remains subject to the Confidentiality and Non-Solicitation obligations stated in Sections 3.1 and 3.3 of her Employment Agreement dated March 15, 2012.

 

11.Payne's Representations. Payne represents and warrants that in the making and execution of this Agreement, she is not relying on any representation, statement, or assertion of fact or opinion made by any agent, attorney, employee, or representative of the persons, parties, or corporations being released herein, and she hereby waives any right to rely upon all prior agreements and/or oral representations made by any agent, attorney, employee, or representative of such persons, parties, or corporations even though made for the purpose of inducing her to enter into this Agreement.

 

12.Return of BASi’s Property. Payne hereby represents and warrants that she will return to BASi all of BASi’s property that is in her possession or control as of the Effective Date. This includes, but is not limited to, keys, credit cards, phone cards, cellular telephones, pages, directories, computer hardware and software, books, documents, memoranda, and all other records, and copies thereof.

 

13.Cooperation and Transition Assistance. Payne agrees that she will be available to provide reasonable assistance to BASi with transitional matters relating to her former duties with BASi, without additional compensation, for the Severance Period discussed in paragraph 3(a), above.

 

 
 

 

14.Miscellaneous. The Parties agree that this Agreement is deemed made and entered into in the State of Indiana and in all respects shall be interpreted, enforced and governed under the laws of the State of Indiana, unless otherwise preempted by federal law. Jurisdiction and venue for litigation of any dispute, controversy, or claim arising out of or in connection with this Agreement shall lie exclusively in the federal or state courts in Tippecanoe County, Indiana, and the Parties hereby consent to service of process from said courts. This Agreement shall inure to the benefit of and may be enforced by, and shall be binding on The Parties and their heirs, executors, administrators, personal representatives, assigns, and successors in interest. The language of all parts of this Agreement shall be in all cases construed as a whole, according to its fair meaning, and not strictly for or against the drafter.

 

15.Disclosures by Payne. As a condition precedent to her eligibility for the severance benefits described in paragraph 3(a)-(b) above, Payne affirms and attests that she has disclosed during the course of her employment all employment and other agreements she has signed on behalf of BASi in her capacity as Vice President of Bioanalytical Services to appropriate Company officials.

 

16.Time to Consider this Agreement. Payne understands that she has twenty-one (21) days from the date of delivery of this Agreement to consider the terms of this Agreement. Payne understands that she may sign this Agreement at any time during the twenty-one (21) day period. Payne understands that she may revoke this Agreement if she so chooses until seven (7) days after the date of execution. Payne further understands that this Agreement will not become effective or enforceable and that BASi’s obligations in paragraph 3 of this Agreement to make payments and provide benefits will not become effective or enforceable until seven (7) days from the date of Payne’s execution of this Agreement and provided that the Agreement is not revoked during such seven day period ("Release Effective Date").

 

 

  Sincerely,  
  Bioanalytical Systems, Inc.  
     
     
  Jacqueline Lemke  
     
  President & CEO  

 

 
 

 

My signature below represents my unconditional acceptance of all terms and conditions contained in this Agreement.

 

 

 

 

       
Lori Payne, Ph.D.     Date
       
       
 STATE OF INDIANA )    
  )  SS:    
COUNTY OF _________ )    
       
Subscribed to and sworn before me, a Notary Public, in and for said County and State, this _____ day of                     , 2013.

 

 

     
    Signature
     
     
    Printed                                      Notary Public
     
     
My Commission Expires:   County of Residence:
     
     

 

 

EX-10.4 3 v367799_ex10-4.htm EXHIBIT 10.4

 

ENTREPRENEUER GROWTH CAPITAL
 

505 PARK AVENUE NEW YORK, NY 10022

 

 

 

 

 

January 29, 2014

 

 

 

Jacqueline M. Lemke

Vice President Finance

Chief Financial Officer

Bioanalytical Systems lnc.

Purdue Research Park

2701 Kent A venue

West Lafayette, IN 47906

 

 

 

Re:       Waiver- Net Worth Covenant

 

Dear Ms. Lemke:

 

We refer you to that certain Loan and Security Agreement between Bioanalytical Systems, Inc. ("Borrower") and Entrepreneur Growth Capital, LLC ("Lender") dated on or about January 11, 2010 (the "Agreement"). All capitalized terms used herein and not otherwise defined shall have the meaning ascribed to them in the Agreement.

 

This letter shall serve to confirm that Lender hereby waives Borrower's compliance with the tangible net worth covenant set forth in Section 4.15 of the Loan Agreement for the period ending December 31, 2013. Borrower understands that the waiver set forth herein shall apply only for the stated period.

 

Borrower agrees to pay Lender a fee in the amount of $500.00 as consideration for the aforesaid waiver and documentation of this letter agreement, which fee will be automatically charged to Borrower's revolving loan account.

 

Except as hereby or heretofore amended or supplemented, the Agreement shall remain in full force and effect in accordance with its original terms and conditions.

 

If the foregoing correctly sets forth you and our understanding, please execute the enclosed copy of this letter in the spaces provided below and return such fully executed copy to the undersigned as soon as possible.

 

Page 1 of 2
 

 

 

This Amendment may be executed in one or more counterparts, each of which when so executed shall be deemed to be an original, but all of which when taken together shall constitute one and the same instrument. An executed facsimile of this Amendment shall be deemed to be a valid and binding agreement between the parties hereto.

 

Very tru1y yours,

 

ENTREPRENEUR GROWTH

CAPITALLLC

as Lender

 

 

By: _____________________________

Name: Charles L. Bert

Title:   Vice President

 

 

 

 

   BJOANALYTICAL SYSTEMS, INC.
   as Borrower
   
   
By:  _____________________________
Name: Jacqueline M. Lemke
Title: Vice President - Finance
         Chief Financial Officer

 

Page 2 of 2

 

 

 

 

 

EX-31.1 4 v367799_ex31-1.htm EXHIBIT 31.1

  

CERTIFICATIONS

 

I, Jacqueline M. Lemke, President and Chief Executive Officer and Vice President of Finance and Chief Financial Officer, certify that:

 

1.I have reviewed this report on Form 10-Q of Bioanalytical Systems, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

 

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions);

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 
 

 

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

 

  /s/ Jacqueline M. Lemke  
  Jacqueline M. Lemke  
Date:  February 14, 2014 President and Chief Executive Officer and Vice President of  
  Finance and Chief Financial Officer  

 

 



EX-32.1 5 v367799_ex32-1.htm EXHIBIT 32.1

  

Certifications of Chief Executive Officer and Chief Financial Officer

 

Pursuant to Section 906

 

Of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

 

 

 

The undersigned, the President and Chief Executive Officer and Vice President of Finance and Chief Financial Officer of Bioanalytical Systems Inc. (the “Company”), hereby certifies that, to the best of her knowledge:

 

(a)the Form 10-Q Quarterly Report of the Company for the three months ended December 31, 2013 filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

 

  By:  /s/  Jacqueline M. Lemke  
  Jacqueline M. Lemke  
  President and  Chief Executive Officer and Vice President of  
  Finance and Chief Financial Officer  
  Date:   February 14, 2014  

 

 

 

 

GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_X0`617AI9@``24DJ``@```````````#_ MVP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4'1H?'AT:'!P@)"XG("(L M(QP<*#7J#A(6&AXB)BI*3E)66EYB9 MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+ M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1 MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15 M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W M^/GZ_]H`#`,!``(1`Q$`/P#V_5-9L='A$EY,$W?=0#+-]!6"OQ"TLR8:WNU3 M^]M4_IFN$U;49=5U2>[E8G>Q"#^ZO852KP*V:5'/]WHCZBADM%07M;N1[1IV MKV&K1E[*X27'WEZ,OU!YJ]7B=HFH6[K>6D=RA3D2QHV!^->D>&/%,>M1_9[C M;'?(.5'`D'J/ZBN["8]57R35G^#/-QV5N@G.D[QZ]T=)1535+'^T],N++SY8 M/.0IYD1PRUQ_AO7KS1=4_P"$7\0/^]7`M+DGB1>PS_+\J]$\D[NBBB@#EM;T MS6K:UGN[#6[EO+!(K M]T?2O"S*]*<>235_-GTN4.->$O:13MY([3P^_B#7XYW37)(?)8*0R!LY%:%W MH_BZ&,O;ZU]H(_@P$)^F1C]:C^''_'MJ'_71/Y&NWKJPM!5:"E*3N_-G%C<3 M*AB90C&-ETY5V]#RE?%OB&RF:.6Y)=#AHYHAD'T/`-=/H7CB+4)TM;^);>9S MA'4_(Q]/8UB?$&"./6X)4`#RPY?'<@X!_+^5:Z7<]: M.#P^,H*?(HMKH>[T57L6=]/MGESYC1*6SZX&:KZWJ2Z3H]Q=G&Y5Q&#W8\#] M:^@1^58\VBW`\.QZTY9O-F(8'^Z>C?BV?S%9<P%5=(U!-5TNWO$Q^\7YAZ-T(_.L?QY*\?AIE0D"29$;ZMF+JX1J-!H>$]4TR-I]%U*Z=5Y, M)D(;'MC@_2J_@:YN+KQ%=274TDLOV<@M(Q)^\..:]#K)M]#BM?$-QJL+!1/% ML>,+_%D'=G\*WE@N6K&=/9/5'-','.C.G5W:T=M?1EG5[UM/TB[NT7<\4990 M?7M7CD]Y>228G.\LE>V3PQW,$D$RAHY%*LI[@UP<_PZG^TG[- M?1?9R>/,4[@/PX/Z5EF-"M5<7#5&V48K#T5)579]_(VO!6JW&IZ0ZW3F22"3 M9YAZL,9&?>BM71=(@T33UM("6YW.YZNQ[T5WX>,XTHQGN>9BIPG6E*FK)L\D MU.S;3]4N;1Q@Q2$#W'8_EBNG\%>'8;_=J5X@DB1]L4;=&8=2?4"M+QSH+74( MU2V3,L2XF4=63U_#^7TJWX#N8YO#HA4C?#(P8?4Y!_7]*\BCA(PQ?)/;='O8 MC'2J8#VE-ZZ)^7_#_J=.`%````'0"N=U[PQ'?_Z9I^+;4HSN21/EWD>OO[U8 M\4G6TTGSM"9/M$3AW0KN,BCJH_SSVIGAGQ39^([/*$17B#$UNQ^93ZCU%>S4 MI1J1Y9(^>HUIT9\T'J6M`O+Z]TQ7U&U:WN$8HV1C?C^(#M7,?%+3XYM`AU#& M)K:8*&'7:W!'YX-=W7F'Q,\26]PD>BVDBR%)!)<,IR%(Z+]>Y_"JIQ<4DW2)%9:E)(ZHBNA9F.`!@\UT-WXJT6SC+-?1 MRL.B0G>3^5<[\/X8[G3]4@F0/'(RJRGN"#6])X/T%T*_8%3W1V!'ZUTX7VWU M:/LK==[]SCQOU?ZW/VU^FUNR[GGFJWUWXEUAIHK>1F(VQ1(-Q516]H'@>X>X MCN=541Q*0P@SEF/^UZ#VJGXE\)OHB"\LY7DM<@-N^]&3TY'450TSQ3JVF.NR MY::(=8ICN!'L>HKSDHTJW^U)M_@>O)SK8=+!226WG_7]7/7:X3QC<2:MKEEH M-LW1@TF.S'_!HSE=V MP`9)8\G'Z**]3%5(U5&G%Z2U?HCQ<%2E1E.M-:QT2_O/1':3:9;S:.VF;<0& M+R@/08P#_6O&[FWDM+J6VF&)(G*,/<5WO_"?M_T!+G_OK_ZU3V/2RJEB*,Y1JK1Z[K?[^IO\`P_U3 MR[B;3)&^63][%G^\/O#\N?P-=CK6F+J^DSV;':7&48_PL.0:\?L[N2QO8;J$ M_O(G#CWQVKVFSNHKVSANH3F.5`Z_C71EU15:+HRZ?DSDS>BZ->->'7\T>+7= MI/873VUS&8YD."I_F/45)8:C>:9/YUGAALTH8B/)5T M;[[/^O,V='\>P3[8=4002=/.3E#]1U%=BDB2HLD;JZ,,AE.017A;*58JP(8' M!!&"#72^$?$,NF7T=G,Y-E,P7!/^K8]"/;UK?"9E+F4*OW_YG-CLHARNI0T\ MO\CK-9\3WFDO)G19VA5L"O>&-2N-6T1+NZ M*F5G8?(N!@'BBJG@7_D5XO\`KH__`*%17IX:3E1BWO9'CXR*CB)QBK)-G1D9 M%:A8W'A+5#K&G1F33Y.+F`?P>X]O3TZ=#7;4UE5U*LH96&"",@BG6HJHN MS6S["P^(=%O2\7NNZ_K8BL[N*^LXKJ`DQ2J&4D8.*XKQEX+EN)CK6A[HM03Y MI(XCM,G^TI'1OY_6N[`"J`H``X`':EK572U,)6;TV/`;CQ1XAEB:UGU6[VC* MLI;:WN">M8U>[Z]X-TC7R9;B$Q7./]?#\K'Z]C^-"X2>Y=6C"1\ MA2>,D].*\P!`&,C\Z^?S2I"QZ!\./^/;4/^NB?R-= MO7!>`KF*TTS5;F5L1Q%7"G)+?\SS MVWHC1\2F,>&M0\S&WR6Z^O;]<5X]72>(_%LFN(+2WC,5J&R0 M3EI".F<=![50TSPWJFJ2*(;9XXSUEE!51_C^%>;C:GUFJE25['KY=1>#H-UW M:[N;O@F&2XTO6X0NY)(@H'JQ5O\`ZU=OI.GII>E6]FF/W2`,?5NY_/-1Z+I$ M&BZXM#C>RYC)[,.16C52]U.QTU0UY=Q09Y`=L$_0=371447%J>QRTG-33I[K8\ M5961BK`A@<$'L:]`^'^J>9:S:9(WS1'S(L_W3U'X'^=<9K=U:WFMW=S:<022 M;ESQGU/XG)I-'U(Z5JMO>*>(V^<`]5/!'Y5\SAZJH5[IZ;?+^M3[+%T'BL,X MM6=K_/\`K0]IHKE-6\02^'[^*8I]ITR\7>A4X*-WP>X/!Q]:E3Q[H;)N,LR' M^Z8CG]*^@^MT4W&4K-=SY3ZC7<5.$;I]@\7:!;7^FSWJ1JEW`A?>!C>!R0?7 MBO,8E:26-$!+LP"@>I/%=MK/BN?6[=]/T:RN'64;7DV(I1Q5=>Q6G5]#V\+7E@L,_K#UZ+J=?<@BQF!Z M^4W\J\/7[H^E>LZ[XETW3;:Y@:X1[K85$*\G)'&?2O)@0`!D4LUJ1E.*3VN/ M)*4XPG*2LG:QZGX%_P"17B_ZZ/\`^A45D>#/$>G6FF?8+RX2"1'+(SG"L#SU M]:*]+"5J?L(KF6QY&.P]7ZS-\KU;Z'=T445V'GA1110`4444`%%%%`'+2?ZU M_P#>/\Z;117FGKK8T;'_`)!]Y_N_TK.HHJY_#$SA\4OZZ%W3?^/@5O445T4/ MA.3$_&%%%%;G.%%\_P`CG:.U%%>, M?0'92?\`(!T__<7_`-!JE117ISZ>B/&I[/U9T-A_QZ+5JBBNZ'PH\ZI\3.=O 9_P#C_F^O]*K445P2^)GIP^%!1114E'__V3\_ ` end GRAPHIC 7 image_002.gif GRAPHIC begin 644 image_002.gif M1TE&.#=A40`V`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P` M````40`V`(<````&!@8<'!P;&QL$!`0,#`P5%149&1D2$A(S,S,[.SLL+"PM M+2TW-S<_/S\J*BHT-#0^/CXE)24X.#@K*RLH*"@C(R,G)R7EY=75U)24E45%124E)145%:6EI% M145!04%$1$1`0$!555586%A[>WMW=W=S7EZ>GI^?GYP<'!L;&QE965X>'AQ<7&;FYN$A(2:FIJ5E960D)"/CX^3DY.1 MD9&>GIZ%A86#@X.=G9V6EI:?GY^,C(R)B8F+BXN9F9F' MAX>4E)2(B(B"@H*.CHZ`@("2DI**BHJ&AH:-C8VMK:VRLK*^OKZEI:6_O[^T MM+2AH:&OKZ^BHJ*FIJ:NKJZ[N[NYN;FCHZ.IJ:FLK*RSL[.ZNKJVMK:]O;VP ML+"QL;&JJJJHJ*BWM[>\O+RGIZ>@H*"XN+BKJZNUM;6DI*31T='$Q,36UM;+ MR\O0T-#%Q<7;V]O?W]_/S\_(R,C=W=W,S,S*RLK)RWM[2TM+3T]/:VMK'Q\?9V=G5U=74U-37U]?8V-C"PL+#P\/.SL[HZ.C@ MX.#^_O[[^_OV]O;Y^?GT]/3IZ>GDY.3X^/CU]?7]_?WL[.SW]_?CX^/JZNKS M\_/BXN+KZ^OFYN;O[^_GY^?M[>WR\O+N[N[EY>7P\/#AX>'Q\?'\_/SZ^OK_ M__\!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,! M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,! M`@,!`@,!`@,!`@,(_P"]"1Q(L*#!@P@3*ES(L*'#AQ`C2IQ(L6+%3W^^_`($ M[$>P0()`@0DU2-2@,*,(D2HE2)B8885,$3,$RMNA8HA.&1L8[%A!8K\:CD(6 M,5D"!4`6@`@11,0((23&#&%0@@B9!F6&F"AQ`D41(RE4'$&RP@P2,2P2H1*5 M2M4J1:J^#&/5*I4K9:->+5J&"-:H6*J8K?I4BA6P/ZV.R9JE$$D+%XQ>G$FB M!`@9,6A@%&E4),D21TR:$'+"),T8-4_6L#G1YH>2%,V0R3+UB%8H2,YJH1I4 M:AFI2,]DV2)42U+P6Y.,O1ITJIDL7(3(.$L8)`"41T`"Q7#3B`V80C(HF?_X MTZ32FS)18BU1)20-G!23?L2)E.2'E$G/EAU3Y/>5,4FX0),+***P\HHIHC0# M2RVZ+!+-)Y^8@004=0-1Q M"!1_5-'&(5808H4=K=!`QQI7#%%#&MY0<\@IID`"3"R?@/*)-*.$4@PTTYAB MBS&`K.*-)-)`L@LTO)ARRB[>R+)&0M7,X,`;1`AR M1`EF,*'$*PHH8D0<7L((*+]"XT@HV@=BB"S:E/#+*,P.Y0M`T2.C_4406BAQ1QAY@9(%&&F6P M<@,>DHQ1R!Y4S&'&$X;((84<*XY!Q!M?F%"*,-EHDPTEIFC3BBS2)%<+*]D< MXTHTBN`BBS;`#/+++L\8T@PUR-""R2K;$%0*09B@8`8.BR0A"@M:T'%%$U1$(-MJ+T@BXES0!2C2"N(H3*")I4,08C.=0AB"!YK)''"6#,+*+],THLMBY1"B3&A_%'*)H3` MP0THSMBBS2ZB%'/+*K`\_R(*,"-/HHLU"!%SQ0,47])>'DJ@(4<3;'#2AB"= M*.`&$GCL00838/BA@QISO!$'&I1``,DFMP2C2C&C)!.**]@`,TLNQT"S:BZQ MC*((+;^PXLLGHI1R2C&D_/**)6`B9,T34WSA"R5)L('&(9MHP<4F6.`AAQ:* MI%%'(7#,H<88F7C"!A^-(.*$+R>($8LWVHB"2RB_7/,+-(;H(@DLJ42I%S*(3CH"$ M-O]J<8I1W$(5DNB$)"(Q"EI,XA::F$0MSB"+,:1"(:`0PS2NL8QM^,(5TPA7 M+[9QBFP0HA'"P,0V5#&*XJE"%)?XQ1^T`899R"(/J*"&-Y(AD&$P0QC"4(8R M`,F-;B0C&N$)(6AB$YF8@QO@D(E$J$(3]V+(+I)ABT\(0QO(2(4E>_$) M;X"B%+(H12U2\0QG;`@AD,``&-9@!$;TP`\E",,1R##_!2C8H`PR,,$3PH`' M+^QA"T_01`J>D(4B,"$)=&`#"3X!C84L0Q>_Z$4Q((&+0(@"%(%P!.PRX8I! MV`(5D5@$J82!$&D<00^,:`,B?H"*(A2B#HX0A!GH`(@G2*(*9DC!'M@0AA^$ MX0F`^$$CF&")(KQ!#UEH"#,`D8M:A.(6WJ`%*5*1"F&,(A*ND(4HJ`$+57BC M%J`X!4*L\(!&["$+;/!#"^8`!C/D`0]F@,(5.&$$,@!"#'`HCR:Z8((CO($- M>!A#&*2@@V@P1!J(:44HFN$(:=#"&KV8!2X4X8M,R4(6BKA%+DXQC44I56(+3"A#'=I0!EO@``*! M8`@Q8N&+;%QH$;-XA2(NP8Q/Q&(5QD"G-$SQ"5^$(A"7($I!S)`!/+3!#RG0 MPQX*$.6BA"'/`PASJBT`8D3E$+3)1"%X]@1B66L8EJ4$(6!=F&!9R0`##$H`Y'B%,* MQG"'(G@A!&/H0AHT\`,AR`$#<\C#'K[`.47$(0F2H,`3&@(-2N""&JKH12!N M<8I%O*(4N]`&)FQQC&/0(A:8D(0=26&+]PVD&RY80AJ^H`0FK.$$ECC!&LRP M!"94H?\+<3!!']*@ASC,-PM=@((<^."#/ICA$"'8@F,7DHM$I,(6?YN%-:X! M#5)8XQ&2M5M):T$+;/CB+[D(Q");10$WY`$+5W`#%+0F!S+$`0@_"-T3U$"$ M/=`@>EFP0A"RXH8P#($31XC`*!B2C$*`@AO<&(0LFK%546Q"&KUP!BB088I0 M:$,;B7`&R[QA#$)DTQNXV`"$(A*8T$8Q3G&*3$!( M%=IX!2PV`6)O^.("!BC%#MK`!R5L80H\@$,7U@"".X!!"D[_*,(=C"`&$K!A M"VV@@AXL,88U)*0E&>(,7H2"%*K`QBT_H8OBA5,8J M`.$*./"-R=5PA1PP#WU/(L,.F,B&_RFLD0E3**(3J=@%S!(B#&L$`QG,Z(8U MIB,-8CR#&<:HUQZ),@QC(",;WM!_\9<,?L0,UR`+Q$`,R<`-K$(0UF`-Q.`- MS/!^PB!>C$0(EO`7H[`(U"`-NI!\5Y<0J2`!&"`"3V`%4_``+2`#4G`#3'`' M7$`!-$($(@`&2A`&*S`$CL`"1I`%4Z`!0,`%2(`$EK`)BH`R_I,-U5`*P&`' MD@`)K'`,G8`-@-`)T!`*R=`*?Y`-@3`*EB9$OC`+S+$3!Z$,@#=R@"I/`&++@"]8P"J?0"XSP#+B0"V*#"M=`#;0$+V``'VP!WA0!D?P`X.@!7[@!9U`!6AP`Z_0!(U@ M`E(0"#3`!V5P!3(P!)%0"4P@"4R`!B2@!-[@#+0P"LP08=R`3MB@;+A`"AZF M#9_0@:.0+8MP/[60"\Z`"J5P:8K`1P=A"BV@!7IP!)W`:E@``6__X`1"\`2< M@`5I4`6%T`)!P`DO,`E:$`=/T`9C4`0L9@)VP`4H(!"Z(`R@$`N\H"2RL`V& MP`O7L`O3,`K$8(VH\`C'8`VDD`NVT`N0X`N_4`O/P`NC9Q!.<`)R8`9FT`>A M!@1JX":%D`@A@`6,D`9:$#IO<`M($"=I\`9FX`9B@`EFD`0%P`W9D`J]@`N@ M4`O`$`V[X`AZQ`VN4`U.MTZT,`BU$`BAL`NH``T7)0N=(`N+<`ND@!#,L`8; M`)!FT`2.T`5NH`9P,%!HD`3#I06S!05)L`9<0`=2X`=/D`AFX`62(`)$P`"H ML"K58`JLH`RJ`'"7,'C&L`O9,`V]``VH_Q`*$>@*W9`(U3`-N*!PH+`+Y/(+ M$7@0HR``FO,(^O4%:K`(*O""0$`%8H`'1#`&>N`$3X`)27`&6:,%O+`$8>`& M7/`&,=`'WJ`,L$`(JW"9$?<+?X,)FD`+N-`)M$`)V.`*NB`*N@`+UL`[W0`* M'&@,M@`-RH`0PP`%,[`'S:,'RKD'/Q`$>D`&.&`(4/`#?A`)6&`$R4D'8-`& M6M`**V`+.M`)?E`'-G`,I@`+B3`,-H,*PL`*KK`+KF`-T*`+P"`-J=`,J@`7 MPI`)VG")\^.>JZ`)J,!*!_$#$#`*,C`+79`(3&`&D)`)AT`(?&`(:6`*90`) M4A`):/`%E8`(=O_P!3,WAYZP"8PE$+/0"UDE3M[P-_=C"K<0"+/@"`MW"MJ` MBJ'@#<#`"M:`#*Y""]'P!]*0$%GP`#K@`$[0!BX0!2'P`CC0`'[0`6LP`4'` M`4&@`7PP!$WP`59`!$<``FV@!#@`!5Z@`37P!:+P"[,X &2Q`!`0`[ ` end EX-101.INS 8 basi-20131231.xml XBRL INSTANCE DOCUMENT 10800000 1.25 0.156 0.75 0.002 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"><strong>10.</strong></td> <td style="TEXT-ALIGN: justify"><strong>MANAGEMENT&#39;S PLAN</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Our long-term strategic objective is to maximize the Company&#39;s intrinsic value per share.&nbsp;&nbsp;&nbsp;However, in response to our financial performance through the second quarter of fiscal 2012, we began to operate the business in a manner designed to place more emphasis on cash flow generation. Thus, our short-term tactical objective is to maximize free cash flow from operating activities.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> During the first fiscal quarter of 2014, revenues improved 7.2% as did gross margin by 15.6% and operating income by 53.0% from the first fiscal quarter of 2013. We also generated $976 in cash from operations, maintained strict controls on expenditures and paid down our line of credit $1.2 million while meeting all of our other obligations.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We negotiated an amendment to our loans with Regions Bank, extending the maturity date to October 2014. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. We listed for sale our headquarters facility in West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> For the remainder of fiscal 2014, we will focus on growing our revenues and continue initiatives to control costs and improve productivity to further reduce our break-even point and achieve our financial objectives. We expect to see improvement in the volume of new bookings in fiscal 2014 along with the continued improvements in gross profit margins. We have debt service and lease obligations of approximately $1.7 million in fiscal 2014. Based on our expected revenue, the impact of the cost reductions implemented and restructuring activities during fiscal 2012, we project that we will have the liquidity required to meet our fiscal 2014 operations and debt obligations. Though our current line of credit expired on January 31, 2014, we were able to pay off the remaining balance while continuing to meet all other debt obligations and working capital requirements. Although management believes our cash flow from operations will generate sufficient cash flow for our debt obligations, working capital requirements and capital expenditures, we are pursuing alternatives to replace this line of credit.</p> <!--EndFragment--></div> </div> 0.53 0.072 1.32 1.35 155000 2.10 977000 691000 false --09-30 Q1 2014 2013-12-31 10-Q 0000720154 7965387 Smaller Reporting Company BIOANALYTICAL SYSTEMS INC BASi 3215000 3584000 2396000 3621000 16000 30000 1538000 1689000 6000 32000 20098000 19925000 47000 74000 87000 87000 1126500 1376500 660902 120000 7.25 24119000 25597000 6072000 7233000 272000 268000 401000 471000 841000 670000 1304000 721000 -463000 -51000 19000000 19000000 7885229 7703891 7885229 7703891 1933000 1887000 -688000 264000 4075000 3948000 752000 566000 3323000 3382000 2891000 2815000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px">&nbsp;</td> <td style="WIDTH: 0.5in"><strong>7.</strong></td> <td style="TEXT-ALIGN: justify"><strong>DEBT</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Mortgages and note payable</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>&nbsp;</em></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We have a term loan from Regions Bank ("Regions") aggregating approximately $5,205 at December 31, 2013, which is secured by mortgages on our facilities in West Lafayette and Evansville, Indiana.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> On November 9, 2012, we executed a sixth amendment with Regions which we further modified on December 21, 2012. In the sixth amendment, Regions agreed to extend the term loan and mortgage loan maturity dates to October 31, 2013. The unpaid principal on the notes was incorporated into a replacement note payable for $5,786 bearing interest at LIBOR plus 400 basis points (minimum of 6.0%) with monthly principal payments of approximately $47 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations. At September 30, 2013, the replacement note payable had a balance of $5,254.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> On October 31, 2013, we executed a seventh amendment with Regions to extend the note payable maturity date to October 31, 2014.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;&nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Regions requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00 and a total liabilities to tangible net worth ratio of not greater than 2.10 to 1.00. Failure to comply with those covenants in future quarters would be a default under the Regions loans, requiring us to negotiate with Regions regarding loan modifications or waivers. If we are unable to obtain such modifications or waivers, Regions could accelerate the maturity of the loans and cause a cross default with our other lender.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Regions loan agreements both contain cross-default provisions with each other and with the revolving line of credit with Entrepreneur Growth Capital LLC ("EGC") described below.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The replacement note payable with Regions matures in the first quarter of fiscal 2015. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. We have listed for sale our 7.25 acres and 120,000 square foot facility at 2701 Kent Avenue, West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. We enlisted a new realtor in the third fiscal quarter of 2013 and changed the asking price to $10,800. We performed an impairment analysis on the building when we listed it for sale, but noted no impairment necessary. As of December 31, 2013, the net book value of the facility and land was $9,126.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We may be unsuccessful in renegotiating the terms of the debt or those terms may be unfavorable to us. For these reasons, if we are unsuccessful at refinancing our long-term debt, our operating results and financial condition could be adversely affected.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>&nbsp;</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <em>Revolving Line of Credit</em></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At December 31, 2013, we had a $3,000 revolving line of credit agreement ("Credit Agreement") with EGC. Pursuant to the terms of the Credit Agreement, the line of credit would have automatically renewed on January 31, 2014 unless either party gave a 60-day notice of intent to terminate or withdraw. On October 30, 2013, we informed EGC of our intent not to renew the line of credit on January 31, 2014. On January 31, 2014, we paid off the remaining balance on this line of credit.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At December 31, 2013, borrowings under the Credit Agreement bear interest at an annual rate equal to Citibank&#39;s Prime Rate plus five percent (5%), or 8.25% as of December 31, 2013, with minimum monthly interest of $15. Interest is paid monthly. The line of credit also carries an annual facilities fee of 2% and a 0.2% collateral monitoring fee. Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. Borrowings are calculated based on 75% of eligible accounts receivable. Under the Credit Agreement, as amended, the Company has agreed to restrict advances to subsidiaries, limit additional indebtedness and capital expenditures and maintain a minimum tangible net worth of at least $8,000. The Credit Agreement also contains cross-default provisions with the Regions loan and any future EGC loans. At December 31, 2013, we had available borrowing capacity of $1,845 on this line, of which $168 was outstanding. At September 30, 2013, we had $1,415 outstanding on this line.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At December 31, 2013, we were not in compliance with the minimum tangible net worth covenant requirement mainly due to the increase in the warrant liability. On January 29, 2014, EGC waived our breach with this covenant.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We are actively pursuing alternatives to replace this line of credit. We are focused on growing our revenues and improving our cash flow from operations in fiscal 2014 to reduce our reliance on our line of credit.</p> <!--EndFragment--></div> </div> 0.05 0.04 Citibanks' Prime Rate LIBOR 5786000 monthly 0.06 0.06 2014-10-31 47000 402000 473000 1573000 612000 0 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px">&nbsp;</td> <td style="WIDTH: 0.5in"><strong>2.</strong></td> <td style="TEXT-ALIGN: justify"><strong>STOCK-BASED COMPENSATION</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The 2008 Stock Option Plan ("the Plan") is used to promote our long-term interests by providing a means of attracting and retaining officers, directors and key employees and aligning their interests with those of our shareholders. The Plan is described more fully in Note 9 in the Notes to the Consolidated Financial Statements in our Form 10-K for the year ended September 30, 2013. All options granted under the Plan had an exercise price equal to the market value of the underlying common shares on the date of grant. We expense the estimated fair value of stock options over the vesting periods of the grants. We recognize expense for awards subject to graded vesting using the straight-line attribution method, reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment is recognized at that time. The Compensation Committee may also issue non-qualified stock option grants with vesting periods different from the 2008 Plan. As of December 31, 2013, there are 155 shares outstanding that were granted outside of the Plan. The assumptions used are detailed in Note 9 to the Consolidated Financial Statements in our Form 10-K for the year ended September 30, 2013. Stock based compensation expense for the three months ended December 31, 2013 and 2012 was $47 and $74, respectively.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> A summary of our stock option activity for the three months ended December 31, 2013 is as follows (in thousands except for share prices):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Options<br /> (shares)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average<br /> Exercise Price</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average<br /> Grant Date<br /> Fair Value</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="WIDTH: 61%">Outstanding - October 1, 2013</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">479</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">1.77</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">1.35</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-LEFT: 9pt">Exercised</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-LEFT: 9pt">Granted</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Terminated</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (40</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: right">2.29</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: right">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt">Outstanding - December 31, 2013</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 439</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">$</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right">1.72</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">$</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right">1.32</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> -0.09 0.03 -0.09 0.03 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 0.5in"><strong>3.</strong></td> <td style="TEXT-ALIGN: justify"><strong>INCOME (LOSS) PER SHARE</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We compute basic income (loss) per share using the weighted average number of common shares outstanding.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The Company has three categories of dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered direct offering, the Warrants issued in connection with the same offering in May 2011, and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method for preferred stock and the treasury stock method for stock options and warrants. Shares issuable upon exercise of options were not considered in computing diluted earnings per share for the quarters ended December 31, 2013 and 2012, respectively, because they were anti-dilutive. Warrants for 1,376,500 common shares were not considered in computing diluted earnings per share for the quarters ended December 31, 2012 because they were anti-dilutive. Warrants for 1,126,500 common shares and 660,902 common shares issuable upon conversion of preferred shares were not considered in computing diluted earnings per share for the quarter ended December 31, 2013 because they were also anti-dilutive.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table reconciles our computation of basic income (loss) per share to diluted income (loss) per share:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">Three Months Ended<br /> December 31,</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2013</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Basic net income (loss) per share:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="WIDTH: 74%; TEXT-ALIGN: left; PADDING-LEFT: 9pt">Net income (loss) applicable to common shareholders</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">(662</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">)</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">256</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Weighted average common shares outstanding</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,735</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,639</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 9pt"> Basic net income (loss) per share</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.09</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 0.03</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Diluted net income (loss) per share:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Diluted net income (loss) applicable to common shareholders</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">(662</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">256</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-LEFT: 9pt">Weighted average common shares outstanding</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7,735</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7,639</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"> Plus:&nbsp;&nbsp;Incremental shares from assumed conversions</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0.25in"> Series A preferred shares</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 767</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 27pt">Diluted weighted average common shares outstanding</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,735</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 8,406</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 9pt"> Diluted net income (loss) per share</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.09</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 0.03</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 0 0.34 -26000 5000 961000 -117000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The assumptions used to compute the fair value of the warrants at December 31, 2013 and September 30, 2013:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="WIDTH: 75%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">December 31, 2013</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30, 2013</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Warrant A</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Warrant A</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="WIDTH: 62%; TEXT-ALIGN: left">Risk-free interest rate</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 16%; TEXT-ALIGN: right">0.52</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">%</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 16%; TEXT-ALIGN: right">0.51</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Dividend yield</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Volatility of the Company&#39;s common stock</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">72.83</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">71.15</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Expected life of the options (years)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2.35</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>Fair value per unit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1.396</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.444</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 0 0 P2Y4M6D P2Y7M6D 0.7283 0.7115 0.0052 0.0051 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"><strong>9.</strong></td> <td style="TEXT-ALIGN: justify"><strong>FAIR VALUE OF FINANCIAL INSTRUMENTS</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#39;s judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 0.25in">&bull;</td> <td><font style="FONT-SIZE: 10pt">Level 1 - Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.</font> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 0.25in">&bull;</td> <td><font style="FONT-SIZE: 10pt">Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</font> </td> </tr> <tr style="VERTICAL-ALIGN: top"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </table> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in">&nbsp;</td> <td style="FONT-SIZE: 10pt; WIDTH: 0.25in">&bull;</td> <td><font style="FONT-SIZE: 10pt">Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</font> </td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In May 2011, we issued Class A and B Warrants that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The assumptions used to compute the fair value of the warrants at December 31, 2013 and September 30, 2013:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="WIDTH: 75%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">December 31, 2013</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30, 2013</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Warrant A</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Warrant A</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="WIDTH: 62%; TEXT-ALIGN: left">Risk-free interest rate</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 16%; TEXT-ALIGN: right">0.52</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">%</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 16%; TEXT-ALIGN: right">0.51</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Dividend yield</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">0.00</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Volatility of the Company&#39;s common stock</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">72.83</td> <td style="TEXT-ALIGN: left">%</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">71.15</td> <td style="TEXT-ALIGN: left">%</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Expected life of the options (years)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2.35</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">2.6</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>Fair value per unit</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1.396</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.444</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The fair value of the revolving credit facility and certain long-term debt is equal to their carrying values due to the variable nature of their interest rates. Our long-term fixed rate debt was initiated in February 2011 and renewed on October 31, 2013.</p> <!--EndFragment--></div> </div> -2000 1103000 1098000 1383000 1383000 2145000 1855000 -662000 256000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px">&nbsp;</td> <td style="WIDTH: 0.5in"><strong>6.</strong></td> <td style="TEXT-ALIGN: justify"><strong>INCOME TAXES</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We use the asset and liability method of accounting for income taxes.&nbsp; We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. We measure the amount of the accrual for which an exposure exists as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> At December 31, 2013 and September 30, 2013, we had a $16 liability for uncertain income tax positions. The difference between the federal statutory rate of 34% and our effective rate of 0% is due to changes in our valuation allowance on our net deferred tax assets.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> <font style="FONT-SIZE: 10pt">We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense.</font> <font style="FONT-SIZE: 10pt">Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months.</font></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We file income tax returns in the U.S., several U.S. States, and the United Kingdom. We remain subject to examination by taxing authorities in the jurisdictions in which we have filed returns for years after 2008.</p> <!--EndFragment--></div> </div> -345000 82000 -939000 -1387000 -151000 -782000 76000 -685000 14000 72000 47000 145000 -74000 767000 164000 165000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px">&nbsp;</td> <td style="WIDTH: 0.5in"><strong>4.</strong></td> <td style="TEXT-ALIGN: justify"><strong>INVENTORIES</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Inventories consisted of the following:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">December 31,<br /> 2013</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30,<br /> 2013</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="WIDTH: 58%; TEXT-ALIGN: left">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 18%; TEXT-ALIGN: right">1,281</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 18%; TEXT-ALIGN: right">1,157</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">235</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">322</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 323</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 259</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,839</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,738</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Obsolescence reserve</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (388</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (359</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,451</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,379</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 323000 259000 1839000 1738000 1451000 1379000 1281000 1157000 388000 359000 235000 322000 15279000 16138000 24119000 25597000 14878000 11026000 16000 16000 168000 1415000 Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. 0.02 1845000 2014-01-31 annually monthly 0.0825 3000000 15000 168000 1415000 5205000 5254000 1700000 5205000 613000 4641000 8000000 -1422000 -763000 -51000 -10000 1036000 717000 -662000 256000 -662000 256000 -662000 256000 2 1683000 1553000 462000 302000 424000 199000 38000 103000 200000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px">&nbsp;</td> <td style="WIDTH: 0.5in"><strong>1.</strong></td> <td style="TEXT-ALIGN: justify"><strong>DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Bioanalytical Systems, Inc. and its subsidiaries ("We," the "Company" or "BASi") engage in contract laboratory research services and other services related to pharmaceutical development. We also manufacture scientific instruments for life sciences research, which we sell with related software for use in industrial, governmental and academic laboratories. Our customers are located throughout the world.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; BACKGROUND-COLOR: white; TEXT-INDENT: 36.7pt"> We have prepared the accompanying unaudited interim condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles ("GAAP"), and therefore should be read in conjunction with our audited consolidated financial statements, and the notes thereto, included in the Company&#39;s annual report on Form 10-K for the year ended September 30, 2013. In the opinion of management, the condensed consolidated financial statements for the three months ended December 31, 2013 and 2012 include all adjustments which are necessary for a fair presentation of the results of the interim periods and of our financial position at December 31, 2013. The results of operations for the three months ended December 31, 2013 are not necessarily indicative of the results for the year ending September&nbsp;30, 2014.</p> <!--EndFragment--></div> </div> 45000 47000 -26000 8000 1000 2000 51000 10000 60000 15000 1000 1000 1000000 1000000 1185 1335 1185 1335 1185000 1335000 1185000 1335000 407000 238000 6372000 5636000 -1200000 16564000 16913000 7619000 6118000 66000 100000 49000 166000 143000 85000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"><strong>8.</strong></td> <td style="TEXT-ALIGN: justify"><strong>RESTRUCTURING</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> In March 2012, we announced a plan to restructure our bioanalytical laboratory operations. We consolidated our laboratory in McMinnville, Oregon into our 120,000 square foot headquarters facility in West Lafayette, Indiana. This plan was implemented to reduce operating costs and strengthen our ability to meet clients&#39; needs by improving laboratory utilization. In the fourth fiscal quarter of 2012, we decided to initiate closure of our facility and bioanalytical laboratory in Warwickshire, United Kingdom after careful evaluation of its financial performance and analysis of our strategic alternatives. We will continue to sell our products globally while further consolidating delivery of our CRO services into our Indiana locations. As part of the overall evaluation of our business, personnel reductions in the Selling, R&amp;D and General and Administrative functions were also implemented at both of our Indiana locations during the second half of fiscal 2012. In total, 74 employees were terminated as part of the restructuring activities in fiscal 2012.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We reserved for lease payments at the cease use date and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. In the first quarter of fiscal 2013, we began amortizing into general and administrative expense, equally through the cease use date, the estimated rent income of $200 when the reserve was originally established. We have been unsuccessful at subleasing the facility. Based on these, we have $898 reserved for UK lease related costs.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table sets forth the rollforward of the restructuring activity for the three months ended December 31, 2013.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> <strong>&nbsp;</strong></p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: right" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance,<br /> September 30,<br /> 2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Total<br /> Charges</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Cash<br /> Payments</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Other</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance,<br /> December&nbsp;31,<br /> 2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">One-time termination benefits</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="WIDTH: 35%; TEXT-ALIGN: left">Lease related costs</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">877</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">-</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">-</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">21</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">898</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Equipment moving costs and method transfers</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Travel and relocation costs</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Loss on sale of equipment</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(16</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">8</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(8</td> <td style="TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Other costs</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 117</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 117</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right">Total</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 978</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 29</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,007</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> <strong>&nbsp;</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Other costs include legal and professional fees and other costs incurred in connection with transitioning services from sites being closed as well as costs incurred to remove improvements previously made to the UK facility. Other activity in the reserve rollforward primarily reflects a receivable for settlement of the capital lease in the UK.</p> <!--EndFragment--></div> </div> 74 117000 117000 1007000 978000 898000 877000 -8000 -16000 29000 21000 8000 -14382000 -13720000 4916000 4670000 1304000 1133000 6220000 5803000 9126000 1304000 1133000 6220000 5803000 4916000 4670000 <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table reconciles our computation of basic income (loss) per share to diluted income (loss) per share:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">Three Months Ended<br /> December 31,</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2013</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Basic net income (loss) per share:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="WIDTH: 74%; TEXT-ALIGN: left; PADDING-LEFT: 9pt">Net income (loss) applicable to common shareholders</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">(662</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">)</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">256</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Weighted average common shares outstanding</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,735</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,639</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 9pt"> Basic net income (loss) per share</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.09</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 0.03</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Diluted net income (loss) per share:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Diluted net income (loss) applicable to common shareholders</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">(662</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">256</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-LEFT: 9pt">Weighted average common shares outstanding</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7,735</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">7,639</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"> Plus:&nbsp;&nbsp;Incremental shares from assumed conversions</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left; PADDING-LEFT: 0.25in"> Series A preferred shares</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 767</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 27pt">Diluted weighted average common shares outstanding</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 7,735</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 8,406</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left; PADDING-LEFT: 9pt"> Diluted net income (loss) per share</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (0.09</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 0.03</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> Inventories consisted of the following:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">December 31,<br /> 2013</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">September 30,<br /> 2013</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="WIDTH: 58%; TEXT-ALIGN: left">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 18%; TEXT-ALIGN: right">1,281</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 18%; TEXT-ALIGN: right">1,157</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">235</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">322</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 323</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 259</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,839</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">1,738</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Obsolescence reserve</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (388</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (359</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,451</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,379</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> The following table sets forth the rollforward of the restructuring activity for the three months ended December 31, 2013.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in"> <strong>&nbsp;</strong></p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: right" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance,<br /> September 30,<br /> 2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Total<br /> Charges</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Cash<br /> Payments</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Other</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Balance,<br /> December&nbsp;31,<br /> 2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">One-time termination benefits</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="WIDTH: 35%; TEXT-ALIGN: left">Lease related costs</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">877</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">-</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">-</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">21</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">898</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Equipment moving costs and method transfers</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Travel and relocation costs</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Loss on sale of equipment</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(16</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">8</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(8</td> <td style="TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Other costs</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 117</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 117</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right">Total</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 978</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 29</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,007</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="WIDTH: 75%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">Three Months Ended<br /> December 31,</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2013</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>Revenue:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="WIDTH: 62%; PADDING-LEFT: 9pt">Service</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 16%; TEXT-ALIGN: right">4,916</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 16%; TEXT-ALIGN: right">4,670</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Product</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,304</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,133</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,220</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,803</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Operating income:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-LEFT: 9pt">Service</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">424</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">199</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Product</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 38</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 103</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">462</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">302</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Interest Expense</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(164</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(165</td> <td style="TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 0.125in; TEXT-INDENT: -0.1in"> Change in fair value of warrant liability - (increase) decrease</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(961</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">117</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Other income</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">Income (loss) before income taxes</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (662</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 256</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> A summary of our stock option activity for the three months ended December 31, 2013 is as follows (in thousands except for share prices):</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Options<br /> (shares)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average<br /> Exercise Price</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">Weighted-<br /> Average<br /> Grant Date<br /> Fair Value</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="WIDTH: 61%">Outstanding - October 1, 2013</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">479</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">1.77</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 10%; TEXT-ALIGN: right">1.35</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-LEFT: 9pt">Exercised</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-LEFT: 9pt">Granted</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Terminated</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> (40</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: right">2.29</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: right">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt">Outstanding - December 31, 2013</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 439</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">$</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right">1.72</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">$</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: right">1.32</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> <!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0px">&nbsp;</td> <td style="WIDTH: 0.5in"><strong>5.</strong></td> <td style="TEXT-ALIGN: justify"><strong>SEGMENT INFORMATION</strong></td> </tr> </table> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> &nbsp;</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> We operate in two principal segments - research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Our accounting policies in these segments are the same as those described in the summary of significant accounting policies found in Note 2 to Consolidated Financial Statements in our annual report on Form 10-K for the year ended September 30, 2013.</p> <p style="TEXT-ALIGN: justify; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; TEXT-INDENT: 0.5in"> &nbsp;</p> <table style="WIDTH: 75%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">Three Months Ended<br /> December 31,</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2013</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: center" colspan="2">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>Revenue:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="WIDTH: 62%; PADDING-LEFT: 9pt">Service</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 16%; TEXT-ALIGN: right">4,916</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 16%; TEXT-ALIGN: right">4,670</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Product</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,304</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,133</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,220</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,803</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Operating income:</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-LEFT: 9pt">Service</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">424</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">199</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Product</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 38</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 103</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">462</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">302</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="TEXT-ALIGN: left">Interest Expense</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(164</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(165</td> <td style="TEXT-ALIGN: left">)</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 0.125in; TEXT-INDENT: -0.1in"> Change in fair value of warrant liability - (increase) decrease</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">(961</td> <td style="TEXT-ALIGN: left">)</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">117</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Other income</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">Income (loss) before income taxes</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> (662</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">)</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 256</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <!--EndFragment--></div> </div> 437000 370000 47000 74000 1.396 0.444 40000 439000 479000 1.72 1.77 2.29 8840000 9459000 18000 20000 55000 21000 7735000 8406000 7735000 7639000 iso4217:USD xbrli:pure iso4217:USD xbrli:shares xbrli:shares utr:sqft utr:acre basi:segments basi:employees 0000720154 us-gaap:WarrantMember 2013-10-01 2013-12-31 0000720154 us-gaap:SeriesAPreferredStockMember 2013-10-01 2013-12-31 0000720154 basi:LossOnSaleOfEquipmentMember 2013-10-01 2013-12-31 0000720154 us-gaap:OtherRestructuringMember 2013-10-01 2013-12-31 0000720154 us-gaap:OneTimeTerminationBenefitsMember 2013-10-01 2013-12-31 0000720154 us-gaap:LineOfCreditMember us-gaap:MinimumMember 2013-10-01 2013-12-31 0000720154 us-gaap:LineOfCreditMember 2013-10-01 2013-12-31 0000720154 basi:ClassAWarrantMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2013-10-01 2013-12-31 0000720154 basi:ServicesSegmentMember 2013-10-01 2013-12-31 0000720154 basi:ReplacementNotePayableTwoMember 2013-10-01 2013-12-31 0000720154 basi:ProductsSegmentMember 2013-10-01 2013-12-31 0000720154 basi:EquipmentMovingCostsAndMethodTransfersMember 2013-10-01 2013-12-31 0000720154 us-gaap:EmployeeRelocationMember 2013-10-01 2013-12-31 0000720154 us-gaap:EmployeeStockOptionMember 2013-10-01 2013-12-31 0000720154 us-gaap:ContractTerminationMember 2013-10-01 2013-12-31 0000720154 2013-10-01 2013-12-31 0000720154 basi:ClassAWarrantMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2012-10-01 2013-09-30 0000720154 us-gaap:WarrantMember 2012-10-01 2012-12-31 0000720154 us-gaap:ScenarioForecastMember 2012-10-01 2012-12-31 0000720154 basi:ServicesSegmentMember 2012-10-01 2012-12-31 0000720154 basi:ProductsSegmentMember 2012-10-01 2012-12-31 0000720154 us-gaap:EmployeeStockOptionMember 2012-10-01 2012-12-31 0000720154 2012-10-01 2012-12-31 0000720154 2011-10-01 2012-09-30 0000720154 2014-02-11 0000720154 us-gaap:SeriesAPreferredStockMember 2013-12-31 0000720154 basi:LossOnSaleOfEquipmentMember 2013-12-31 0000720154 us-gaap:OtherRestructuringMember 2013-12-31 0000720154 us-gaap:OneTimeTerminationBenefitsMember 2013-12-31 0000720154 us-gaap:LineOfCreditMember 2013-12-31 0000720154 basi:ReplacementNotePayableTwoMember 2013-12-31 0000720154 basi:EquipmentMovingCostsAndMethodTransfersMember 2013-12-31 0000720154 us-gaap:EmployeeRelocationMember 2013-12-31 0000720154 us-gaap:EmployeeStockOptionMember 2013-12-31 0000720154 us-gaap:ContractTerminationMember 2013-12-31 0000720154 2013-12-31 0000720154 us-gaap:SeriesAPreferredStockMember 2013-09-30 0000720154 basi:LossOnSaleOfEquipmentMember 2013-09-30 0000720154 us-gaap:OtherRestructuringMember 2013-09-30 0000720154 us-gaap:OneTimeTerminationBenefitsMember 2013-09-30 0000720154 us-gaap:LineOfCreditMember 2013-09-30 0000720154 basi:ReplacementNotePayableTwoMember 2013-09-30 0000720154 basi:EquipmentMovingCostsAndMethodTransfersMember 2013-09-30 0000720154 us-gaap:EmployeeRelocationMember 2013-09-30 0000720154 us-gaap:EmployeeStockOptionMember 2013-09-30 0000720154 us-gaap:ContractTerminationMember 2013-09-30 0000720154 2013-09-30 0000720154 2012-12-31 0000720154 2012-09-30 0000720154 basi:ClassBWarrantMember 2012-05-12 EX-101.SCH 9 basi-20131231.xsd XBRL TAXONOMY EXTENSION SCHEMA 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 107 - Disclosure - DEBT link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 001 - Document - Document and Entity Information link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40701 - Disclosure - DEBT (Note Payable) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 101 - Disclosure - DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40702 - Disclosure - DEBT (Revolving Line of Credit) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 109 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41001 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 309 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 104 - Disclosure - INVENTORIES link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40401 - Disclosure - INVENTORIES (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 103 - Disclosure - INCOME (LOSS) PER SHARE link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40301 - Disclosure - INCOME (LOSS) PER SHARE (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40302 - Disclosure - INCOME (LOSS) PER SHARE (Reconciliation of Computation of Basic Income or Loss Per Share to Diluted Income or Loss Per Share) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 303 - Disclosure - INCOME (LOSS) PER SHARE (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 304 - Disclosure - INVENTORIES (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 106 - Disclosure - INCOME TAXES link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40601 - Disclosure - INCOME TAXES (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 110 - Disclosure - MANAGEMENT'S PLAN link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 41101 - Disclosure - MANAGEMENT'S PLAN (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 108 - Disclosure - RESTRUCTURING link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40801 - Disclosure - RESTRUCTURING (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 1011 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 3011 - Disclosure - RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40902 - Disclosure - RESTRUCTURING (Summary of Restructuring Activity) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 308 - Disclosure - RESTRUCTURING (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 102 - Disclosure - STOCK-BASED COMPENSATION link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40203 - Disclosure - STOCK-BASED COMPENSATION (Fair Value Assumptions) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40201 - Disclosure - STOCK-BASED COMPENSATION (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40202 - Disclosure - STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 302 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 105 - Disclosure - SEGMENT INFORMATION link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40501 - Disclosure - SEGMENT INFORMATION (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 305 - Disclosure - SEGMENT INFORMATION (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink EX-101.CAL 10 basi-20131231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 basi-20131231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 basi-20131231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts payable Accounts Payable, Current Trade, net of allowance $87 at December 31, 2013 and September 30, 2013, respectively Accounts Receivable, Net, Current Accounts receivable Accounts Receivable, Net, Current [Abstract] Income tax accruals Accrued Income Taxes, Current Accrued expenses Accrued Liabilities, Current Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Additional Paid in Capital Assets Total assets Assets [Abstract] Assets Assets, Current Total current assets Assets, Current [Abstract] Current assets: Current portion of capital lease obligation Capital Lease Obligations, Current Capital lease obligation, less current portion Capital Lease Obligations, Noncurrent Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Class of Stock [Domain] Commitments and Contingencies Commitments and contingencies Common shares, no par value: Authorized 19,000,000 shares; 7,885,229 issued and outstanding at December 31, 2013 and 7,703,891 at September 30, 2013 Common Stock, Value, Issued Customer advances Customer Advances, Current Derivative Liability, Current Goodwill Goodwill Refundable Income Taxes Income Taxes Receivable, Current Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Inventories Inventory, Net Liabilities Total liabilities Liabilities and Equity Total liabilities and shareholders' equity Liabilities and Equity [Abstract] Liabilities and shareholders' equity Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Line of Credit, Current Revolving line of credit Long-term Debt, Current Maturities Current portion of long-term debt Long-term Debt, Excluding Current Maturities Long-term debt, less current portion Other Assets, Noncurrent Other assets Preferred Stock, Value, Issued Preferred shares, authorized 1,000,000 shares, no par value: 1,185 Series A shares at $1,000 stated value issued and outstanding at December 31, 2013 and 1,335 at September 30, 2013 Prepaid Expense, Current Prepaid expenses Property, Plant and Equipment, Net Property and equipment, net Retained Earnings (Accumulated Deficit) Accumulated deficit Series A Preferred Stock [Member] Class of Stock [Axis] Statement [Line Items] CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] Statement [Table] Stockholders' Equity Attributable to Parent Total shareholders' equity Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Unamortized Debt Issuance Expense Debt issue costs Unbilled Revenue And Other Current Unbilled revenues and other Unbilled Revenue and Other, Current Fair value of warrant liability Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Common stock, no par value Common Stock, No Par Value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common stock, shares outstanding Common Stock, Shares, Outstanding Preferred Stock, No Par Value Preferred stock, no par value Preferred Stock, Par or Stated Value Per Share Preferred stock, stated value per share Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Supplemental disclosure of non-cash financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Deferred income taxes Deferred Income Tax Expense (Benefit) Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Effect of exchange rate changes Effect of Exchange Rate on Cash and Cash Equivalents Fair Value Adjustment of Warrants Change in fair value of warrant liability - increase (decrease) Gain (Loss) on Sale of Property Plant Equipment Loss on sale of property and equipment Accounts payable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Receivable Accounts receivable Accrued expenses Increase (Decrease) in Accrued Liabilities Customer advances Increase (Decrease) in Customer Advances Increase (Decrease) in Income Taxes Receivable Income tax accruals Increase (Decrease) in Inventories Inventories Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash used by financing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used by investing activities Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by operating activities Net Income (Loss) Attributable to Parent Net income (loss) Payments for (Proceeds from) Productive Assets Capital expenditures Payments of Debt Issuance Costs Payments of debt issuance costs Proceeds from Lines of Credit Borrowings on revolving line of credit Proceeds from Sale of Machinery and Equipment Proceeds from sale of equipment Provision for Doubtful Accounts Provision for doubtful accounts Repayments of Lines of Credit Payments on revolving line of credit Repayments of Long-term Capital Lease Obligations Payments on capital lease obligations Repayments of Long-term Debt Payments of long-term debt Share-based Compensation Employee stock compensation expense CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Stock Issued Preferred stock dividends paid in common shares Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total cost of revenue Cost of Goods and Services Sold Cost of product revenue Cost of Goods Sold Cost of service revenue Cost of Services Basic net income (loss) per share Earnings Per Share, Basic Diluted net income (loss) per share Earnings Per Share, Diluted Change in fair value of warrant liability - (increase) decrease General and administrative General and Administrative Expense Gross profit Gross Profit Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) [Abstract] Income taxes Income Tax Expense (Benefit) Interest expense Interest Expense Net income (loss) Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income (Loss) Operating income Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Net of Tax [Abstract] Other Nonoperating Income (Expense) Other income Research and Development Expense Research and development Restructuring Charges Restructuring charges Sales Revenue, Goods, Net Product revenue Revenue, Net Total revenue Sales Revenue, Services, Net Service revenue Selling Expense Selling Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted Average Number of Shares Outstanding, Basic Basic Other comprehensive income (loss): DEBT [Abstract] Debt Disclosure [Text Block] DEBT Amendment Flag Current Fiscal Year End Date Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Year Focus Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Filer Category Entity Registrant Name Trading Symbol DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract] Fair Value Disclosures [Text Block] FAIR VALUE OF FINANCIAL INSTRUMENTS INVENTORIES [Abstract] Inventory Disclosure [Text Block] INVENTORIES Finished goods Inventory, Finished Goods, Gross Gross inventories Inventory, Gross Inventories Raw materials Inventory, Raw Materials, Gross Obsolescence reserve Inventory Valuation Reserves Work in process Inventory, Work in Process, Gross INCOME (LOSS) PER SHARE [Abstract] Earnings Per Share [Text Block] INCOME (LOSS) PER SHARE Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive shares not considered in computing diluted earnings per share Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Warrant [Member] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Reconciliation of Computation of Basic Loss Per Share to Diluted Net Loss Per Share Schedule of Inventory, Current [Table Text Block] Summary of Inventories INCOME TAXES [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] Effective Income Tax Rate, Continuing Operations Effective income tax rate Statutory federal income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate Liability for Uncertain Tax Positions, Current Liability for other uncertain income tax positions Valuation Allowance, Deferred Tax Asset, Change in Amount Increase in valuation allowance for deferred taxes Managements Plan [Abstract] MANAGEMENT'S PLAN [Abstract] Managements Plan [Text Block] MANAGEMENT'S PLAN The entire disclosure for management's plan. RESTRUCTURING [Abstract] Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Summary of Restructuring Activity STOCK-BASED COMPENSATION [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATON Award Type [Axis] Maximum [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Forfeitures The expected forfeiture rate assumption that is used in valuing an option on its own shares. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life of the options (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility , maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Award Type [Domain] Equity Option [Member] Stock Options [Member] Allocated Share-based Compensation Expense Stock-based compensation expense Employee Stock Option [Member] Nonqualified Plan [Member] Non-qualified Plan [Member] Represents options that were granted outside of the defined benefit plans. Plan Name [Axis] Plan Name [Domain] Share Based Compensation Options Outstanding Issued Outside Of Stock Option Plan The number of options outstanding, as of the balance sheet date, that were granted outside of the defined stock option plan. Options outstanding that were granted outside of the plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted-Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value Exercised The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology. Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Grant Date Fair Value Terminated The weighted average grant-date fair value of options forfeited or expired during the reporting period as calculated by applying the disclosed option pricing methodology. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Terminated Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding - October 1, 2013 Outstanding - December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding - October 1, 2013 Outstanding - December 31, 2013 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted-Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value The weighted average grant-date fair value of options outstanding as of the balance sheet date as calculated by applying the disclosed option pricing methodology. Outstanding - October 1, 2013 Outstanding - December 31, 2013 Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Terminated Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of Stock Option Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value Assumptions SEGMENT INFORMATION [Abstract] Segment Reporting Disclosure [Text Block] SEGMENT INFORMATION Number of Reportable Segments Operating income: Product [Member] Revenues Revenue: Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Service [Member] Number of segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Operating Segments RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS [Abstract] Accounting Changes and Error Corrections [Text Block] RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Schedule of Effects of Restatement Adjustments Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] Summary of Assumptions Used to Compute Fair Value of Warrants NEW ACCOUNTING PRONOUNCEMENTS [Abstract] Class A Warrant [Member] Class A Warrant [Member] Class B Warrant [Member] Class B Warrant [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Derivative Financial Instruments, Liabilities [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Assumptions, Expected Dividend Rate Dividend yield Fair Value Assumptions, Expected Term Expected life of the options Fair Value Assumptions, Expected Volatility Rate Volatility of the Company's common stock Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Liability Class [Axis] Fair Value by Liability Class [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair value per unit Basic net income (loss) per share Basic net income (loss) per share: Earnings Per Share, Basic [Abstract] Diluted net income (loss) per share: Earnings Per Share, Diluted [Abstract] Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Series A preferred shares Net Income (Loss) Available to Common Stockholders, Basic Net income (loss) applicable to common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Diluted net income (loss) applicable to common shareholders Weighted Average Number Diluted Shares Outstanding Adjustment Dilutive stock options/shares Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Plus: Incremental shares from assumed conversions Diluted weighted average common shares outstanding Weighted average common shares outstanding Area of Real Estate Property Area of headquarters facility Assets For Sale Asking Price Assets For Sale Asking Price Asking price Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Debt instrument, basis spread on variable rate Debt instrument, variable interest reference rate Debt Instrument, Description of Variable Rate Basis Debt instrument, face amount Debt Instrument, Face Amount Debt instrument, frequency of periodic payments Debt Instrument, Frequency of Periodic Payment Debt instrument, minimum interest rate Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum Debt instrument, interest rate Debt Instrument, Interest Rate, Stated Percentage Debt Instrument [Line Items] Debt instrument, maturity date Debt Instrument, Maturity Date Debt Instrument, Name [Domain] Debt instrument, principal payment Debt Instrument, Periodic Payment, Principal Debt Instrument, Principal Payment Made Debt instrument, one-time principal payment The amount of cash paid at one time towards the outstanding balance of principal on a long-term debt instrument. Schedule of Long-term Debt Instruments [Table] Fixed Charge Coverage Ratio Fixed charge coverage ratio A ratio that indicates a firm's ability to satisfy fixed financing expenses, such as interest and leases. Long-term Debt Long-term debt Minimum [Member] Note Payable Six [Member] Note Payable Six Member Mortgage Notes Payable, Maturing May 4, 2013 [Member] Original Covenant Terms [Member] Original Covenant Terms [Member] Range [Axis] Range [Domain] Replacement Note Payable Two [Member] Second Replacement Note Payable [Member] The second replacement note payable, initiated after the sixth amended agreement with the lender. Sale Leaseback Transaction, Net Book Value Net book value of facility and land Scenario, Unspecified [Domain] Scenario [Axis] Total Liabilities To Tangible Net Worth Ratio Total liabilities to tangible net worth ratio Ratio that indicates the amount of net worth that has been invested in tangible fixed assets. Credit Facility [Axis] Credit Facility [Domain] Debt instrument, effective interest rate Debt Instrument, Interest Rate, Effective Percentage Line of Credit Facility, Amount Outstanding Line of credit, amount outstanding Line Of Credit Facility, Borrowing Limit, Ratio To Accounts Receivable Line of credit, borrowings, based on eligible accounts receivable, percentage Element represents the ratio of allowed advances to eligible accounts receivable. Line of Credit Facility, Collateral Line of credit, collateral Line Of Credit Facility, Collateral Monitoring Fee, Percentage Line of credit, collateral monitoring fee, percentage Fees associated with providing collateral for the credit facility, stated as a percentage of available credit. Line of Credit Facility, Commitment Fee Percentage Line of credit, facilities fee, percentage Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Expiration Date Expiration date of credit agreement Line of Credit Facility, Frequency of Commitment Fee Payment Line of credit, frequency of facilities fee payments Line of Credit Facility, Frequency of Payments Line of credit, frequency of periodic payments Line of Credit Facility, Interest Rate at Period End Interest rate at end of period Line of Credit Facility, Maximum Borrowing Capacity Line of credit, maximum borrowing capacity Line of Credit Facility, Periodic Payment, Interest Line of credit, periodic interest payments Line of Credit [Member] Revolving Line of Credit [Member] Minimum Net Worth Required for Compliance Minimum net worth covenant requirement Line of credit, current borrowing capacity Travel and Relocation Costs [Member] Employee Relocation [Member] Equipment Moving Costs And Method Transfers [Member] Equipment Moving Costs And Method Transfers [Member] Equipment Moving Costs And Method Transfers [Member] Loss on Sale of Equipment [Member] One-time Termination Benefits [Member] Other Restructuring [Member] Other Costs [Member] Payments for Restructuring Cash Payments Restructuring and Related Cost, Incurred Cost Total Charges Balance Balance Restructuring Reserve, Accrual Adjustment Other Loss on Sale of Equipment [Member] Loss on Sale of Equipment [Member] Capital Expenditures Growth Decline Ratio Capital expenditures growth (decline), percent The overall growth (decline) in capital expenditures during the reporting period. Gross Margin Growth Decline Ratio Gross margin growth (decline), percent The percent change in gross margin during the reporting period. Long-term Debt and Capital Lease Obligations, Current Debt and lease obligations, current Cash generated from operations Operating income growth (decline), percent The overall growth (decline) in operating income during the reporting period. Operating Income Growth Decline Ratio Operating Income Loss Excluding Restructuring Costs Proceeds from (Repayments of) Lines of Credit Net paydown on line of credit Revenue Growth Decline Ratio Revenue growth (decline), percent The percentage change in revenues during the reporting period. Operating income (loss), excluding restructuring costs Operating Income (Loss), Excluding Restructuring Costs. Lease Related Costs [Member] Corporate Expenses [Member] Corporate [Member] Operating Leases, Rent Expense, Sublease Rentals Rent income Products Segment [Member] Products Segment [Member] Restructuring and Related Cost, Number of Positions Eliminated Number of employees terminated Restructuring Type [Axis] Restructuring Cost and Reserve [Line Items] Restructuring Reserve Restructuring reserve Scenario, Forecast [Member] Schedule of Restructuring and Related Costs [Table] Segment [Domain] Services Segment [Member] Services Segment [Member] Business Segments [Axis] Type of Restructuring [Domain] EX-101.PRE 13 basi-20131231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0`:,QE5V@$``#$6```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%UKPC`4AN\'^P\EM\/& MI)MSP^K%/BXW8>X'9,W1%MLD)-'IOU]:/QC2.63"SHU%FYSW,90'^@Y&JZJ, MEF!=H55*6-PE$:A,RT+-4O(^>>[T2>2\4%*46D%*UN#(:'AY,9BL#;@H[%8N M);GWYIY2E^50"1=K`RK[?9HII4'Y3N^GD&&@T>8 MBD7IHZ=5^'E#8J%T)'K8+*RS4B*,*8M,^$!*ETH>I'2V"7'8V:QQ>6'<5<`@ MM#6AOO-SP';?:S@:6TB(QL+Z%U$%#+HJZ:>V\P^MY_'Q(2V4>CHM,I`Z6U3A M!&)G+`CI<@!?E7%SC2M1J!WWD?QFL:/-A9T9I/Y_S>`3.3@2C@0)QS42CALD M'#TD'+=(./I(..Z0<+`N%A`L1F58E,JP.)5AD2K#8E6&1:L,BU<9%K$R+&;E M6,S*L9B58S$KQV)6CL6L'(M9.1:S*TG?'A$%@?0'[%K.M#=PGAGKT],"#.A+J`E:";,FF3>$[ M_`(``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\ M(V(T'4\4"_'L)MI< M3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?```` M__\#`%!+`P04``8`"````"$`_GO?E-(!```<%0``&@`(`7AL+U]R96QS+W=O M_%[)K?BL"EJL2UI0]@)88@((EL]X>W MKX40%*F=7J*]1+*C.*/)>KYX9XNOPS[[<#YLFSI7U.NKS-5%4V[K3:[>5L\/ M$Y6%:.O2[IO:Y>KH@EK,[^]F+VYO8WHH5-LV9&F5.N2JBK%]U#H4E3O8T&M: M5Z<[Z\8?;$Q#O]&M+79VXS3W^R/M?ZZAYC=K9LLR5WY9DE'9ZMBF5_^_>+-> M;POWU!3O!U?'7]ZA/QN_"Y5S,2UJ_<;%7%VF@C[=(=-+FI7^0T[R0U;.!,GA MD;`<'D$Y)"V'D!PS$)9C!DC.6%C-&(DA%E9##.5(FT/0'1X*N\-#Y(Z1#D$# M0U"Z='#E2$<@X0A,!!4%!/=1Y?!46LX4R9'F`\2#=.'`NB%Q:Z`W+(U.AN@T MTI%C8.:83FD5*NM=^1I]^ND.:;N>?TQOIM&FDF851!5)JR$HAZ7)R9B"'XJD MK2'H#4O#DB$LN5-87MHUUYRY3)T[.`R/=D8ZA/EWA MUI:F$H92TB_9\+L`6]_T-.??````__\#`%!+`P04``8`"````"$`CZZ:?7P# M``"S"@``#P```'AL+W=OFWX'A?8N`IDTF MIH.*"5,]',"T[VZN!,\9OWP4K63C225_I@OOC77S\T#7>+;)8Y$]C?5U-/_T5==*R;*8)7G&Q_J)E_JWNX\?;H]Y\?M7 MGO_60"`KQ_I.ROV-892;'4]9^3G?\PS>;/,B91+"XLDH]P5G<;GC7*:)80T& M5T;*1*:?%6Z*]VCDVZW8\%F^.:0\DV>1@B=,@OUR)_:E?G>[%0E_/%>DL?V> ML!1\OR2ZEK!2NK&0/![K(PCS(V\]*`[[R4$D\/;:'MBZ<=<4N2JTF&_9(9$1 ME'=1AWY90\NZJGY9M>)1\&/YFE2%VLL/D<7YL?HIM/;41#88.-:O?HA8[N#] M8#!HGCUP\;23EX<@;R#]NH.P3OVI975YEXY0F!1U,RGDB7K9N?LBAQ%67?>@ M,E/7BAL!7PHO-BOC6&7JDYE+0G=&X5OH+[R9$T$P<18.F;I(I7+?R%C_)P,. M&C?V%=*I._X..V$$KI;8SA"I#-_IYJ\*=H.+&G5E9FXX#;Q5Y/F$^G,:/;AT ML@X]XH8A=0BNZ0MR4[.!:PHC?_I]XIQ[O%Q!MYU*$N?#CFMZ^Z5KPR-3?^G2 MA0_+KMR`A@].@%MA7Z/LKVKVHTLB/_#<$*TX!#*;%:^[.:%[OX0DZI&Y'RR[ M;HT4+K6@J',[<283]V?C7"FZ!&T;!>AJM`X_\@#XZB[5;S7/N$6#< M8(%&[%<"Q^SK-AEBI$R%J5XF>E0P6&8/60T;/;D8*U/AJH<156.$,3,5SEIC M[,G&H,%9VCFZ_CW-UB['[%D*>V\-A;"B8!(-Q6KI*%2^I1,>TI056`?3;2F8 M]@_W[$8\8QV,NZ5@VJ\3\$V>;03\.39GLH5QAZ#3:(^\8C+CDHD$DSIJ%:.0 MVL=)CTBKDAY0ZR.P/E.HFFUAS"'H^*_.%DIRR>F*G:J-UB>!:;<44FN)@#_G MR3-$1V(KR+9USH"=*DB3TMMO&,(0`K1BT/%YL-2S9PXZH^ MJBM+W3?CVJ9S.#[SX6/B];>/\F2] M\[HI1+6QV=RU+5[E8E=4AXW]]U_/L\BVFC:K=ME)5'QC?_+&_K;]^:?U1=2O MS9'SU@*&JMG8Q[8]KQRGR8^\S)JY./,*(GM1EUD+'^N#TYQKGNVZA\J3X[EN MZ)194=G(L*H?X1#[?9'S)Y&_E;QJD:3FIZP%_W\RP7 MY1DH7HI3T7YVI+95YJL?ATK4VB$?MV#G0."AWG M'#NQ`TS;]:Z`#&39K9KO-_9WMDI]UW:VZZY`_Q3\T@S^MIJCN/Q2%[O?BHI# MM:%/L@,O0KQ*Z(^=_!<\[(R>?NXZ\$=M[?@^>SNU?XK+K[PX'%MH=P`9R<16 MN\\GWN104:"9>X%DRL4)!,!/JRSD:$!%LH_N]Z78M<>-[8?S8.GZ#.#6"V_: MYT)2VE;^UK2B_!=!3%$AB:=(?%"OXM[PC1"*4S-89? M:I0/P2@,2A*Y/7U7V`0ABP$DH(CT'H)(!)*AQ/^?W6OY)'AC0_Y]MR*C70E" MHJ[;BYB%ABX2#I?I4G3A=!@.(E<_343!SGF\4A)LB#)*D2`$1?F^IU=%430< MZ3H34?*`&[C'_9F28$.4,%#4-HT&H!XY(BJ=(DF!#DJ;%YB$$ MZ[1PEX;B=!CVXX7V&"**@1<\7J@.;<@:V:EDW-BHRV,+4Y?BP#B+`AVGP@S_ MO]]!AA9-'$MGC/52&-C^O77HM;&/=R%4GG3@AP>,H5\3U])^K>0A!D=LX1ME M314%AOU;KL6DZ3XN"RUZ*"LV/"#I&#I%C#X(=)P*F^3T M;&SUL296XX48-5ZAH3M5%&J\7!VFLB9Y/1N;?6R:O<+@NC,6&O'4C-^:,,/O MY=OBUZ]B;&S\L5Y`U6WH[;,X-"8Q51QJ?S"];6GA)ID_&[M_;+J_PJAU^]<% M-?Y(@,$;O?0F.7^'ILX?ZURQ5`JC>AF.9HS$O4!G1$KE33+^#FWHTIM=Z<+# M`2Q!&[\Y9XKG!H8*E$;]L)MY:.O$S4SK5YC;A4,.U:&KN$(1?1&9AI%=6LH9Q;V!]5-BDH\`;'P6CTS%1H+A[FYVY<]<8 MR)0`(*X/$RIMTG'@C8\#9GX/2A3HCC1D0<`=:<:!E-I%EJZ20>"-SX0F&M,>:)`^.JQ7/IZ935N2*+BH:^;3I3)8W.X3>]7 MKD.;V],\&!3HIC(2CQ:#S%`97G_A[5#)ZP-/^>G46+EXDU=;#,:X_R]>NR5P M[=;=43E]`&Z]SMF!_Y[5AZ)JK!/?PZ/N?`E[L,9[,_S0BG-W._,B6KCOZOX\ MPOTFA\LD=P[@O1#M]8.\#^IO3+?_`0``__\#`%!+`P04``8`"````"$`*N@[ M]1P$``#5#P``&0```'AL+W=O&9V>&&7;YY;VNG#?:\9(U*Y=X@>O0)F=%V>Q6[L\?SP]SU^$B:XJL8@U= MN1^4NU_6O_ZR/+#NA>\I%0YX:/C*W0O1+GR?YWM:9]QC+6U@9U\ MWG8T*Y117?EA$,1^G96-JSTLNC$^V'9;YO2)Y:\U;81VTM$J$\#/]V7+C][J M?(R[.NM>7MN'G-4MN-B452D^E%/7J?/%]UW#NFQ3P;[?R23+C[[5Q9G[NLP[ MQME6>.#.UZ#G>W[T'WWPM%X6)>Q`AMWIZ';E?B6+-`QU^Y(=RX+,1^Y4:Q M-YT%$0&YLZ%ODKURP^E\M(L:5=A(9)_#?."&A%\ZG9!K?]^)K(K7! MITQDZV7'#@Y4#=R3MYFL0;(`SW)GDZL[@RU)FZ_22)F"FD,ZWM91&"[]-PAA M;C3)N8;8BO2HD)$'FA,21`DC19"RR\$^(DDC&RFDMAL8&3(9M,Z?WX22-5H#UC&"%& MK9GKA`=!8"^G>AD^3R[Z+5B`4%]#P-O!DV(,-K'OG&C-5(%-2#S#9'I]!%EL MDXT+G31"A"1&A%HS)(C"/CJJ!-)S3:^PXC?[#*4TPI1]<>LBU)IIK`(9>+A( M4[T^W,450CGX!EWE=H:E&)&%.'Y:8\CFT&6A_/J_R;<'U'Y2;3`"]=%&'9=R M:821<;O1FB%!%**`I^>:*P$ET`#'1U2I,=\C*DDCZK.-0V@$PQUZW M'*('`#3=4\.((O3H)D9D*,-O#Z@II48PAE*V]T%5RE23&'K#[?(D>BK8F&B6 M)48TI(BBLX!J3T/1M8#*9H]01XQE/2)L4A2OA&C1*>VS'D&W(2,80PD:3#DB M[=(*%6>$.SK1(MV)YO"DV\6;FO4QD++YHU".@-0CPPXEBE0B7P%A)QJ2S"=H M/37K8R#1X+E3D1Q(SH)M_HZ4(^-5Z4%7Y$4`83(QIR1@0] M[>D%41]L*]-P?OK$-$:D7QP'E::3;5:'^\"(^F"FSRUMMJ-_9MVN M;+A3T2WT\,";P8/8Z6.9OA"L58>!#1-PG%)?]W!\IG!X"3P0;QD3QPMY_#@= MR-?_`0``__\#`%!+`P04``8`"````"$`M,TY\JS.>%_5QX__Z^?AYX7M"TCJG):_9QG]CPO^R_>/3^LS;)W%B3'K@ M4(N-?Y*R686AR$ZLHB+@#:MAY,#;BDIX;(^A:%I&ZY8+=&D9265P"].12,N;E7F8E?1]NFY^9SQJ@&+?5$6\DV; M^EZ5K;X=:][2?0GK?B53FEV\]<.-?55D+1?\(`.P"Q'T=LW+-_Y6L4K+PP^U:!^AWP=/2OHM M5W^"R>'-[$>=@7]:+V<'^ES*'_S\%RN.)PGI3F!%:F&K_.V!B0PB"C9!G"BG MC)<``)]>5:C2@(C05_U]+G)YVOB369#,HPD!N;=G0CX6RM+WLF?4OBDAG MA29Q9P+?G0E)@FF)&09/8^2XCKTF%ZH))NURT_>U![ M0"X:JBJ9K,!Y/"X0$*7]JL1Z"BQ90#)?MI-HN@Y?(`%9I]G=:HBI2"\*E3>@ MN*)`>(8H*E432/A])#7)1(KGYO_;C4A,13JB6%PE!B.$:,AXGTV)80V^-PA7 M^+#P`=O,8D/-0B=Z26)K.,5A^+Q:].@& M&.P4=S`EML'LC*)FIL%(M(@B$SS%<0>RF4GF5G)JDDW8EPNF%37C!%J1WE,8 MT9N;C/=+3HG?*SG4W&.[IS#8U#'IW#V4V([;TLS<#C68V22.^H+"H)G#2=][ M#*KE1ZB4V*(B5CWM4)/H>IN2Y71B4JPOYN$ M?>W@CNU$4TRRU7'2Z^B[S8ZH?NV.AMW=1.L7W:&A"!LQW!IN,NQ\1!!(P!#. M,<-JEEV'%L1.6V]\,\,W842GH:A?K)EAZ]!P)!TY/8C=F]7]#Y;3[QBK%-). MX$+YOPX0,G*"$+L3=J*>T@IXV@E<*#]TA!#L_D9)QG9'[$2X6PCX>J@WL!Q/<*O#`W],C^INVQJ(57L@-< M>J)@#J74XEL%/DC>Z-OHGDMX&]`_3_#VQ^#V'`4@/G`N+P_J_GM]G]S^!P`` M__\#`%!+`P04``8`"````"$`+F9+-9T"```$!P``&0```'AL+W=O/^<]@.?7SZ)!3TQI+ML"QT&$$6NI+'F[ M*?"OGW=7$XRT(6U)&MFR`K\PC:\7GS_-=U(]ZIHQ@\"AU06NC>EF8:AIS031 M@>Q8"R.55((8>%2;4'>*D=)-$DV81%$>"L);[!UFZCT>LJHX9;>2;@5KC3=1 MK"$&^'7-.WUP$_0]=H*HQVUW1:7HP&+-&VY>G"E&@L[N-ZU49-U`W<_QB-"# MMWLXLQ><*JEE90*P"SWH>Z5KNOBA>?N,M@["A3;8!:RD?K?2^M'_!Y/!L]IUKP'>%2E:1;6-^R-U7 MQC>U@6YG4)"M:U:^W#)-(5"P"9+,.E'9``#\(L'MRH!`R+.[[GAIZ@*G>9"- MHS0&.5HS;>ZXM<2(;K61XH\7Q7LK;Y+L3>"Z-XFS8)1DX\E'7-*]"UP/+DF0 M3+(XR__/$OJZ7$RWQ)#%7,D=@J4'Y+HC=B'',W!^.Q<(Q&IOK-A-@9(U]/)I MD4;1/'R"!M"]9GFNB8>*U4%A^P84/0K$DE`T:(Z)CQ,IL50PT8]7'%TU=?%^G2:T9'FJQ_LU.L+BD&;&!RS/:^ M_.RD`D,`/6,:G31LZ343U_`X/\'[Q^"`#+;*,=GEU*SXE"@9OG3I-5GND*(@ M'0W'5WX&ULE%=;;ZLX$'Y?:?\#XKT!0T)"E.3HA*J[1]HC MK59[>2;@)*B`(TR:]M_O#,/-)J7D)2W,Y\_?7)BQ-]_>L]1XXX5,1+XUV)5GCDO#6#(Y=8\ ME^5E;5DR.O,LE#-QX3E8CJ+(PA(>BY,E+P4/XVI1EEJ.;7M6%B:Y20SK8@J' M.!Z3B#^+Z)KQO"22@J=A"?KE.;G(ABV+IM!E8?%ZO3Q%(KL`Q2%)D_*C(C6- M+%K_..6B"`\I^/W.YF'4<%,K M6&P-5K]4&?BS,&)^#*]I^9>X_%^S6*2HCWXC"1=IDI;J?OL[$!41$**O>>FW$$4CQ*ZO<5P;@E$;5@K&;]^\Z&+C M^(MVHPH3$&99%6H_.G-U9\S@U]'!18#K).,',J-55WT-BZ]9UN197WB"H$JZK8JJL%2B-A5I4JSW%L M35C?O%C9;FM65$&U38\5@C55OM/RDBK"4*SFGF8-^E;7[JR*)AQDO2XQ7MT( M5C4->@%!2-(3\[16$6CF3]+GJZ*F%3XNTL1U]!0O@M3B?$_O4GTS8UUA*@%C MT)^F1ZQ":ZKTK['&D"Q=DV+\)(=,:_7C2:S0FJ3.5PI4C:DCY0U*2[$[B\XC M-5389"<7%Z.6K':'E5;Q-6BL=8U"5'W8>'OZIM49HW8]WF%KT*A.XKD/475B M-^[I_"*_B%;S.^QGC$!>U=#F/NLR6!5`H-J]9=?P5&4/M7\\6.G*!CVM!E'I MS1V]@2AFYG=]6M7UT`!@PPG@])CK3X)`]]-5!VT,HNK31L'$RJ.._D7E-6W_ MWI"L=8Y!5)T/C0 MU3H/WD*P>,G*!B.>;AAT`,]X<>(!3U-I1.**MP<'OK/V+=UL]GBSP2.?]CYP MUG`@Q(-R:X`+QR4\\9]A<4IR::3\")3V;`F?4T%7%GHHQ:4Z%Q]$"5>-ZM\S M7"TYG$/M&8"/0I3-`V[07E9W_P,``/__`P!02P,$%``&``@````A`"K"I8@. M`P``M`@``!D```!X;"]W;W)K&ULE)9=;YLP%(;O M)^T_6+XOQ!`"1$FJAJI;I4V:IGU<.V""5<#(=IKVW^\8IP33K4MOVL!Y_?HY MYS@^65T_-35Z9%)QT:XQ\688L387!6_W:_SSQ]U5@I'2M"UH+5JVQL],X>O- MQP^KHY`/JF),(W!HU1I76G=+WU=YQ1JJ/-&Q%B*ED`W5\"CWONHDHT6_J*G] M8#9;^`WE+;8.2WF)ARA+GK-;D1\:UFIK(EE--?"KBG?JQ:W)+[%KJ'PX=%>Y M:#JPV/&:Z^?>%*,F7][O6R'IKH:\G\B_<,K^X;G4BA1:@_L?`OZ.N?4 M3WUPVJP*#AF8LB/)RC6^(C/2^,*]@L?]J]5W?@&\2%:RDAUI_%\?/C.\K#=V.("&3U[)XOF4JAX*" MC1=$QBD7-0#`7]1P_ M9P2I&.V-$?=+`%9!%QXW04I6_B.4+C]IME838W36N(KL+XIDD/C`-VFOE( M$[ELV5L*APU,+FND&3F[KRUFJ3O*PF226,S)TRB]K":;7&T3`XKW68%N]A,F*7B21G7WM^K,8RA4'H$F?C:!"E M0]1A@B_(Y74R8I[;JUF8;N7A.=M>^3,"5M+Y8;_5:OT/51&[%*%\Z$%MGU63$<&ULG%;;;N(P$'U?:?\A\GMS`Q)`A*JAZFZE76FU MVLNS20Q83>+(-J7]^QW;7&+30+LO0/"9DS-G)I.9W;[4E?=,N*"LR5#DA\@C M3<%*VJPS]/O7P\T8>4+BIL05:TB&7HE`M_//GV8[QI_$AA#I`4,C,K21LIT& M@2@VI,;"9RUIX&3%>(TE7/)U(%I.<*F#ZBJ(PS`):DP;9!BF_#T<;+6B!;EG MQ;8FC30DG%18@GZQH:TXL-7%>^AJS)^V[4W!ZA8HEK2B\E63(J\NIH_KAG&\ MK"#OEVB(BP.WOCBCKVG!F6`KZ0-=8(2>YSP))@$PS6V+#=E\X+;_1AH#;4"=5@25C3PKZ6*J_(#@XBW[0%?C! MO9*L\+:2/]GN*Z'KC81RCR`CE=BT?+TGH@!'@<:/1XJI8!4(@$^OIJHUP!'\ MHK]WM)2;#`T2?Y2&@PC@WI((^4`5)?**K9"L_FM`T9[*D,1[D@&HWY_'?CP> M1:/D.DM@%.D$[['$\QEG.P^Z!NXI6JQZ,)H"\R$SH^.8:U^JD*,BN5,LF@NR M$%"?YWD\GLR"9_"TV&-R@TF1=\1$-F)Q0*A2@+RC1LCDK+T@C>=35>UJ;`T`-=*Y+$OG5N,,,.9F0C%I<0EC8@ MZ6I3-;[NGPK*$!AP*E>2V@IR@QGK@M\DB>M>]S@>G1*TQ,$#\'%Q*L@5=RJ, M[LG<8!(M+DT'KGO6<3(X15OJ$EO=Y;(JL*,J'#B6&F^6O6B>P[' MIW!+%CQ%7=,NRU)@I]M2Y]'+#08*=JRVZ]4A8XUN:;,4/]EX`"M/B]?D.^9KV@BO(BL(#?T41BTW M2Y.YD*S5;^8ED[#LZ)\;6&X);!*A#^`58_)PH7:!X[H\_P<``/__`P!02P,$ M%``&``@````A`"1Y6`WJ`@``;P@``!D```!X;"]W;W)K&ULC)9=;]HP%(;O)^T_6+YOOH`0$*$J5-TF;=(T[>/:.`ZQFL21;4K[ M[W<T$/%:NU-9&L)!KX5<$; MU;E5]"-V%9&/A^:&BJH!BQTON7YI33&JZ/+;OA:2[$J(^SF<$MIYMX,+^XI3 M*93(M0=VO@6]C'GA+WQP6J\R#A&8M"/)\A3?AV`#\EREA.#J7^)8Y?&=\7&JH] M@X!,7,OLY9XI"@D%&R^:&22Y_3[R3!;!Y,0I"C M'5/Z@1M+C.A!:5']LZ+P9&5-HI/)!.A/SR,O2F;A++[NXENB-L![HLEZ)<41 MP:&!/55#S!$,E^#<168Y^EC?"Q5B-"9WQB7%5H#V,I_@IS2DV9S MJ0E=Q;93F%(`7L\(D9\SOIWU#L6(#8JI@F';V`GP?F4;['NIF"]ZB4,"&?HX MB1&G&,Q?-T[BWM?"63TW3/:9, M5C/&.*9P&(%GR#B!MW&\HF;1,(_)@-%JXO;HA6$4SX+`56P=Q63N*!S&V&4< M9S-BERV>NAMOK&0L?6,*!PU>L&'ZKI?8++I68JL98QQ3.(SFRALTE.LE-HO< M-$;)L,168TL&ULE)== MKZ(Z%(;O3S+_@7`_?"MHU,DH'TXRDTQ.SLQ<(U0E&RBA=;OWOS^K5-!6A[IO M5,JSWK+>M5KJXLM;56JOJ"4%KI>Z;5BZANH,YT5]6.J__HL_![I&:%KG:8EK MM-3?$=&_K#[]LSCC]H4<$:(:*-1DJ1\I;>:F2;(CJE)BX`;5<&>/VRJE<-D> M3-*T*,V[H*HT'GQR+AO1J M5?:,7)6V+Z?F!3JPK6&6!(^M9]GXN<'I>Z.S4FON7: M@&L[1&A<,$E=RTZ$XNH/A^R+%!=Q+B+P?1&QIX;G3/S@(RKN107F[5497E3@^Z+B^(;M61_1\"\:L$9ZC>!94TQN<%>O,*7I:M'BLP9K`"PD M3M9"_,5.B*[,.M'C"TR&\[X M7=68<"@/1+T*:Q%&Q/V`-DPMB28]T8=L;P9,R'I('?KBXZFS(#%UQQ>S6M\C MKN>(S.:>D8A0242<@*X8K'`"<9KX7L2?B4ARCTA/LGU`7.<1'(6U!,Q MF#G9UVG=#USS<3U7?-K-(\83F?`1,Q&9B#/7SHL?!4W%H.01(Q5_.\X(;GFB M6\\M/18$2_2FZ*YWK4:W1M:<@<^A,:3T-THB5!*1DHB51*(DMF.$X";LS\_W M'H.7.C3VX)#K20MCS1F8?V!D%WN";8`^O,C$=@GY[6FW/]IP_K"D+3+JX_\Z M0ZPD$B6Q'2,$!^'=]+R##)80P;*!TJMLS9FQ%E02H9*(E$3,B:`K)#2RV.>),GX[1@@.LN/_ MS6ED_`7"8-E!Z=VUYLR8@THBY`3/WK8L:<>/;F_/?&DOCI7RR6U\,)/BX9#. MDN23!_YU;FX;/X#S`UV%V@/:H+(D6H9/['#M0,&&47[NW]AS.&3!*U<:CYPY MO!-AW!QNP'F\20_H1]H>BIIH)=J#I&7XL)^T_$3/+RANN@/1#E,XB7<_C_#' M"\%IS3(`WF-,^PLVP?!7;O4_````__\#`%!+`P04``8`"````"$`P6F$4DD% M``"W&P``&0```'AL+W=OEP+E>,Y\ M'CMX^>VS/`0?O&X*4:U"-AJ'`:]RL2FJW2K\^Z^7A\M6BDYH>L!?^;?7%LSM;* MW,5'7)1',/%:'(KV2QD-@S)?_-A5HLY>#Q#W)TNS_&Q;?>B8+XN\ M%HW8MB,P%Z&CW9CGT3P"2^OEIH`(9-J#FF]7X7>V>)J,PVB]5`GZI^"GYNI] MT.S%Z9>ZV/Q65!RR#762%7@5XDU"?VSDOV!QU%G]HBKP1QUL^#9[/[1_BM.O MO-CM6RCW!"*2@2TV7\^\R2&C8&843Z2E7!S``?@;E(5L#3\6FW:_" M9#J:S,8)`WCPRIOVI9`FPR!_;UI1_HL@IDVAD5@;@5=MA$U&:3R9/3I8B=`C M%>!SUF;K92U.`70-<#;'3/8@6X!E&5D"^>F/#$*2:[[+16HIH!LHQ\`*N_!W*1[4$\NYA73C[U0"X(RX'D_S@@%T&JPL"D M('V\V$8287A.4!0*Y3<#OY$KP*(3K#/$DO=I$9,8^J-/.9\P#QJ["QX!F3ZTY(?YB5["FU7OR?_*'RH MMH\SDR";F`C?G:;O4SP3$BH>ZY&\@::/B>;=9E=H&C8=.0VR"C_$[B5V<5?L MNB.G07J+&SK&>8F"B<6ZNK5=0!PZ`=Z%&Z_GF+ MH3370N?HA%QU;Y]3IE>A5?L!)[ST3CYZW"\!@BQR4R9KZ&(OO5-HFG\Z=!KD MQ$X$[\[0H8;=WN?B'J$;BMU+Z6(4L6OVGJ$[*]V5S`ZQ>\E=W"=WQK+N?'>Y MDX^+UZU_._,*3>MN3LW(KD%6W?M;/B%JYS9W:M6]N=,@%R>\I"]QD3X-LLA- MC:RY2XC^W[!$%.L7LI7M)5O.[< M:9`3NY?B)3TGO,YSG08YL7LI7M*C>%/Z**M!%OO`W!'!;<'7J$INXD+ M!5>#G-B]Q"[MBEUWY#1(G_/Z:YUZJ9Q"TZ!-.G70*(6ZUN;L9Y<:4T"#//V,!37.HE<`I- M4M_9V#3(BMJTA5UXHG!WI@Q%R]Y6.U/6HVQ#[%[2EG:EK6?*$.02.]RE>#2] M0M/,F[BPZ34(?Y+NEARO7O!FXICM^.]9O2NJ)CCP+6P5X]$,>KK&BQ?\T(JC M^OW_5;1P8:+>[N&"C,/UQ'@$X*T0[?F#O-JY7+FM_P,``/__`P!02P,$%``& M``@````A`.&ULE)??CZ,V$,??*_5_0+PO8'XF49+3$:`]Z2I55>_Z3,!)T`)&F&QV__N. M;4*PDX-L'I)@?SS,?&=LAO67]ZK4WG!+"U)O=&18NH;KC.1%?=SH/_Y-7A:Z M1KNTSM.2U'BC?V"J?]G^_MOZ0MI7>L*XT\!"33?ZJ>N:E6G2[(2KE!JDP37, M'$A;I1U3-BU.<[ZH*DW;LGRS2HM:%Q96[3,VR.%09#@BV;G"=2>,M+A, M._"?GHJ&7JU5V3/FJK1]/3R.6/MLB_%S4&M2%/+`-[0EX9^BUG0[#8O%N=\`S\W6HY/J3G MLON'7/[$Q?'40;H]B(@%MLH_(DPS4!3,&+;'+&6D!`?@6ZL*5AJ@2/K.?R]% MWITVNN,;7F`Y"'!MCVF7%,RDKF5GVI'J/P&AWI0P8O=&'/"^G[<->^$AS_^$ M%;>W`K^]%=LU`F0MG>!Y5X#D\?B#D>?C,84V7.HH[=+MNB47#>H7HJ=-RG8# M6H%AIK$#F7JL,8C+UGQEB_A2H"D4QMO6\>VU^0;)S'HF%$R@:P.C$+L'Q$(V M$@G$"_@]7&2Y2`;B>T^4NR0/B-M=3%!AD`)2_7DIV")9BN!FGJL5"B3@9<7D MVZD#T;T1QW>42!\QKLPDTXP4+-3S.-CI?#.8!#XGN+_-"/Y#SMI[#^K6_>79\.U;MDBJ.]133J^+_L0"@:^A[I5O-S-$M$L M$<\2R10A*0%1CY68SB2#-SK4R1"=[5F*`H*!^P^,JL`L$L=Q/W>RLT5J_$HB0L%,Q3]+1+-$+(AK_$9@+^QQA2@EF:@X0MZX/FXY ME#1BK>+HZ3>]=Q@L:^/X@;)W!#.ES2P1S1+Q/>'XRE,G><0L!V\E%9:?48'! ML@JVIR0C%,R4"K-$-$O$@ECR`P09SM(;U\121-*X="W$].R,[:=9:]QX@( M7;3CHD>L<'O$.UR65,O(F;7:-C@^C(K7@!"MH!^`UD`9WZ'5CH^;PP1TYTUZ MQ'^E[;&HJ5;B`YBT#-8#MZ*_%Q<=:7A/M2<=].7\[PG>PS"T'I8!\(&0[GK! MWB"&-[OM_P```/__`P!02P,$%``&``@````A`$7,6_TN!@``_1H``!@```!X M;"]W;W)K*)` ME-U(N])JM9=G!N,QBC$6,)GD[[>::KNI8DQ@7Y(Q=2A.GZH^Q>7A_;?JY'PM MFK:LSSM7K-:N4YSS>E^>GW?NWW]]>A>Y3MMEYWUVJL_%SOU>M.[[QY]_>GBM MFR_ML2@Z!S*ZJ;(.?C;/7GMIBFS?GU2= M/+E>AUZ5E6<7,VR;.3GJPZ',BX]U_E(5YPZ3-,4IZX!_>RPO[35;E<])5V7- MEY?+N[RN+I#BJ3R5W?<^J>M4^?;S\[ENLJ<3K/N;\+/\FKO_,4I?E7E3M_6A M6T$Z#XF.UQQ[L0>9'A_V):Q`R^XTQ6'G?A#;5,6N]_C0"_1/6;RV@[^=]EB_ M_M*4^]_*Q;__]KN>^..U>% MJV"S5@+@SE/1=I]*G=)U\I>VJZM_$21,*DPB31(%[$U-#4[\ZT#5PS?:2Z1X46\BL5Z9`G[=7!DO2YWS0)_6G`KJ%DX@WK_G08 M#>,[E/0$&]C#M$X:S"C9#D&=$((Z"3^P5^W#*0FKC=TW1*=X"2D-9J18]R0( M09W\-==I&)7JCD4)\,SY0O5H1HJU3&(P*%6XWK".2TE\(Y4M/M%*,(.?KF"/ M9L28'HG!F!J&0E0'KOU0,H_?,06COG4\*G7I(RN=6WV<$_^O]P1^1 MP@PF:IN`*J6-=SXIM&E"BCE`HF^K8+]B":4O!),RI8`@B.]18U;_@\9'AX9" MW&:,SW9<(A`S-8*$F)R MD??W:&JQ/O=^@\&])U@T)='!#1PEMVH,'3C;O04BB);=H",CQ$.#W.(G!7'>I M'-S;F[+2*2`&8X)26S0&)%KX<*X'S$\3@R&ZT2>I=!)"Z.F7)]Q'-M#VT[$`$;&,F"C&&8#QX(L$*TW@4 MV052@HLFA!I/B(`[L,$@,7AU&C/F*0&(.);WM&-#X@=%'0^'D+NP0@Q2>R=\ M%3&S21E";:3-075C(V*>WZGQJ`BM8Z&Q&(P9!6QKD*"R["FW16-"C<=$:!,; M3HA!X:*(/]RD)@?&8W_0$Y38_QH2:CPD0N[&!F.:[HT'&0JX_R"C%@V*'DV= MA#^@)P8S97B3$*K@HE&AT.4G_=A@)NEAFK.1&P3J5]6L^,I M?/WHCWNW`'Q\N&3/Q>]9\UR>6^=4'"#E>J5]OL'/%_BCJR_]._*GNH//#OV? M1_C,5,#+\/4*P(>Z[JX_]`>2VX>KQ_\```#__P,`4$L#!!0`!@`(````(0"< M7H6Z8P,``$0+```8````>&PO=V]R:W-H965T&ULE%9=;YLP M%'V?M/^`>"\$*!^)DE2%JENE39JF?3P[8()5P,AVFO;?[]JF)"8I2_*0!/OX M^-SCR_5=WKTVM?6"&2>T7=F>,[,MW.:T(.UV9?_^]7B3V!87J"U035N\LM\P MM^_6GS\M]Y0]\PIC80%#RU=V)42W<%V>5[A!W*$=;F&FI*Q!`A[9UN4=PZA0 MBYK:]6>SR&T0:6W-L&"7<-"R)#E^H/FNP:W0)`S72(!^7I&.O[,U^25T#6+/ MN^XFITT'%!M2$_&F2&VKR1=/VY8RM*DA[E?O%N7OW.KAA+XA.:.\M,B^PW?52&?2'X#T_^F_QBNZ_,%)\(RT& MM^&2I/X/4D`ZOMYW_&3T`NC_[.X6I$*\`$)M%XRNK<@:V!/WB&9 M@]X"F&5D`?AS/C((2:ZYEXO44D!S.(Z7=10NW1=P,.\AJ8;$MC5`?!.1G4$D M`\0%>8-&B/QZC7+12&,TT*LP4@V)E%264@WIL^ULLDTA#&D>%-++;5/HD;C`="7M,89Q(V^S M:8PI<%3]I\_5TQ7[N++%H\W3'M/;YR6C:R$SYX/@,&\*DY7XXH3S=-TVA!V( M]&POL2-(-DE]>]H]0?&CF],2R2&H M[G4X]J(`%,AJ`2@8!8AB7^VC./91_"C[)/O[G\RL*F050,IC[^[%>NP)$:C* M/'GR?/[/R<3W__9E,DX^9_,R+Z9_?+*_N_WV20M=XM9 M-N6;43&?I`O^G-]\5\[F63HL;[-L,1E_=["W]^J[29I/GR2#8CE=,._^R[=/ MDN4T_\LR.W(?/7_]^LD/WY?Y#]\O?C@N!LM)-ETDT)&<3!?YXCXYF[H)H/O[ M[Q8_?/^='G6//T\^%-/%;_O/XR].LOYOLNR]? MQ%]69!QVDI'\^;!?+N;I8/'?XS>?Q1]40UW?S[+XRV?[>SO_$7]X"`.&QH33 M<7H3?_MLE([+UD#5+)?9/"_$NF%RG"[6/W>:EX-TG/PI2^?)*4PO6_/`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`YUF MZVZ+\9#`YIG)]>*^)3SHSRC#:`^3TFSB=I(N%[>HVN]\M+^-I=?_JB^G13+# M+=H._H'O]]^\3'KX5;3WT#\D"_'4WE3,M&`8M]^F'4.GY+7=76]/]K>?/W^I MK]N&)6:%-^YA!:M$'C;6\S9:T+\FK[??O'FY?7#PUFGO5]#W>OOUWO/M-V_W M'T?CX1!U0$X171FLG7P:1#E>#?JZG"S'QKIA-LH';35J/F(6$ZLSFA^LB%;MFV/>;,2AEJP3`Z3/W\PY]"*"A_I:"]QV(2S MV2(G-OOV<8XW^S+`)SEGGPS31?HUOOBP\GJ$V,FP6/87H^58!E"A>KC[I9+:A=(]ZW.G2HQXM:EV+GZ^W"`>@L.A!8EIO;%IHZV$_?#?Q MZY[^*OJ;]@:7[A84+WN-Q/6NB?`^G)P3UEV<)A>7)U>'UV?$?LGAN8+`#Y=7 M)S\1$9[]+#2;+U_J+7^SI9)"OX.^6QF;$=_+.7M#Z)0[\_YX2"/FB+ M"2&4&BX'BW5?.PNTYMTC`B=Y^'+S%.&QV6.F4C"F,==,^>.\P&,STJAM8R\0 M("(+0IH0.+6<9R\;$^ZTKK"1W'+AP?$AT.RXLHHR9]6,V90IL"F%G.ISD M4\OC%"W'3SJ^*4I=I2A^KJ:YVP.<30E_,ECBEQ2_?W2;3F_D/I+1YD`MV4FV MF`)`H\R^)9QR_XJ'".L^B_WP&IK> MI64^L"1KA?1DK>$ZSL=+Q5/*RQ[YRJ^LX5;OL'3EO]X$-XQJ:^%&5KPL/W7\ M\:-,Z=%A[Z?D]/W%KVOSY5ILP8WRSVO2G(KG9;(HT.A!,1T`$G2P@Z_%(\N$ M4>[/.0A8TK]/:@7:,,]QQ@8.D-IABR8.:H M$?JU!.0R2KE=2+\AP95V/FHO8BJ5]Y=F@C?L5TC'C#_$V$L,7#Q01<&R=)*0 M=XP-39/UQV?6[ M8CXO[J#8).*Q;S5G6I==/\S140>W8HZ>C$:@06(5H;G3'!P:D(G]NW..H"J2 M5),A..ETJFV5MA@F'-.Y\7T0Z/5O]I:SV3B31.#7AP#) MN#<$4B],B^F.$=[%J2XE"WFYF8(A9G'(U$0K@KO$C:9%CU=P?-([NCJ[5`"K M:/;ZIY/DWV?E)S\6SX,EG%N<2U?:(>2W4_8<,LJ$`\"XO4O+?>\OA0+I+ M\,)R&Z"96H2V-4>-RF6_S(=Y:I#"UI-?L^TG":8E>2+'"KS[)"$;>R(X_,FW M%&EN4A>NX`OPS\C6..T7R!20,5KCPS`?4#8`QA!C"@1UB38N8P8`,DD'V=+1 MUPC<=I-?,V#0LD@FZ70Y8A[M:3G(V6>`W`';`0)OU9DR4;HXSD?^>^"TBI#M MY.XV)RR\XSLBQ^0N7]Q6!)3%:`$>EMG[F"EM<3X=$F;,\W2\G=P4%*BF7K(L M8AP`TDZ8O%HR*,PNF/:Y+:Y;3=(F9Y:MA!>&7&5%_V,J(OBP;LB9-@ M-)"%"5FD(K&M)[V3(T2!M].Y55`"5?7T+,75"'83@)/"'AO?;VO^>S)[-!-C M/!V,ET/M\EC*JMGSNKAFTX^*8L&CMJ&`Q&(.,<6-"^+'H,<#P0U\ZC$",6LV M9^`24(#[V:11#]^K M&H;]87EM/&X7'3:6%3.2&-Z'@V@*NJE--T9_E9!(A30I$DLL1-RJ.J:;G#2X MH_9`,>H@K,^VL`[02Z]TTH0I+Y=EBFW0#*E+BN4M!2!M<#>NC+@G[UZU6RT!>PU)R!`\S`2JF MO#&(;I@H#!UV3R)9;=_?_NI+32]:5J!W?7'T\PY6UNI?'R[!/3H]Q+KG-CB! MSE9E83"?[/2\F2+QM2QV* MV=X119925I<,B`MI,LG(Y\2P=&&NPSY%,^?9(D6*>:888=NQHMMX\)3$]_5J%!OXD M,W#6^$9%&LA:HOY.,8WD6ZP5VY%]R>8#E36Q=0!#U,^@P%OW23K_1/!?%7Q$ MLXTROA>#\2K-I-0M4,Y#S+)9S?/ZS,=,@O(!.BJ@9A6A<`E3H%B^TAX/^4/0 M7*_?-C;.$F^G/)*]^QW*70G1V09<,;$6T\$.1^MF9PL$?!!' M2[ZT=VZ":_Y%^74Y\?)N!D7##F4*5**&[UX+O6#_\Q2O9^%^/W7A5(/I3?$4 M[5_G'._2,GGZ@O(]%N[IZQ>KI?F6_:>6MYR@O$`FWFH957XK?3KLO.BC24'" MH&%4J*Y"-&3FS/=(*!U4I48*8O;1V9+RVU9:=.&V*/866_96V<)3`ORU$[]P MB($@/(D_/@FV[%*V+/[V1RM6'V-]XF^LK/V+RMKQ-Q=U^07,]`(GHL:)-8U7 M3^.W`SW#^(O6@HRV=D?)-=5NW`+V,AYAZT6K\Z;%OE7B6QH8#[E:%J&`0IO, MX=7)(Q_;$#-@IG$5,\#/!,6P?(N_*_`8,^+%IK;*=P'X))G13B?3I;6L(,^\ MVO0Z]0:UU$"&`5LW(^\D*U(HK7A4V10]2:IY,]I0H*Q"KQF.F700*[PRP1_, MT%`V<37R651O=X;3+,P';"F![+ZL#5$^9M^\B`\AY*G4Z(4U&_IXA.FQ\/@A M%V'_ZKHI\`?J0PF91&N8DB:QZDW-%>9UB8/3)!M#S23) MK-1VQ9C`E"0)"H,`*3JV)!_ML"RV0][;^4;3^`9+S,KX]`C`G>K"$AOD?'OC MC55GK^=QUU).7'K/M7:)!QOI)PO'PD\)I2%*/D%\-66N(AMO6?^"FK=VSCKU1A+.Z M0;%1DZEPOLWB0A,]!516HL!0+$%E3%FJ/'.S)2/."/('@M!E[%J^\=JLTX?- M7;]5\APOP,H^5C9Y['P"U5>?30$_R41E-J"_*:L^X8DGW7KUJE7+#CX["9:[ M.8XXN;9G MF)Y:\%LX^%KGL6ZM+>?W:!:>G?\"&GQQ=7;2BP=O?+7!53=:-;6D4A[+\'*9 MRTI!6ARO0`FUO\8S7Z5W)!K869QKBSF_%O-/LMND]C?`'JWOR8IS>NZ'`*C% ML/7M11^\DKR;=G^#9V@]:(5P6\_?O(E)VGK^LB5IO9,?U3Y"=\CIQ=6';KRD M_<@&7A+V.)C(P.#%G2`.%"Z?$6.4V8U+\'>("[IP[NI3&*.6#%SC!48(65+_ M!JFM&T!\4V6A1JDM16B`WZ0"LX`+IMI3![3+?(%9&#`"3H&^1_@Y,D?@5&'2 MEYZ,]L1C#CQ0TA@`3[/+[&(ZNP6=S<8$0/-"YRG4\V5D\06N85S]T4RY2L%)@$_XG!4T.O?[M!I$[7X<2\(\<<7A(SX1O;2^936<&>A M=^7$X33Q`%O[KUYT?/:R]=G;5ZW3%SYSN3[\;UUVSYJ][+O-RNH#.F$)N$:) M4"BCWX=XEYBF(3.*[;P'M9:7W;_]=162HOW3->=:[W5G>=Y":#.N2ZM*Z4D9 M7L.(I.@!D0IN.8`M^JZ?+>ZRS.%N-9)=E6M(=>9S0^KH@5CZ*G?V!9NN?7(= MZROKE/QKW=`##(KB^.Y_ZQW'8OBOZY8#=?^X-T0V(7A./*Y)88U!<)9F`-5: M%?4Q['`I8#8%I,#HBQLJ,1.A(S7N(T(YXA0S67QM;/&;X!51:+GIL2O7.?`, M0!4K*$BDR4"I=G/DO@,4L3+R>J2EV6(!@!0AC=JNS-?"IQB"AS=9["$OD,M<*"ZGGL<^[ZLUU86AWU0#0,@2+W M2P6#>1C!UW:,_L!/LK2Q[XY1/EQ+:BN=]C,ZM%5CZ-D^]3.Z[QSR!YQ,X8L, M$03>OJV**L548/B(&C&IJ0/(Q_DGCI5HI5/+XS""L+]<(KZ<00"N=IEK:@"( M**^69'-G@]NI=%W9S[N#?30)K*E=T`@V3C'Y#[`![+%R]H[6MJV8E++F& MB%JG5FU2-L0KN`+RTA7UD5WMP?,7WYC=4&+E5$E,LVX2OMW[1MP9+ET>XKI+ MI#=Z6L6(2-K%?'VEIK$.;5PGR*A.J/08+0#D*7R6D?-';IC2&@PD?8CG9DY@ M4"4"A$T<,D5-64>#8;(R6'7@<,"H0;TD$S!_.L@ALO4LTJ^PO4#O5F?.BQ$ZS;Y0 M5+C+QNP5T1MEW2[>CM35UU@Z%;GEG%J='^3C;F^77G540**AOUS!BY#.^Y[D M(X$AHO\S;FI83+RMTV%;S$-5TQ;?03_K:.9!TA-FT(F9KD<WBW.54 M<=^L^[P79M;H2A.9;=H_L$R6:EX!(!(9)._2Z2>JJ/Y/BJCI#:F3CE')J\^( MI;^8L6#[GG(V9N]E9TD[=+.@:*7Z-.!!GSBG(M/K%-TR_N":]N]7V<'WZ2B] MQS%B18D53CAT5G[644"U`M'Z,TU;_+I0_>6SPR[>VO'(`Z:7ZV5F[72:E/D7 M*DM@F_Z`L,&F8<75AHV6<^1P#IE8'$Y@2O,K7/O`P?('53M#-.9V$L9+X1:FH120#A#Z>S@!WVF.%;U M51%'>C%7)*)E8WZ(9K`QLS&-2V;5FY)AWHDM?/WF%6:5GBJ+KI$*\T9LQ-F[ MBZMD!D21O`!<="G=K&!4"C3J1Y\L)S)#KW;WOOG6E>Y,:Q&,FD*D4!,;&!X) M#_4F&SQ82;?&M=2N2I(*GWN2%A MSW07$V.N(>0Y\GU\SU4)-[E00#E4^LS4YM8<$>UA5P6A8YH.=O?WPJ`4PBFX M8DOT@3PADM9HH1!]].0B:YB2DN30*04=2C=(VHK9D%%T365F1)W14*>-K"AV_BXU/`%[P5E6)H;NY33D M647?6%PNZ?A;]V9M43A51A,8<0.PAW3;M+X2`G;"_+RH-\:[Z@'1@AU@">LU MXJ4H[DP@Q[]9?\N87N.(@V#8NLR:.1WN\Z;21R/=!M\)@^,6Z$FPI=L\6(1+JM$1PMWB MKG,1:S5X91.-BLVJ_DXO;G`C<;U]C M0]G)YTY)+$IVSCDM;:O8!VPZBWBZO[?]9F_/IB%EAIG`?;R5*#[.^4/(FYJ5 MA7)Z)USMTAWG;*7PGCIEKWXSJ.PM:<[#6W-,AZZ8>K"JBV=S0XN9S'Y1?%IM MFJHW#Y[AF%3QI*'C[3;5MI9N("CJR\$4+J>8'X">4D=789OTSEDZ<5N2AQF> MF.O6'W8LP617`*7[JAIIE'XFZO"UG26^]=2>!'S6QI281.M6@BW.#C9F1N*" M+MDN([!U@YXFW3;1J&$AY-CZ+[70&I="CL"'L$!(E&^9Y=A,"3_FJ"]_YJ@B/#F>+G"!6J2#`$9>;/?5[[W`["K[5NE1'%A+D)DD-% MB9(D[)F9)$S;;G*Y7.V`7MF!^$T7JJS>J>`3.1?CDQ5CX(1CP`-M[QV2!X?^ M';T26.57\@)1L-L)Z#A3_#NC;DWO,B4VW.6KO9TA\H+42CE0Z%K719SUCYB[ MX]WA/+T#^VZ$/M5E'^R\:YF&`E:J@>2+_&",[FRJ-%G"%BVJ@V:;)UZ(;8D% MR70_1%:VBMD4-*.WJU.T)*-[QSD_$`[1U/%#O"\63MO20BR-Z0C(NMQWU09Y MA,3V2;AHL[ZD61[7JZ\M+!X9SD/WI(S-ULMO:`U'I=Y@RK\1%@#_N@12#70A M-@_1N'ALA/#.4_FQL_`!7#!F^2==!+[*%]?`)]35P;=A'8W,;43;"T,?0!<: MF29[N_QS0"L7:YD3IC-ZJ,3PZ&[2.(BT@8>R$XW4,4WZ6#;UB^)?`60<)H-Q MQK8P!_$'_UY0&2(%`M:4)0E0(8B8"S@]N&[-C/YR&SWOKH_A59$O9I%MNH[) M,*I'LWE")&%HZ@3.$[(Q^9`)K+,5\8C^V5!U=;US3AL,KE@YY"*27K'C\%=J MT?62C@YY2,-:>QO'9.Y7F"V.8@H&_O:("O!\[<;?Q*9=0),AED$TQ-(.5X@K ML&1#M:3:$U;<GCT,^F-^=#*RFB]0"188]/=[3RD>8$P?6NMO[I0Q=I9%4+8V229%<), MSEKA5FE4=D[+\!4WW*KQM`!2:C?237'.]]XX_V'4$"_4EUL1#BJ)4J`+H>XP M(,F-0^?JV!=.A+"66/:%HT`MY'Y$&&+(A#.0$3UQ6,/YONNKCT?7'Z_.SG_< M^.4&\/%,78*ZT0!Z'/*&KZ,BJ*[V%&>&\[-\"?6GU4#YN^W$RGF_1N!?+]78 MA[FM3XWIQ<:CL.+#X`,'-CU">$%.CD'&AH-/\&A7IG/+.2J?#]!P[/!'G9)9 ME^3(0,A/:AD&L8$[6-S&ZFQ9CO=X'T1"7D@TO3;CE M,1G(D2VX?&D*6F@'4&H):*R1CH)00:N@1RK\@DTZLQNW`T,.J6./12$YID,O M&L=-Q9QJ[;*K_76[(<:DW$PW^%2249$+KJ+G1-9H`])*"$\6D=7U$PR3"F=U M@.X3*9-.35DG4*&+7-`&S1LK&F8RH$O58*Q/%%F3Y<9:!"IC_2O)S9B*F,)< MK"'84H!R:^G1W@SQ<:0$5>/ZT=4%0_F>ETIJ/,Z\@A0J4-+I-^>�F#I-7E MBIZ^*LPXJVTUN9;JTU6+B$@T;`1NRGCUW-4@`#S_-9W,_O78Q*5YX?VB<8C))F6;L>+L$#NWR@W%EDZSS3RR5'=)PZJE.NBRL+RJIBKR.&);=VE; MA9.P*-$[,*NO[@FAX\8I2VZTL[XQ=Z3&:W2-3)%XP@VC/VD(L^/BQK1JW>^6!\!%;YMESL@Y[2;Z\!N!X]< M$,9Z_%DHL8+Q\I-\XTT%C>5S?( M"FK`'GF.:PT:+UB570I)WN/QL0BWF(.4\NF;MV_"M&[C/_[L]SZ2WEB M-WID\'FKN5#7",2/7OIJ2?RY7943?Q@"24YJ[K6\JML+\>+(38K.9"\U6Y_%KDH> MO-L)NM[4$FP91[ET4!@/KKR7Q?+/<='PV;GB3KM/+=Z:1[RR(1:5C1"O?"W"DUN? MP$H^(.N$H%J,V];C^AZ.:TZH#U0?D@N'F^$V4HQN90[%'G,]M"YC5D=S,E^* M6)^,4:X539M;OVR";R2%7JO&S1^-G(>!^R1BS3=]9YO1ZL-01Z(=JEREZ38G M`"4(=Y8MGW),Q1]^9G%I85?4FMV5<_D.(UR^'B M1Y?3]L,4^NL2FLVBL2=VV5IKY+[-"F(MAY2&#)ADKO6D\BA/CB?=C@\K+J.W M=F:5/^?3M0Q6+3C?/`6SNZY+!1DA7V2?[>XU5+!"0OR)9`*-%";X3C&GN,15 MZHD4($&KS5![[X7KR*$=@DC:O(B)]DIFW/8O@OW]MAQ:P[87`;'+.O_]D5-/ MUM^]TFI]&KB/W+`,O*2@8;Q"Q73Q3$\,\CFM9D@\&1PAS34?U=)%*M2?%Y_8 MK&%QYU,M=_)M+'XV6@,U5!`?^6@[VMEJW/U?_^-_QA;@O09*]CD1^4OHQFH, M^Y>EU4^TN5)2MI0HD,Q`S=B^Z;2QS0(M69;+XK&7$AG)N@\N_18`AC@%:.1H MJK:6[0XD1]S!HXB3YC5GE#!,0;H]-9`I\AU\(TBPT1Q5<8Y7:JG"$#F$ONJL MU_()2S'8B_%]R_PZ8I^O(;:I3")M19>E\4UZO)<)F4_#OC6L5(N`L^8!0@)` M?_CP:,Q.<2>P)GE7GV:S;1$E?D@RC15[*&&5;\+U2J\1ZQSY!*A1P]G.L!? M-MYNL*#D($%U^O\=C3>?DMZ``T[((75^Y-IM-VK42&`@TF3^(*Q<)G\[$2L: M@*V!5HU90Y^?Z\^P7%\ZA^*Z^QW,E#M<0BT)8C8YP&S-!82[B=N5QGX`LB)9 M%N3X8Z`'-HIFJ;DJ4,127)Y$2G[/YH4S&DT3ADFV;T6`3NIJB,92O"GUH!ZT M=I3;;.J5HT`"G)ZW+`IP!1$8Q>O8KESEY:<=RQ4%\BOAL[;&^+%OX@^._>U: MR7V>C5M'I7\IQMA1;E\W5$'KJNTZJZ7XX8ZHQJ.>A!9INP[*,\`?GTVVK$FP M=>3ZM`I)[`PM)U86\;#7$-!JS)>9,4#19$#WGRFR!JM!S!#8C741+"A@!MT4 MS8OT;2]<0.QL;F,0$G@+'327?\2U0[.M,P(AUSXH"2"^JF5`8;%K7'&\X$O2 M%J&%&HC="J<%P#+,<3DAJP<(_K@NPH(8Z\A`"(MMH('O'U\M,:LA&);@0IR= M8_**B8*TT-X&%OV9@-F6Z`FL"%Z1*TS3!6!,/9'KIA+(Y6KIAB9Z<,Z4C)]6 MX?Y\X"GDFHO#;=E5S39J\7K>LK4?^"&/'^V.XF>]Y))?HHA%H_7`ACAZE7(R M:*@6-%=8@ZQ*DW`,7H7XT12Z%GP8@8G687SC7GWBFT,L^K^?BCL,WES5-]M: M[),E,D*ONA'#)MSA(:Q&5T?=IN/@3P>O0)\#DYV]"=B<)N6&'T#JC+N[,WDY M9YP\<:E^8P-G6MM[W$-X;DNI4[TEXI'553P6>-0_3_?R!<..4A'^0'7 M2U@"J*667.K!K_A2NEI!V'A"845\^_(YS9VN`F$6VV"MSHF?FR.VQ,1S"9X^ M??OZE;CMUJN[9FIP?QLB$!/^QX,(F"J#N$0.]1%$PO56A<\,D`6=8OIJ88-* MUB[.$YA8_MM!P`+9Y>D56:&A>LF9H_IG(=I<)I@(33"0E2(HN&+WHT*2)DUL M;7;FBT/1[QV%:4(S:_8-L475G6>H)>\&_571QG@E8P';^2JTOS@Q_7^AE:RK MB^QK"R>AR*8LP')E5FIXP3^].RPV?*>X/XFOZ[@;9@A"$_A&9PA-K<9@=3I) MW]HJG434VM5\6254`;WH(L*A_./53W"$X?^`XG:L+)0F7,QD,J6JY*<=+")) MJQJL31^I4]I)'@E=;1,KP^(B7VD)B@-K2S#P!DXDM=.::6]:.MQ7K37J'4-" M+2>J;>8+=(0?'JDW+"P2K]1$GAC2F0^6I%-9SHHX0@P@5K$^(%ZV!H#\Q7Z^KPLNS2J)BR.Z M:Q6^0E+/[AP)*W5W?/GC528EME8QUQU.UKYZ(,?4V:I[;M?LM\*D\0W#9XPQ M3C7X(G]B<+[>,VP1*8AL'.NW.DU##Y2SD'Z; MS63YHJ092Y8FQ\A>-B@TLH5TZ?&`_S7Q*YH-QIR&5$VBOMZ1H,[.HV'2M3"% MGJ.NHK;Q-3@.:@JZ7$_ET>8K:+$&B0E#>S=0960'&=;?5=B/34SG MQ86Z7W?K6I%B^_*I7GV%5L]:@-SE5=Q!:N6S^WB"-=5&%*S]]R$(^VTM2P=IP&95>D@G4!<]T.G#Z,93]FLL/&77(??5;L MMB;3^8:Y@5X&P_I$ME4EN<;R_%_*K=>+^;FR;O7$\),GQW8S'C_30:GM_?J]NW3-PCK+UFT'^%CAL1747 M#)X01,'L(Q=($(T0[?(MP&'P&VKOB.7H!-]A]^VO*.BZGRJRA_RB")_K19G1 M:?_RY'I6-B1S9>8@F"LO!J/$X`V)F?<->=9MQR%AVC#63"FP9^W3,KXM4M/G9O$6TF`"Q"*LEW_>HMG37;Q#)A`])CAX+: MZVNXCH?,Q:_U)3Z"Y..Q?K2,-K3QDCK'#W1ZEXSM`;S-^-$F(4O^!^XL'0(R>@X6AY_*`==]XZUSEF#+\BJ$=( MY;$BUK/JLOUDXV80W:P>I%E!"?$&+:#WL'%(**87`Z.N<(2B.FK;)'[MCKU? M^;W'>%1;4/WK`4),`$25;@A4>/!II=UK4>[6V`!3JG#P6T;$BA@F?@V9^)`T MPLK/\63/_)&!^//6L-3I_*54?J@'WV`CB&_L2ID'GZV0V'JMNB^%99#M=_#H MF1UJ?G!8JRSQ2[RDY40*4T!,#_AVC=E:L>JJ1W731AP1A2X_!VB2D8/X?#VVWL,74G M2FE=2F(X634(MP[XXU'Q*\_"F1DZ9PE&P#:N.MA[UI1]E9,$M56"'8\9+V!% M%[QA$-]UTF6M1K@#/NV?,FX-7M]YP'C6**HS/IR+?(BLM6=J_KY!XNF>_?^# M.8(_B->JHIU$1IC#/_Y@3LS\6$HJW:'(X#(E[-"F(SJ;9(`6>5/(^L1]./80 M@"L9^8=("K!419I@(#N=\M";SIHW,[+XC4#ANM`G9L^*AC[HK>*WJQ4GRSU;,6R.L4=CU3^ M9=3:NQXF!:?%#[L`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`>JK9EC+5#9[41#O.M%6608[/YJJ>G9)B=_YL)JJ5ZH2FSP/ M5@#B=__>!=&WOXG_O/O#NW?]?WWS[3]^L%?__/'WQ?=^_$;MI6J(3/!!O#N6W$LLN+U9!SXQ1`.:D*WK%S_XXIOX'@0#F(`&H1*!E\$^=L6W/#O^Q-QRG47HX,?6EN>X;_%E'2^PP$@^YSG@)KS8BS6< M5\\"T:0VC1$&9],`KU";/##)PHOU-ED_E=C$Z1HVZSJ&/TX7LZ+>KLYT%>.B MP.$QNC)?$3WATV*JFB;D$*W?1UJIPTZD;#+O@[ZS*;L:GLVR@3DP1YU:QL5B MT6^H<&!V266#0O/]Z.YL=':OK,JZ)`V?JP=@A^N610>Z;DW_'IGX.$>SM\J#_47Y(?`L'XFE@QK[-#W#7H$77,Z5&5[E2"0Y%6"0))7V=2[UT'F3WH*5"$D]U6"0))7"0))7AUU MG(%'TKU*$$CR*D$@R:NL8-1A7X7JGN2^2A!(\BI!(,FKG4T^DPP\D>Y5@D"2 M5PF").5*MKH8JM&6*47K,MVE M<0DT(K?-AA,._4Q)$@YYY:J'7DC<)]B"N9IY6K`!Q$0:$H(MNK`QK^**VDA: MB-E(&@C:2%J(V@A=IZQSI4RN@AWL*.X[V#3'_7Y<,!/54R^0`"^)F'(0I$V1 MS\8F)8PVMFEK*^270M^8Z?A@L^,22QM:%.UL:%!B94,+41OYN$F]RPG/2A>8 MGDN0[/'-??PP&*`H;ICBV4N"27["0GY=M["#DUV:H.I8%>Q3)Z_FK&Y2O[ZO>L\^9[- M:H-J+.;[,(CL9<1.E;"R?A6>004>.)(@C.<8_4:%?N#I+/JA]E3J1.!%JGX( M+F']7<8#GI])@AI<0(.Z#D^7"*#"D"(`)\A`@.=]$@X@/&4@@)5;B@`"-$<` M<&JBXIA^J)%L!C&0JP3]IU().2:UDE-Y0BNKTB_HK['2Y-+O4323?`N!GM,, M+VH`'*6R*L7*2C'$[=#3<@K@10T%)HRZW0QY6E7.ET8(2;J`(6<$TD`=(]U% M)X$9(21@`CY1>D<\3-&[$.",-!(*L#$FB09>5(BD&63DR=X4N*T42"+(R M)/6$K!1),@%)6M_8 M#T8>826F7#\4UU6EC?+.^3D"R_%$-%K.%O6-A?F]R."+[8T1T@@"BSNR,2#7 M"8;.0Z"C+H(]5S9-,$A*QT!=A7B2FC-`BJ9VPAM1X M1-?78";P?XN%]H>?=MO(6;_1,:-]SN[:<8T9BX0@/A6*P,K1ZKS:OJ:@+`V$ M-G1TWF6_/D2'TC'87V&7Y\-DKL=JXL>/Y*1?4-><`@OU%)[&:3G-(RGCU.C8 MR9\CX.V7*3IP9#UY"GX7*ALN>W5S=<[+)P!Z" MU$'A%;MK)Q&'&V#B?6.6[,(U)KUZY(>[_0QP.XT#N(W*5TXO%[9G@'LDO1"N M7]F"A89Z4LMI$]^<04WA?5#_.QH4E/7J4L0QH-J5F2KG'TV\F=Q4[2#`Q?Q; MZF52EN&&>;Z;%9)N>74H77^7S3B[=)6N]0P$2*[=>6@MKV'JA]H@N&JHP%(G$=*+HI2R>! M?-$>'#C*X[&=)6RE!=XL MOICL==;)RG*_CGF0R())4%M9("&>9.AXE(O(@G5N6UF@/I8U`&N)+/A686M9 M<+PND84'[7)5^!,=166!R6UFY'P$AD66`DK:RVLC(_&N`X(FLHR/U5J1_Y M6,7S8R*XJ*S<(0S!/4 MQMR///=#0>[W,RH?\;I@Q,=2O&M7PK"L(W!<]$9N)X MIP\%Q?TQ"#*.>`DZO!0!]"?X>0/XY00%>(D9XF,8S\.U$9/U!9X>_()4&S'0 M.D;#QQ].B-N(@=:Q&#ZIXOQ)1,P'?[/+/,3G4ARZ141\=/P7>\5'#L^P#B!% M)#W8NRBTLOCCNY0N2,P#WB0AD\&GB/A6QND='9+YYP/<$R$E$6?:I._@TD@$ M^%]V$:$16Q$A<`]2(2&/3@2WLTD[,2<"88G@>`S@G'(F8B^C",KXFQ7ZV%NX MKKL7HQ46Y:>^8?:_>LUOF,%XC_`'0-BM-++U`!"ULM?6SHT>LS>G:O[\S^Q& M41!,R:>^=SX'$1,Q5?/G'_$.7-"+80$.Z>;C%N[J!'^57>A,U?_:9F66%.B0-))?1O: MXX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C M(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6 M^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5 MUJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+. M99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#L MXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^ M_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@ MK3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+ M@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN M4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<< MNDA(",Q*A!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>],9&R M;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,( M48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q- M,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63% M\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$ M#6C\S210*:D`XD2 M+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S, MUJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^ MS1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V M)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G M<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?Z MO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A M84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2 M;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U8 M2QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W) M-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?D MXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965T;]^_61RZ> M9$FI0N#0R`272K4KUY5I26LB'=[2!D9R+FJBX%$4KFP%)5DWJ:[

W>ITBEU-Q-.AG:6\;L%BSRJF M7CM3C.IT]5@T7)!]!7&_^#S'[H"?!4HHSDY5.H;/WZBK"@55#N"@'12O7`M"5&Z4$J7O\R(O]D94R" MDTD(]*?QP`D6D1_-_^WB&J(NP'NBR&8M^!'!IH$U94OT%O17X'R.S'#TL?XM M5(A1F]QIEP3'&$$4$LKSO`EC;^T^0T[3DV9[J?''BMU9H4L!>#TC1#YD_'/6 MSRA:K%%T%33;UKP`[YXML-:]5,3+7C(B@0Q-)]%BJ/1PX6C1^QHXH[D9:**Q M8G=-,6(#D^EL6IQ@"+Q/2AA;Y=@:333OZAD[_G+T%WV8V7DT$^"S-WT+9H0* MFWXZJA;;J-;*6Z,YH7H.'`DKBT8P`6T^1M/G(83[XOJ>TY-LQ'!,L#6:'C&R MQG=F?`(AG++IR=-BF^S&(C.:15=FWPOGGF<=W=U0$?OQ4#"JJVYW@\OD>M*T MV$9[VR_F>!B-V8$S'YK><.E.LC.2"7E;_@^<%MMPUI[:<I;SHI%WDSBFML MIN68&[FFHJ`[6E42I?R@VTD`->G?]IWN+M"7F_5^"QVPZQ=N/P`=J"4%_4)$ MP1J)*IJ#I>?$&PO=V]R M:W-H965T&ULE)==C^HV$(;O*_4_1+X_!(>O!1&.EJRV/5(K M56W/Z;5)#%B;Q*EMEMU_WYDXA-B!;?:&?+UYY_'8XPSKKV]%'KQRI84L8T)' M8Q+P,I69*`\Q^?[W\Y<'$FC#RHSELN0Q>>>:?-W\_-/Z+-6+/G)N`G`H=4R. MQE2K,-3ID1=,CV3%2WBREZI@!B[5(=25XBRK7RKR,!J/YV'!1$FLPTH-\9#[ MO4CYDTQ/!2^--5$\9P;X]5%4^N)6I$/L"J9>3M675!856.Q$+LQ[;4J"(EU] M.Y12L5T.XWZC4Y9>O.N+GGTA4B6UW)L1V(46M#_F9;@,P6FSS@2,`-,>*+Z/ MR2-=)71*PLVZ3M`/P<^Z$9S!P)<$9V M4K[@J]_@UAB"Z%J`0?2_ES"/$48)VS#=\TO(YWK:_E!!QO?LE)L_Y?E7+@Y' M`Y%FD`;,QBI[?^(ZA6F`6*-HAJZIS,$"?H-"X'J"-+(W2R@5P73%<_70%SK?3`OE`[2.*8[*`B8N)AKEYW8S7 MX2MD/VT46ZN`WU9!745R4>`$`D,+`KD9#H)B!,'Y0K*MO=&-&WEQ^XI)JW!` M(`M=$%PP$UBK'V<&7P)=9]S3UMT26L6THYBYBN0CA4,()EW"C\E0'!,8?3LC M1]!5WR.:?(4.Q2T;] MA6XEL[H(IG0^\<'L\R[Z'3"HIN$I0[$'YM77UDJZ@:E?"GW)'3;\<@[>'%#L ML5TKS-:`E3AL7IDD?H21]R=7$*0,*^\7PQ-5J MC\ZKP&VC&*IW;*[6PCUEONVT73Y(J]DDAN:>WRX60_G MLUM[ER_RJX):C'S*X/V-__(+XT;FGM\,,XNW[!O M&/1N?I5$UP"V2AI--X^>!%M`M)G76^-B.9]-'JZKV9:)[=QL'U)P=>`)SW,= MI/*$G1B%-]N[;6O9]'SM`VC2*G;@OS-U$*4.C!7P1E&WS[(615=WE M[*2!]JP^/4(/SZ%K&(]`O)?27"ZP)VG_%6S^`P``__\#`%!+`P04``8`"``` M`"$`&&#!A8$#``!2#0``&0```'AL+W=O0$"Q^?<<^_UM5G=O^69]THJ3EFQ]E$P\CU2)"REQ7[M__G]?#?W/2YPD>*, M%63MOQ/NWV\^?UJ=6/7"#X0(#Q@*OO8/0I3+,.3)@>28!ZPD!?RR8U6.!3Q6 M^Y"7%<&I6I1G830:3<,0^64$>D##YA@3>KBIT\ MZ!K0Y"66/8B6P"R=32$_EYV!);GF02Y22P'-H1ROFVB.5N$KI#"I,8]=C$&$ M(-Y$`*IN!..;$L2O/:!VUB?+1I>E9Y'C9FT M,'&#L)0!TK9^75F"H7%:K-'<.-+*&M-#&=JNO[($VYY1/&H<:66-F:AFF+0R M8OF=#E&58%?5]:LQEM])$Y@E/1LB+<&NM.'5AC6FC[0\!5I;['J5)=B5-MVC MI35&Y_IN8BIA&5X,495@5]7=3QI35WAL>MY21;!S^YM5:+>GQTT!M=L:9&6Z M@=CBSC"[GFFD)U1[*W?;N@8M5%^C8#;[0%D.F]XU1GHTV2Q>?O00GI@L_VQ M*8QM?]!(0Y=FFDELK7P>:N9@;36EK3YHM*%+LZV3]/-PNZT>#9IP"GVKW6M0 MGZT>#1IQ"NVJNRU?@YJ:F\KHK.M;L;XTEGA/?N!J3PON960'73\*9K"O*GTG MU@^"E>IJMF4"[K+JXP'^NQ"X.8X"`.\8$^<'>>MN_@UM_@,``/__`P!02P,$ M%``&``@````A`(EN[+[U!0``(Q<``!D```!X;"]W;W)K&ULK)A=CZI($(;O-]G_0+@_(`@Z$O5D%/G*;K+9[,CN=T4U66E6\9$U_)+5NV+RW&E M__U7\.U)UYHVO>S3=1_#JK\2H#HROS2\N#U/DY;>'^FU-Q;3!:F7TE7)G6KV_7;UE57B'$2W$NVI]=4%TK M,R\^7JHZ?3E#WC\L)\TP=O>%A"^+K*Z:ZM`:$,[D-TIS7I@+$R*ME_L",F"R M:W5^6.G/EI=8KFZNEYU`_Q3Y1R-\UII3]1'6Q?ZWXI*#VC!/;`9>JNJ5F<9[ MAL#9)-Y!-P-_U-H^/Z1OY_;/ZB/*B^.IA>EV(2.6F+?_Z>=-!HI"&,/N;B.K MSG`#\%\K"U8:H$CZH[M^%/OVM-*G,\.=3Z86F&LO>=,&!0NI:]E;TU;EO]S( M8C2.X[1WA&OO:-T?R>D=X-H[V(;]Y%KNC-WNG9'@URY/N/:. M0IIW_&:]'UPQM;OCS'M[N'XM(UB(W8W!];&,%KTC7!_*R((:XU/.BJV?\ULY MF;Q4NLKSTS9=+^OJ0X/E#%/47%.V.5@>BX8UQV469B5#D)! M?36P9D-M+-EBBQ:L'EE87P4[%00J"%40J2!602(`$V09 MM($E\']HP\(P;3"K#0)!+$4(M$`77P4[%00J"%40J2!602(`20A8TD2(*13+ M[8T):X)YP18DUH1CRXENN`W;Y(;"<663[6`RB$'(CI"`D)"0B)"8D$0DDB:P M:Q%-6!X/+AP6!M8>;$F#`/;#'FH$Q[*K+7 M3063!_OO#0&F\!CA#Q<61,Z_)UT[U=EL"?$Y<=WN:>18L^E"7E6[P0!K(R!! M0D*BP8L]Y!S+=>9RV'@PP+")&$12AS7N].'[H#HLB*Q.3YRQ.@CQ.7'8/`Q/ M;$=5:##"5`(2*"0D&KSNA(X'(PR=B($DE:`IDE2Z42O0,&*Q,&M9CIX(@E)$9.:*D!RQ%Q%!2$6!+7O!`4=[+"T?D5!)B&9<2'DR`OQ5'DE)/T2K<:0( MT3A2C.CF2`G^^ME(LH2L%Q3WIONKSN*M(_0QN)XW/5)J47DIV*+56!X^HK$\ M=HAX>P03-/QM: MUI4UE`_HVO>?HJX<*:6IM(Q;J[<:"\9'-!;,#A$O&-N8*OU3@`:C3XAHC!PA M&JUB1!B9B#9D`;++"K%F\@&%^MY35(@C89:W%D$^(K',>BM[J.*`6H6(Q"+J M'<=8,5J-L1)$G96<,ZS)1W)FYLJ&Q1%L16+]*].Y92\HZH;5([@,"\=RE86S M0T<^G98Q7;@+\4]>$@&:CP41(A++YBM#Q^C8;VJ&XSC"8IQ,E%ME)W1=CMW8 M7&5^XL;//(6D_-GQGN%&Z0\;QX.WJ1O<]>!UX@:?>=!]4^[//6AP*8_F'G2HE/M/ MWN[I!H^>/.C5;M@O/&B1*(\6'K0\P,U!(3BBO*;'_/>T/A:71COG!Q!]TG6Y M-3_DY%_:Z@J3`0>550N'D]W'$QQ&Y]"-0?>A:X>J:O$+&V`XWE[_!P``__\# M`%!+`P04``8`"````"$`N]#-=R`$``""#@``&0```'AL+W=O9!B=! M#1AAI]/][[?*V(X=F&SW;E]">"X_/S^7RV;U]:6NG&?2L9(V:S?P)JY#FIP6 M97-5,/?KYO.GU85V3^Q$"'>`H6%K]\1YF_@^ MRT^DSIA'6])`RX%V=<;AM3OZK.U(5HA.=>5/)Y.Y7V=EX_8,2?<6#GHXE#E) M:7ZN2<-[DHY4&0?][%2V3+'5^5OHZJQ[.K=?X$0=/8'O1_$ M"OS6.04Y9.>*_TXOOY#R>.*PW!',"">6%*\I83DX"C3>5,C(:04"X->I2TP- M<"1[$<]+6?#3VIV&WC**9O/E`F@>">,/)7*Z3GYFG-9_]U$!JM(L4\D"3\42 M&RQW>H:R)SQES[DWFT:+90!R[PTYDQWA*3N&I``F3*PUZPM_9FC8`*2;)%E[2YK/QG6+I< MQNQ&8NR(O8I`;Y$V-0`?]&K18/0'B$86%*V&VRG@.HOIC4(5H;JD!F`IA`7] M`(7(LG;AU[!U:4O:]3&8]#HHLD/V.D3+-A%+-Z3`!^A&%DBHN:%IF`\RZ)YP M':*%FX@E'&A,X>,%0*4K!@M]BG&P;8RB2QUFNX'2&HBUMBP(\VQQ>X.9A[6MG?N<&2RA4D$CE*=>$$R48ENK^"&&S+D4A\]6F`I"9BC1W;8Z-/\_"_V(1$MBZ)P$/; M!)>$&YMTD+;)1"RI`1R2;_=)1-N"%&0X-812"[(%8%4V%@K-"I=XOKXWIX*^ MOD.=4-/>*@ZVCX8 M0*D%V0*PMAH"_D=ZR2IMBI.0;5AXFUXZZII>)M3K[2^E_66J)MV1[$E5,2>G M9[QP0@)M5AKN;\.[8`+787&C';3@15F!`UIFD[2[:C`^]`ZZC4>0+GVLBT%PF<(2/X M,H'Z/H+'2=KO23UC^`)HLR/Y->N.9<.&ULK)I= M;]LZ$H;O%]C_8/C^V);D+QE)#FI]"[O`8G%V]UJQE42H;1F6TK3__@Q%CH;D MJ-JZIS=5\VCXDAP.AR-9#[]_/9\F7\I;4]67QZDS6TPGY>50'ZO+Z^/T/W_$ MOVVGDZ8M+L?B5%_*Q^FWLIG^_O3WOSU\U+?/S5M9MA-0N#2/T[>VO>[F\^;P M5IZ+9E9?RPO<>:EOYZ*%/V^O\^9Z*XMCU^A\FKN+Q7I^+JK+5"KL;C^B4;^\ M5(2I:&'_S5ET;5#L??D3N7-P^OU]_.]3G*T@\5Z>J_=:) M3B?GPRY[O=2WXOD$\_[J+(L#:G=_,/ES=;C53?W2SD!N+@?*Y^S/_3DH/3T< M*YB!J'5P'.A]I M"//K9@Y7U=#Q9AMGX7L;0",-UZHA7%7#Y6SIKC;;;KHC#3>J(5Q50Q M;O7'!#8]Q$QS+40*<79"%B-3#KN/U>^%*L2H4/DD9!ZGX#((PP;VUY)X21(;;_"24(&-B.DG-X!?"LI MHS$O]2:]EQB)&(D921A)&`F&;'AI^`3$M"*L.V?@)/:*R*--Y(A` M$;?+.E:LA.HF+-J@-XVA@FR+;?Z`$C(2,1(S$C"2,I(QDCN4Z, MB4*:-B8JB,,A)B1A)&4D8R17!*G&Z(Q=U'A&).7Y9$?:(&LK9T5DU3N&HX2CE*., MHURA(>^(0DC?`S_G'5E.P0F&P]\["BU[%'`4*K1<=9G<73B>%3!D@,HQETDX M2JFAJ$Q!V:JW,C)`Y=R0,8-(E$FZFP:"!1ZI^FB1597A#X5T?S`4.A)Y\H%0 MG'411[%"#FDE'*6\8<91;C0TYRS*GCOFK*HD/08DWPH4( M$=&1'R%R^WB*$9%5@JA[-.]V;HJ(K#)$I)4CZJQ,-XBZY@XWJ#)(=X-$+LR3 MW.`O;#F1%J$!0Y#(2(*H`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`[%&^S7._AM9(!O=O#SP`#W=WMX:,BQGDJI>Z;O$/F,>\_^#HZ4\` M``#__P,`4$L#!!0`!@`(````(0!5IO%U7`8``((9```8````>&PO=V]R:W-H M965T&ULK)G;CJ,X$(;O5]IW0-Q/"(><4">C#F>T*ZU6>[BF M"4E0AQ`!/3WS]EO&-M@NII7,SDW3_5'^[2J7BX)^^ORUNFA?BJ8MZ^M6-V=S M72NN>7THKZ>M_O=?X:>UKK5==CUDE_I:;/5O1:M_WOWZR]-[W;RVYZ+H-%"X MMEO]W'4WUS#:_%Q463NK;\45[ASKILHZ^+,Y&>VM*;)#/ZBZ&-9\OC2JK+SJ M5,%M[M&HC\6JY6Y??(55GS^G;[E-?5#21> MRDO9?>M%=:W*W>1TK9OLY0)^?S6=+.?:_1](OBKSIF[K8S<#.8,N%/N\,38& M*.V>#B5X0,*N-<5QJS^;;FJN=&/WU`?HG[)X;X7?M?9?BMO!80;=@G ML@,O=?U*3),#03#80*/#?@?^:+1#<+MV?]7MZ9W1^!)1.!*U_(;+&:VX]$$4+6+P2N3&/TY8/@;]@P MN+)AZR$$'PPS(=?HUI.D8[MZ[YH-FD9]5OI9E^V>FOI=@Z,.>=+>,E(X3)?, MP/.1+F3(T.\E*&0F47DF,EM]I6N0>BVR+KJR!00:B"2`6Q"A(5I`(P("Q#;.!T_(S8$!D2&^[5GH,Q6)82"&[!A_@J M"%00JB!20:R"1`6I`*1`P$G_&8$@,EL=?@I)LI(]WU,;4A$'HX5LX@TF0W00 M"1`)$8D0B1%)$$E%(@4)2MK/"!*1@<,(=6D(`#Y*S.BC*`TF0Y00"1`)$8D0 MB1%)$$E%(D4)EBQ%:?JYQ\L*L>Z#P9W8,T(?9Z1&>(Q8?=5QY%SQV4W8M,EH M2DN#D#^P-&(M+XV1]7#0/41\1`)$0D0B1&)$$D12D4B.0IE^P%%B+3O*"#R_ MA*"NY!@EYMA&SK%D,.+2J2@DA8/T-E(\:*,S(RUC=R[SUWT-R0R=P$1"V%!:6)M# M5.0X]<+P5!,"A9'/D=-7*6MNVK(KP6C`?0DY&I4CC&*.OJ>6H5Y;# M1'JA^\^'25LG>%IQ[3U'SH`\C'R&G+%8!AB%>&"$48P')ABETD#99]+V/.`S M[9(DGRFR(!IC15S/Y2WV3&;5OR"R_G9JX,*4!P9LH#.GC;6U5@Q"KCP^%2.. MQLEBCJ15JI,ERF3F0NG0TE$&]EP.).F-'@@D:Z7$Y*&(O`P*@53<]4QF-::8 MSQ%]929]0<#1DAXY6ZE+(;\_#HDX&H5CCD:KA",J;%M*\Y[R^_T0.4"D+1(# M]&-%B#578MPH4A)069AG,JLQ)WR&[%$K8,BA#95M*94JY"IBLB'A&`LGLK"U M4*IY*@G+<2-MG!BWB2(-.3-4:=;UC4[MR0L%%&YKW%D/(Y\C*?W4$Q(P*X?N MO[FV%4?"4897Q8BC4 M:WUO1CD_2;OY_R/-FE8QTA1):8N0#]\K2:1MZ`7'JHG3EEHY*_H4<52#D,G` M01K3%DT6WS59PJSX9/9*.2/D&VN?'4*1I-],Z=>IJFA.A5=<+JV6UV_D>RCD MT>YIP/1C[=YQX4T35JORI0MO/Q-\Y<*;P01?N]!(8QYO7.@Q)[@Y=TE?A>^D M&_A\/'4#.AZ7M#AX"/0O(#9U![Y%/_^48]H;2W7/B$@V?8VRY\ML#\ MV7&?81_PC?W&W4]ZX6U<;_*&OW&AT<=*T/B"VU,!"36^U2'"$CYGWSWM!OZ/2/KK[U3?Q+W<&G[_[7,_ROHX!^ M8#Z#0GNLZX[_0288_GNR^P\``/__`P!02P,$%``&``@````A`%^(IRP5"0`` M%B@``!@```!X;"]W;W)K'[2I[.5:G MS=,>QOW#FVVVI-W^(>0/Y?94U=5S,P*YL>JH'//M^'8,2@]WNQ)&@&X?G(KG M^^&CM\JGD^'XX:YUT%]E\5$;_Q_4K]5'B==S.P'].@UWQO'G?-_^M/M*B?'EM8+KG,"(>.!_>"IJ)NX1,WA8/M>-]7A M?\K*TUI*Q=?J9 MAB#;#AZNNJ'G7?;(A6X)5WKD:.E-;J=?='6IV\%5M_-]P]UG^@H+MNTK7'5+ M%ZY2`]B$85'!B6:MZ_Z.Y8A5<;K>&FV3SM/J&KC\BJZAM=TU36Z[A1X($@H2"1(+D@B2"I()DIO$&BBDZ2L&BM;V0#6! MC8N=NO!LSP>=$4U=*$@D2"Q((D@J2"9(;A)K[%A?F_O=^?A#:WOLFAB3+$@H M2"1(+$@B2"I()DAN$FN@,#O60'%C7T+Q1Q7;Q5L["MD^T,2>?W<+ZXRZ^1)Y1:L<2R_G`^`UMP>/2$C!"0*)8HDBB5*)$HERB3*+62/ M&0N4_40;$$T=6M"X%9CR3O)-F`K:AA*%$D42Y1(E$J4291;R'8#EC=7 MN$%50Y8;-#*G7J#0$RB2*)8HD2B5*),HMY`]9BQ7KABSKF[,J=?('+-`H:?0 M%"Y&@,SL/2%B*PJ06*)$HE2B3*)<(Z_MJNT&K$=,-ZC7G!&^%3:OY?;;NH)N M0]SW9(,I%!;Z)4=7-:9W-#*](U#H*32%B^$=IZZ-V(J]TS4DE$BK5*),HERC M/N]@E?3_>T?76J9W-)IUF23`RAZW$T:A1K-Y6\'Y$\_)*Q$;D!=B*9-(E')# M?",%96>3RMB`E'-+Q@XB+*A,-_4$"YS-=-&BZR_3'QKQX`,L]%U_*#15QT)8 MXT;:RD"Q;)A(E,J&F42YU=`>,Q925XQ9UUWFF!7R87$9L;^P,T/@::OV4$V_ M^W<-:6XBLO*[>(H)\0M!0HBU4D)LE1%BK9Q0:V6[`CSY$3:C1EK8C0LAW;;9:.J=",=&*UEQ)U*2/]N)C*QNVQF=C-SAY:0LPQ7SF@A7T^]_5&^?519&FFAE',>K M,AP>3?DOT%8&"@EQK$6$.+/%A-@J(<3R*2&VR@BQ5DZH)P:Q\#67[OD-TM=U M,B^`M4:85HUH<))+0%8\SR$A8\\DQ/(Q(;9*"+%62HBM,D*LE1/J"0FLA4TW M7+Q9X")SWK4ULA/7TJEC`K+BR0P)6?NN7'[JB3@8=KC8+/JUQ/+36MR)M+^A M,Y\96:DC/%]L%G2_)^*P/C9=_47$J7(:RAU:4FM?(;@0"B0*"7%(1(18*R;$ M5@DAED\)L55&B+5R0CWA!8O#&O/EX84MG22CD!U>8E_$]>CLBX0X5T0:S2:? M[8NR34+(C!G],%;.'&6Y+Y),3X1@,6U&R.7>TI4Y3\K:5PCCD5?+4NR%VHKG M/*2&/.<1(9:/";%50HBU4D)LE1%BK9Q03_Q@7>UZQ-RQ+GH7QHAQ8TFAF95Q MELX90*`;6GN8:FC66-IJ9N6EN>/IF+0X5!)"9D`)^8SE\<5PN7!264XJ/?&$ M-;CK/32_O#SU51EO92&%9G9@.75EH!M":J!<%1*ZZ5"DT6SVZ3)4#X,U0S() MR;!R2HB5,UOY9C9QJWIJTQ-T6%F;;OLB4:M"W'*1J,T#7Z"0$$=$1(A+F)@0 M6R6$S+C1\FR5D15KY81DJ,#G)?:8,?5HM!HZ-8$9/5I24[*1JRICW'4YPV' MXO12!,5^7P^VU3M^:`,USL-=A]570.N;%?R"`LO`Y;[<@V<&ZSPH,:>0>^6WKLTUKCXWOLU_#P7OLI M?/_48_\X6SV":^6#U[,5_*K;PQFJ[4Z_G/<$<"=H/<. M'"^#._JZ"T>K<*>O7W`:#![INP,'CN#V-FZ<'L"!(:BIB.INP5=9;YN7XM^; MTTMYK`?[XAF":=*^6)_4=UWJCT:_Z#U5#7R.!2L6/J:![^\*.+^;X,]NSU75 MT!_@EG'W1=_#WP```/__`P!02P,$%``&``@````A`':$J25`"```6"0``!@` M``!X;"]W;W)K%5N)A;4M0U(VN]^^0XDC'J.J<=N7*/YQ9DC^>8A#^^'S]_-I M]"TKJ[RX/(Z-R6P\RB[[XI!?7A_'O__F?+H;CZHZO1S24W')'L<_LFK\^>GG MGQ[>B_)K=@01+M7C^%C75W,ZK?;'[)Q6D^*:7:#DI2C/:0T?R]=I=2VS M]-`XG4_3^6RVGI[3_#)N(YCE1V(4+R_Y/K.*_=LYN]1MD#([I36TOSKFUPJC MG?]%\O19D^GZ#?WXUENL?8S0<2 M_ISORZ(J7NH)A)NV#:5]OI_>3R'2T\,AAQXPV4=E]O(X_F*8R7PVGCX]-`+] MD6?OE?3_J#H6[VZ9'Z+\DH':,$YL!)Z+XBLS]0\,@?.4>#O-"/Q2C@[92_IV MJG\MWKTL?SW6,-PKZ!'KF'GX8675'A2%,)/YBD7:%R=H`/P=G7,V-4"1]'OS M?,\/]?%QO%A/5IO9P@#ST7-6U4[.0HY'^[>J+LY_MD8&#]4&F?,@\.P),N"X MX([PY([KR7*^VMPUM0\X+KDC/&^K$3K5]!>>W-$P/E;EFGO"DWM"C($F;K@] M/+G]_/YC-<':;-H(3^X)=0[4=,_MX8E]6D[F=RMCM6:#..!IP'QKAQ\&^,96 M&CCJ[)\/M=/`X6;_W-I2''%##/D_Z#EMIWJSRN)]!-L1]+6ZIFQS M,TP6#M=,*U2WBOYN$<'J85&^L#"/8QA>6!\5K/QO3\;B[F'Z#5;KGMML>VQ4 MBQU:L*7)PEHZL'7@Z,#5@:<#7P>!#D(=1#J(=9!(8`K2=OK"?/@_]&5AF+ZH MS!:!$'RNB8D6Z&+IP-:!HP-7!YX.?!T$.@AU$.D@UD$B`45,6"I$S`4LV_X- M'N"MIPC&7J'KQ60#HM^X>%@D54Q.X#0C!FYIJ,MIUQGA]+`(L0EQ"'$)\0CQ M"0D("0F)"(D)262BZ,O2,_F(,KQ6F+6J(2?2A"3$(L0FQ"'$)<0CQ"$31$UX57AV>+Y!^/:LK0C?(D5X@BR6Z<*^L5"; MOM2%[ZRPZ0XZ"F5(>H2'6+<( MS\RU':-%BO`$6>S"H!4>&V53Y"`2,K@4>8@@I'2^V.@JDQH#=!3A0XHB1&IX M[5X@%E;8H011C\KL2"U/[_;"HCEMU<=\_W5;0$]@-^DY)2S@;,RO*_C!7-YN M6J2(3Y#%KDB8^,MN4[(IQ2%*[5.4IYCR))R)#JX8QDEF_4"61PMVAM9ELO8%#G4T:7( MHXX^10%U#"F*J&-,4:(XJOJQA.$&_7A^(>O7(K@REP9UI273.Y9K@Z3MQ3J_ M-N-(I(XA@?8EIMM+R$1^MVKJ,R4;;4`(T M$)6%B$1E$:+!RF*TPLH6VLLY08.F,G6$6,IQPPCQ#$4>H1;-E0UNI1^5#6XE M3WJ.Y$G/$8R=I*UVDG$PEG!T$8GP'B)AY2,:#!^@E7`,$8GP$2)A%2,:#)^@ M5>.HC@7+9FX8"Y[\R&/1HCG(*.FG'4AV!K<2\\Q")&:CC0A.+U(L,A8\EG!T MT5&$]Q`)*Q_18/@`K81CB$B$CQ`)JQC18/@$K1I'=2Q85B2/Q;][Q_+<2AZB M%FG+15NP.X-;B0EG(;J37KO<"A[2$&D'1`<=X;4C66G[D8M6HD8/D9CB/J)U M>\4VF6M[:(`&PB=$)")'B(15C$A(E2"B*X6]#O[[Z#11U.,G1^PA::6=UG;" M"L\0%D=P$X_(1F0T6BT7FE0.1A&SUD4DHGB(!M\`/EKA&V"C[;\!&HC*0D2B ML@C18&4Q6F%E"ZTR]@5W\SJ6EE7[A77[M=LY*U^S778Z5:-]\<:^C(8,ZNFA MP^TWY=NU"?>-H*;.-R;:W2A&MYZ@`9N\D.V[0$$G>3G;EI">3OT+V^YD*""25]#8:D"$KZ MF@R'>"CIJP8N]X2N+6!J=37-KA6@)*^MD'>"R5];8.D#$J:MDV[V02_ MZ[BFKUF'3#!6L#(=C:[?]\9;L&$1ANI+R$<9HZ/SXP95H^O M>6:\4"$9+]:F:SFF08N(QZPXKLU?/Y\>%J8A%2EBDO&"KLTW*LW'S<:(LH+-KH==[7MI+&Y@V MJYC!#M!V0]!D;6[=(%R:]F95^?.;T;/L_3=DRL^?!(N_LH*"V5`F+,"!\V<, M_1(C!,GV5?9358#OPHAI0DZ9^L'/GRD[I@JJ/84-X;Z"^"VD,@)#@<;RIL@4 M\0P$P*^1,^P,,(2\5M(U)'!M2%S_0G(CT6\2X=HD>M9B.IW,%G-8_4;BI$F$Z]VR[=J"RM&0*+)9 M"7XVH$MAD[(DV/-N`,2ME;6,SMQ_>0NF(LD66=;FW#3`-@G]\+)Q_HT(<^'^_0UD5,@E[47)SJ"G9U#'9[9_4@9-^%="K[B"83*CZ4B=1W5A]9 MH']F/4W7Y6^";@GO0CKA?403#C1#X=[4`O2VPYA6*6U7V#5(?;:QZ?8-XM5M MK-L?-@_U&ETZ7=,(?O0UWE:&P;JR!KGTY_X*"?N(MC8*P72WP;WEM; M)-)U-0C,TJX#77^F^[3O@EJCPSZB2<6AW'L#W;8)@W4Y#;+HCO'^"@G[B+;V M4E\;;?(<:+H[#P#2Z*H:!"X]D^8#D[J@SJ0^4@NMAV#]RLZI.-(]S3)I1/R$ M`\YUH$L[N!N^6P_=&.`[&,I5FP]Q+X#7V$B\'X3^"+Z=!-MJN`]Y)D$X&8G? MS0+HTQ'^>0!-,8(O`BC8"+YL/BKL;F$8ZB4YTF]$'%DAC8PFX(ECX1P5]6=! M?:-X"5[!:.<*QGGU-X6O-PK'W<&71L*Y:F]@8;O['MS\!0``__\#`%!+`P04 M``8`"````"$`2\G"VS:*,1:0R_S] M5E,-W57X.B])G#Y=/EV7N(P]9N-`A$.]='=-WXR@KBR.$>,GW>?.C#>HZ1?;X;7LH MJ_1E#^?^%&&:=;';#X/P19Y595UNFC&$\Y#H\,P/WH,'D5:+=0XG4&EW*KE9 MNE_%8Q*$KK=:M`GZ-YU^A=L M]@:[G]L*_%DY:[E)W_;-7^7'[S+?[AHH]Q1.I`[VN/[Q).L,,@IAQOY41^/?-WLEFX0C:>S22``[KS(NGG.54C7R=[JIBS^0Y#0 MH3"(KX,$P%ZO^V-_/A73Z'H4#QFU!WQ*FW2UJ,H/![H&OK,^IJH'Q2-$[DZ& M//JSGCLJG%$%^:JBM+'@%#74YWTE)O.%]PXYS30F1LS,=0R&(I(.H4H!]'J. M<'+.,8`:GLY^1TEMHI3\&?V^^`2$(I(A8O;00PA'R)W-\3(W!88>L%,Q,7'; ME,:("2W,M/_F%I%<0A!N$.1V;@J\=.'@?9D>.#6$S-LZCZ+(9[SL97\:]:N$ M$_2]S4GU77AVHKJ:JDTL;V+2Q\>\(08X]/QYWBXA",>(1-",&Z( M"=O$A1.>-[(Z"_J]A!/,#\_;]5E0FS@W]NTQ8I#;0\28)_;J2`@S282<\CLF M)M?)J4V#IM#S_#3&WBS$Q\9(88TFX,DG00)8LF MZR1Q`N3L_LRUN_@\L&Z/-8@P['.$";P(H3R975P>"8&";FM)P!HKUAC==P&3 MFD0O1^@IP=S4GO)20FUUWA5>*.N$%RM:+!"#O$8S4S>=,K(VF^A$7S732##62;]LJ9_!T)0IF;Z=FT+S61B00Y#.F0A9*R;"7C\W MJ>JYZ@Y>*.8D9UP\VHA@+^A7P9!69P@JIW-3:9JNN\Q`#-T@-'70I;3U?B2F M;#(2':/KP+/$F"-<:?VA%?!\Q,(6^QDK\0)PR`S-<.G$( MTIHP"08,B2&<\RK!+.%*WE#$8?KZQPHA!D^XG=(;D,F.UHU+$))`GUG"97XM MFL\G$]-8@W1'#1J.+EL/5I3771;@#RU`^/R138/.\L(8>ODL+Z7(-^N9C_I- MZNFS"8PU"%2K+SJOYT4(S9M2[MOYH<[;NB9\(TTX"#Z"=&)"5NZ$+HO(S`DE MIE3Y=F*HX9085US?%OI1Q.J=T&5A#4#E<@,4H91 M-""R1YQRN\L-_*$;P(L_?0B+-0B_.@H&3QQD?1I9JD>9W64'_M`.A&_Z1+>9 M[0?POD>))SI&/YZFVI08,X0K>G;""(;O[[81P,,0'Y#$MYT`ZFWZE%*[RPI\ ME'`Z`=P*-$@GA:9DSZ5Z1;[^-M7N8D;@LS:/-:@3#BLOZ%)T MW3(*2I`YP8T$3SA"8'H&6RY`D+;X8,(&.='K>("9)=R4H!)Y2]EN)*AVL0P. M7EL"!"&!>J7K\`][3'="N_I]4V/]3.7FY@ZV0\`R>H\*87/S3E ML;U.?"D;N*%M_]S!C;R$Z\_)&,";LFRZ#^H"L[_C7_T/``#__P,`4$L#!!0` M!@`(````(0"IB,\*S@(``,$'```9````>&PO=V]R:W-H965T45UZ^6%*.:+KX5C9!D6T'?+^&4T([;+L[H:TZE4"+7 M'M#Y3NAYS[?^K0],JV7&H0-C.Y(L3_%]N-@DV%\MK3]_.=NKDVND2K'_(GGV MG3<,S(:83`!;(9X,]%MF;D&Q?U;]:`/X*5'&*9J MB3F"X0*8N\Z5U$R6_K/X"D]8-8.DV#48\(A M8M,A3!0@K]<(G8\U3B##M]WO))FBL:3A\]9O0(:(S3DBN>TA`XW@W5CC]-T3 MTFDT17`63BR)DJ3GM]:N'69Z@HF'B,TEQ$`CD(PU7O?1%*48C.ACBY+Y4,': M8:8V^#`>Z^MVCPQ'Q$`?^'6J[W*^!CS6=>^_')%K&YA!AHFPVU MF??D>KZFZ%J^#G-)XR7$0".\6Q_WSX!'_LV#4:X.,[>Y3D<'$^:M(7";R;2O M=(K<*'63IF:R8!M650I1L3-C,@3&_JZ;X&N8X';>^?T&3-"6%.P'D05O%*I8 M#J6!ET!FTLU@M]"BM2_Z5FB8G?:RA$\E@\$4>`#.A=#=PHR6_N.[^@\``/__ M`P!02P,$%``&``@````A`/32Q.OR!0``>QD``!D```!X;"]W;W)K&ULK%E=C^HV$'VOU/\0Y?T2$KX1<+40;7NE5JJJ?CQG@X%H M"4%)]NO?]TQBQYXX90'MRP+',^/C,Y.QXUU\?T^/SJO(BR0[+5V_UW<=<8JS M;7+:+]V__WK\-G6=HHQ.V^B8G<32_1"%^WWU\T^+MRQ_+@Y"E`XBG(JE>RC+ M\]SSBO@@TJCH96=QPL@NR].HQ,]\[Q7G7$3;RBD]>D&_/_;2*#FY=81Y?DV, M;+=+8A%F\4LJ3F4=)!?'J`3_XI"<"Q4MC:\)ET;Y\\OY6YRE9X1X2HY)^5$% M=9TTGO_8G[(\>CIBW>_^,(I5[.J'%3Y-XCPKLEW90SBO)FJO>>;-/$1:+;8) M5D"R.[G8+=T'?QX.?-=;+2J!_DG$6V%\=XI#]O9+GFQ_2TX":B-/E(&G+'LF MTQ];@N#L6=Z/50;^R)VMV$4OQ_+/[.U7D>P/)=(]PHIH8?/M1RB*&(HB3"\8 M4:0X.X(`_CII0J4!1:+WZO,MV98'?!OV)GY_-I@@RI,HRL>$0KI._%*46?JO M-)*AZB"!#()/&60P[HTF_8&/.2\Y#J0C/M7L4.#"3$/I@$_I$$Q[T]%H.)X2 M7]O3J]=;R1=&9;1:Y-F;@YK$BHIS1!7NSQ%-Z59':)3\/R&A(`5YH"A+=^(Z MT*A`]E]707^X\%Z1L5C:K&T;GUMLE`6EA\*&!N"!;T,:`G\!:8I"I-5T:P48 MJV@Q5!;*)30`QA"9_`*&%&7IXJ\AZXA36M(-R8-<1-AQ!'&)-[]W*MR)>.*GXJ[EDC5H:K:VT@DJ*IY MPD4/Y2#/C"YXQ@PJ7,^,C#DSB>@RW5A(:")L;CR1U\]-QGSN&AG.6!['7(M- M8Z3$#$V$T:'=UF@VEY-$QIQ.C8".FFEC(:&)L+FQ"'-N:G2#*6T&LEM>W>LH M$.7+SFSJ)2&NUZRM5V.E]3(A3I?:J$'W$[UDTS4Y28AQ M\OMM3HV5YF1"G!/U5(,323C!\>GFYY.VPM8#JB!.USI^2$==!*%VQ`HX7>JY M!MU/))0=VI100GJV#6V8Q%Q#(8,X`>JR!H'[2ZYNU^QQD!#7*VBGM['2Z34A M3A>Q3+J?Z$76K9XF(:/[0ZC*2D,A@S@!:KDVS/)B<)Z8=L$UA0R"!.@+JJ0>#NODY'M59/4!`OHO8! M55MIO62L:E&<[DU]/;#[NH),O:25AD)FQ0E0"VWIY4^F=VR$@6S&9C(EQ`5K M'U65H\FW<82&G.]-C3VP&[N"]&P;&PH9Q`E0!VT)=F>;HDBM'BHA+EC[L!HT M5KK"3(CQ'=S4URMKSDE!AF`V%#*($_BROHX;O;9@"N*"M4^KVJH1C$$UW_JV MK[ZN2D6^%QMQ/!9.G+W03=Z`7LT;N+YF7`?3.94*HEHC,XQ4DK5'!GW<35;7 MB]9(\+I& MH#5>O;I&H#7>F+I&H+7?J;4/K7&LMWUP1?W0/0L<.NS75`)=.$AU<7H8SA]0 MY/;$:W#MI(H\=J8>6>Q,(G+86?K(8)5`K\DMKK[/T5[\'N7[Y%0X1['#`]6O MSL)Y?7E>_RBS,WH/+L"S$I?>U=<#_LDA<#G;IQUIEV6E^H&%>Y_?_9DG/DPI>7N^K"TO]@>V^.9\9"]^_K]L!]\*^JFK([W0VJ?FEV1=$. MP,*QN1_NVO:T&(^;]:XXY,VH.A5'>+*MZD/>PI_U\[@YU46^$4J'_=B=3&;C M0UX>AYV%1?T9&]5V6ZZ+H%J_'HICVQFIBWW>@O_-KCPU9.VP_HRY0UZ_O)Z^ MK*O#"4P\E?NR_2&,#@>']2)]/E9U_K2'N+\[7KXFV^(/9OY0KNNJJ;;M",R- M.T=YS+?CVS%8>KC;E!`!IGU0%]O[X:.SR-SYO25%^;QK8;I] MB`@#6VQ^!$6SAHR"F9'KHZ5UM0<'X-_!H<32@(SDW\7G6[EI=_?#Z6SDSR=3 M!\0'3T731B6:'`[6KTU;'?[NA!QIJC/B2B/P><;(!<6I5/3.*GYR=/!3A`"? M^[\UNYI<5YU(1/FG`^6CN3&ZG'RC"HA.> MPB?E2>7Z@J>W4@\^:A`.76SBW75S=SE&,==>8AJ"_(V?[BKJ[5!Q:>40S]T-('-14`ZOEVX/K.7?C;U#A:RFS MY#*6Q(HDL)S1;&"#T`:1#6(;)#9(;9!I8`QIZ7,#9?]_Y`;-8&XHJB4!+5EF MJE8D02J!#4(;1#:(;9#8(+5!I@$C$;"<62*F4"SG-R.J"=2";<>H"=<,=-G) MX,;6%XYOBJQZD3X9C(2,1(S$C"2,I(QD.C%R`EL;RPG&<>7"03.P]F"OZA/` M5XX4NI2E7J3/$B,A(Q$C,2,)(RDCF4Z,+('++$NN/P)\N7903Z2%PEE*XHK- MY=:J$?D0)NML%@V7(-6&2Y<=06G3$4G4>EXQ$C`2,A(Q$C.2,)(RDNG$"!1V M8R-0W-IGTY$ZRSZ]NZ,E,PF2P,&E)7QJS4HO1),8,!(R$C$2,Y(PDC*2Z<3( M"[;(^I%WN0!0VHQ=DMM^0U\Q$C`2,A(Q$C.2,)(RDNG$"!1FQP@4"\"'P^YR MP*AE!BQ)UQOBN;SJB3[]GCG]P5DAM;L;KF+K8?AZV4AE\;EL.5WS`!LX%?F2D.Z)E((/;;W8"5.*NM2L3ZOI+Q[6NK\?9*P[VPT_ M)=+]9"AP=&1Z@&>C[@%F;'J#]Y$/2LR1IZJ>-(ET9WJDIX,E[:S4_)VDX4&E MN_Q!TN2YIOLID;;Z'88"CD*.(HYBCA*.4HXR`YG3A(>C'K,V35H7J*/B@+>>3J92&1 M7A8,!=CF8?Z45,A1Q%',4<)1RE%F(#-F/!_UF+$L'%^T!^VN7+\L*P1GE_(4 MFC!Y[Y.GK)X*B<3W&W+Z&0J<#OF^Z.<\9S:U>KI025#-1!+!)DXHYBA1BG@/ M]1S?4[N!\"=5$F0G,^R8B<+S];\G2I[2>J(D\OIH5@Y#@40>+#UM@;%D=8H@ M11%%W%;,4?(I\ZF2(O.98L(^6$VR3]`S(Y&>&88"6$:XFJ8JYI"C M2"+8'\GUF*.$*Z8<98:B$;-[7?\BQ,W^12+7:!'\B;61DI1:`0$A=7*&A+K+ MTF3D6]?NB`3,P:RO8V*24H,EA-1@*:%^,,M,1@+O#68F$J2N*!Y,EW4B281= MB%HP=@96)*7*(B"DU1.AF=BEK,F(Z*DYDA5^3%)JI(20&BDE=':DC)Z^-Y*9 M0NS8/K_^7-G@:>M/(AQ52Z%]O2,I51X!(54>(:&N/.;NZ,:R$Y&$.1I+8^-/M!_52XN#("/Q]X8V\XJ=YA5YE8VIGM<.6:5I=;0K M5TJI@@D(J8()"74%XXZFZF8E8HM(0.G$A)3EA)"22@F199:T/@I(NYFAZ]IK ME[?7$FFSO.(H(*2766<+)I1J(>)2,2&]B*2BLI62E+*5$1)29LRP)J^I"A2W M=OX.X1#::K.FIRW&R<1R-2-Y,;:99>RB%*QG[CP!";HC(X[I_>_E@Z\&'X4&X?%E_#"6.P>-G?! MT+D1I@MX^![>*ZPA!C.A@`1G+5SLX"O%,_8<6"`KHVV M1H;+W`*O:UP'[F(+O&WQ)W"O`9USX\"5!'3./8&.'W1$%5@>0/\..EU]](_@ M=?@I?RY^S>OG\M@,]L462F,B+KAU]T*]^Z.M3N*B^U2U\")<_+J#__A0P!>= MT#H/!]NJ:ND/"&3<_U>*AW\```#__P,`4$L#!!0`!@`(````(0!N%D"ED`D` M`%PK```9````>&PO=V]R:W-H965T*^P780`RN)*O"^7R&=R:FX"^2S]:EKJ MMBW[_N^?IV/NAW<)#O[Y(6\52OF<=][Y^\/YY2&_7G7^JN5SP75[WF^/_ME[ MR/_R@OS?C__]S_V'?_D>O'K>-4<*Y^`A_WJ]OKG%8K![]4[;H."_>6=U_)W[R?O?(U$ M+MYQ>Z7Q!Z^'MP!JI]UGY$[;R_?WM[]V_NF-)+X=CH?KKU`TGSOMW/[+V;]L MOQWI=_^T*ML=M,-_A/SIL+OX@?]\+9!<,1JH_,WU8KU(2H_W^P/]`C7MN8OW M_)!_LMR-=9!]!XGLN>/4_NI?#?G0X>S3;E">5@6^^_UV9]O<* MD7-1>'?"#,PNN;WWO'T_7A?^1\\[O+Q>*=U5^D7JA[G[7RTOV-&,DDS!KBJE MG7^D`=#?W.F@2H-F9/LS_/PX[*^O#_FR57"L4KWLD,HW+[AV#DHRG]N]!U?_ M]$]D9,52D8@=B]`G1.X*5:=4MBCF9T4JL0A]QB*5@E4IW2F)C-AT-/P!]!F[ M.3S^#+^[V(\^8S_KRT.F113&ID\,.7.L]=B>/F/[U:U:K^OV3:5/_AC*HO M<,V<4AL%K+[$'K7/3:J-255?8M=/UT`Q6D?ALFQMK]O'^XO_D:.]CH81O&W5 MSFFY2A@+,IIIO41_MT)I:2J5)R7SD*<)I,47T+;RX]%VK/OB#]H*=K%-0]H8 M%DU8J'6O9%LF:)N@8X*N"7HFZ)M@8(*A"48F&)M@8H*I"68FF)M@88*E"58F M6)M@DP!%2K'.,Z7V3^19R:@\(T,-@$3BTVEOP@(N+1.T3=`Q0=<$/1/T33`P MP=`$(Q.,33`QP=0$,Q/,3;`PP=($*Q.L3;!)@%12:8_\$TE5,G0B32Y>VUB: MC]DI*WZ7WA+XV@O1`"`T%&6FO MI'0M+3W61I">"*&I(#/ME9`NE]+2X5M#3%;:WTA%78C(U;*2KT0S[E:%6-^FW#D>XXM;Q5->JC`RL^476!.&(/*#E4$;$/ MJ\R(`UAQQ"$01QP!948*IL5LV2QPF#V60*R[`F*K-5`\W77C.FV#XZ%+NFRHWE)EHTYJ M]IUZEG/K/);$%OU@3+E![!BQR$0RX^`V&H,E"D_@14[3H%8?@;$5G.@3/D%K-AQ"<3R M*R"V6@-ERF]@%3JFBTJUP#Y_V:R>')F5%"%C+S(NY)NQH\V+HP7$BZ,-E+FF M.[!BQRX0R_>`V*H/E"D_@!4[#H%8?@3$5F.@3/D)K-AQ"L3R,R"VF@-ERB]@ MQ8Y+()9?`;'5&BA3?@.KT#%=2:J=]H5*BKMOX?/P\"JJ847(V).,>^0FK'A= MM(!X7;2!DNO"+HMSVXV(5M6PZD*+(_:`.&(?*!GQQNE.1\0%[1".+#\"8ODQ M4*;\!%;L.`5B^1D06\V![.@J('W/LL!1=E@"L>P*B*W60,E1VV5QSM.3DCR! M:OLYJPZH>3J=E\6\) M2[V#X[S^ND"\2GM`+-P'HKN@WY]K![!B^2$0RX^`6'X,E"D_@17+3X%8?@;$ M\G.@3/D%K%A^"<3R*R"67P/]9M8W.!X*IXN*=KT_4%1*Q;C.BI!Z^J_S9=MB M3XNM>#&UU$,CTBK3G:5V%#=X;5A989W5'6-E=>+CM*5BN^D"<:P>5#)C]6%% M=Q6)$1DW'0/(<\0A$$<<02LSXAA6F1$GD.>(4R"..(-69L0YK*+YM(W%OX`N MAUH"<:@51#)#K6.K:BG:(DHE8X]0KXJI"HAR%U5K].I7]([)R;N\>$WO>`QR M._]=O=955INWQOJ=LZ>P.67PAGH7316%R6V7GHC?X&67GI9*_E1QGVB@\D"C MXM(#MAN\ZM)#FAO\SJ7>O^0+QZ5&DN1+QZ5VDN0KQZ6N\0U>(/776HR M2;YQ7&HU23YR7.JEW^`UEWJH-WC=I1:;Y!/'I4:;Y%/'I7:;Y#/'I1:;Y%W' MI7:AY#W'I<<)-WC-I3;R#5YWJ:4H^<-Q&[=XTW&;MWC+ M<>F)BM1IU5SJI-_@=9=:J))W')<:J<2+NJ+IW<:W[8LWWEY>#N<@=_2>:9&4 MPB;P)7H[,OKGZK_1IDTO)_I7>JLQ_/I*;[%ZU!TI%>C<_NS[5_RC`NCW8A__ M!P``__\#`%!+`P04``8`"````"$`,[9HH-X'``"/(```&0```'AL+W=OVW:Y^Y8 M5?T$&"[=_?38]]=@/N]VQ^I<=K/F6EW@R:%ISV4/?[9/\^[:5N6>-3J?YLYB ML9J?R_HRY0Q!^QZ.YG"H=U74[%[.U:7G)&UU*GL8?W>LKQVRG7?OH3N7[?/+ M]<.N.5^!XK$^U?U71CJ=G'=!_G1IVO+Q!//^0I;E#KG9'Q;]N=ZU3=<<^AG0 MS?E`[3G[T MK?>_UY<*U(9UHBOPV#3/-#3?4P@:SZW6"5N!/]O)OCJ4+Z?^K^8UJ^JG8P_+ M[<&,Z,2"_=>HZG:@*-#,'(\R[9H3#`#^.SG7U!J@2/F%_;[6^_YX/W7=&5DN M5A`]>:RZ/JDIXW2R>^GZYOPOCR&"B7,X@@-^D6,U\]8+E]Q`LA0D\"M(R&SC M>$6($=3>EC4P@-H'$!%(3 MR$P@-X%"`>8@RZ`-;(.?H0VEH=K@K+8(*&(90F`$-HE,(#:!Q`12$\A,(#>! M0@$T(=R?(P2E@;2DF(1LUOK,MSR&)K[!29X>$@XA@SH6$EM(8B&IA606DEM( MH2*:2)#O?H9;*`UL1LA9@P#.>J%+L!5!;ZDTA`PJ64AL(8F%I!:264AN(86* M:"K!D#65QH\W3"LTFHF!D]@*Q!]V4V@A$4=<6*E!0K):ZA+&0Q!2)Q:26DAF M(;F%%!PA;(C:W&%-M;GS7#NCQV)_K'?/VP;&"\EH1!,700FVE313*HALF2J/UB7+$@>I% MFGMC5!_A$(3"1P+A)3";NT"-$R/$*.F&""&:?K!J(YY1D\4B:KEB^V3IDY7NZ$32H+(I0K*S#*$W M.\N-SE;FP5=(&NA,%Y)6<>IV^:[L2G@M",Z:B4G5 MX\6CIAR''&F#D%A0)"`7TH/4U[8A;[CD\ULYCF'P!)EE*DL1DOUG[^HL%U&B M,V^SL,04TV"=Z6+2^O`M,3\U5]B_HX>\DLV)*#/E"F\%!&D.K1G:4(20-%", MD)+6$))1*4*2/D-(1N4(2:X"H1%CT2I0U>+M$XR(HE&=,X?H[8/TAF^!T(@E8/2WR$##C13/(2,%&3L@ MI"]-T%`Q2(00^$WJ9^\MT=#A*=ZQDI)X+GV0(K'JEB'JC;YR;,C[(KYQ3!?X M?,1-M(A4W?1]"5Z4HG+EMO1=B^JF'Z!6@A=1TA@1-MP,.S)&R&=2NAOSK!0D MJN$LW@Q))&^.$.+RK<0TUJ-G7"FER"5[S!"2/>8(Z3T:K\@% M1FES5'K4)*5O))JD-&,Y*WI_/_:.KQS_K*5^!@A(RU*^,;P0@Z0O(H2D+V*$ M(&4MC0DWHV7 M)HS%T),2PW*H*^D;&H2B'0P/71X)2*WJ!;049YJ1\Y%#>BU%2-)F-FVNTYK9 M"SGL[.70XO3].YF%&]J(\E8N:BBBE(06(237.49(9H4$(1F5(B3I,X1D5(Z0 MY"H0&K')M\KN=]VMT]$/GC%JQG2OSF('*,(JUDD<]4^56%U M.G637?-"OU!"#?=P-\#\\VFT">!J"0@,/-L$<%5DX_"Y]2-[R3#BM_`9EEG> MQ!WX/#O"LW4#N+(?X5\"_]B#[3*`VVN[P=8+MLR*1L>A%X1C>.0%<#=L\T2K M`"Y(;;SP`K@FM?%H'<3LVY'1;[8.X#(1XN?#`_@&PO=V]R:W-H M965T-H'#<*VMO%CRAX,#D-T`24#\_.??^]?*7^'AN(O> M[JK>1;U:"=^VT>/N[?FNNEIV_OA4K1Q/F[?'S6OT%MY5_PF/U3^__/M?GW]& MA^_'ES`\5<3A[7A7?3F=WINUVG'[$NXWQXOH/7R3DJ?HL-^O:_O-[JV:.#0/'_&(GIYVV[`5;7_LP[=38G((7S;P_WZ+#Y]BK'_;=WN=G" M._Z'[/>[[2$Z1D^G"[&K)1WE8[ZMW=;$Z]%ST$WWSY4"<]1-I\.:^;"+7)\#.[B=AY&KSR-/$0-?,E;01ST6MS6GSY?,A^EF1"5Y:/KYOS.7":QHSS$))X]F\]*MI2>8CX_+5V-Q5 MY73+C'.4N?2O+[Y?_US[2^:_;:JY9XUG*QZ@,).=L6VYH.V"C@NZ+NBY('!! MWP4#%PQ=,'+!V`43%TQ=,'/!W`4+%RQ=L'+!.@=J$N(LSA+:WQ%G8V/BC`C= M`^0"[P05"E1IN:#M@HX+NB[HN2!P0=\%`Q<,73!RP=@%$Q=,73!SP=P%"Q9+$#>B'[P&-D1W;E,BM="Z/?"?9,A%RLT6D3:1#I$ND1R0@ MTB-X?GFE?+;UDJ=WN1G'L+L'DM3)74,OG>&J M*E1L,6HSZC#J,NHQ"ACU&0T8#1F-&(T931A-&"G6*\D.84,LLUIH9755M1AU&748]1@&C/J,!HR&C$:,QHPFC*:,9 MHSFC!:,EHQ6CM87LN)H'\#/BFCZOYX=P@JZ2G1>SKOE@UL\EB%=^-M!;0%*2 M&^C.&DM;51CH'2#UZC+J`=GVU_8\$J@*]GT@M1\P&@+9]LYSY4A5L!\#J?V$ MT13(LF\X"\PS5<%^#J3V"T9+(,O>=\[]2E6P7P/%]G;:F"?W,](F?=#/ITV" MK+1)D1Y-RTM1ONO>S:T=U[:JT/4.D'IU&?6`\O:^?V/;!ZJ"?1]([0>,AD"V MO=/[D:I@/P92^PFC*5`C&V8S1G,@]5HP6@)976TXRZ0K5:&K:Z#8WLX1L\Z2 MSY%D\^7"[$F>7G;;[_>13`5R3U!PU]"0A9MTZR5=K@RV:^I>\Y#0%L%.)@.D-IT&?6`XMWSN)@T8#8'4:\1H#*1>$T93 M(/6:,9H#J=>"T1+H5V=OI0*R:="0;J:DX]Y@GQ) M%[U^--S%%K/.*S&7+4ITJ@64K^A=.8G=ADKN/C)[[\K)F`Y4>JGK`FF+/:#2 M%@.H2EOL0Z4M#H"TQ2%0:8LCJ$I;'$.E+4Z`M,4I4&F+,ZA*6YQ#I2TN@+3% M)5!IBRNH2EM<0Q6W:">J65@Z(U'3=:A\HB;(['!GF>0WG$QZ,%OW)E%UJ+:` MDA_#F/NH-M!ULHQ]XUR8.BC7*ET@->X!J2H`DN&2=9+2O0^55AP`J?T02%4C MH%+[,51:<0*D]E,@5F^=>[OUBB/J]AI M8Y:S\FD3KS)?FU\V%5W=\E-=NA"6SZ`$.5,=/1.G*ATB+?/K#I-4.I#:0*7C MH0.55NP"J7T/2%4!4*E]'RJM.`!2^R&0JD9`I?9CJ+3B!$CMIT"JF@&5VL^A MTHH+(+5?`JEJ!51JOX8JKF@GE5E/RR?5_[AHILMO^4Q*D#,7.3?^#^:W0.Y< ME%7$=;0-5>F8[D"EHZH+I&.O!Z2J`*C4O@^55AP`J?T02%4CH%+[,51:<0*D M]E,@5T,LG\9.N,3(KE]OIKBIPYR7F^ M?H!*QT4+2,=%&R@_+OR&>VV#RK[>.ZHN5-IB#TA;#(#R+?+E#BJM.`!2^R&0 MJD9`I?9CJ+3B!$CMIT"JF@$5;F;/4:H5%D!JNP12U0HHWVN_X5[SH/I5&.P\ M$Y659__7$Y]),IF/Y"8-D\]]BIR)S'F0?H!*!U,+Z%/FU0:ZC6^J/,])J0[* M=?QU@=2X!Z3&`9#,G24W55"I_0!([8=`:C\"*K4?0Z7V$R"UGP*I_0RHU'X. ME=HO@-1^":3V*Z!?G/4URF-C.ZDD07]#4AD7)ZD29'X6FL7+]VE.2U4ZF%JF MAG@U9%;-*O(C)51>G&>W-\[(ZJ3E.OJPUQ8' M0-KB$%ZE+8Z@*FUQ#'MM<0*D+4[A5=KB#*KD?/K.X)_#5YM:`&E32YB4-K5* M55?U9(JHUYTY8@WGN#$[6V4!K31;E]'[KQ:]HX!1G]&`T9#1B-&8T831E-&,T9S1@M&2T8K1VD)VO,T"]<=OTN6! MG^*:HOS$ZU\ZB_\/J'B;S18M1FU&'49=1CU&`:,^HP&C(:,1HS&C":,IHQFC M.:,%HR6C%2/S3E02>.W4K>,WY%VM>)6?2B[Q%I=3(J]W?2WT M,LT7M2Z-%^JEZ:*6OUZ*?WS)=QJ^EQX5\NNF_$BOX+!OFO)KK@+^J2D_$BK@ MMTWYH0ESV0MKFK5M+I$ML:99XN82V1EKFGVOHI)+*2DZ#ED9EY(B-]DNDW-; M5"+[ATVS.\CMR!:1E!2U(SL#4E+D)IN*3;,CP&ZRM]@T&P-<(EN,3;,9P"6R MF]HTFQQ<(INJ3;-E6E1R*25%O9:]$2DI=V_'RFOX)--`/=[7.B0O.B;_G-)+_;?H)"\HQE?]%WDA-92EW;KY`>I3 M%)WPCVD@>\7URW\!``#__P,`4$L#!!0`!@`(````(0!+-$1F!`8``&87```9 M````>&PO=V]R:W-H965TGBEQ$M001T!/S_GV.\8V8$].U&K[4IH?X[\]X[$]^.'K M]_IL?"--6]'+QK1G<],@EY+NJ\MQ8_[]5_QE91IM5USVQ9E>R,;\05KSZ^.O MOSR\T>:E/1'2&:!P:3?FJ>NN@66UY8G413NC5W*!-P?:U$4'/YNCU5X;4NS[ M1O79OU2TOH*$L_5N>I^]**F49=!=KS0IG@^@]_?;:\HI7;_`\G75=G0EAZZ M&V%:CP]]@/ZIR%L[^=]H3_0M M::K];]6%0+1AGM@,/%/ZPDRS/4/0V$*MXWX&_FB,/3D4K^?N3_J6DNIXZF"Z M%^`1?,F"=:?KM6@&3]%L M]9YF-J0#GQV6%R+R[QVSQ6>Z3YRPZ(K'AX:^&;`:82[;:\'6MAVP'F3*\/$/ M2?2S'()Y9RI/3&9C^J8!Z=%"XG][=);^@_4-DK44-EML8ZL6.VG!THG)ACJ( M=!#K(-%!JH-,!_D$6!"6(3:0P9\1&R;#8B.]VDHP"986"&DAFX0ZB'00ZR#1 M0:J#3`?Y!"B!@#7X&8%@,AL3_@Y)8OMZDG`;MFD-1@LM.(/)$!U$(D1B1!)$ M4D0R1/(I48($6]9G!(G)P&*$?6D(@+-J[(.MA)]DA$B(2(1(CDB"2(I(ADD^)XBB<`Q]PE%FK MCG+B.J.CB(2"P'(<$V&I;1718"03(49""2+IT&HB[:_5)9@-1E(ZGPHIX6#E M-3YC9ZQ"Z4Y5^;*EX`(<0C?6@@MG*3]AF8@:)4ZF44(D%,3C1_+<=E4OHN&] M]")&&@DBZ="J/^B1:C:\EZKY5$.)#2QD)38W8@#EE`P"LU:#((@WI@HB(2?> M:K")$(E1JP21%+7*$,FGK11'67'U`4][<]55@1S(E#'E5W-U1G?2JO]2$%44 MZQIJ>:7A0BN^(M'0F_>Y8CLKS2"6RKS<9_59(M'862K1WK;2![:35 MF!.A0.ZH%0GD.7W<7$?;F&*I,DTV/B)G%$ZQ<*8*.PMMW\X5835NK+2;QNW^ M7F2+2G!T:BN0,\[L#J-0(B7]\'+D\AZ??WOE:H[$HXR3X_13P]KV-A`)OOF+:HL_1=G65:9ZY> MI+'+MO[DFVR2_/*,WX'4I#F2'3F?6Z.DK^QBS%[#N`?,;^VV7@#?,S!:G2\" MJ/5O\&4`I3'FJ1]`U7B#KP*HF##/_0#J)LS#=0`%#.;I.H""!'.X=7SJ2VE] M_.PV\H;]U@G@)@#K;-T`OGXQ?_*")P@T?K'U@^TM!W9^L+O%0S^`BAWKA*L` M"E7,8S^`>U.)+?B^9875KC3`XPV?-^DVKX/2G_T=$K M)`%<5](.[C?[?T]PGTW@J)_/()D.E';R!^M@N"%__`\``/__`P!02P,$%``& M``@````A`,*X)&ULK)E;?;;P]# MSPS3+"?9W9<8?W;_!_YS87JX^^7;Y3SXFA9EEE_OA\9H,ARDUT-^S*XO]\,_ M?G>^K(:#LDJNQ^2<7]/[X?>T'/[R\/-/=^]Y\5J>TK0:@,*UO!^>JNIFCDG*4W](K_/*<%Y>D@J_%R[B\%6ERK),NY_%T,EF.+TEV'7(%J_B(1O[\ MG!U2.S^\7=)KQ46*])Q4!RL/R7:UXD3V>X[V_&/#F@=OV%R%^R0Y&7^7,U`KDQOU!ZS^OQ>@Q*#W?' M#.Z`V3XHTN?[X:-A[8WE`0;T)(!SN_%7F&2')F9#8XQVQ!8CV(QBLK8.=CIP=.#JP-.! MKX-`!Z$.(AW$.M@K8`S6"G]A-/P?_C(9YB\ZLT&@&*Z9B1&88NM@IP-'!ZX. M/!WX.@AT$.H@TD&L@[T"6F;"!"%FSF"N=J_+.#99%JS`RM@T9NNV61L>P]9X M,8`7[9"M"!&&$K(CQ"'$)<0CQ")M\R/3RX$3`;6 M$G@D"".GRWG;RDT3U.>V"!%N$[(CQ"'$)<0CQ"-F0M%M4M(38A.T(<0EQ"/$)\0@)"0D(B0F)"]BII&0:/ MYT\8QJ+;AG$RFTK#"+$;`LN,,C"UGK/HMM.D[;2VTNY$$%ZS0X1< M0CR1I=JQ;*\NO@A"Z8`(A81$(JM'.A9!*+U7A5I.PPKX":=9=-MI3E2G";$; M,A/C?D>(0[)<0CR1I=Z[J=DJ@O#>`R(4$A*)+%5ZU9:.11!*[U6AEJVL`FKY MRNN"$:OLJE-V>-WD,+]AT]LQLF>P_V^J`J;2]KL6AMV8LHA09".:2\LI5-VTS&,DH8C:B6;SO-*H>/KQ4&+S3XZ4?M M\@:1O,$M17:#9OR\@E57.XHM*4DP`!Y?2$BV5B$J+>Q&*.PL9GVX-UC0-U8NX=8 MS?&)'FI*E/I\KQGA'$U;S[J%OMUEYR>LA^0\L!&I@[Z)@EV2XJVV0W%HHHM( MRGN(I+R/J%<^P"B9&"*2\A$B&14CZI7?8U2=V.X+5I%\HB^:`D;M"XZFL/=1 M_-/V'5MVE*3/E@;)T;C#*)@TBA;I"Y+H8J(\CZI4/,$HFAHBD?(1( M1L6(>N7W&%4GMON"539J7_R[9VQ3'ZE=Q)$V7;0)NV7%O3Y=&K02:]P.HV"G MH'21MA=T,`KRE2AM/7(Q2@YQ#Y$^W5$;^96G!D M2G4V,PO.^RA_G%N/X!_]83.WX,B*\L"TV`:9_A":%MLFTQ\BTX)ZN8.O+*CN M.OC:@O*D@QL3,*FK!<>T6`%`4US38F4`_<$S+3@>Z.`K"XK9#KZV_*YK@HH" MNK2KA8UI;3I_V)K6MO,'V[3@-(2V;:\LJ-T[^-J"XK.#PS7M>`MC,6K@E>0M M>4GCI'C)KN7@G#[#/)C4-5S!7VKR+U5^JVNYI[R"EY'UOR=X^9Q"C3`9P9+^ MG.<5?H&FQ^)U]L/?````__\#`%!+`P04``8`"````"$`B?NRX)P#``#V"P`` M&0```'AL+W=OCT/=8F8J,E_NU_^OGW=7"]Y2F949S4;*U_\R4?[WY^&%U$O)! M'1C3'B"4:NT?M*[B(%#I@154C43%2EC9"5E0#:]R'ZA*,IJ9344>1&$X"PK* M2]\BQ/(U&&*WXRF[%>FQ8*6V()+E5`-_=>"5:M"*]#5P!94/Q^HJ%44%$/<\ MY_K9@/I>D<9?]J60]#Z'WCU3^HXCHN^E1Z5%\(LO;GO@?G59#(QTTTG:^"1Q`_K7VV0Q_B>B2- M!^8,Z+4<09MWX(@HR!'SB*2WC:%#ND>H\>@3`J'>@1"B0,DXHBUOWQ-H:&S8=-FL;9$ MINI(V!.G7G5%?JE,I\S@B*\G@LXND=KR4F!)U^)$@HO2C60N70C%]L9;AS`N MA]JR=)*U[&G2.O4S@=^U3B^XG`ET=H/7ED5[PY*NQ1$`"'8CH0"+)3;9MTJ` M0"Z+VN)(,.N71>O4EX#`1Z3+[+(&QML-WYB6+RHX)D<&70_$-DMH%.W5;$Q=+6HO8W*UP#[6B88U$GHYOP.V'`."4*<]8<`9LCJXT_B M&SM]]1:VDSB9G`LPBZ'EG3G"/$Y,5^SC+&+H$&?\EW%B,]!N@*FKHGOVC&ULK)IM;^)&$,??5^IW0+P_P`;C8(6<#C];K515 MU_:U`R98!QC9SN7NVW?6N^-]&(>0-F_.Q\^S?^_.SLZ.U[G__.-T''TOZJ:L MSNNQ-9F-1\5Y6^W*\]-Z_-?7Z-/=>-2T^7F7'ZMSL1[_+)KQYX=??[E_J>IO MS:$HVA$HG)OU^-"V%V\Z;;:'XI0WD^I2G.'.OJI/>0L_ZZ=I4?IF%?3U124'NYW)8R`N7U4%_OU^(OE9?9B/'VX[QST=UF\-,K_1\VA M>HGK2[`VS!/;`8>J^H;,TUW#$'C*6D==3/P1SW:%?O\^=C^6;TD1?ET M:&&Z'1@1&YBW^QD4S18\"C(3VV%*V^H('8!_1Z>2A09X)/^Q'MOPX'+7'M;C M^7+BN+.Y!>:CQZ)IHY))CD?;YZ:M3O]P(TM(<9&Y$(&K$+'@<7>.Y2R9RI66 M"]$2KJ(E=.2*/:AUW86KL'O=]`5[>"* M[6X<&JRPKJMPO6EH*V$/U_<-S8*@Z9[$_G-;)Z<\"KJ@"O(V?[BOJY<1K%28 MY^:2LW5O>4P.PXE[M@^PU^(+`HNI?&$RZS'X#$*G@47Q_<%>.O?3[Q#(6V&S MH3:6;N&C!8M:)AN8(#1!9(+8!(D)4A-D"IB"6WK?0&1^A&^8#/,-CFJ#0'&6 MX0BTP":!"4(31":(39"8(#5!I@#-$;#,/\(13`;2C1(DUG*FCWS#;5A"ZR/) MB"._-^F]0TA(2$1(3$A"2$I(IA+-29#1/L))3`86(Z2MW@'V5J@3"0@^$L#?"0(@(B0E) M"$D)R3BQNBYJ8VCYT]<#T+6$E8R5`Q/(3EO66 M8Q3M(5I!RI=6RSM=/D(K7TJV1$VH1B%'-M/I7;=H8GRTDI,9(-+V7;K\A#QL-M+A=+,05KH667["2G8BN:D3*5K9KVT6_>/) MZF.%K.KJ-R).U+VJ?SE28LFW"`H0R9`($4FM")&TBA&IX27DI56*5E(K0S00 M7JQ`5<=\>WB)TE8^9@.O`-U2`@\K\V]L.SY:R9D-$,E<$0JTF+VZ+XJ'R38Q MRDCE!)&T2@WE@7U15=;R,^3*_^BMKJ6>D@72]T+7W`O12LYY@$C.>8A(3D:$ M2%K%B*16@DA:I8BD5H:(Q@^KQ$G\O+M2Z%0,[_""?:%E"==XS_=%0^@?9NI` M(+7&$FBAY27'\'2$6C)48D12/J'RJ91GKX7NTDAE&:ITPGH\L;*R5PC;K2%U9*K@H0W?5:(6HM7EN&V$8&4(Q(#3/>2ULJ MI[KRW6)F5O4H,Q!T9E5_/5&S%6:40P(I<>-3%""2$1$BDB5,A$A:Q8C4N!'O M#-(J12NIE2$:")4/*'>)0G*P^.X8!/^P[!!_)+_E3\GM=/Y;D9 M'8L]3."L>YFM^2=V_J,5+U>/50N?QF&.X8,I_"E$`<=`,_8-8U]5+?Y@#^C_ MN.+A7P```/__`P!02P,$%``&``@````A`.\8&<8S`0``0`(``!$`"`%D;V-0 M-TSS$ MH]M@R\4[WP">Y/DEUA"XY('C/3"U(Q$-2"E&I/UP=0^0`D,-&DSPF&0$?W<# M..W_O-`G)TVM0F?C3(/N*5N*0SBV=UZ-Q;9MLW;::T1_@E\6#T_]J*DR^UT) M0&R_GYK[L(BK7"N0MQW;O;DZ\7Y;XM]9*45O1X4#'D`F\3UZL#LFS].[^^4< ML4E.BC2?I*18DAN:7]&+XK7$Q]9PGXU`/0C\FW@$L-[[YY^S+P```/__`P!0 M2P,$%``&``@````A`(A)\Y[L`@``]P@``!``"`%D;V-0&UL M(*($`2B@``$````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````G%9=;YLP M%'V?M/\0\=Z2MM$T582*`&G0$A-ADNW-N??/' M.?<>'U]\<>Z>MWFO8E)Q40RMJ\N^U6-%)E:\>!Q:BW1\\=WJ*4V+%,Y8[=WG1`'6;9D^1ZY_8=NSUU<$9SYD-@=TUSQ1S[ M=<&9,%J;-J=<*M>I]&W%,BUD3_$_8-NUU7N@BM5RAE9%):>%!EDUK)GLQWFI MM'1_"OE;;1C3RK$!T"SNAVUL>\P'[LU@CX#1*;*.T"B!C5.-*=9@0//$2L_@(+4.4QDD48F,D'-[/ M`$`B-(Z3V;L94^_7F4!!.$J-&9(0I\G"3Q=)A.Z-B+$7)63I31=A[=4X0G#C MD3<%33732)EYR+N'"T,I&``58@2=<92D]`%JVT@Q&MM-./K;!3/8W`4_\:P+ MV&V=N3;/V8*HE%0;;3E'P4_;+95&BMG))@>O/D!)6":*C,-3?'PKZJ>Q>6A: MY4T"IBG/S?=J\K\+_Z)^7^Z=@>NR)TAH1N9T5]?5^^B$52*OH!V0*2\8$6OB M2[;BFAA/>%H*!_\.:?Z#TMS1KLZ3,&@A1DIW'5T;.6^_0=/)3SK,FYX"I_^M M%F4J`JK9H6F>+CIX0\$;:">'_=<%9P+]4N9U$']#BT>V.F#^W:A;_++YCW&O M!I?]FSYT[]::8[_^L;A_`0``__\#`%!+`0(M`!0`!@`(````(0`:,QE5V@$` M`#$6```3``````````````````````!;0V]N=&5N=%]4>7!E&UL4$L! M`BT`%``&``@````A`+55,"/U````3`(```L`````````````````$P0``%]R M96QS+RYR96QS4$L!`BT`%``&``@````A`/Y[WY32`0``'!4``!H````````` M````````.0<``'AL+U]R96QS+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`"YF2S6=`@``!`<``!D`````````````````RAL``'AL+W=O M'@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`()R MB%)N`P``H"``!O"```&0`````````` M``````#2*0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,%IA%))!0``MQL``!D` M````````````````]S```'AL+W=O#@``&0````````````````!W-@``>&PO M=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+6V M56`9+0``J8@``!0`````````````````E$0``'AL+W-H87)E9%-T&UL4$L!`BT`%``&``@````A`.FW\ANC"P``$V8```T````````````````` MWW$``'AL+W-T>6QE&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0` M!@`(````(0!Q?.[J%`,```$)```9`````````````````'*$``!X;"]W;W)K M&UL4$L!`BT`%``&``@````A``VJ)4V4`P``6@P` M`!@`````````````````O8<``'AL+W=O+``!X M;"]W;W)K&UL4$L!`BT`%``&``@````A`(EN[+[U M!0``(Q<``!D`````````````````/X\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`%6F\75&PO=V]R:W-H965T&UL4$L! M`BT`%``&``@````A`-VA+=9?`P``5`H``!@`````````````````\KH``'AL M+W=O^``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*1"\]G&!P``CR$``!D````````` M````````KLT``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`%LGH-S)"P``)SL``!D`````````````````A^<``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`(G[LN"<`P``]@L``!D`````````````````:P$!`'AL+W=O&PO=V]R:W-H965T[`(``/<(```0```````` M`````````.X/`0!D;V-0&UL4$L%!@`````K`"L`GPL``!`4 $`0`````` ` end XML 15 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
May 12, 2012
Class B Warrant [Member]
Dec. 31, 2013
Derivative Financial Instruments, Liabilities [Member]
Class A Warrant [Member]
Sep. 30, 2013
Derivative Financial Instruments, Liabilities [Member]
Class A Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]          
Risk-free interest rate       0.52% 0.51%
Dividend yield       0.00% 0.00%
Volatility of the Company's common stock       72.83% 71.15%
Expected life of the options       2 years 4 months 6 days 2 years 7 months 6 days
Fair value per unit       $ 1.396 $ 0.444
Fair value of warrant liability $ 1,573 $ 612 $ 0    

XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME (LOSS) PER SHARE (Reconciliation of Computation of Basic Income or Loss Per Share to Diluted Income or Loss Per Share) (Details) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Basic net income (loss) per share:    
Net income (loss) applicable to common shareholders $ (662) $ 256
Weighted average common shares outstanding 7,735 7,639
Basic net income (loss) per share $ (0.09) $ 0.03
Diluted net income (loss) per share:    
Diluted net income (loss) applicable to common shareholders $ (662) $ 256
Weighted average common shares outstanding 7,735 7,639
Plus: Incremental shares from assumed conversions    
Series A preferred shares    767
Diluted weighted average common shares outstanding 7,735 8,406
Diluted net income (loss) per share $ (0.09) $ 0.03
XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES
3 Months Ended
Dec. 31, 2013
INVENTORIES [Abstract]  
INVENTORIES
  4. INVENTORIES

 

Inventories consisted of the following:

 

    December 31,
2013
    September 30,
2013
 
             
Raw materials   $ 1,281     $ 1,157  
Work in progress     235       322  
Finished goods     323       259  
    $ 1,839     $ 1,738  
Obsolescence reserve     (388 )     (359 )
    $ 1,451     $ 1,379  
EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V M-CDT.#,T-V(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5D5.5$]22453/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T M4V]U#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DE.0T]-15]405A%4SPO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1%0E0\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-43T-+0D%3141?0T]-4$5.4T%4 M24].7U1A8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DE.0T]-15],3U-37U!%4E]32$%215]486)L97,\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)%4U1254-455))3D=?5&%B;&5S/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+0D%3141?0T]-4$5.4T%424].7TYA#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-43T-+0D%3141?0T]- M4$5.4T%424].7U-U;6UA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.0T]-15],3U-37U!%4E]32$%215].87)R871I=CPO>#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5D5.5$]224537T1E=&%I;',\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1%0E1?3F]T95]087EA8FQE7T1E=&%I;',\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T* M("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^1&5C M(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)U$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)SQS<&%N/CPO'0^)T))3T%.04Q95$E#04P@ M4UE35$5-4R!)3D,\"!+97D\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO M'0^)RTM,#DM,S`\'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A M.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T-V(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P,%\T,#5D7V$Y.3)? M-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!A;F0@97%U M:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'!E;G-E'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO3H\+W-TF5D(#$L,#`P+#`P,"!S:&%R97,L(&YO('!A M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA&-E<'0@4VAA'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^ M)SQS<&%N/CPO'!E;G-E&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@V-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#(\2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG)FYB'0^)SQS<&%N/CPO2!I;G9E'0^)SQS<&%N/CPO6UE;G1S(&]F(&QO;F6UE;G1S(&]N(')E=F]L=FEN9R!L:6YE M(&]F(&-R961I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S&-H86YG M92!R871E(&-H86YG97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7 M,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W M=W&AT;6PQ+71R86YS:71I;VYA;"YD M=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE M('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@"<^)FYB6QE/3-$)U=)1%1( M.B`P+C5I;B<^/'-T3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@0FEO86YA;'ET:6-A M;"!3>7-T96US+"!);F,N(&%N9"!I=',@6QE M/3-$)U1%6%0M04Q)1TXZ(&IU"<^("9N8G-P M.SPO<#X@/'`@6EN9R!U;F%U9&ET960@:6YT97)I;2!C;VYD M96YS960@8V]N2P@ M=&AE>2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N M9"!F;V]T;F]T97,@28C,SD[3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T-V(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P,%\T M,#5D7V$Y.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z M+R]W=W&AT;6PQ+71R86YS:71I;VYA M;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A M8FQE('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@"<^)FYB6QE/3-$)U=) M1%1(.B`P+C5I;B<^/'-T6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^("9N8G-P.SPO<#X@/'`@&5R8VES92!P'!E;G-E(&9O M2P@:6X@2!A;'-O(&ES2!F;W(@=&AE('1H6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\ M=&0^)FYB6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG M/B`\=&0@6QE/3-$)U=)1%1(.B`Q,"4[(%1%6%0M04Q)1TXZ(')I9VAT)SXQ+C,U M/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F M="<^)FYB6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T M>6QE/3-$)U!!1$1)3D&5R8VES960\+W1D/B`\=&0^ M)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^+3PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D M/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S M<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@-#,Y/"]T9#X@/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA&AT M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I M=CX\(2TM4W1A2<^/'-T6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB M2!H87,@=&AR964@8V%T96=O2`R,#$Q(&EN(&-O;FYE8W1I;VX@=VET M:"!T:&4@2`R,#$Q+"!A;F0@2!W97)E(&%N=&DM9&EL=71I M=F4N(%=A2!W97)E(&%N=&DM9&EL=71I=F4N(%=A6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^5&AR964@36]N M=&AS($5N9&5D/&)R("\^($1E8V5M8F5R(#,Q+#PO=&0^(#QT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXR,#$S/"]T M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/B`\=&0^)FYB6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/D)A6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$ M)U=)1%1(.B`W-"4[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)U=)1%1(.B`Q,"4[(%1%6%0M04Q) M1TXZ(')I9VAT)SXH-C8R/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@ M5$585"U!3$E'3CH@;&5F="<^*3PO=&0^(#QT9"!S='EL93TS1"=724142#H@ M,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U! M3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M="<^("0\+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O M=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG M/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^ M(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R M,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXH-C8R/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/BD\+W1D/B`\=&0^)FYB M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-RPW,S4\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E' M3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SPA M+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@ M5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^ M/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1) M0T%,+4%,24=..B!T;W`G/B`\=&0@"<^)FYB M6QE/3-$)U=)1%1(.B`P+C5I;B<^/'-T3L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@;F]W6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^1&5C96UB97(@,S$L/&)R("\^ M(#(P,3,\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R M87`^4V5P=&5M8F5R(#,P+#QB6QE/3-$ M)U!!1$1)3D6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^ M)#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,3@E.R!415A4+4%,24=..B!R M:6=H="<^,2PR.#$\+W1D/B`\=&0@6QE/3-$)U=)1%1(.B`Q."4[ M(%1%6%0M04Q)1TXZ(')I9VAT)SXQ+#$U-SPO=&0^(#QT9"!S='EL93TS1"=7 M24142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^ M(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,S(R/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO M='(^(#QT6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)! M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q M<'0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T M(&1O=6)L93L@5$585"U!3$E'3CH@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T14 M1"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM M/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@"<^)FYB6QE/3-$)U=)1%1(.B`P+C5I M;B<^/'-T#L@ M5$585"U)3D1%3E0Z(#`N-6EN)SX@5V4@;W!E7-I;VQO9VEC86P@;6]N:71O M2!O9B!S:6=N:69I8V%N="!A M8V-O=6YT:6YG('!O;&EC:65S(&9O=6YD(&EN($YO=&4@,B!T;R!#;VYS;VQI M9&%T960@1FEN86YC:6%L(%-T871E;65N=',@:6X@;W5R(&%N;G5A;"!R97!O M65A6QE/3-$)U=)1%1(.B`W-24[($)/4D1%4BU#3TQ,05!3 M13H@8V]L;&%P6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0^ M4F5V96YU93H\+W1D/B`\=&0^)FYB6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`V,B4[(%!!1$1) M3D6QE/3-$)U=)1%1( M.B`Q)2<^)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$58 M5"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,38E M.R!415A4+4%,24=..B!R:6=H="<^-"PY,38\+W1D/B`\=&0@6QE M/3-$)U=)1%1(.B`Q-B4[(%1%6%0M04Q)1TXZ(')I9VAT)SXT+#8W,#PO=&0^ M(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/D]P97)A=&EN9R!I;F-O;64Z/"]T9#X@/'1D M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF M;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXT,C0\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SXQ.3D\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXT-C(\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS M,#(\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T M;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D/B9N8G-P.SPO=&0^ M(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXH,38U/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/BD\+W1D/B`\+W1R/B`\='(@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ,3<\+W1D/B`\=&0@6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U9%4E1) M0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@ M/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT M.#,T-V(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-? M-F4P,%\T,#5D7V$Y.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE/3-$)U=)1%1(.B`P<'@G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=724142#H@,"XU:6XG/CQS=')O;F<^-BX\+W-T2<^/'-T M3L@1D].5#H@,3!P="!4:6UE"!A"!C;VYS97%U96YC97,@871T"!B87-E"!C"!R871E'!E8W1E9"!T;R!A<'!L M>2!T;R!T87AA8FQE(&EN8V]M92!I;B!T:&4@>65A'!E8W1E9"!T;R!B92!R M96-O=F5R960@;W(@'!E8W1E9"!R96%L:7IA=&EO;B!O9B!T87@@87-S971S+CPO<#X@ M/'`@6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@5V4@2!I9B!I="!I2!T:&%N(&YO="!T;R!B92!S=7-T86EN960@=7!O;B!E>&%M M:6YA=&EO;B!B87-E9"!O;B!T:&4@=&5C:&YI8V%L(&UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@ M070@1&5C96UB97(@,S$L(#(P,3,@86YD(%-E<'1E;6)E2!F;W(@=6YC97)T86EN(&EN8V]M92!T M87@@<&]S:71I;VYS+B!4:&4@9&EF9F5R96YC92!B971W965N('1H92!F961E M2!R871E(&]F(#,T)2!A;F0@;W5R(&5F9F5C=&EV92!R M871E(&]F(#`E(&ES(&1U92!T;R!C:&%N9V5S(&EN(&]U6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M"<^("9N8G-P.SPO<#X@/'`@2!F;W(@ M=6YC97)T86EN('1A>"!P;W-I=&EO;G,@=V]U;&0@:6UP86-T(&]U'!E8W0@=&AE('1O=&%L(&%M M;W5N="!O9B!U;G)E8V]G;FEZ960@=&%X(&)E;F5F:71S('1O('-I9VYI9FEC M86YT;'D@8VAA;F=E(&EN('1H92!N97AT('1W96QV92!M;VYT:',N/"]F;VYT M/CPO<#X@/'`@7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L M+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A6QE M/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)U1%6%0M04Q)1TXZ M(&IU"<^(#QS=')O;F<^)FYB6%B;&4\+V5M/CPO<#X@/'`@2`D-2PR M,#4@870@1&5C96UB97(@,S$L(#(P,3,L('=H:6-H(&ES('-E8W5R960@8GD@ M;6]R=&=A9V5S(&]N(&]U3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&IU M#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@3VX@ M3F]V96UB97(@.2P@,C`Q,BP@=V4@97AE8W5T960@82!S:7AT:"!A;65N9&UE M;G0@=VET:"!296=I;VYS('=H:6-H('=E(&9U6%B;&4@9F]R("0U M+#6UE;G1S(&]F(&%P<')O>&EM871E;'D@)#0W('!L=7,@:6YT97)E M6%B;&4@:7,@2!R96%L(&5S=&%T92!A="!O=7(@5V5S="!,869A>65T=&4@86YD($5V86YS M=FEL;&4L($EN9&EA;F$@;&]C871I;VYS+B!!="!397!T96UB97(@,S`L(#(P M,3,L('1H92!R97!L86-E;65N="!N;W1E('!A>6%B;&4@:&%D(&$@8F%L86YC M92!O9B`D-2PR-30N/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..B!J=7-T M:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3L@1D].5#H@ M,3!P="!4:6UE&5C=71E9"!A('-E=F5N=&@@86UE;F1M96YT('=I=&@@4F5G M:6]N'1E;F0@=&AE(&YO=&4@<&%Y86)L92!M871U2!D871E M('1O($]C=&]B97(@,S$L(#(P,30N/"]P/B`\<"!S='EL93TS1"=415A4+4%, M24=..B!J=7-T:69Y.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E3L@1D].5#H@,3!P="!4:6UE2!O9B!T:&4@;&]A;G,@86YD(&-A=7-E(&$@8W)O3L@1D].5#H@,3!P="!4:6UE3L@ M1D].5#H@,3!P="!4:6UE2X@07,@;V8@1&5C96UB97(@,S$L(#(P,3,L('1H92!N M970@8F]O:R!V86QU92!O9B!T:&4@9F%C:6QI='D@86YD(&QA;F0@=V%S("0Y M+#$R-BX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"<^(#QE;3Y2979O;'9I;F<@3&EN92!O9B!#6QE/3-$)T9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@070@1&5C96UB97(@,S$L(#(P M,3,L('=E(&AA9"!A("0S+#`P,"!R979O;'9I;F<@;&EN92!O9B!C2!N;W1I8V4@;V8@:6YT96YT('1O('1E#L@ M5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB2!A(&)L86YK970@;&EE M;B!O;B!O=7(@<&5R2P@86YD M(&EN=&5L;&5C='5A;"!P2!A2!O9B`D,2PX-#4@ M;VX@=&AI6QE/3-$)T9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB6QE M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@)FYB7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I M=CX@/&1I=CX\(2TM4W1A2<^/'-T3L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@26X@36%R8V@@,C`Q,BP@=V4@86YN;W5N8V5D(&$@ M<&QA;B!T;R!R97-T2!I;B!-8TUI;FYV:6QL92P@3W)E9V]N(&EN=&\@;W5R(#$R,"PP,#`@2!A;F0@8FEO86YA;'ET:6-A;"!L86)O2!O9B!O=7(@0U)/ M('-E#L@5$585"U)3D1%3E0Z(#`N M-6EN)SX@5V4@6UE;G1S(&%T('1H92!C M96%S92!UFEN9R!I;G1O(&=E;F5R86P@86YD(&%D;6EN:7-T3L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M5T5)1TA4.B!B M;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^("9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@4$%$ M1$E.1RU"3U143TTZ(#%P="<@;F]W6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z M(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N M;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!B;&%C:R`Q<'0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E' M2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\ M=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U=)1%1( M.B`Q)2<^)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$58 M5"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U=)1%1( M.B`Q,"4[(%1%6%0M04Q)1TXZ(')I9VAT)SXX-S<\+W1D/B`\=&0@6QE M/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE M/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U=)1%1(.B`Q,"4[(%1%6%0M04Q)1TXZ(')I9VAT)SXX M.3@\+W1D/B`\=&0@6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H M:71E)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/E1R879E;"!A M;F0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/DQO6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!R:6=H="<^*#$V/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/BD\+W1D/B`\=&0^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^.#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^*#@\+W1D M/B`\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@ M6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F M="<^("0\+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\ M+W1D/B`\=&0@6QE/3-$)U!!1$1)3D3L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@5$58 M5"U)3D1%3E0Z(#`N-6EN)SX@3W1H97(@8V]S=',@:6YC;'5D92!L96=A;"!A M;F0@<')O9F5S2!I;B!T:&4@'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SPA+2U$3T-465!% M(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO M;F%L+R]%3B(@(FAT='`Z+R]W=W&AT M;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T M1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!T;W`G/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&IUF5S('1H92!U6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@)FYB6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T M;W`G/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@5TE$5$@Z(#`N,C5I;B<^ M)F)U;&P[/"]T9#X@/'1D/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^3&5V96P@,B`M(%9A;'5A=&EO;G,@8F%S960@;VX@<75O=&5D('!R:6-E M2!O6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0^)FYB2`R,#$Q+"!W92!I2!D971E2!F86ER('9A;'5E(&UE87-U6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS M<&%N/3-$,CY787)R86YT($$\+W1D/B`\=&0@6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U=)1%1( M.B`V,B4[(%1%6%0M04Q)1TXZ(&QE9G0G/E)I6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB M6QE/3-$)U=)1%1(.B`Q-B4[(%1%6%0M04Q)1TXZ M(')I9VAT)SXP+C4R/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@5$58 M5"U!3$E'3CH@;&5F="<^)3PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,38E M.R!415A4+4%,24=..B!R:6=H="<^,"XU,3PO=&0^(#QT9"!S='EL93TS1"=7 M24142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G/B4\+W1D/B`\+W1R/B`\='(@ M6EE;&0\+W1D/B`\=&0^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^,"XP,#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SXE/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/E9O;&%T:6QI='D@;V8@=&AE($-O;7!A;GDF(S,Y.W,@8V]M;6]N('-T M;V-K/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B4\+W1D/B`\=&0^)FYB6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^-S$N,34\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BXS-3PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BXV/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO M='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+C0T-#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\ M+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2`R,#$Q(&%N9"!R96YE M=V5D(&]N($]C=&]B97(@,S$L(#(P,3,N/"]P/B`\(2TM16YD1G)A9VUE;G0M M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T M-V(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P M,%\T,#5D7V$Y.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N M/CPO6QE/3-$)U=)1%1(.B`P+C5I M;B<^/'-T2<^/'-TF4@=&AE($-O;7!A;GDF(S,Y.W,@:6YT MF4@9G)E92!C87-H(&9L;W<@9G)O;2!O<&5R M871I;F<@86-T:79I=&EE6QE/3-$)U1%6%0M04Q)1TXZ M(&IU#L@5$585"U)3D1%3E0Z(#`N-6EN)SX@ M)FYB6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE#L@5$585"U) M3D1%3E0Z(#`N-6EN)SX@5V4@;F5G;W1I871E9"!A;B!A;65N9&UE;G0@=&\@ M;W5R(&QO86YS('=I=&@@4F5G:6]N'1E;F1I;F<@=&AE(&UA M='5R:71Y(&1A=&4@=&\@3V-T;V)E2!I;B!797-T($QA9F%Y971T92P@26YD:6%N82!W:71H('1H92!I;G1E M;G0@=&\@;&5A'!E8W0@=&\@'!I'1087)T7V$X-CAF,F$S7S9E,#!?-#`U9%]A.3DR7S0P,C8V.30X,S0W8@T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A.#8X9C)A,U\V93`P7S0P M-61?83DY,E\T,#(V-CDT.#,T-V(O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&AT;6PQ+T141"]X M:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A M2!O9B!O=7(@&-E<'0@ M9F]R('-H87)E('!R:6-E6QE/3-$)U=)1%1(.B`X-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N M/3-$,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960M/&)R("\^($%V97)A9V4\ M8G(@+SX@17AE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$ M,B!N;W=R87`],T1N;W=R87`^5V5I9VAT960M/&)R("\^($%V97)A9V4\8G(@ M+SX@1W)A;G0@1&%T93QB6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$ M)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL M93TS1"=724142#H@,3`E.R!415A4+4%,24=..B!R:6=H="<^,2XW-SPO=&0^ M(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G/B0\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U!!1$1)3D6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M('=H:71E)SX@/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N M-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A M.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T-V(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P,%\T,#5D7V$Y.3)? M-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE#L@5$585"U)3D1% M3E0Z(#`N-6EN)SX@5&AE(&9O;&QO=VEN9R!T86)L92!R96-O;F-I;&5S(&]U M6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^)FYB M6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VTG/B`\=&0^)FYB6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R M)R!C;VQS<&%N/3-$,CXR,#$R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U=) M1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS M1"=724142#H@,3`E.R!415A4+4%,24=..B!R:6=H="<^*#8V,CPO=&0^(#QT M9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G/BD\+W1D M/B`\=&0@6QE/3-$)U=)1%1(.B`Q,"4[(%1%6%0M04Q)1TXZ(')I9VAT)SXR-38\ M+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#PO='(^(#QT6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXR-38\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXW+#8S.3PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U M+#(P-"DG/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U! M3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!B;&%C:R`Q<'0@6QE M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\=&0@ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T-V(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P,%\T,#5D7V$Y M.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!O9B!);G9E M;G1O'0^)SPA+2U$ M3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A M;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M M+5-T87)T1G)A9VUE;G0M+3X@/'`@6QE/3-$)T9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE"<^ M("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`U,"4[($)/4D1% M4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\ M=&0^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)! M0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)U=)1%1(.B`Q)2<^ M)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E' M3CH@;&5F="<^)#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,3@E.R!415A4 M+4%,24=..B!R:6=H="<^,2PQ-3<\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR,S4\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#@S.3PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^ M(#QT6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)U!!1$1)3D3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T-V(- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P,%\T M,#5D7V$Y.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O M+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W&AT;6PQ+71R86YS:71I;VYA;"YD=&0B M("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T M>6QE/3-$)U=)1%1(.B`W-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0^4F5V96YU93H\+W1D M/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E M)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`V,B4[(%!!1$1)3D6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F M="<^)#PO=&0^(#QT9"!S='EL93TS1"=724142#H@,38E.R!415A4+4%,24=. M.B!R:6=H="<^-"PY,38\+W1D/B`\=&0@6QE/3-$)U=)1%1(.B`Q M-B4[(%1%6%0M04Q)1TXZ(')I9VAT)SXT+#8W,#PO=&0^(#QT9"!S='EL93TS M1"=724142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO M='(^(#QT6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@ M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^)FYB6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM' M4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/D]P97)A=&EN9R!I;F-O;64Z/"]T9#X@/'1D/B9N8G-P.SPO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)FYB M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P M.SPO=&0^(#PO='(^(#QT6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXT,C0\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ.3D\ M+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"DG/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXT-C(\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS,#(\+W1D/B`\=&0@ M6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z('=H:71E)SX@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\ M+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXH,38U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/BD\+W1D/B`\+W1R/B`\='(@6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXQ,3<\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U M+#(P-"DG/B`\=&0@6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D/B9N8G-P.SPO M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@ M5$585"U!3$E'3CH@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T-V(-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P,%\T,#5D7V$Y M.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA'0^)SPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T14 M1"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM M/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VTG/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'2%0Z(&)O;&0[(%1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M5T5)1TA4.B!B M;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^("9N M8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q M<'0@6UE;G1S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!0 M041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.1RU" M3U143TTZ(#%P="<@;F]W6QE/3-$)T9/3E0M5T5)1TA4 M.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^ M("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C M:R`Q<'0@6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T M)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/D]N92UT:6UE('1E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B0\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^ M(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)U=)1%1(.B`Q)2<^ M)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E' M3CH@;&5F="<^)FYB6QE/3-$)U=)1%1(.B`Q,"4[ M(%1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1( M.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U=)1%1( M.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE M/3-$)U=)1%1(.B`Q,"4[(%1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D M('-T>6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U=)1%1(.B`Q,"4[(%1%6%0M04Q)1TXZ(')I M9VAT)SXR,3PO=&0^(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,3`E M.R!415A4+4%,24=..B!R:6=H="<^.#DX/"]T9#X@/'1D('-T>6QE/3-$)U=) M1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S M<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT M9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO M=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H M="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S M<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^+3PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/BD\+W1D/B`\+W1R/B`\='(@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@ M6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\ M=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D M/B`\=&0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA&AT;6PQ+T141"]X:'1M;#$M=')A;G-I M=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A6QE/3-$)U=)1%1(.B`W-24[($)/ M4D1%4BU#3TQ,05!313H@8V]L;&%P6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0^)FYB6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$ M)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G M8B@R,#0L,C4U+#(P-"DG/B`\=&0@6QE/3-$)U=)1%1(.B`Q)2<^)FYB6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^ M)FYB6QE/3-$)U=)1%1(.B`Q-B4[(%1%6%0M04Q) M1TXZ(')I9VAT)SXP+C4Q/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)3L@ M5$585"U!3$E'3CH@;&5F="<^)3PO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXP+C`P/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B4\+W1D/B`\=&0^)FYB6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4 M+4%,24=..B!R:6=H="<^,"XP,#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)SXE/"]T9#X@/"]T6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U M+#(P-"DG/B`\=&0@2!O9B!T:&4@0V]M<&%N>28C,SD[6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^ M-S(N.#,\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT)SXW,2XQ-3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M)SXE/"]T9#X@/"]T6QE/3-$)U9%4E1)0T%,+4%,24=..B!B M;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/D5X<&5C=&5D(&QI9F4@;V8@=&AE(&]P=&EO M;G,@*'EE87)S*3PO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXR+C,U/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR+C8\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T], M3U(Z(')G8B@R,#0L,C4U+#(P-"DG/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+C,Y-CPO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#PO=&%B M;&4^(#PA+2U%;F1&'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA65E(%-T;V-K($]P=&EO;B!;365M M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M6UE;G0@07=A'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT M.#,T-V(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-? M-F4P,%\T,#5D7V$Y.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2D@*$1E=&%I;',I("A%;7!L;WEE92!3=&]C:R!/<'1I M;VX@6TUE;6)E'0^)SQS<&%N/CPO&5R8VES960\+W1D/@T*("`@("`@ M("`\=&0@8VQA&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A M.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T-V(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P,%\T,#5D7V$Y.3)? M-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M/B@V-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2!F;W(@;W1H97(@=6YC M97)T86EN(&EN8V]M92!T87@@<&]S:71I;VYS/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS M-"XP,"4\"!R871E/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6%B;&4I("A$971A:6QS*2`H55-$("0I M/&)R/DEN(%1H;W5S86YD'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^3V-T(#,Q+`T*"0DR,#$T/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS M<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG;6]N=&AL>3QS<&%N/CPO6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A.#8X9C)A,U\V93`P7S0P-61?83DY M,E\T,#(V-CDT.#,T-V(-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M83@V.&8R83-?-F4P,%\T,#5D7V$Y.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!O9B!F86-I;&ET M:65S(&9E92!P87EM96YT'0^)V%N;G5A;&QY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO2!A(&)L86YK970@;&EE M;B!O;B!O=7(@<&5R2P@86YD M(&EN=&5L;&5C='5A;"!P2!A'0^)SQS<&%N/CPO M3QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65E M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO65E M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G1S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB'0^)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#XG)FYB'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N M/CPO'0^)R9N M8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB M'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO'0^)R9N8G-P.R9N8G-P M.SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]A.#8X9C)A,U\V93`P7S0P-61?83DY,E\T,#(V-CDT.#,T-V(-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83@V.&8R83-?-F4P,%\T,#5D M7V$Y.3)?-#`R-C8Y-#@S-#=B+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-E<'0@4&5R(%-H87)E(&1A=&$L('5N;&5S M2`Q,BP@,C`Q,CQB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2!O9B!T:&4@0V]M<&%N>2=S(&-O;6UO;B!S=&]C M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'!E8W1E9"!L:69E(&]F('1H92!O<'1I;VYS/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO7,\7,\'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M M;6EC XML 20 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEBT (Note Payable) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Debt Instrument [Line Items]    
Net book value of facility and land $ 9,126  
Asking price 10,800  
Second Replacement Note Payable [Member]
   
Debt Instrument [Line Items]    
Long-term debt 5,205 5,254
Debt instrument, maturity date Oct. 31, 2014  
Debt instrument, interest rate 6.00%  
Debt instrument, frequency of periodic payments monthly  
Debt instrument, principal payment 47  
Debt instrument, face amount $ 5,786  
Debt instrument, variable interest reference rate LIBOR  
Debt instrument, basis spread on variable rate 4.00%  
Debt instrument, minimum interest rate 6.00%  
Fixed charge coverage ratio 1.25  
Total liabilities to tangible net worth ratio 2.10  
XML 21 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Sep. 30, 2013
INCOME TAXES [Abstract]    
Liability for other uncertain income tax positions $ 16 $ 16
Statutory federal income tax rate 34.00%  
Effective income tax rate 0.00%  
XML 22 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEBT (Revolving Line of Credit) (Details) (Revolving Line of Credit [Member], USD $)
In Thousands, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Debt Instrument [Line Items]    
Line of credit, maximum borrowing capacity $ 3,000  
Expiration date of credit agreement Jan. 31, 2014  
Debt instrument, variable interest reference rate Citibanks' Prime Rate  
Debt instrument, basis spread on variable rate 5.00%  
Interest rate at end of period 8.25%  
Line of credit, frequency of facilities fee payments annually  
Line of credit, facilities fee, percentage 2.00%  
Line of credit, collateral monitoring fee, percentage 0.20%  
Line of credit, collateral Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary.  
Line of credit, borrowings, based on eligible accounts receivable, percentage 75.00%  
Minimum net worth covenant requirement 8,000  
Line of credit, current borrowing capacity 1,845  
Line of credit, amount outstanding 168 1,415
Minimum [Member]
   
Debt Instrument [Line Items]    
Line of credit, frequency of periodic payments monthly  
Line of credit, periodic interest payments $ 15  
XML 23 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
12 Months Ended 3 Months Ended
Sep. 30, 2012
employees
Dec. 31, 2013
acre
Dec. 31, 2013
sqft
Sep. 30, 2013
Dec. 31, 2012
Scenario, Forecast [Member]
Dec. 31, 2013
Lease Related Costs [Member]
Sep. 30, 2013
Lease Related Costs [Member]
Restructuring Cost and Reserve [Line Items]              
Area of headquarters facility   7.25 120,000.00        
Number of employees terminated 74            
Rent income         $ 200    
Restructuring reserve     $ 1,007 $ 978   $ 898 $ 877
XML 24 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME (LOSS) PER SHARE
3 Months Ended
Dec. 31, 2013
INCOME (LOSS) PER SHARE [Abstract]  
INCOME (LOSS) PER SHARE
  3. INCOME (LOSS) PER SHARE

 

We compute basic income (loss) per share using the weighted average number of common shares outstanding.

 

The Company has three categories of dilutive potential common shares: the Series A preferred shares issued in May 2011 in connection with the registered direct offering, the Warrants issued in connection with the same offering in May 2011, and shares issuable upon exercise of options. We compute diluted earnings per share using the if-converted method for preferred stock and the treasury stock method for stock options and warrants. Shares issuable upon exercise of options were not considered in computing diluted earnings per share for the quarters ended December 31, 2013 and 2012, respectively, because they were anti-dilutive. Warrants for 1,376,500 common shares were not considered in computing diluted earnings per share for the quarters ended December 31, 2012 because they were anti-dilutive. Warrants for 1,126,500 common shares and 660,902 common shares issuable upon conversion of preferred shares were not considered in computing diluted earnings per share for the quarter ended December 31, 2013 because they were also anti-dilutive.

 

The following table reconciles our computation of basic income (loss) per share to diluted income (loss) per share:

 

    Three Months Ended
December 31,
 
    2013     2012  
             
Basic net income (loss) per share:                
Net income (loss) applicable to common shareholders   $ (662 )   $ 256  
Weighted average common shares outstanding     7,735       7,639  
Basic net income (loss) per share   $ (0.09 )   $ 0.03  
                 
Diluted net income (loss) per share:                
Diluted net income (loss) applicable to common shareholders   $ (662 )   $ 256  
                 
Weighted average common shares outstanding     7,735       7,639  
Plus:  Incremental shares from assumed conversions                
Series A preferred shares     -       767  
Diluted weighted average common shares outstanding     7,735       8,406  
                 
Diluted net income (loss) per share   $ (0.09 )   $ 0.03  
XML 25 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING (Summary of Restructuring Activity) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]  
Balance $ 978
Total Charges   
Cash Payments   
Other 29
Balance 1,007
One-time Termination Benefits [Member]
 
Restructuring Cost and Reserve [Line Items]  
Balance   
Total Charges   
Cash Payments   
Other   
Balance   
Lease Related Costs [Member]
 
Restructuring Cost and Reserve [Line Items]  
Balance 877
Total Charges   
Cash Payments   
Other 21
Balance 898
Equipment Moving Costs And Method Transfers [Member]
 
Restructuring Cost and Reserve [Line Items]  
Balance   
Total Charges   
Cash Payments   
Other   
Balance   
Travel and Relocation Costs [Member]
 
Restructuring Cost and Reserve [Line Items]  
Balance   
Total Charges   
Cash Payments   
Other   
Balance   
Loss on Sale of Equipment [Member]
 
Restructuring Cost and Reserve [Line Items]  
Balance (16)
Total Charges   
Cash Payments   
Other 8
Balance (8)
Other Costs [Member]
 
Restructuring Cost and Reserve [Line Items]  
Balance 117
Total Charges   
Cash Payments   
Other   
Balance $ 117
XML 26 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Sep. 30, 2013
Current assets:    
Cash and cash equivalents $ 841 $ 1,304
Accounts receivable    
Trade, net of allowance $87 at December 31, 2013 and September 30, 2013, respectively 2,396 3,621
Unbilled revenues and other 977 691
Inventories 1,451 1,379
Prepaid expenses 407 238
Total current assets 6,072 7,233
Property and equipment, net 16,564 16,913
Goodwill 1,383 1,383
Debt issue costs 55 21
Other assets 45 47
Total assets 24,119 25,597
Current liabilities:    
Accounts payable 3,215 3,584
Accrued expenses 1,538 1,689
Customer advances 2,891 2,815
Income tax accruals 16 30
Revolving line of credit 168 1,415
Fair value of warrant liability 1,573 612
Current portion of capital lease obligation 272 268
Current portion of long-term debt 5,205 613
Total current liabilities 14,878 11,026
Capital lease obligation, less current portion 401 471
Long-term debt, less current portion    4,641
Total liabilities 15,279 16,138
Stockholders' equity:    
Preferred shares, authorized 1,000,000 shares, no par value: 1,185 Series A shares at $1,000 stated value issued and outstanding at December 31, 2013 and 1,335 at September 30, 2013 1,185 1,335
Common shares, no par value: Authorized 19,000,000 shares; 7,885,229 issued and outstanding at December 31, 2013 and 7,703,891 at September 30, 2013 1,933 1,887
Additional paid-in capital 20,098 19,925
Accumulated deficit (14,382) (13,720)
Accumulated other comprehensive income 6 32
Total shareholders' equity 8,840 9,459
Total liabilities and shareholders' equity 24,119 25,597
Series A Preferred Stock [Member]
   
Stockholders' equity:    
Preferred shares, authorized 1,000,000 shares, no par value: 1,185 Series A shares at $1,000 stated value issued and outstanding at December 31, 2013 and 1,335 at September 30, 2013 $ 1,185 $ 1,335
ZIP 27 0001144204-14-009451-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-009451-xbrl.zip M4$L#!!0````(`+9P3D2,FG&P]E4``';3`P`1`!P`8F%S:2TR,#$S,3(S,2YX M;6Q55`D``P=I_E(':?Y2=7@+``$$)0X```0Y`0``[#UI<]M&EM^W:O]#K];. M)E4D!9#B)<>>H74XVM$U$AU//DTU@2;9,0@P:$`2\^OWO=<`<1"@*(F@M4DF M-8F(OMY]-!JO?_S;P\QA=\)7TG/?[YD-8X\)U_)LZ4[>[WV^K0]NC\[.]I@* MN&MSQW/%^SW7V_O;A__\CQ__JUX_\@4/A,U&"_:S=`,^$?5ZU#3W/3NTH,US M6=,P#^I&LVZVV-^9:1Z:!AM&XB'X`:7Y*KNC6G- MNMD$XJUTQP&A*W7OS[?'>\P6EIQQ!\A0;^U],(V>@?_[<7\MC"DT3N6#L(^F MW)^((P^T#13EA@?2(S3*&@&N@V:CV6WVVPVSU3&+L1G[WBQ"QD!A"+PL:C"% M43C)$L-YZ(LTBDW`L-%L1]B509?"[I/O*74!/:0+?]X'TV-A`8M3**[M$0-9 MPJZ-$"SF71XSX)W1,-N="+6U4*7P.X=G5V.P=;8,3KDE'1DL/GH^#`%6G\L9 MK(8CAM[`LKS0#=2-L(2\XR-'R^D+QFO\6B;\RVQV.B^@4,$/A,?O73\.+[9C3?C;DT_ MJ+%;XF8J!DZ-]S;MOQ[WMI!U.(J`SC[5X"D!]# M\_/)S?#L:'!>'YR??;H\9($W3W6SXVY?SHZ'/\&*C;9T]V*,5>![[@1_F48# M'^PG3^AG8!=,-3SYUS!>[==0!7*\*)CQ8G`Y^'1R<7(Y_([/YN_^N]5_=\NN MSP>7CZRS'_BIOY'NRY_S-1`\G05$?OC_0T*N%%0(LSM2\W=%X,Y707KVZN\8 M87-V>7R",R0,8E>ASR!0GM1!R6>PC@_:/I$6\T:_"BN0=V#4%+";S?@#V,[? M!0NF@AUYLSEW%TN:*P;A-)@&!0/ON!,*-A<@.^"&12.%9,%?/WGW`MQT#29@ MOE!SSU4"E_,`K+%T(5*3W,'9QIX_P[@-UO>]<#(E."`B]5R;_1:"0L&"WAC& M*`L&@(UHUMB]8",QX2Y-"',`:C1L%$*D+A1"S3A@YKHPV!9*3ES(`*#SW.&P MTLSS!1.S^12,F\+$P.)JRL:.=\\FPL7I0/$;;#@-@>X(L)IZ?J`)&7`@'D)2 M2L>Q+T1J1C1T$9"@DPR'WX%E$:I1)@S;E<]R"V&QUH!)E) M2`U)FS<3V-IN-8RWFA./+-QJL"^"@1/U8E&`A=_TNQT4*F9O=3"6YC)H06',?!CCC(`R3@WR-'3C00I:+T1Y$:X(DK)EX@B1^@^!Q< MK(UN-K8IC@<>&[Q=,&4W8.>`*.PC=[_6@`$!,B"2N1D'3D#XPVRR&1Z[L@)O M!-1$H2/>`S.A/S9!8DB&2ML6/J.@$N7`D2)$7LPX)EEL!*SQ@%]SOJ`PB(%) MHR&^0-G`+G,0>DO.0=R@,TX)L@%F!7QU9+>D8VN1!1!`-L_YF"]$$(@:.P/@ M(<0BV!RI$'^<7T&21XA/!;IV-@DDAKB@-0PB5HIR8]'WF@#9Z_(`$'/H<`1Z`5/=&4/[R0 MGF;8;N?]U@'YK7M0;B"I%9)UF.CLA&Y-)3S*.>:E=U,D M>&C%+!(5!#HCL+M*S= MI67-@M4`2Z'T#B$20>,*OR.&U+2R0&`$%"#=$$1^35F]'.TH(?1DG7`HN((P MUH'$YS-;/\E',P#IKT1@U+M82@A77,V1OX721K[Z`O[R=2R#CB'B6D+A1-T( M#J)4VE%`4$-!%HZS0M]'%N9\$.!/2P`Y_A=4F8-:M\Q:2H(%&`7*:#"@X@L8 M.LZ9N\C(11XL8C.9X`ALQ[SR?+:O&Y#`"U"&T2CP8;.(%&8K9, M/2$<=%"*E4:L,/CRR#_`PK%C9RH;9H[UVMX%&&T/M5H3AHX"E4+W1.EV"8FGKCO<&C6Z\=5,* M40JG6TS'R(1A^B9<10([\'WN:L9_7"1=KG60,KCGOGTU)\D^>1"^)9509^XU MN#S/_B+D9`JF;*#W63_!1,$Q*,PIE_[/E`4BL7:_K*:DV3,ZC5:[GQ#S`8C@ M2N?]'MA<\0S.K,Z8WG;_-XC7ORGE7;YKR;T@BG:2FH9A[O_KXOR6WCK4DY*069"#Z0 MMK@:WP80(^E>&#:MX=53I]KJ:V&BN5IY,]QN)^^%MP-UBJ)##X+<<\E'N-4` M2I(2Y=L0QDQ*H,X&7;UL'%_9,B@)`,]] M[IRYMGCXAU@06(4M6XK.9YY++)7>=]LMIV-=T:[3[ M&YE\*$K0RS[?. MD%M``.9G-V(.+AP)&KWE3J.1`2$/-[Y0PA?H;G#)9R(%>+9AZY!_/+L:7`[. M?Z$3&NSVE]OAR<4M.[L\2D.>A2$!?>ASY,'M8C;R'!V+I9]L']C!K=1P9=;1 M`$5'10_CHUD0WN,.B#E7SI=GJ=PHQ*@)FNWA5RZE.TWP^7CXD:'J3>\@?A,HA5=Q:^2GD%3X5 MP[$M9*IEC_$"9%*98P$RJZV56-V>OUGHA/.0CSL&N6% MX/U],16NDG="L_;<4PK4[FH,/(Z1?,J8JCFYHF)/`>Y;4*-:)6UND1RV'1WS MO>82%/TH>H5+:!>W5>[Z#*.?T]MB0+:!2;4:V^\WV\_`Q'$\"]E9O'-Y@F_7 M5?3IS49=RUXU;?G=4A[]@VX6]XU@W0$I6AN2HIDA13,A1>O)I.@>;(44]_@* M[M3SC[UP%(Q#9S5XRGBJIXRH6JM[J\*P,6R[)D2E1F&+A(#\UY9.B"=I;H6% MYSHA!CAYL)S0%O8I2#$*51CH]QWC$^[CX21U+7P2NP$=Z-0$VL9,VDBTVQV@ M2?LW;I4]XG8D-?-*>^L:X\]#XPS5R.2>L^#E:E M+K/9;O>[&X*5\?OI)]7GJ-UF`8S%GOM14"NE9[?9:FT*:I2AG.,)\ZOD-'`: M]O5=*I?9'-G70[-]Y*J5_$YOV\A=>J[U.'Y)KZKY=V"8FZ"8`%05EI4R\J#[ M0BS5=.#:^)^3WT+("1P\SSX(CKCO+\#))^?I-NI9>;)WD,=V`Z`JQ[B_`<9) M>)SM_JCU[QJO#^-J-[=:QL$K1-GU`36*(=TQ45J/$V5MEKPY4=J;2,A&-$G.E5QZUSQU M8KJPI<"BK_F0X,D&?FN?#3P?O;PQVPR]S6Q;E>CI4T&#,)AZOOP=O_7,(IEO MK_AX-)UCHB0O*ZCE`&T3L^UYI!U@I@^$%V.EVW;!JVZOUVXV^VL0TK!L`YG* MV=/M`@7ZYDN1R9\.7'\N\#7P:.54X+9PJY)EQB8,VP2S0NN^DTS$[.>V.O(` M/`_F:B/K7NX=T:,PY]_W9TXOK&G?;<#8Z?7R:)4!ME4,=Q;]-3L'ST50P>-/ MGF?CUZ2WNK*#NO6^4@0=&MYW#KPRN+:*W,^ZU^@=Y^7PR>D4X[9Q/ MW7:S#(]G`[\S+K0[G:<"'W,F!7O\:*=T;[6:>5^3AN49H.].]EN](IDI`3U4 M`9@R?V#?42FGS'9Y<5OE+P%Z_5SB70S'-A"I=L._ESN/OQ$BQV(4'$ME.9X* M?9&M3UK2MO7O'_XJ3_KMRY-&U3ASU;\*RY`^4M&TN^V"IL(+"\%-$!E]:=*HZME6Z MUB'[?B_ZN?<#XY.)+R91S=%L);1VK6FT&0_8L;#$#(L?1O6]6K6HPI]46($U M]/65"K,E7Z(*:5&50:QGME)GD'AW`K9:W>%'V4G]PF]-PL=+`NX*DBN776*Q M.Z1\OY84@1,/0'.J(,>4?`BFJ2*7F;J6FD&N&=-@)4F0V$M]OKL)'@OJZ7"7"B M_($TGY]]O+IA/M#YJB,_#X4U") M!,)E#<_5`H('73UYO*;&L13:K`[Y`NO"T5DGA!6U:#.]87126M?N&P0@:_,@ MTEDCUME@'1A3CO(4%^0#K%#]VP=_J6-:'?/BNZ*.6%FB7"&SFI,A?VF]V;BD MXFMBQ*MA24S8J,*B8F%48EM76@:.C/$Z$&;1?2`0N.LZ0(QJD%$14B]@#A8" M#Z9@K_`:$1P/0;>A:Y["+_PVQDD^'^^]T`$3@;[=%F,> M.@'835OH4K(Q(:BZ<2VB!QH^39!E3>2L/*+C]VD#79MK<@]67!G5!\LK\:HE M\`SCN#IEZ,85/;T1D5B%UK1T9.([+(*>6Q#7)V78ET(?54O5M9EUA-\27@D\+6CD#\7Y-B?&-(ACE)T!Y;^ZD1T(PR5V0:D;4>DQ5+ZDH5U3V% M7H(#2S6)J>^F9X&%QKO]DT:@:8X%1A\:1B.41%S:YALG\@W091Y>575\.00<*'#.C!IVT,&)>G9[,A71!*>XO(+JD MH+<@)Z2@!CPB5O6.;@&)#'O"/"S"348%@OHW_9K9[/P_L-_5).HSOD!W'KK@ M0I&XX]#1EZ#$WCJ^BP!3+!634I>;]J.(036*5^>6ID'2X,1%YI/;H7!1?4-)\FM&:"LX#RTPB;UX/$Z%MIPC#P^QBLV MA@*8&O'QF"JF;]_FOVAS9FNKWBP=Y'GD(/5=6E7"\,KD>E"\6Q3GEV]:9-A+ M(XEEP`+A@J8=&\2/]J)D',*(!KO&*NE<6_05'4B?0BPZ8QE>Y1)-A=D&N'1U*`5(%,-,ZA07Z:=.EO"@_ MN8U'2\W_221X%%\@J%)95U[.:+LIL]=$VV)`>H=1T@-I&?P)##P"&SGB[M?4 M!5K7/L#+;K`;;1^-\X\85"$/74.U5YE<0[CBSN^Y*BLQB?U-[N6%#_YMLH9S;P_B5K M>6\@SAY='(A=&^SC1K1$#Y7:&.-L!&+Y5>`U%!"^1#O,0!^%+[ M,?S.D^Y?@`>8[0A'ZG2=1]^+@[#''XQC?]RS@8"NIJ])`=HX#KBI,#4K$!P_ M_*K1%@_=.+;@,-#I-J"-UN4,BPRQD:)@XBQ=`P4W/K65Z^KYUY&I MP3Z7O:*E:V)2R-:`M3.4N&7Q#X;7 MXXP`6+JLK>SJC"@27^[YQ/)?L$V#N[4!I0`!>]-#7Z1E?E7Z2.IUNJP>R9?S M&S":Q8!_M(6#9IRV-AJ/N,<[+AV*WI;6!O$%1=-;)&_,6N^@G;'+-7RN,Y4W M9J='8;67.O=8MA4CG27`)N#NC"+?I&(]=#C8+DV.:>]VKNMFI$?1=`5T63^@ M2FGY$(?8ZG]2H749.=;#N7.25"4N'^C=]_:)<`KV-55.IJQ1'U=\#+FR0XYK MQ;_HA&RWESTB6P;66LS0BPO76ER-]=>(THJN'"G"M+1SQ6R-\K=25$OA6H=Z MG"6B!)S0SAUXU.3>=WQ\@SO4%U$LM$J/)\[P;4UEIXQZ3\1B4Y)2KF8G\SQ" MOWSW"G7I!?3)0[F.&!?1V]_DTH+2YHK5AZK=PYB6689C&IAU..74ZWKYWFP5 MO[*NN]*"QPM1;@9OGAP04UA27]GDV@/<)Y&_T\^(!O_7WK<4Y.E*$UT2Z"F6PLDR%[J"S*X.F^DI/3PG`SFDO ME`]5O<%6,C'%\E5NG2(QJHZ5L=5M=>#_VBVQ+6XK]29=MGLP<.RK=NQW:4SN MQI]WCIW.@]BO#X1Z,3'_QMHH!V=%4COV:Z-)`6E20%)20*2B4T`>GZ97?UQ^ M'C].KH6KZ;?[R=WC^.EV>E=`6LB^5]V')]$?7G4XRT+2R+S4O`V3)<9RX6@ MU=EM?B=J8`%P&M"HJ+",VH;)?()_DK5`EBO-6!/N)90U]47GD1NJ&>@S$.?) M+VXHD,#"T!0:8_G$.4$^_!@Y6*8Q?E^CUWC"'3(U&"`*L%1_>'%>:[RUI-V%CI'0M%(SCU/R;CM9K*>)EW>AL"#:BK:F]QS\8HM");@12S06 M&MZEO;*0*@YDCD]!JC3F7A'F,DC::YE?CG&*,>27OOZ*[V,,%=W'>K$"M&T6 MKP4#:\#8_>UW@Q*2L;0HO5/[+PP\L@.?H*SG51F=1G MAVKKDL#(*Q?<$\RBWP+T^T62: M4_".S*XN`VV"SL*QU62.:J:!;M]<9W5!5M`>,;^&Y4M"P>LR&B`'[Q-^5Q98 M0?&/I6K;A(4ST5LS%9%)Z*TDCC]+.`F."1$?@RXJI;4B M_!KEY*^-QC!MEDN\4W.M<%`UZ6T27K?F$BW,&!G#9A&BWA+.J7DV'`L$#-^\ MSV!H680EJB6SC=:'3W40=&@[Q[W= M%V_O*N(&=,>VN*SSGV10^ MTD[/F57[4`U3-1>06]C[,B0B7N8[]-O$W9/+1@NH!.S]#/6#Y= MH`A+9)[)8Q.V23:KY+=(=M]N&C)V&VI8G,97?WQYF'Z_N\8%:OKP23!? MGL^E=O="ZF'.>O=#RL&_+S+O01`^[M*+P^4K^E9?`&\DA_=`_"4\5S4RMW.W MT8XT8N)$IJUT!Z-J2"B.\7_LPZ_8&@Q^,H8[O3(8WG?JO2U4F\3--WM[\PS\()RK1AH0XLE&ZJ M`WOU7X5X'7]R4YEBU#QMZU_&<<<36=3!L7?+_N@)Y]UV+DX32,QY;,\JKNP$ M%-*:+Q>I):5L.$LGJ_X"JHJX*I<[ETZIU>-#$#Y%;7A&L[/N-[GS7*9-"(KA M/&ND<$.1W'C`5G0[.>8$;;%`7&)?5)JR&"PV$DH&/827@W4,(BE;&^V2@L43&0+ MWNSLQ=4UUESEM3,2GM5RP#AMA3!7MV'+Q%LX6B[Q:1,'YYOEGS$.#GFZ?+S] M_Q/&V*_"EL"X3M&!<;=W5]-O$^'\Z_3Q\8-P/WD0'O\Y?IALZ:74N+B:13?\ MH!`!*YCR%-=T1H%3ET0XAQ7:^H!1-CP*P0]:>N.W@8+,P1%UA^[A,2DU')05 MR"NOD*6#Q1P&40Q8&,@,-C0O!L5E`.FX)<:%E8'8+`S]*""P3U2\V#.\/Q96 M)ID3$]$LN#Q57FE*%[[):SPNB2S;7-:"0#OO2!4%W[+P@\Q'I$@H`;# M6_C!#3<8U8\E+XGT9[)N&;+!2.!L0$1$*#<&074Q@SXQUSS7\.?!&.[6-`8B:/X'O,2+^? MW`]$80B8Z8H,64*:4YARXX(\6,YMX5;A\*H+X9DP;$MH9,TH`>K52U>96OY@ M8E?B16?0O^BUVY&Y6`$+4FY212F.5(I@TF]?C-I2Y$EXI)B&(*P&CM7&;"F0 MX\0QBV$8`QK#7/\,IH^%LM'I2P<(XT'UF:K15<#D0F>QB#!6Z2N-;7A#D_!* M\:%PIQ[V5H7G=*_`HWYLK,\3746_L6#*"4Y"[-(+*PI.R")Y*BN0Z.!29F$W M^1RM>SK/*V8LAS_L<'J0521-)%3J\E';- MS5?Z03K^X<^';/$\!ZN&($=9LGY M>3:8I\1+:78TE@[W$KPY9AT_+XMNLEZM<-I:R]YI2P-NQRBLBZ(U=*< M>B`ZM`'Z>6;@*?%RN*R;?CFJU1P_)5X.YKS;IHWMEN1=Q2?&#F4_ M9QZU'RHE=:[QWB5[[_HIF?%'Y;N+\79+@\B182-\L7%[-V[OW20WO.BV4PY& M=9@ZC0/OU'BI[45(!E]?]KERS([]YBJD[EP!-T_G?AX0 MB"#UC4KU8-070URG4E8XFY4-[:4H#O;GDQ8:AM$/U,7X1K.AB#+5'[`>,F9O MP0MWAFZZ?](";?@]-3=/9+;0U;\<8CWANAC.[JVDIR93V'MK%7(G=-"E3Y9%0)9BTEI2T\J-:?EW-,MW0K$`DF MAW&/%\EA@:W[BR ME?BKDYWQKAO579W<#:YW>YGU9>;6[K2[G1$KF2WVNL.6U&Z+._K'DYO*>.^; ME?)JA-/KY!2.%!&.6WB]UZFG<)YH">(M0L&7JM.4W^^E_]?]UK_.QC;25@Z[ M%8T]LCLHB5W_G)-)^<.OU\$V=#&P82`-.]FD$V:@.CD=W$PP.8EBKQPYH=_N MQB3DEGOM4J44]W)M=*G=[DGI,HHCOQH)U4.+0$)B81+R8?BMA`O_N#>:BWI_ MSWLRD-X)<-RCHN&X;\:W#\*_QE^_3X3IC7!S>S>^N[H=?Q5N[QZ?'KY_F]P] M/6[I,0LT=[%Q$[[<`E2%CS,1GS.$`S\\6,5_I/.8-(0]+5=]\ MU=$W7WY><[X8;C7T@A\L#.H50#(:/_6N89Q?B6:LH.]GK*@B M&+K;I"+;,I!JRZ`'"DM1M0S'G"'6LJZ0%>(>ZW;$$=\2OL?((DJT2>8:`H_' M>_#_ZRC4G')5L",A2/MR[/&)SY_Q+E/505N6#('8$SZVA&_,5'/F+#'M"SAO MT:GE:QGHXK-I_`F#IAAO.MZ.&AS=74.Y6N'.7&E8'!+9JE_,TW$O55ZR:Q:/ M5W(!BG`SSXZF)3G6X%]SV.$D-$G;^(J*((C"I>`YC@)J\9=CX"T%JBQAR.?H M#`#%EC6FNU90>54Z]P29AHCSB6#YQB5<8P"4GVL\**4\@_8MMF8CQ8&%,J^/ M-3((^SH@=W8!-GI;@=Y*F?16U@ MY+H=7"+\A0/V&BIHL,DK5&AK@2[G[E^-'C=ZG$^/.PEZ'-R5T#(CP=T+K6,2 M4%6ZN(.:8FXX:''\'C6';A9>/VC+2E]Y]/AML"K,&W$KREQIL+0)8RK?SW[= M#V\0N#05#!\/!I?#RB=X=S&T4`0K'X,%)4PLP@&C8P6CS_%($-SJVK3>L+LW M#)Y.:%8J6;$B%(QJD84:BRWAT0&=^,O!+2DO^@$&*>&$&V^*@$QH.\KU0S5%-(\HKJ^%)] M`RG#6\Z,D?`W,8U6DS;0I`W4(4"^21MHT@:.,;#^M+EKT@::M(&CBZ)OT@:: MM(%=/FS2!BJU24W:0'UTIDD;*%>^3=I`E1:FIN)KT@9*U8@F;>"DT@9.LK[R M#`[I:_0YRTO#<0MHSV1KP7R^^`_B(S]=X%TP>\\D,Z+R^S95?X6GM!S]!2)$ MKV1500\PT2U>=MN@%W+L4CK0R$I>>Y/[ M?"VO/C9;9>%W7;8=DS7D5SD7%(=YL)E3>=-I;))70WM%]FY_02'/-OK?022RQIWFJND+D5.G.,3UJ+_*IDI9Y`1Z!(=. MM59+F#IFH*.Y^@X;"7S$^D1'N0JF0I59]6KAACR#G$QV/\+9ULD;NYB:SFPC MZ+F,5@K?-P$F+GXS'`SZ!>3VU;"LJ?X(FC.=WYMXFV"O[S59MQ%*;$5O&3`J M--NK,>&A[Y;Z25>UW\YLTR'%HH:]+S7=^@0=_!83`8I!M1___>WKXVQ!EO*E MJK/XGC/A8P4RJ`Y#3`HAB&6C,"(`T$A3UL:Z,E;PZLRR<3:^D@FS#(SS]'O2F(<'*/SZ M5I([P\@`\8ZST=9M9Z+-C:@/OUX4;29,(I@\=/5O/!_S@E3PFAOV M'FQ?Y;'Q-&S,H8=P?!-#Z&A<'L8@R[9MJL^.[5;W5-0Y-,J>/1/[C1"6A#%7 M=3CJJ5A\S8N4V_"@`!_D'7;/]+=X>G@DG&H&G15(%<:6S;V2F&FXDL.S%A[)WN'O)X]HDLJ;^[3_SF(AZ9D[.Q[@QIE3+X:2) MQPE6NE"'+8OK:L.G*X.MCR!8T$!U+JC4Y[:$?0B,]Y\$U1)&F28),'6RP':Q M3#-G!=^1=]D;B5`.E4U!5S`]9@ELV%YRH]MC:")1:T6GM/L:]TT&\Q&PLQ5+ M1*1SGL8-TQA7C*NU[$`++M.NIKB:,W.6&*2+%F!E&L^!3#.5AS6_8:J9IA(, MNTV5`U,S5PR.9C/W*9M@;EAOB.%35[]Q]F!@&F2^D#&B^A]B/[`\X7#[&NJO M29X4>6:?;_/":P8KN$%7#%IQ@[EU820ZW5^8J7=,;NI0"=RG[5]PM+DKV8W7 M!@+P[1AKA,J$C[!(4HRU+'ZD#SBJV/ZVU`W?='N>=II&#"9>8VLPSF;F3#>) MQJ0)DDX?:986@)'HAL[G4^`U?N41D\6QC=JQO@Z.<3A*/JR`87I8\JJZA'VZ M'5$D=P&D5DTQJ)U@*Q(SA@86D?7MDZ-[AEH)6FD+I1+(9-'6P446&M+AX"6` MOFN85@A\+B*I@J>D>3]P#^AOAJB(">PI=6_8OK<>6Q=@#_U+P%H[V)F; M__`=3N@@XS]@$Z882[[+6.+86L[S?^GX&.%%;(T]T?VD`SLMTTOFQ-;^ZYBJ MI:@S7NC)W9%18_;*R%4\(E&5V-9-GL.L`,/7'A9T.Y1V8D\X_'//\F>^,H;. M_>%G1WC]LR.7G=Q<[NH:*HI+V'58!%99^M];?RMYI?%=ON.')+8;C!R\,8`O3_HO5CO6H,\K(N4]ARJ,QR4P3UN MG+X&<062N(^\6.W0BSUQ._,1"DMFOKJA'V29\3F9OX)S-JQ;YEAY90Z0>-:C MKU4ZZH.-&XXMU)7(='6CW1]N6]'RLAVX\MEJYF+?K39TH[N%_5@2*Y'!T6_H M;OWHOD3>O3>JG>O;3%R`L,*YK&QR=[)H:-`UJYH&A2M6&V-`S=J3\:5`2IJ M(J`@1@[RQA_MP&7_/FU4YAR@I>:M(@WMX057CO*YDHKNS6),V>[D1^7)W+S! M>,O(;]6:IWYTLH5HV8GXZH+M^E';FDH\6W_6R<$\R2\TP3Q-,$]*,$^W^&"> M?TWNGJ8/MS6,Y3G@Q49P^^N"\RKN=3%#'`55*1XP:0=PI%Z[`4$\U`J5(67$2]/<&LP(7L"]\,0PEQ4Y5!3SG$1;=0.[=LC^: M0D?*MUKO8>U.2FY2;U2NW$J!YZ@/KH5X,>RD2+#FJ!SBQ:`S/%$S.'VV$)1Y M1D-]8?TDYFL*+N%)3>KSSC!E5+.+,`8(ZT3E58P5W)!7:1O&*$U2J[<'Y&R^ MKV.%3)L0%,-YUDC2"*:8IYQM!L9.O.BF`5G&LEK@XG_E0V-`;L4B,7-G%4[,]$J1@:L&7_@('QN/2[?A MPX2IN4%)<0R5.CJ=)'N>E2%T5&)0DH$%Z,+,A!Z5/3)2)QH.$4?%_DR4.QI2 M-%QR.Q/1./=P.'NYUJDG10QK8J1Z.I7E&J"^&%E0LU`YUED$T\+0%&):##(G M2GKL2Z5K>E<4$Z4>2U$Y3):\S^R-!L4P>>68IHOBN/ES^7NDX2!1^S@-NY-> M\LK=EOH[D;Z^,721RB>QVUD5<-YR9:Q$,YU,IU? M4=";&X[-.Z8IZU/'QL!:C-7A;&=XDPU?1^Q*+5'J]_.->"C%XT'4N0:RK17"PQ)19&J.^T`T]46E8-EI$-QK!C.`F!<:EDEW`JWZ^-M(DH$%Z0W3?I%? M//"0'PB3\56>RVMBVPQ->_(JZ]:K"HU1>!F!4.0K^@CKF`9+G]"BD=`*!3VP MG&=+5539=/&N^KU?W'C"N(]T0[_DP`@,+\%O8=U*5R-_P+/HSW*I4HBG&T+N MB8G17"B`9&6*?;],S?+GU0K4)CBQI+/?X05IFS1B*&MX$%(B>;WT=Q>YORM5&+*N@XG3UNFBV$)A+M'P;ZPLXG#?C8J@TQE* MK6ZGW]M;$.&6?J?X.SFDX1*X70)N!L@#Z-+8OJ<(>A-<:1*DD/!^:;8A:BN[ MU%8.I5ZZ+!+(W"Z/;_*[NG26V:UET@=56DN\(]IJ+9,(W2X3)CYUQK7*E6VB M2!+>KVJV;'$_;154`OF;;XH=7+T\&HT:ASS4)Y-`PL,*Y_7WRVBW.HW#%%48:!2V:^)BK&WNI';QOV( MKZ$L*T3MZ'>J%B4KW+&7*#,V4:U:1D**]B.]AI*L$%JP7;4DIVY%A-TEF;&) M:G%"VIU^%E%FI+V&HJQ,*0?BH$Q)^G6.7,'XOU1KQJ*%N4*DY*;[8.6GLI(] M?I55S44#HCA!@0"-S[*ESC89V_Y-C89L.[$'D4X]%*,\X5RKFD/KZ>82#__J M6-2'DWLP&1V!$L6+R$'TCNG\@:S@B(>?/I(7_^8G^7%YBF'Q'H*7RRLI4Z3'G9$D>C"D9+ M*F*THHVDIW94,%A9N-HZ6'FXBM9+S\X6O42Q'F!9XE;Q$?-)X;<'B@9JB6%N MM[[...@.>B,@O[^/#&+:2-UT1!S#V4F.2,9\D75>(A`.HS2KG/XQUI5[Q!B` MCVR*@7KCUJ!\=$M06DFXFT4WVF!U^LG,#5;G2Q1:4RP:J_-Z\GCU<'O_=#N] M$Z8WPM,_)\+G[X^W=Y/'1V%\=RU\'C_>/N*3^X?)X^3N:8QO;J'A8*B>(\!2O9]50X8)LK9IFEK1DM5A98J& MX?&.+CL*#1NG=1[5)>J9@@NN0H%LV9H'?\34;K:$E6-:CJS3BGO8M.EH7`=- M\N)HW`W.P]8?,8[?+^`\>>=U$&E(J84(Y3`;'B=7H/7PM6RR[`Q.E=^]24_F MF(\A8/$E^IJVOL`NUFZ=1EZ5F(;8\]Y5';1NR:M^0O=SP[#A5:J[[/89$PQ> MB(Z!\-H:I800I$JPJ/;*A(;5E4;G[9?Q^/[L@U>6T"1SK"QK+6A%259-5N'S M]K^.3NL+LNF`X?JNT+>*V"][R(BE/=F&F^'`"G#2U`DVIE0!_Z7V06=Y>AH905G*>L-5Y!V,0"FIAXBV6SL0=9F,NJB1KO M[<]<%8"?',TO6^RJ%BMGS4TGRZ;PZ?>J** MBI6;=06,-"U%&J$_.GJHFM[P^1:(CV.WH`*51>^&(QMXOT!&)$`G]DG945^1 MK(A8&O9EH-P`H\%.#*`5,=A8S-UO04(<_XX-._F*T? M>Q/TCMC3^9/\[DN@\*:KO4&(9-N6P]()C$AU)3D/,QXP?8RPGR98="3]E8H# M(S;DDTA8"7Q6=V^U,Y]N]@[H!T7O((IU`Z3!OQ6'U@`/E*?*^&ZE(QR)QLI( M8B4RJ.Z^J%VH#!X(GG+Q\.NFAB<]Y%DV@WZGU>U+@6R`?6MGQ3190D3T/CSW M![VB>=YLLEX\2P.I<*;CVJP7U^(03@_%,AW39+UX#EF>+4H6`]*E@0OS^K8"\-4_^9!H>FOE*8#FQ5F/993N(Z25SRW MY8QS5=SB`I#"*7M<^9B*PUXZBXRNXMBK=A`[G8+8BZ+";7FG?N.8"`57#+BK6A].S#2&E+Y"9D>Z=41LK%<"E_%+(0ORM8 M_@Z27\FJPOW?03B*V">EWZNV!U'Z-XG8EX-RP8\CLZT=2A'?@[0%&V3WJI_.9^&9UX]G#!/-H:'4F&C<$ M0)%/[S591P@?!/->\?M1E^_$%THWY/U>OQOE,)&:8ADK&?EY%('MRG#]F)OWC@44`)@UB:WZ>]7NXSTD[E/)[-2>51[ M/5V60#QXNZ2'U68\IDSJ1,R[G=FJ;@0SJ'0<7RP>'HSUM1]D'XR@27VCVD"A M;B?"80IEA;-97;Q8;P\N_9M$>/^!Y3/X\"=)"62[?-@DB9U@DEA"QM>PZ(RO MA\GCT\/WJZ?O#[=W7TXSDZN$I*U;7?A&LZC0NEQ@[I*LZX:CSS#[0UC!IAOS M6TQO,A.:(_`<2O4*)&7Y20`TJ2J4&($?!EY5H>?9-U77:86("V%JDA<#DZ*@ M/WP5#G$78+4$ZR^'Y4T9MK`@LH)_VIC\-.=8RMA2N/H$)ITI*E"(20JJQ=AX MDV&[M%QI-"B?I83!9M29$<&+EP1Z\(9W&1ZR1JN#)#FQ%%!`75+[&$OF+472`DA)DTE0K1-FJ6&_5FJY=(#8@,J7]29(&O0 MIDYS.)@NO*FTY@<%RR+($TV2HS5,6(2B);QHQC--0'I;J&#]YB@@),S/N`"Q M*D2#-E'76)=7#U,_W\_3'JX`+#N.Z>,8%$'&;""648()=YA8$V:7:K=CX6D% M9A.KKJ(3C:D*WW/K/*5+TX">"^&!:@'^[YK*Y`O+HZ+_'BM+K#^+4L%DECE/ MAK)@>$V>%0U8'&G/^+D-4SU1<4*0:@N+)]K M9:J81L5F"C-8+%7)-TZJ"08U8)3\\>]0V_1,7L"FRE@%2/V;)RL:;@HA,PUA MU2=L=WDAD+]HU0TW7S5&1BR]#L$?EU1-F=.;QK(C*?^08%5X0\O,E19'@)IW MEU5H'6L-P7D2*S^WO%309P(?.;KES##5#&T=C!&7N#NM7(O:$C[+F-MGT&Z0 M\#?>RC^&HV%XX+__(;B#QK)]Z3K2S!-.T1-=[32-EH00^,Z6L&0^FRF`"8_A MKS?95%*MT3I7;N%1C4!HQ\\WSZ/V+[\*GZ661 M["1OW?-GV.;#PF0;R[B=?E":,`,7<,30C3=37OUVQOZ;&24"^;G\,;G]\L\G M[%!3?A7NQ]?7L*'W#C_B*K[Y:/IY;/M M%C'Q4(JRU+&J5APIGV4--T@7V/>S*7RDA(1RC$-/4%,/)Y+3$/D3[G9"4KU: MR.8+L1K![B=8!,$-R=6-^FT$NY]@:;)>(\02+*V[#0B@`8B'M[A!E].V138. M[L1\>3Z7VMT+J=>[@/]^V+80:V3.@%"F.KF$G;1_\,,3P#-LU.=JW"S.NE3' M]O6/;.^S30*^=)FS@S3*&LH;RD^?\GWM"(5-2O'7=WJ_A$VQ1]/7S2-N,E>\ M-?&7O`AQ8E+W>=IH1QKQ!V(X&%1#0MT83]'`ANV38UL2?TZ^AZ-A&20<;//F M1;L)2W:IY-]0+8F],!2!7CO/B5GT5B[OAS5_V8M.<[>MDV+#0L-"P<>*M#"Q6`D;%DC5[S$G?K4QLAGXO]G'U]J`WM MC8[7@864P\FQL'">EX>-.5#:3B;&2Y]PTIORN+)4%U:OS9`?>_/<_"BJRLTO&<*9D M982DO>7BQ7^GY2='WSURV/?2)'*T$-KE2>18`>/+FS7'6B"B-(F$H`WJ#K!? MGEX<+Q1]:3(YXB(;*7S>T:35Z?R>5Q*T)IKJ)A]O$5'*IZW>*`M,B!B!3N&( M9*.4R>.E2@B<-WR%F=+;QVYW!T`#6E$$0?K[M7=(`'F!'EVW\=F8O M-'SU9`^MY^:^,9.YW+;=C.(K#Z(X6QOT[&\I,[,2-HUU8Z5<@-1VNX*AR$+_ M;CBHHT$42K,$\<<).,IELU=83 M4*2J;P7#DH.7L+'*RXL8!:K!2[':&4H3=;425 MQVNI1XA+D94UV8O75Z([Q(699W]XB_MH@'63I#T4-:Z1=)CUC7T>HRDCV9W, M9*?";N!2N[N_M+.0O57:N<@6.U%,]YS2KF@Q M[DL;TS.G?+<26E`-H6$[BT0?98U0C)!G>?8GQ5&7:7S,';$_&T:@>%B6%\M> M"4:B%#8E68C:Y-?BHOAB&(KE%M")>U!M58/HS(VC:$]FJBM"$9W/^9B)XZ/J M\=B8Z1%B=J+^<-,_,_6//`HNCHO`LXI+M8B;$S^&J$*XJFR,-K88V;B"HZ[B M:&0Z=W>$;BGGS[*ESK`\B*HYL#M\PJ#`<'V/';]M2GQ4$ND:![EL(F#\3`6] MH+C?,V.YQRPWT M38&#;A;%4YXLK*.2LL0`NU(A2?@!UE%DH'E?;JI!1D'PP"A6P=! M)W;Z*E,''(12NCP=7LJ&*1UT8U#\?*#FKY,;6.A'W)K<;2B4O%IIZHSN(&!K M`T^6B#R#&K8P-"463:\\Z,.4U++MB(?G_7Z*?=W6=0Q`34WYE'HIX#OU1G:, M34*/U]0?!!G&_#"L3O5"0JJ)^W8;;R5Q%WKX!;^2[/[!Q:#3R\5K@XO@2J[? MR9&6>PADA,Q(/@F)KTFS2-BZC\B9?GV6">$B_58KMROVQSS#H!7@YQ4D]:=9/U:H?3UE[RREV>(_T050FT M9VZ:4P]$AS9`/\\,/"5>JCP,%W?N/9#\MYQ,CT6-MAP3#VU(\BY"PKWF6)\" M!'K_NM5G)D6SD357K2@XCVQ9SI(6--)!]Q#^ISX0]XV]JHV]2O631+6QW9*\ MJWB\4`9=&R."TYQ0B">F?MG/F4?MAVI037?RWO5KCFJ:#X4[/#VD0>3(\-:X MO1NW=S&2&UYTVRD'HSI,G<:!=VJ\U/8B)(.O+_M<.6;'?G,54O>KD`@T[8X@ MHCN&)2?%1=_"F5"W#7-]A7AMNIT:")W^
-?-Y:YM[1F.&M=M-%S9BV/.'Y![HA)Z)"N;BZA= MK8@.%NI;93SO407MNH9KF!1H]R"_"4L9U$J5M;K%4$:)]O.H6KH8Z4]U+\"%SU],,;55,-TJ>7/&BVTLYWC0%VM)$UQF47MNN3"]XND\ZR>T=AP'X>?VT7L$S+'21Y`'/ M_%WC#/?>JAH&Q"*VA?7=L&;=(EP5CGO)S>`H^N7DL"8_;4X19K5V=1PC/Y<_)K=? M_OF$'6J*?Z6\S8%;R+8CIO\=?-6?90TQ>\-NZET=V&6+Y#1$[A6C]J1ZM9#- ME[3PQD:P601[)5N+D%SOY34M!=H(=C_!TBJIC1!+L+3N-L`G,]^M:CFB.1B: MS50GES;L!000*"T#AU!KST0G%D6*@VI.W)E%^)1NT,;/B,&3LU)NSYCEZV#0L-"PT+!][J?#4L2\!L M:UDC>`=(W*U/;81\+N;%.BH:GJD."M*PL#L+Q87P'6X2Y.7A<+%6*2&'>/FR MS85U4I%SHE@RDL>)RJW!C6FDUDBMSE(KW;(=(EH^)H339]D+=LG&\S%'OHX& M.>+CFY#AG6Q)([9&;'N*32H].OTTY29>M-LY5J_Z!?9G#K5/BO%_)+3K![(R M3!O:N-7GAKFD[N;/:_XP*NM)[-R$#"@?F+H5O=BE':_5L^H MM3TY[@_:97!5P==D2 MCS)[<9H[B:\KI>SKJE6,_`!RHR,HK]:<*1(V!FG8?\V!(OE`D66!#+%B;O*Z);1>^)]DJ.R+L[JD]V M!!"?%RF]NK#V:/>;93Y%K/,9P=^[A)]=0+JKA:R_$(2HG\NJ*;S*FD-3;-YD MTY1U6]!4^5G5$%WO4CA7L4*M;)$/@D+8O^HS3*-^2EY[S74L-4ZUAN8G;S8% M.\W_+#O+9C^^"X9]O7?CS=[L)'BI2;Q^8,L6K'CY3.:&2=PRF+;\GJ<$]S%? M;ISWTXZ03>G+36O9RU%!N'ZAP;FB"Y2R7LKG&0XGAH,W&,33HT.P&_2VHEB!;'';< MPE,-?&8XEJPK\,W[C`!-V!XM/BRL3'5&K`_%U^-,YCDR*=-QP(?'%)U]HA4H MN:'`?KR0[7.J/E;.\BLG*J`?!-<6I^DO=(Y]T<"0:55TTM M_0(P$?2]E0>'XW#WD@<34%7$'>P&*N84M>$9SL!7=M*K?]4I& MRD--RKDE%Y88G-D*NI4[5?ET2I=/J;=P.]Y\12[D(G=YUZHUTPS+,:,W;MO? M:Z[4?#T*WO2PBR-/D]JH1WFOG2Z?IO?TT^WW/&^J8B]^.Q/;[5^RW/+8QBIN M$>(NCO;J/:]#QK\)P\=^4=P>J]D;J9*[=:?.B_C&-/@X^?)MDB9CB45$-YR(UA2K\EWDS^(8-`L/1HS:K\9>$&JS]25K`D6F^(6 M;"U,8A'9G"T$B^5G6;Q>!/]UQ5)TK)8P=4SAT7V'-X"/7U4%?O`^P*\5\DHT M@Y6\L9P5VA$$A9>ID3#EF2T\RY9J"8IJDIFMK4$SA178N*4\(XZMSH#"&1@Z M65<)[YAG"L5TK*E_.:HBS!9@#'EU6)](1`-6C8-,*%+VAZ2!0\LU=", M%_K+TM!5VZ!UJ5TFT^BX$!Q=?24F6@[\Z\6`/W1*B\<[<]^[E7T4VH#W4-5A MK&V'FFO&E#R;&8Y.LRA7<%2:0;MTJ!;PB3]$>+6-%^:6O"1X&VXO#'@,K,], M]9DH_(O@Y;NEONCJ''H'VN+ZF,,O]+L[`Y1#0JZO@"@\K=&J<#=P#@5%`>+! MZ-F$D0&OXZ6^K.L.YRO@5]^HQ^JEUQE->^"KNP;0+4B M+TT;0+4JI-P`JM5"#W;Q;3:WT`V@6NW<[#4,[FX`U8[^/KX!5/NYP`\:0+4& M4*T!5,O':@.H1MMI`-6.9F-W2KPT@&J-FM1L5]D`JA5,>P.H=LP[XP90K0%4 M.[#M:P#5RK%]/\_^X91X:0#5HD)N`-4:0+72AZD!5#NP@S_^1-\`JC7[\090 M[9CW,Z?$2P.H5LO+C090[:<`5-N>4A'-U=`T>(\?9WA:1O"GHC,P,+J9??K] M\?H,-[GJ4M:LW\XN.V>_=SN#=KL=9"=(R@Z4=[93+H4HEWS*.WDHIX1GI3PV MRX9Q$/NHVC&(#$$L104P5-G0#+H%,33&X]H+#5/_O/9?N9?7^-,8CG/*Y"\' MSG&W.M8YI^'L='/^!`=`GC]%$0:L6_V>F*JAN#A.'+F)/D2L)H1GHNA,*3(\ M`#5,ESH@_U%+;(OP?[WNL"6UV^*.2IG<5'!`_[,BYG\H=EIP:&%DQ59GU-\V ML@>04Z-,V92IU\FI3%)$F=JCRTZ;-;2W,K5;W6[W=)6)=WYCF'.BVK`A\"C8 M3RV2VV637!RV^ZU.;[3'TK79A#>@#%%Q8PEK9[#X>_%6[*"$->*+"2>50@8E MIMVD07FWU$^ZJOUV!EI+RAFC]Z6F6Y^@H]]B$FAQLG[\][>OF(N\E"\QATW6 M9T#)QS)%7;+)W&>5K72((G:Q%B,5`*:X!8AR!B.%P9CP=P7/."I^^P2QCI[?Z6P\R4C[J]47[*;RW+ M(8KHT\Q_J/1B`)1M@W!.1TZ2*W/]2S%:LHWD:P>A>MB>C74<8R M?G;L_I?ONKS$J\6_@6/R;"/O^%[P%B[]E;)-0Z\7&O)T8HKGK53C(8D[\Q99 MG=A1=3J_5C4'?F4*&X0"169S?E.>,8H_R0\&G?!8YZ3W(`(JQ_3%"P@6R7[I M`MKX"G9+ZBQ-//%?U%5[XJFM7#15ZLV@'W%3[B":]V=34S]A1\QN@C&C#[Q' M2R)C6,KOJF5T)7'P"=[XWX_A1[2ACWY+L2VOX,V$IME?^,).+8=WT.$N%!5! M`?EOH4]!.)A@:YC>P[PLTR\^IK48Z.Z:Z`:%NM+%))FE[ZW_-[82V'=O\A(]W:E>>)>H3MHN/=Z.7PRPFM(TXE9_<=W;J M@"Q7FK$FB1*G/7@OY>F"&QO:2R8[W.OUX?\&_F8T3!&PZ!YS`K^"7L'OW?YQ]CONZ@?0;:_KDNQ_'&V6RS0Z.10@XWV%.)7V M-P;[IZCPG@6;]=_.7+LWAC857!S55_)(9K##1TC.R?M,/:[9X=9P@@C^'\_ MQO*Q,:'#`G!_#8T!%]7*O]H."A#QB/&"\G=_V+VVO6>1CXBN!#Y!W?`[5@(? MN+\&NG9_XEJWGR*VI4ZCB,4K(F*-PN?W)ID3TX2M(QYU&[7,JI:=41].?]V^ M)!Z[8CX0#'.:V=3Y<658]EA7X#=BOI+Z&2NVE:C8)D5 M3$2_N-3OMSJ=H=3J=OJ]8U:S*]@5J?:-/*.)W3MKUE=5AX60-99-EW+-!;SI MW)FV;ZJN+IUEH^+Y5?S(;>C!E+O1HI0TAV-5)DV&+?^<^S:FY@/ZFG<[/-"F MQKF\)'DH]2*T/Z^_NI`=K,M=9\`UJ,BKC(=RKQ1*(''$[02.VLWTR#H]I($T M&K1ZXD`Z=BOKU<3Y[%A@*2V+)_?F5SR$J39U0OL:K3O;RFE0#?C$:A\BB4U)BH3=URBZ\U)BJ_1C7NF7B= M\IW(QBMOTH(VOQ%[82BTMN>^&Y7*DD[EQ&26:RU2A39F5JKFYJ?W5SA!K5>-IK M[6D_,HUJO%3U]%(=F1H=M2^A?K(6([+FOH31\?MMQ%UD7`8Q,N@+>S??4Z\QOF3PB05P;!@V6CBH'/LBX>W&>%N+;H$'',R64`G M(E[/LG6B206K2J;R+7`=6B2<.J?QK6`=6CR3"I28;)X72@"5<. M;B)J$JY\4'5HEHSC"0T]G*(T@9TU#NP\I%HT#N^:.+P/J`1-4&6-@RH/IQ=' M[/LM7U(AC-_&]WL4OM_0S4G9.M'X?H_&]UNM7C2^WR/Q_5:K%HWO]\A\O]6J M1^/[K:/OMU(=:'R_P4U$'7V_5:M#LV0^W4D5I?+_'XONM6"T:WV\=?;_5 M*D'C^ST6WV^E>G'4OM]R)>4'^W=&QRTIJ60ON>3KE'CLDBI;I]H]&`R45+=% M`1*P=C<")!RY62X:&N'S09*XPYJ`([6')K!?X!__!U!+`P04````"`"V<$Y$ MUNXC$+X/``#QPP``%0`<`&)A`L``00E#@``!#D!``#E7=UWHDH2?]]S]G]@O2_W/FC$[\RYLW>- M,3.>DZA',S/[M@>AC;T7:;OW^H6$",@*$WHV7D8(S94U:^JJZNJ/_C] MC[>UJ6P1M3&Q/E?46KVB($LG!K9>/E>^S:O]^6`TJBBVHUF&9A(+?:Y8I/+' MW__ZE]__5JT.*-(<9"B+G?(=6X[V@JI5[Z<-)8:KPV_$4AIUM56M-ZIJ4_F' MHJJ?U+K2?]JW-+'UYR?VWT*SD0+,6/8G^!-_KJP<9_/IYN;U];7&+EAZ32?K M&WA44VTTU8K7]FU!3<,)6K.O-4)?H%V]?;/_,6C*R!P]][7)VZJWM[@ MZ3L&O(;P4/7FGT^/^0LBQ@1'^U!5%R\\5=G_55P[C\Q=^1=<704-G MMP'KL?%Z8P)D-\(8FVH46C#):UH< M;:(O"V9QLD&4&[/=MZ#1>D/1"F[`6S0"%[%&C\1.SSW1=&SF*\`]6CBIZ!LY MTR6ZRR`"5(:6@YW=R%H2NN90I>-'0SAO*&R=X@WC8+*\<^%'9#.MW4$[T.24 M(AL8SL`A66@+DG.?>-`P_:Z9+IHL'[`%'19KY@A\*.5HIC.EY98L<\9N9&V! M/*$8I6-!'/E[Y&C83,E%SD9]Z-)31.6 M(9RW9VUAIC4M(LB(&Y-YM" M1)**B?4F9S!FB+E4W7$I!/&I6*`"&('))/_[9>LY* MB>8E&!'[MNVN^?"=R8!M?;G5R MKP.[$)QE8]@F-BD&T0P=P];S=IAS],*\5-;`U0NBZD,6E\[QD@W6]67.F7HN_&<9/CPI M\NXK9]*6#!SRY*5@]K)T*,Z?\+QBAG0"7)I8VZ>KS"FZCO>%):SZ_IX)/8JS MR3TV73"2J!^SY@64Z&2!"8O'#?Z1]S#%2A-CXJ"IMF/FD84_P]KD7:\`9F9H M2\PMQ&./V`)+&5!D8"<36]0D>LZ,'06*P1A^=/6249S:A&IY:_1=:)^%G_4F M;V:.(+HH-*.I(C-=,W77Y%T3[.9/OSUV3+BA7F\H525PU?#W8#*^'X[GPWOV MUWSR.+KO/\.7N_YC?SP8*O.OP^'SW*?*!,FI!+T7`+TY".XP]B5O7P2P6J^5 MJ2V0^;D"%_X%X3;JZ:V:IUCY,)3"DO-7O#BNFM77S1MP^DCADVV5P!H3[DB1RSM4VG'(A9`0:B#*)[G8OXKR MBO#+RME?J"@;B@D%3P.&75%<&[@G/(\XS"%H5#\QVN-9%Z_%C#MMRZ'!* MT4;#QO"-5^;@$"Y@W+VKC/;S=456#_BB==A`93BRY7'/F%$.,5 M0JZ:6N\V&\*TYY,I0E.1(LD5+7ZSM#6A#OXO,EC5C=6Z6;G"<^XUM=MMBXL? MDXD7H<$,XLL5F/!D9B_]F%BZ/T@W>PUQE:-(FD5H\;RP9A>JE4\;X`%"^Z7$$8R$-=9$1@ MT.YVQ`WAL60_0J'G`9!KP!^XM@,I..T;6S;2!0)UVVUQ&HTA6K@^4P@O5PW) M,]!06>5@H"UQ)8A8LA_50Y,!D"MT>V1KX?T9[P,"K=NZP/'_E&3AJCPKMUQ! MW$#;8$:'E2C-#8O04"NO'-` MUFOL\`7#?/N\Y6#K!5DZ,](N8"!N7(TG_,'Z30F)7`/L%%2'8'S90[%?=*JV M.CUQHVL$Q3P4F\K_A%:M)$HME^MEADFLD"A=M2EN>N4]M<*5ER2N7)VO;QAX M3W^J86-D>8%\K2URG68,T<+5F$)XN:+<&=O`8B%CJ%$+1@:[K^ONFJ'%EA,L ML8XAA._4V^)2TO,,%*[DC)A(-]_B"[-?+AY]R-`8.9/EL_96:W=[`KMU-F:* M[^Z7@R57Y'R/*-[R'6T1Y;9>JR5NXB:)!J.G^?*Y$$9].=?E8?'R8\K-Q@FGM&6>:-A]!ZU*6B6L$E6R@J. M]VC_6>OT1`:=&3BY?+72<+E$.OB?X9N^TB"WFP&8$RN:=NU65<7M5LS"21Y= M^SI-^WW^4OSD&O;9/CZ094K)%D,_NMM]L]F:`[81R78.F[Z9N^,U`A>N'0XC MK*G-1EO<&'`=6:@SN8+)\T?05Y`MV%MSC4U':]?2MR:T<: M+LIM+!<@6;J(ZQ)OZQT6DP8Z@1'W=A:YIC^.K,`N M#R6(%%A)YD"/9`JOE.-"B9MSBZ4KCP7$HA57;"RI"80]_SNA6K<"-XW' MTBVU":1#2ZX\),JQQ2P%8H:NBHND,G!2:BNY%-&X`F5)74<,?AY$:?`3./]_ M'7.7AU1`]U"%9C(*/*+HB);`'G&Y1OT>$8^*7%/D]VA#D;X_LQ$2H_Y^GR__ M6NLU6^)<8P+A4BL^)6!RY9*'`ZN-?[NVLS_;]0<[@)`7)#L""[J)I$MM":E! MDVNVGI^\>O?^6.N:VKFMBZL71!,MM?I3X"17V,PA8B\,>R#TGK@+9^F:_EYM M=J)*5YP32")=:B-(C9E<4_5?-&RQP&9B[6NG1X?MA(JG]8[`&F(Z)DIM'A?@ M&+=]LZ0IT[VW7C386NP="G.'++3$3JW;$[AB]@SQ4IM&!N#DVN[Y?E9\9)V> M^%I3U493G%VD8:'4QI$9P[C=I"7U&J?RA=YX!8(U.T4:1\2;XB2QBCC4/'.X ME=@LZM):BW?6JC^D>B.I?UBUORQ$;0D\4/$R MIB2SIGZG'I&N**ZB>9T`R^TC$S[>.\A7:"]E=D*,:2CMY_9%`7K(:N;3SOQ\) MY"7A9NDF3Z_=!M>Z9!O<9#J<]9]'T$#ICUG+I^EL^!5N&WT?*J,Q?!\JOSY. MYO/??+ZOWR9W4`@_U2-R5^HQ2EEVT)T^+]CAVE4%'N*90/C_=(U4)E7\;.N? MDK9"F-GMU<6NGQ##]8;94@`Y* M.QS'.$<;9&#O3>%G,2&ZQ1#RSHEIU+K-GCB[BJ=[N6OJGM39CN(F66RX5\H>P]ZI2]F)Z]=ZDK M;FMQB-+E7H(MC[&]EXSR%WAU&EUQV_7>40B^3I.J-\ MLP1^F`)P1*6R=V@)`4QH#O8)6UR$D>4@BFSVYKKCI^S/"WI"SHHEW*SPP-.Q MF@K8"JTH%R7)Y4XB*&@=91[M6W$!103%/)S%Q]I-$':?@;.T#BFF+^Z!"5Y* MIW;:XD:0=]1^'J-(@C%N.?O'>^?S\Q2)Y9GC]RX7KP+9>EKTBE55%7FZJM@U MOAG,(UEPR2*88`SP1.(C0%=<]?6$WA4I`S+-PX,@E.Z*S!B.B.5A=&F0#]*& M>%'E[UQ)E>(NVB-9H>",G*#N`2J6:RC;'& M&EO8=A@DV\.K@NN=6W%%I#/4BU9R%C!*-\V9%8_$G"Q`)*964%HOEJOTR;8C M6>0`'LRAKNZX%`0:K#3ZPN1IWPI\/VH4R5S[="HMGA5KR5'E6/C1"^M:SJK3%YL]0$0M]0PBN3'J3%2:+EBJ)_Y,(YR M%+FN/KFCI*Z<+Z08$XL<#VA!O-FJU\6=?Y=,_.)[5($7T;C[\/Q\V0V&LZ57^_96TU,._TBQ-`&5N_>BU<4^H_:\20# M%-AKB#/V8V*7%[&"Y\RTUR<-;!1K)N==X`M1(FGFTS_/:.!02#TGM5Q15R#/ M#T+_9-LD"0227*!N`29X1/1C]!@O=^E<8#I%/K!RS0H9/)QD`JDB#R2((OHQ MBHR7N[0%JF1%\E1`%?G:N#"I7)46S?J)RDYU*ZGS9!$Y?Q@KCM,MW^/5ZXC< M8QM'^"/4F"Q]^8J#UX:2S7KC-)0,[6-1IL.9,O_:G\&%&=*)I6-S?^JF0I8* M6RWN.L'7.P@K=64?B`-6"HONE2FB"C^D3W$($#)=!QFQ;7Z[*'CU,PEX#'_* M,:.398C-R9(SN;]G0L-W/1./NZ@?KPV+?W!+049_"^G*"QJ[ZP6BDZ5'D9.P M)ZYC.YIE0#)34WOUEKBQ+B,WUP36.N4;F333>RTJ?W;?<2A>@$H6)L`.*23P M87/M'+_YEIUB(?!U/%=REX=_NMXNCC;KY@2U7$-7)(9Q"!YJ30Q+5=RX=B%7 MY3*J/*"5*_>(P>Y$6#Z,,#F;XLZ:S\2+!(:3"L;293BQ(9;W`_L/8A($5_X' M4$L#!!0````(`+9P3D38_1G&0R(``"M$`@`5`!P`8F%S:2TR,#$S,3(S,5]D M968N>&UL550)``,':?Y2!VG^4G5X"P`!!"4.```$.0$``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`6)RMD^\;L]"WR MT')EHU?R!\8:C<@4L40/V.'G'JN:88H5X`[-72[ZNF"Z6/.HBHA6AI9KN.\C M:X'MI:\J/GY49(A6A:/9QHIR,%G<>N1+Y%#4;LES!,DG&SF$X1P.`LW)6+7I1+1&N11$.+-T<-Z>U;G):SB$ M(Q?,>/(P(IP+JI5G]8V;/@@L/@.Y3,05/(@>58OXP/YL]D0\$BXFEBO!RI@B M.J5JKF<3)YZ+!1N0@1QF:0LVRYF+-=\)]IT7XKGPKW^.)A@4-B_QBMAW'&_I M+]^Y#-C1%FM5L`VS.3UJ"G8TX1,PF[N9MURJ]OMDX7\]\179UPB[Q#G+Q["# M'5R,1G,,#$<3/6'.T`N=I?(ZKHY@WV>?C5QHB?:!]MG)`Y+H595.H^%FS/?@ MUP;V'/-]1*8*?\^VOWF+O>K-+HYOXL4K0],6@G?J0OC/LWR$4H@>*P>V+3DX M]#K=OL]Z1R3!PW+H*LQ62I^1(\;KDF> MK]7JE>M*[)V1GP>3\=UP/!O>T9]FDX?17?^9_'+;?^B/!\/*[!_#X?,L(DI% M$Y1U"OA';RXB?Z$'6:Y(`K)0A4^9ZAR97Z_(!__J:QKVR.1-O`]DK.FB/$;N MP+-IKJ@_)].IJKG59KU1[53;3&7[BEZHSMS7MN=U(L(6-E\>CYN)< M.L&VCFP_]4W_=U59V0:VB<=!K/VJXCF$<^S'$S:YQ'"0'CG?!-H@CW`!^\V: M&Z:)=.*_(\UJ^UN$VRJY.)` MA+7R(!699UZU2#.M"-1!ON$M]S"-,F?O1(2JHG3AQF>24M%6FR9EB$U#5FSB M=-[&U`C[2K<+!Q*#9/%H'9`[A*TI)VQ/-EJIACY\HSD.%"W<2K/3!H.-2;)H MV`[*'<+6DA.V+5FK[5JW68BG4C1*:6*&X+1E!F1MA(H[0Z8',@ M#P>%`9A7'7([A]\L=8EMU_@WTFD^DE8!T*ANZ#15E4ZG!;8#RZ9=&*#\*I#; M8?3CC("<#` M5!TG+$Z\\U]'%F6XP;)/[OAH\`S1VO(^V>(N$#%[W7_IHZ^+:JL&ER[+H"O` MRC@`B4R-3P%R;U,>#'5NF$0;:&^CU:BUP;RI=+*G)SK#PJI-.@\P:L$D*<`* M<\"R&X%/%5]N0R3LVQ[2]P6OMCIML*U7*M72,#RH!+EWS`//K,'N*3O4RP'O4.RR[V%'J@KPU7-!Z0Z:#(WC9?@G'VLSZ5K`I?\4FX=BA22CW/2E\$4!F,B$6WGSRIH/-L`^Y=X\IJT0B)-MN MPY6:'*0N`\IY5"3W'C.YHB2#[F11`7.-V#1EP/6P-N3><&:(W%)Z8(#*/25S M*47V'6BV#JA#T0`[?'*(N@P@Y]&0W'O6^-B7?^*=F&B[46U!C=LDJ1.R5]%[ MD@F?_IOA$.X[\-SO4A5@CP=`V$PMAP4'=/8.'D+-;7,TW#,B/U(!VLUJ#QBY MF)P`VTL@!]9VJZ8N^85'$W]HIG80?K7*]?VS_"$'V++16_N MT/3?]/7*"1JQ"+7)O:/EI]H@F,]RE`T>!VAJ;<5^!88TVP5ADAZQMLON96?. M^FT9E[M*'&?/$O59P6%G" M#=Y\O)0TJ(]6F.S1]_W,0:=1`ZNW!U;!S3U;+RV]9-8[]'O`GH(.I!=&9E4R\20+;O<`5Z6%0;7)U$9>F`S2CK=\D?AOOQR!W!9 M,DP\U[]0W;!>Z%2B@&4Y#Q`O'\T43<@=BMT6A$PK$]M7@^Y/+]&=5-1$01O? MI$_?!MF=A.K1T=IP76^9U$L%L1#0LM]E#?!_9[3UE&:190BE.NX M\BE`[K.]>S*$:WY':8"%V5-HE@S>GN`A<+TS`2ZYO'<`M\!9A$N&D*V"*-91 MDQ/(OFGB7S0=<8_M.^S-W85G[E_^$;?+Z<&E,G-Q4BS4QRHIQ+XF9V+S.U24*K;_5 MK1>KD`UM`1-`@:82^U3<&I5^+8/6'M!2G`XXS+!VF#UT!6,7+Z_B M@Q3":KVXYC"HN)2(58$IU5_4T[?#_[V^[0>G]1Z?AN-9_WDT&5=^NU<-N^+7+U7ZCN,M?<&<8^+QOC=# M/J1']I;TMDY?W?3]_NL3;S\Y//]+M?5G\E?^=JS1@@NH)PF=X`WX6\I=S?2I M0__BS__.[?OFF2?UG7[FT]XP8.GT`NFDCUGKML$RS0`,BYA'LG"/EW=89@3"2F",.!9!7*R)2.(),1KP_%T1 ML_R!82;>F/:S=N+`^#`).U%ZAZK&*',0'TN;E;B8&LZ/>QNA$;$%&SGN5'51 M56GW.F"W]X&S+]&H9U7,%(F>W#U2A*IB^+9"&FWU;:P-'5EZI`JX6]C!V?]$ MAGP(/;D[PX"HXCLVR6M,(B151ACI(3KIPC6`*DZ.3VC:!_&4NRM.$3H)(F>^ M3N3SW'++<;'Q?3SE;B/D"[Q7[[.ODWD>G=#[VQ6B`Z77`[5I$+[/P(;!\9*[ M:Q+(.+[']@(9KD?V%-5ZI]YC]+.CM7*^/2KUT!KI)^#LG(%!%@2&W#VAP+>Y M&P>JUP0KR2Y*BD]DU9Q82IXM!==([#KU:N<1P,B0XK-;]SZ6?ABNI+,N0 MH>I7V>JCIP8F/G[124@%,&:S2ZV(T2;"`+9N>DM15^FKP*G'5O8:1Z4?6SFI M)`LRX'3]G-L%\B8(0= M4&@T-@X+(7>E7R1F4$52(ZH%*MU-$CK>9EBH`#,L[+!$IJKC5NUI`DI_!FA? M/*#3`W"6!,PPH"4Q#CVD"BC_@9E+J6M.(]X8`I"LN<=2M#,$=&_0#0T=A\^K@*3JY5QNU9N/4K%=> MHA(-2.XXZ2F*E;LZD=[SH-%KK-B"T^R`Q4+X6)#;;'*K$?"(R24V M7G9L?+A+_ MA8R75Q?I_36RU1$MO28.U/+[ MNFX$W&]6?*<_=UQ;U5P*"*-X2PXCS^3\8]LS+VAG7O9\]*C^D]YSZ*"X9 MK]8[C1KCV(KH4U5'L%:FJ1XU"<#/RMGX?6Q7)%J1G)'UA(AD.H]NZJRSKD"V MG9_!3VOAIV'YL1T/7_8@K:N=.)`J[3>$%"2#`@!,3!"H[9 M))$_\XU!:BZ*TYO1 M(<`"SGQG<4@I"7>36S.PG=,*E.8R0$39PJ?99XR]H,"WW>LQMM/2[2@"=N6R M\ZQ*#X#]P3YBDN\$:`53<&SGSK.)`,%(],5U$N5-L:>G5Y5.O0W;TB87/V=H M;B?I_,P]Y_RK`AU,;6D#*@R&S]`B85'[H.OUP^54_.54/%"E3K&GXIOG?RK^ MTMCE^5G^/-%O`Z@%N=QRVID=-JYZQ:C>?GPS\?A^+DR&M]/IH_A MD>O\YZF#F,'(6F![Z:O\Y//2P1NC7K2]+MR%,$E*QR\8`VROL$WOA@CGN7H= M[%S;#BT1PS13W='H2I=1\@*'0+HI(MR[M)_=QDXW\;DFY`7)'`P<;WK1S211 MXS5%:;?`,GD[Q,397CYT(I/,D#T.@M9;$MKDYJH9_?\\QZ4:F"S^HK<[D`6H MVFLK#2@$,RF7C2>O6F)P&PJ!5S9P@W*!R2+0`8U.ADHAWD2CV0;S`=/IEHTK MGT9"5&M51<9E9.*^(GN,+;Q"]#@%U0#Q@%`\]31K-;#C8]FTRT:77S/QK=]* MMR/?N$TD(]+50;80P9=QVJ%50&*)EY\3XI,N\>S\/9)'O'OD.-$(]>-L+:53 M!Q,SB[+8'-/1L&ZJ?/BT=`[I)?XQ#Y7B!_6+CX8=OJ!!Z&@6-;%G%R<4A&LQ3VF`UUQ&5LJ%B M22MW?>G&INZ)"@9D+C`LCX@=&AVVG%M$%(""YY[5-^0\&I8O0!0!Z%OZ]EN& M/SWR]2-R7S'Y9HV"W211BE*#B_04*$C95E829J$AM^4TY!FRUX:&(J]P<[MC MC_^*2N8["@OR'I1`[KS=DXUU3W,9[#,6ZQ0`F.\H#("#$L@]E7-LD*"*N4[> M1O*FHJ`$R)V*.F!ON:#83`!L>:4O".,0%ZI2JC#+@Q*@>,MC%6VER"M%M=5) MJ7>EMI]ZO^^/II7O_8=OP\KDOG(_&O?'@U'_H3(:SYZGWVA6?G9$*CY.H$P6 M]X:E6IJAFB/+(7MM7_^GYN4'INHX<49F8D_IT5X?5*6F@)4GIU(](5_/>F5H M>4JM7BM4%&'CCA^>.*?/I0?IY_X#@@--FV7899&B%&67C+6`3P]2K`RGX0E5 M(W0BGNG"],-WAAL3>OLC?VM8QAN@S"M%R5L&EBZ+W+M:;_-T9&6\H M$XAT6>3>[<;NUNW[@Z'.#9-P%E@6G=SJQ.V#0O:9IGY&U\ESR-28>IVF$>:%MQD([J-<:#7"E M0'$O8(SD,YF]PJ@"<)'>V^-0(9";=-ZC#EHIYSWJ&%YHD;C([\MNBC,=![FT MM7"V6L@#8VS96UJB?^_KXQEIKY;QTT/.0YQJJM?@;MZ&9E[`X"><>"M0$.XW"R\1'LYP#BCZ3?0M#H._8)`JB"U4@4K,+%J7@9^.C6D^JLN4N MJ,H2Z1G92S(0X&);AXA_5%O94>P'[;\6U``ENLZ4L M8IZST4NCQ*2MQ$=5I!Q>Q6`%5`E_'GLQ@9P%E?%DKZ^&S^`EH?1^J)0!,HO3"IDD-`D> M-0)&Z(290T$)*.A`3:F)P0-^#JM,=HO?H-=1JPG6W"$G+R+'9&%FM>\.Y=5[ MZ:F8TYJO=?8KP.^&M\^5W\;8194G]9WJ]_/D#OJOV"!C@(*$"2*0)$TK[TMDMJYT.9'SK!,Y*,`91FHP,1M(2FFTQ[Y"CV8;/ MSF3Q7;4-NH92X7Q/N-IIU\'ZT.9AI'1SX-93B'[O',"_5S747V+/PX`/I$]JV:L5#-,$3^J.O+7+D:`(V4U/OS"TF$Z)*7A;_Q%*E)!XSN+C=)!Y]21W)5^VR(]JJY'>:-U542$ M%F#4/(ULZ;"FZ$#NDO`';+W0"E,J2E6IM[M@3?*2E$K`*DU0N2NN^S92:?]T MU1PZ=*9XLFFW;?>]VFKUP*I;TXB6@!J'_%&H0=)YVU2NOO/#L%Z(\ZX% MFS1&_"AE*YKVFC+&'H=$$2AGL1GQPU2S%9E2](F5C%\18=HML'H(7B9*=V"X M]!,A7CL'Q!/94*`:JF-SP!S,!X5+C3986>`^.>$FR`:`;7X[\IY#W9Z?_?#Y M;C;:8!>"Q%0*AH"F5-P-%U$?RAG95)-I#(?])]OP=YDD*1:,UB&I8^3$ M7V,I#+FT"0&H<="1$R`'ZXG;4N,?0GQTO,[45$WBE),\ M``MRPA1!7H&]R=NOA`'C1`*!:6A2NDQ->6K4^KI;34O]!Y:<=T*I+052L#E3 M(16ZW@N>*J9K'MX6GL-H2UQ_XQ,O&]QAPXW84U)MKEPKYK_XG(DBY3UTPEB$ MAJ."_Z`?L2E9J055TF=X/K)1#QER/5,_9D'/D:K]A-?DH$"!..N@:$[W*17) M<89L-7[T?E8)9.B94IUH(12(?K10-EM*`S\*K^W<*N.QO,IX3?8TV/OARP7_ M;^2";BX6C'A^W+3B.%]/++?:'!8[>[I4LLJMXR;EY(?WOC'<'?,KN>;GZW2M M[-EB;,/-Q)(0;.%4:8@@[[%1#AF]35=!A9JPU(FV=;)Y<&V3#80JAXS"=C>4 M&=0(J*8RDVZ_:.>SJ^H(KDKN*[G6U4TA@CQ-N`PP[CN3Z>%A>GB8'A[@&EJT M$)E1N7/>Q6/>#66,_L?=XX6SY?\2?W`S`]@\L\Y.>D@N;C8T@.?@:;!I2%QE3&U9^X.O4AB'-MJO5V^S2MD<=W4DK=M*[Z/4Y MA;P4N\)O7="W-S].NK(0DG5AX>;LJB\77[8A)-:_!MMP-X.3@3M%=%1T#FH, MUMBDQD:0Z(`&FY`7"\M1!0$W=,P)[BCG'Q4=T4_QB4(`_?2P1C302+@&+Y"W M_"S'ER@M7.N;4MKHA%UD!O+.OS(@^>/R;Y_;IZ27\1.=NZ[H<1FMB4O\_6&* M"-==R=M\C7.L20F)@!OP!7DS[C2'.N\ESGT2GT.^I4Q,E`Q\)W1%'.T'W(.= MS@YZ$']=QB#OK2,U5X=A:M)(DMUIR$VU$R3'7H=1R-OXR&`=>A:O=G$4.Z'' M<0D\5J=1MR];0"+Q4M9DHA[$(\W`^O>H$MN@YK8LFA3%MV"WIBR:%,6;?'TO/YU__/BK\?= MVYO#/D2-UIJ([[LKNHF'+Q=S$6_C2)O4;)VLE%(0[90+OV;+GUO%=;+H@D;Q M//3X;X3M4YLA4D*@OH_EM)N?M2?^/S[Q*ZT?L":S*10<)=4VSF!-,>63_#0X M@=]!T`$/]2WN24>!X/2NHQ+W0X<3`W!&U.B/ST& M+GLYLF:`UQ`)Q4YU7-K3KYP+N`M&9+N?NR[;.<'<^[.+XD-2%(<#EDFJM06, M4B[E$^[:@:S2Y9:R$V27HRF_N4))6D6U;^'J<`-W'5#)Y_57Z(HX:O)WH:`V MV*N+YB;ZEG8#7N6^=_L=Z%MI;5?3RX*:)="R8]K\)@P5#FOA)ES5-*^Y**7Z M7PD>\C13"Z'H$9'171?N1:S0'<-]M5 M_$I.W?G,JMAP=UD5T7[L:S4'<-]J%C2,F>/&A2]$IH2C&=@U1DFU%R'J\"#_ M.HXMA%+\3:-H%8I1G*O-\6N1:N+L:E*CDD&]4B^RT426V\F^;H_G90!<_QA5 M9`#<.TQTR]F3LR/]^4HFJ&^"^B:H;X+Z0]%1$]0W07U,;Z=8@_H3$]3'?2!. M5W]UV`N)1"C$ZB9LE%)$%2.2<"'W+4Q`J.^`4#Y7XV;'+Q8DBAX/UB)*YVO8 M\+.S9921!(-TN3.$4)`)_;4>^H.(:+;!JA`B_^Y\MO,_8W6_*6,N(Z4>89 M3&T+K,FKG&0K5YVZHX$KT>/V2\U0X"&-8S5#@8>IA68H\#`^R6K,T`^UM=6P MPP=:!3?R.V7[N5VM/=2M^#I.+/JS$BQ\]_$3TX0C2Y' M$PMN\)3^/OJ.+S7C&.XRI#DCCC@)3K",A%(_,,I1QA^7E@57J*$BVK>`-9B! M.VNSQ*+=[\2RJ\T#C1+F1&UL550)``,':?Y2 M!VG^4G5X"P`!!"4.```$.0$``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`I"[^^1,GZ(EULR'\IK"9EHW,&.IME,7I\C*9F.;F8>40?[\.LP[5 M,IS\^L!3,_"0KL/5M*37AYR:Z.MHXM7>'W#R5<9&J[`BZ5GEVI`3$CU@>==U M.GG7E.YRG_%/K"49L<.TA)T1K.7*R-'W=90LHR58G.78Z8*UHK/\^T_X%__K M;+%(-\DZOPW?P\=5=+[),KR#GSKNW#XUC%-OZ`Y+?K._P;)?M\RYR\**&.]I M5JS.SOJ<904C3UGZ(L;'.L7MP\>V]H8_,ZW9J>GXMN&N38X)35^)J1:6WS;,%CT?C;7X99'B`\OK^L.J#@W< MI)'SO>\GR@<_IM8M(I5%>;K)Z#GK987I(,?-*/GPV_U/*%Z*4Q04C=$KM/ZO MOVP9'`U>]P1KGJ;9IX&PWP\[2.YL1=1&88'W\"#;S`_"D@+<*-4)?/3 M%3QDX1+#&ULN*'U"X6J5?B/^-?1?YAX*U^@"C_3R&&7(,DZ(G]!"8;)$]W@% MV:]G\.L3A,E[C1;K^"U:O4N0$JDZ_D!2TJKO&WM9/MM57?AX_O&*2`,KJG0_ M)SW;'6#;X03A+A)V@K/'?)V%"[(160?9$`H"Y$&^E44>Y)>=J09SX4OY]$MY MLZ,5@AZN#KY?=-.WE8^L["M/(I0K?_42(;07E)TMUX0/@^@F?=[6 MQ7)@N6>PW-:1PKF!#P6:FYN8@#5&#,NT^7!SG@SU.0X?XU6\CJO?WS5EZ^?Z MM).@F8>;/30W=*'Z`QQJV+*A:V\?`Z"Y65&IGWF)*K$=?7^-DCP:IIP[`"!3 M.:N'[_G.8YMM-OGO`>@$$Q=V5J;!%B1@-_'.<5<1`:B.@DVX9/ M"C$_3_MHZ@0,JMH)QI,:5$9!*1D&+:KCH)@.I$;09.TE^@M:T[XC-)!KF?!E M(53I:1_Y'-G\DX?Z/^(1)IPX,)2MMR&:&Q.VK>=*1TL/+22DE+1VHJF/?`R*:GN9Q8R%&U&PO(B0% MV];H%3?_$"=H`1VF!;.<+>(08*ZK_)8.KL><;A"#]#0/[_)S(5V%=#X(OGD>K?-3=^9X\M!*YQ@)SA8Z2RS"WPW#8@8CQ#;FFD=5VZF6CK76 MJ0/XTR@<^4>"([\-1WC/,"'#R(1(\5SS@&07W0+;;TOVOP"@FB@(Z*T"%`X& M5AF[=,V99#TU4<"\F^Q=N&T3%(P9^/HM\/7/-8\']E.O1HUUD<#4V?``=N.7 ME'-&D0[`^H%D;_U(A@P8&Q:$3.>:Q_!XZ%=S_."@9,366CB-MO<2K47\=%##$#0U`-'Y$B<:=1.BUF'K58"2[ M/6%!,'*N>8",@WR%AE\G(!8[;N>;Q*6XFE.K*+DKV=>9(T['E;$R\!C^#!9&\N>;Q M'@$V%%J77`0%YSMJ]N]BF&5>Q,]1F$2).4L"Z(-H'53H-/.ZUD'"-5[R$ MAROOSD;O]%*0W\5=#_@K7:EVFL,'`K>WKW?H:2A+A]P*^H@K!6)?]9_@W^1Y M>?YDFX4LX5"Y)Z@7#MZ=8>=C^XH*0OY\ MEBS)?R[_M8G?PA4>(C];GX=9]AXG7_\1KC;1J3NWY5T!YR)AK$`,XG(K%#S= MZ?D-;%H;@@2^WA&_,6PIVCD&$QB03K0HR(+\$&V[RY0/29N%9O+1L&GP=#>- M.:02V!#.]?4.1@YG2O[F,9"RK5#0'RJ=3TA1G:(_H@,(RLDJS/.;I_MUNOCC M(GT)X^34F)GR@IOU^49*``?])=SK;4W'@L6>@S?#USO6RQW+,]$/BN&Z2=W1R[)GGLL77.YXJ MP(4:@YN;GAJD%^,@G294N8/IXI$\9IDXKLXV'KS=M%<1N].27F6!,[X-R16^ MWG%43@Z4(;6?E@":H?PYS,C%[21%KV&&WDB/OZ.SS?H9K_#_CI;(\$]FLQGY M?];V_T'>R7SNG)BFC^(\)U?`""KBC"!8&Y MR=?I2Y2=+=](9=8RMN4YCKQ*,RV3CH0I+R1R6Q7@J`-W9RYX;>L=B.*B7#=]^ M$H)MD[(@TOM`X/Z:ILMO\6IU:LP\2Y[!4$PS#I$=Q!;PVS8A.?-P<\/V0-[U MCI#W4*YDU^^F(2C^/!9B4A2A+(C5-%S9Q/.+>*<+2Z2W;NND6[96ZYI\(*XJ M93VW%9;Q%S/F\M+I&N<-@KXM;0GT7=FWOBPL'K'=4784*+[!`@*[J*G M3;(D#7;*Q4Z*7RE*4CU^:^JSN?W<-9B/9`ZKK'?DEI\)V8J5FY*@BM2=FO2# M#,>K9(W)B?$`<(WF.EI??E^L-L0GN]U$#<>3=[6?AX2QV![$Y!;J/-V)J07W MC1P#/I;><=\17"E2Y$/I"[9=V44O^O253,&0I.7U$HR&/8"CNV^:H,.<&7P@ MO8/(@WF2OT,,(ZPJ#<7M75*>\N>R-RJZ_TU41-[P?I-F[W@XC`^9)2JK4XV% M?"?16VA7FQ'K$6Y4.!:LJ]ZQ90[J%>GP/CJ"HHEPGD/SAY2DB.6BKT&Q5IKY MK@-';<>$5=,[>-M+NWQ%V4U`";EWJ@C%4%=QYIX:IN'*`UUEIG&8ZR:Y@-Q. MJYGCZNT$:Z!6-JSJ4P:57TV`(BFU@^2BJ%8XJ-K*<1W;Q_K>M3Q#[^VR@VJ! M;7)XF:#V^5EUH-4$0#M+EC1-Y3E=X0^1D^L*ZW?R*2UY3^_V33\9)'F9:\!I M2]>9X<-SF`X+,^N=>S*,(84ZDY^JJEJE&8#05A;P9:O=@P*_2T&W="69G^R3 MT,P@R]`[9V4@1ZH5NP!M=:5/Q8"FTK+N_T;O8$XM%-MG4&=J#-M.*N3*2#NO MO*)2J9-FL"KT#@1##;U3%,8Q=N@]HY.ZEKUC<)DZ811)\7YI*C$UIQG_IR-N M>^8*@KP4S1/*1G*FQ-DVCL::Y$RZW91YQZ9A*ME9)DF=Y&*@`?QEX]G,9\$I MB-\:>B=S\+*@<`OHHJ,*V8'A[ZXO+/M@(!VB7<;_SD4`N"/N0&*,H7?*!CCV>:>&;SL_[2BNFH0V++T+\4]#[QP,45;4 M*]Y.>AH5\!2V=AL69%O7JK'=94$W%30V(871A5070^],"F%>5%O)7%25970K M.ENP;O3G.(GRFZ?S+%K&Z^TN;?LR]75]RK%HYF)B"^2FYC/'ATN'+D1CM8\+ M\3(A7S%S4A*0EJ2Z#S0=;!9W?6Q)6E@M8AM4;U-S8LS!N<.%G!5#[^P+`2X4 MJ5M>>H*[Z"U=O9%\M!7#\(+V$H1NFGQ]B+*7B^BQ\M$]1Z+7H3[C2.!RL5#B MMJFU,6/7OEP(JQF:1R]Y>9"N9SD)"4C##U@N7A!INC5^OX3K33;D8-?US>4H M7*6PK:O;IM9$+T`TS(5HF*EY[)&;"37*EI>VBIJ>%M3ON4"KD)"=)U MLBI(=VKF_6<%V.D8HD:FYC$[$3Z4Z^<^BBK07E)HCW^FX6;]'&7L\DAE=FLN ML;)PXYSC`,W+1H'GEO:F.V/^3`@HF7K'Y@2XD*V@^4D):-/MM:.!SRKT?'$I MJE@]<&N*N*4]\5(R@P[B2Z;>$3L1-I2H80&"&("'O,IZB\$8X:&7U;*:6#;D M&<0-,XX#+!\+!5R;6\_8A40/HD:FW@$Y;AYDZUA>0H*RX01%*#N_MQ0MJQ:R M-0W;V)JDY+)EABB0J7>">']*>L.8Q=A"O,O4._PEPH6`[X"0E8$T1:SLP`MCSQ65M M!HJ!V[0A-+4GIB%37Q"O,O6.`HJPH6I3X"6H!'`$C87-[O0URM;OMYB.]5FR M)+G/K^1A!7KCWC$->6_3=$T]%L9"3&W1W-7-]@T(:WD0UC+UCA&*,R-?*0M2 M%!0]3A#M4]Y0H;T&5"/@PX4D97U8L#>H[JYN1--`KHP'43!+[\CB`&X4*7)1 MNDK04[1'6[0+E^2ZB]9AG$3+RS!+L/F>GRT6FY?-BMCY%]%3O(@Q!>[,D6=9 M]Q,P#OF#&"SPS]798)=-/0BA67I')8>R)%OQ#Z0K*/JAHB/ZN=(5L;Z"5;A$ M0"-E)]!)*FJ[`D]GXIQ@6S6$WRR]`YN#>5*R0PRE+JB*PA):BDD".(/.=AU0 M7ZC[YM0A.5RR]H6.B<=!7XBC`O)=G0S/=*A:D=]13F1;;J%R4H*#V4 M>XYZ]#OT$KPDO8]SD\=&L+;IAV);WYN2G2W=C&\^=R` MY6=*1>^XJ"`GTI$M1$[M&6'2:\#NZDU+OYKP@2"WPM([ICJ"*V7P%R8M.+^YOKB\ MOK^\0/BG^YO/5Q=G#_@?'\\^GUV?7Z+[_[B\?+@??'^W).R!OEV`5:$">^1A M_,L7?737D`[MB,ZAP3?'@&P,2^]H)@_YRK#;3D-5;=-6PBBL%UGSK)F\!ZNF M+N['Q<`6D_7&\QF[Q.RQO5#O6"4O"_*QR45'4&WW;T5]L;/U.HL?-VOZEM`Z M1;>A>,B]Z\-+J46C$KFU6C1MQ1#ABH?'-BV]0Y++4K6GH`'8 M@A4[.)"@R)90AFP.TV*[[O.9`7EG<[#;;+WCB**LJ#.:I(^3E[19QA;>R&664.B>?!SVA1DK!*"OX]QSF.Z!Y$M;[ZCA M$'9D"\(`FH)*'WKI%Q6]BHQ7.;B78LGH@/N:2=/7D23Y@$TYAZ1-6^\8XB!^ ME)@V0R@+*.;IA0:T2'/16VF_)8_Q:A4M[Z*W*-E$9\F2WG`K,G)-?%YK\MH] MAGE,06R8#,+D-SVCC<6O(*5;_'9V)*LZ@U/]'#(S;;WCA(/XD:^YQ8D*BDZ( M]4*X&X(;EH,N*?!"Q#L:,#N`]LHLHB]\P`V]10ZGLN6W+*RC9-?,X`1#CB8"?AZ;_M7I'*=A38OA,0&A0CH&>T@PMV2@H9,.HD"HICDGMI:IV^A4;9@ZO(_LS"SZE MWBDLHWF3?2H>2^">'!5#H&(,M!UDH#UVGKZ\I`D-*%RGMV$&]3D\PVDZ*$\C M0XU3CI,53BX*F6AN3BQ@!VXKSGWX`GIGRHBPH63G$"`H@+8HAR)%U5HN4P)8 MRB:@',`UI=[TTI% M9V6E(_S5;7EW'CHFG@S!_1PUX+C6R?1L4!H^#7R;CM[),J*L*,0T#SU[R(8N M:-MG>GC+MBW4P[O+SMCOY,&V")=>?0,^@]Y9,P.X46UU<-*U9WP4M>*F`CN4 M6L2PL.1ER+1,.C'(VSAI!3CK8'KL.1??A#77.Q5&A`WE>KN=ED:=/:S29]^7 M5Z.L56"X7TE#!Z8ZV)K#B=S1.[%%D)/#*.=.FIH5A7@)0BWX&OH'?RRP!N#H/S7KJ:L5XI1RL!\&I,$;6`[S=* MJKU,;*S#AX!@A:-W>HPP+\K-DQZ"6FR4FZ$PWRVT4O4RVJXGM89RX[3C\"W` M3'.%\ITN,^9D]5U8?+W#H6*,R(:U$#7U&OO#'8']$%!09U\=GGLJ[N]%#>PY MK+P'*Z]W,%*0$R56B1A-U0+\8\,RNS/C>6\R>I%_2>>_C3*Z$Q!@R*U\ST'$ ME)@78+19`CH&F,W9!X-PA*-W<'(,6VJUO1!M==U/%'^:(1@`M@"$AP!31Z[0 M*-@:]!":GFVC?0!R\(*D5A]"SX[>,=%1?!U@2Q&CL+[![+S*\HJE)A\K-;7H MC&%[,YDU_KLFGU)*.!AKEHZ&CGCSAUI0$/]S]0ZM#F%'[1;"15-]ZQ@99>7% MAX)MXC#`[]D6ZAV)U0L%IF80#'3U#KD.XN<`VP`?90WJ?USDM8D(%N[!IH,O MS^79/O'TP&]EJ`OT9:>9QRH00]30U3L0*\K*(;1\!SVM&G[\XXO-6%"FV56! MFTNC%YV(CF%57B&"Z.H=GQ7FY6":O(NJ5BT^)$S;-/E.Y,SVC)E2-3Y9\$J< MM2[,[_8T9LRXA#B+JW?,=A`_AU#M?42UZO>)PED=(%&FZ=7CGTOGU\+I,_@V M$$YW]8[B#F/H8-J_E[36+6!P]L+9\C\W^9I<;L\?TKN(K'J\BJZC]56R2%^B MSVF.?W\>YL^W6?H6+Z/EQ_??\FAYE=R\1EFXQO.=+=;Q&[WENRUE!Z5&Y5RO ME4#P.'E3LH3EK4(9DV&L63-J4[L&U-?5_?ZANE50H@S4\1-4IB+%"K-B,O(* M((KI=.CG%9[P;^3/Y)<+/"^&`$R,'M]16DR*PG)6P;J>,F5&SOWC/Y7:J5]F MEC&99S)TPF,VFE_Z5+4$LNUO17SL*YIR)O*X+KIBBN9SH6C(A.BVHF1^)I-B MA?0W5,Z+MA,/KJY*YCE+EN0_I'SK6[@B!)ZMS\,L>\=S0):&.[>AQ:*S1-5G99[VCO&/8XI=+C-.X'SZ?`73<;3&1"K;\F:8+,.)*Q)U!1(EIS; M.'I+5OVVCL@H)GN]QC6A_K7N]XK'\B;[$#:6P.U.17^HC'&"8!14#(-^+@82 M?,^>C/QIE7Z[QE\$_WB5O$4Y/?XE2_;>8?4H>!'GBU6:;[*H/!3Z,NM-C"1N MO`1.NC15H1PU,%:^%"8$+5!-5O>[TW(X5N*VE4-[<+]Y?5W1EQ?#%5J6O8CQ MF:3)![IA/A7C#_?!3@5B:;OI\L(@QN%P?PN_L59./41(]Q>M3;SZ7 M]T)@S^3CI%28LT(*^SJ2$XS!G`,0.=/\MOHPAI3LD8-("XI>141R'7Z/!$^& MO.B0LGUI@?O:[M/7T9K[[*`!81S-;[(/84?VWC&`IBW8650,]RJ>4$,_LXZ" M9[>+Z#6+%C%]L`)O6V?PNA7]YRF)$TA4^*T3CP6]`$=;P+=WHND1L$U;\,*C MYO?GVLXC-(ICLT"&!<:OYM??1_,F>V\:2V!% MB(HA$!D#X?VJ-<`D)EGDE2^:<;%-![QY^B<\]H5AY4H4I%L'1W M.$Y&3?)/=8V]\\W6;DLL?Z M_18SL":;P.L+?7MNYMKR;@?S$3$._H,9+02!)+H*ZG<-FS'&4=E0+H2`:PV>"5%O-*[$,94F)/3:0N*!\ M%/05FDD3`"G6ECX"4+.Q^OO./98[8$-JK.8%688Q)-NR&D15T)!?3`XII3#< M3BL,VP=W"6`L>:D;/"3($HE.)ONEHM)][LW!VV=#"IKFA5H&\W0XV>@FK%<\ MMMUE2HBJ<\C>)+T2%C#(U;6RJ;4CZR#6:& M^8L6:.VB/%'@D2Q*.?R4[IJ'4GWP?"KC:$75V]\Z-&<'6XXP47?0%K MB"+("A0,8(BA19U1=4"1X#.J]KO//1LNZ]@LA*IWJ&,P3P83[W8'-W($KKZ1T6 M'\.6>F'AIJU-8K;WD*(I'54]8%+EJ])!<'@\5HU#%(X3*+?H0&S6TSLV/I:U M@_FMA,@,KLJKJB@D!Y)P-<%.\Q8E&(CL[.JJC'I4YIY>.+K8ZI*(;;^Y/V/J M#$)2WK$%OON8.<2^T4E1^VY1=I."=W7[@EK`\^T!9<="[X#9ZT#Z@>89X\,8 M.J"^[R4NF!#M96'C\_`U7H>K;?T0SW(5NIK:Z)A:"OCY;1>(UC'HUV(J"\)) MWK&%O`5Y.Y`G2HQ*EKZ>DXVB\FY`GD>DJ&JR+-/7Q>M7#0"8(M-)&X'BL*E: MQYC/'>9>A*0&[]@BXT*V1,AK,[VVI?'9((.K1-7IN\VBUS!>%L5)6$&2 MLV1YLWZ.LC,JP>1`:ZE,3>0A:FHI&[@0[2+'->!\[D/A#`?"7]ZQ!=\' M%(>2VB:6;+RRB`_9Y^A0",92*YJJSD_ZRR;/B8MGQ.)PP/``>1K>L24#C.+T M8&>T,50'A6`6>314,E,JF>$`R;R.UDT/Y304B2PW=\OVY14E$J=GG#Q.P7\A MB0/&,@S/A?.&"R&-N=Y1I*E8E+U!3D0G+?G?\:Y38\'3H?;K""A*\;(I'$-O:TU4C![8L:Z9Y6M1$'`ILH<.?L)J&5BJ^M'C_)@?1;7J(8Q+)W#X[ MT&"Z.1)3#<7ID2*`0OSWR%S76(8QM\'?[H*_?:YWW'`J%@^T78K2V;=A;A_1 MD'>*Y(&BRE.DCJ+(>XKL_/[DS,+<"!!!GNL==)R,QT.>(H6I#2H/UTQ\BFR@ MIVXXOFE=VG(9!?;;%#BJ';(HR3Y'"Z%1YBCPJL>4] M1?(.3,\M>E]"FXC#0YXB!6FMGR+CAAUU$LDL,X2:33=#]1[:08\4`13BOT?F MNL8B1Q7"A<2YWO>?IV+Q0-NE*)U]&^8VD4[>*9('BBI/D3J*(N\ILF,L M#PXM@``/KL;[1[D##F#RD.=(<7*#K=A-?9!L(*;-\-)B$U1FD0Y?&'&1;#O! M6'K?6IJ&07UVQ@XJA^R+,@^2PNA4>9`\*K'E/4CR#DR/+D>9TR/*X2$/DH*T M;@^2KQ7Q31MV56'IA-OLI.([P90KKS33[(HH5-L9B3A[D+OK: M1]W[J%>P]_200)')*B*PES?.UNLL?MRL21$%M$[1;9@)OQ;0\H7GQPG,>0\P M;<=P[5/3=CQ3>V]".]W\8'R+LL=TQ*FDE0:*QIBA<470*`:[V_"=O&R1?THS MK+$74;3,/^&/>\N>;WV+BILFMNG+NVC*2<4XJ`YGM0`Q]PB6[4&"J@A>AQC'.(SQ76S440&Q1UL>KML&:\WF:C=7ISD%C27Q%9B.F:>1"3Z6]L6@N9=AZYT6Q$&]JOV@G82MUD^?$&F$BE:( M-I.`7+FJ_3#0;5?AC=T\VS6\4\N9NX;>ITP!+A0KYWZ*=J"])-"."V@O!D"[ MLA-\CI,($W">15B_8Q#X\[D\E=PV[TA4"[!30KJCC^,P>Q*N6?MZ9T\+MRP%H M?9.![UH+PTF*$UY/R:DY[CE'P#NY.2.U^>AG9`XXO;/J1W*FR/D_CLH],2J> MMQ[XHC6-Z>;XFWU*LXMT\[A^VJR*9^TPA$Q/WO,I75./%A$1IBIRT=$-6V80 M-YPS)YK>42YQ9A3L'6(4!64/ZNLO^I3/DLI`NJQCQ$&1WG28Z.A&LA_A5;\Y MO=EJS_3.2!W`C:HCA2!=>XA?%H@/!R'^+GHMO5![1QIG;LISS[?..P[K(NP4 M0._JX_G,0G5A^?5V<0IR(EN9BY$3;)L36V64+X@#!G)<]X>#==UMW]&)>"O@ M(8"Y!^NO=R*D*"N*'/B"9%6\^%-Y@W8H2).O#U'VPJ*VGTEYT9O'5?RUR*1U MYH8\CY``)1/*@C#+C<+!,0K35G/XEGKG]8SF3>G&,(#`_:T"#_$!VV`O9=%X M.@JJ#*-`JA1L*-J)5<^FTS<,49)0TGCNP[?5.^5G/'.'V)B&$+JS52V85*VH M5*532A4)?%,;QE:Z,9%IIQ>7%F:Z1*/HP@J;^C/X`'J'G,48.<1FTDI-Z\Y! M>DP-9W4[@@H\\^EZTH=5JS?9XANP^'K'FX5Y.:`F[Z)K)U-H5<)[*0SO^^

E2/-@B".HUWDB(=K]Y(G=M/ZW2;]N*(X[ARDO= M[)IY)+Z%>"I!WM6+?@T#OH8-7T/O..P`;J1K;&&2@O.;ZXO+Z_O+"X1_NK_Y M?'5Q]H#_?]X&I$]T2:2+9TM#3P%F(Z M\JYR5Z<:"_-.HK>XWFGFN\R^@^B?H7>,M9]X^:CMH2"@+1`TF0)VY;;:4-O'.CKWVZD5<%9K&E>\OH:/-K&=OAE3$I6),L<4QQ9@3,VN&U6X3)"G9ZC"E$P(,)*5O[05%>V_>[.IES8P[K M#T<+C;7S$%9DVP2"].Q!>Z?BRPDB93?2)X3[GDQ2_H5<]KMY^C5-E_E9LKR/ MLK=X$>7WZ6IYZEES7Z*.;YMW+/CY^=EBO[4/43Y0W<&!:OVVH7>$4)@71?I= MC*K@@5''96<3O4-^@IS( MU^DBY`3G#,BT`[U"5'1!I,]@8+.O[\E[=75OLLD@W$QY`VZW2H*M*B3A&'I' M\_@84.(RYB*E1.@K%&89K7)WOJ]L/2L/F5T:E4F[8\!:0I:EH7=,CH=\A;JS MC88]A3E41Q9*]M2S;5.RBBSFF@*'[73OPK!L1V6:!C(=J`5N&WJ'UKCH5Z@> MNRDIX9A#LS':L?9M)2I'J9AL48UE.\NT'1!K2.HS]`Z!<5"O1C%VD5`"L6@D MAL#+,$M(,8C;*"L"R?'BU)_-Y=TJ;)QR'!XYN2A@V=R<>A5AV_$@]"$F6L!-6]"KGHX%C%ND-,Q]0[7";" MAFJEW$%+HUIF[<4@_"F,LW^$JTUTMOS/3;Z&G+-_AED6DA((OFM8\O)L.N<> MAV=1M@I8=_6TR/@8XH#S%]0DN8H+S9]R7I#&@)]P>O9$.Y)CW#1JB M51P^QBN\R.@#^AGK[8Q?XV2*`M79\GR;/D2)S')@225N"\A M(_C4F+F^O(!"S^SC,"_.6H'ZWI[$+^2##H(PI:EW('@80TI,ED&D!:P7C9Z% M._TDP5^*Z:('_&NV3%]/;^Y!"I8'04U3[VCQ$'9DVS8#:-K!_&XO=#GD_L:O M&;;U;[/TB50(F7F>*RV_IS+32$QWDESBM]J*J`_PG$*A9]O4.UC<3[R`6AZ> MI--+1D!;D!#QDVB9F,:O*$?!2@5>77%66GG^G'D^(9!IZFTG]Y$N72%VS\_0 M=CL`;=M7RTCUTJ;G'C]&3VG&DC$?PN]1_B5.Z->Y2K!A$^5KK*9W1R$53]?O M7Z+UZIMYCC0UJI"3<=)RV"4OI%$I%5A%SD%%SB%2;.H=\(M)F4O?DO;<:UY(?09G-[S@)?D&R@^?.H MAUX:V;;1@?DK51B\,TQKN#<^45]H-Q@;P>"H,OI)<8&%TGB"CZWX`(N!%2=A M]HZNUM$+_N4UA@0>':_7B@Q?<#!$39;7QLN[XJ9KRW/GM$PZA?;AX&174=0[ MD.W)A6\[AWBVI7>2BQ@C:H20DQJ^Z@,WMY=W9P]7N`$ZNR8MO]S>7?X'[G;U MCTMT=8W_?8F%[N;^_F^#JQ.4*H%YB#Y&243/L(9AV=+<^BVS3B$(/*SL2D)# M#V*HN?#)((1HZ9TH(\:($K>]$$G%#C+8WNWXZA(UN6H`MZCR>H^Y8[$EAJPZ M2^]$&1$VU*AQ+EJ"K;%2.-C1SZR]X+WRPH@I8R^&ZT@LRK@WW5C8]M*^Q>M> M4Z(,X'81>S'"TCO]A8\!1=D"7,0$1:MA-;Q:/ZXDM:H"EPUJ=+>E;\+#/0X\ MW&-;>@?O>"F%;Y;AR%6 M#,R*!Q>[I7>D6)`3Y9JVDYP&C3O8E]J/`BG.U(-ANN9/[5AZDB$&NQU[W<+2 M.V0HRHH2GZH@415L%TKZ[P,1O7.$<7P%"GJJ\Q M83%N'I1IXAY"*CC=B21/B%6YQJ\2K+8;P/OG7;C\QMZHL/6.7/$SH=8([B.G M@EGP)`B"=?T<90VE/FGV19I%\=?D?)-E4;)X?\C"),L=LE.Y#-+W*76\!'0N MU%FTETV)BCE195)ZMZ#*Y7LP11; M[["LTG50<]13R%%0:)Q%H7'6%0T3EJ-,IU4*>FXCC"22>$HOIE^P"^I;1\-\ M)J]&TWCZY"F+H>O#HQ79](>&,_-)F;7A["MF7MJ6=;,U]RC+\2(.B./ER0&]B'>IKLH MC_!"/6/S\")ZBU;I*S'GRFF<^5Q>\DKGW.,P+B<<#&%' MB3X?0-@N\)?;7L*`7V>;Q7J3X5WD_#G,OI+\'3R3O$AMTY2CX.7B<>@81 M<4?O]`(1-E1I75Z"]J"[&`+=^W`5Y7?PI`=]<.8Z6F,Y(:\D27O7NV'*<=#E M9*)\Y[NYN>V8L,`0%G?T=FSP,R%;U7)3$M"6B#4]@0>.J.-N2LQ*4;>J,5M3 MM\W-B0TV@U6&H*RC=YQ=@`LERI:?GN!VS.-PU7F*[RSOWN'>;-/AM)GT)H@6 M*L"!983@G*-WV)6+?I7*M(V(H-2@HU3GSM>4DE*H!HBU5,):2R+0S'B"D)*C M=_2/CP$!#3D\A9"+%':+9K1J+%[V8I]7XLV9EEFG0V@W*TU(W>UA%XL,]SP= MO>_+"O&A4H7V$;-ODA;M1ZK6QJ\OW3!5!^1.\W2G!RD7Y<.BP[U01^\+MF*, M*#=2>TD*[L<\TWD?T2ITI8_7]62:J3N3C41L'^$E4/<:>J9AP1)"],;1.SS& M0[YT_=I/0\#:#(MWM7U,.0I4`0KKZG*O(3&J/%A#B*4X>L>LN.A7HQPY*"G0 M*(;"?T;QU^=UM#Q[B[+P:W2]>7F,LILG]LP6?70KO]FL\W68+/'@I\9\9LM[ MS%"0FG$X'L]Z`73AD-9B?6^^(US0,*A&524@-!CTS-QA04@R/XY"E MFNDB_OU,*,GB&A#M=/4.Q4W"GVSC9PHB@V(0Q$9!,`Q]W)R.@"I##'S9L870 M&H5EWK7C2+2R1*F1(G,"O/?(7/M(5&F".6Q`\,#5.XXX$8>'W,$$:=V*WR)] M>4D3>/HW1^EV`,'"$H/QIG)[TTW6>/>WKJ]KSL"A9T",V=4[^CD-@P?:X<2H M'+C%#;ZYPTLTO'2/;2PL,X>6/TJ+&N%K8UM4]-@XOFG,X8-#3-+5.[`[`7>Z M"%T[B:(21T=2(F0'-2@/)V2#;4DZ#J3\^39\98BTNGI'K2?A3RL[LHO28(`` M37A)6GD5BB.[1+XC?5/<2B8)N$SG0O38U3$X+-, M=+;&$+[V]`XXB;"A%K>=M`2D+=HV1K^3YHBVGQC#4DRC@V"X=H1HZ>"!JC!@ MS2'N/=<[V"/(B9)C@1A-5!&+(??L)4J6Y#KLIU7X]=2P^WS`>;0X_9J^_;*, M8D`J_F$?H/A7N^..@V0WB04.=UM18\MBU]]=O?/[>BB7K3&[IP_*/R/R=S%P M00&U]2<,X'#U/Z,PNTR6%^&:W*3O,TEY<=8VQ3C(<1->H*^U@SF#!049=?5. MY1/@0C8J^4D)6%,$;1%IC"Y)D0O<7'`;3Q<;^K1LLKQ,UO3QYJX%:?^6S MOU[S1:G',`>$&B;#)_D-UY@CM^QA5)<;.$]W%<23=1 M!Y,6%%T1[HN@,ZKT'GX&8^.""($WXQ/^78[%S9U(4[?.,0WZ^TG?!WR]AP&O ME]CL/KNK^;%+A`]5H.8A9@MCIK*A.:+MQP"7J/[BVT]E8+3,,"5HV\ENANRV MO6&:L+80Y?8T/V#Q!TS>J6GTE2H4!209=AH<-A*X M#S_:R&)B#+D(GMY)6#V4JP);\_1;C)&_BP$++-1SW#D+5U?),OK^WZ/W4V,^ ME4G9./XXJ/&17&"NI37DGMGL-KJG=RH2-P^R<YNV#>;>LS-PH+_.F; M(\//@!JP]E!1@),V0T6[(5"\B[[&Q&^5K*_#%WS`F$]U>&\:?@HP]A"\B\;] MQC,PX]GE*T_OX!0O"VH0V4M'@&-Y6YNC/N M.!AVDUC@;[>5RQ:+'1_U#D7UD2X;;SWS!^SO"!H(YMQF7\,D_M_497^>)GFZ MBIUWJ%M.&[5KZSYNG3W$2)HLX7-WCWT3D%%9Y)-HS^H`Y(NUV"A)'9M[* M6:7RV8U)AB=I&#.:ASUW:$32\?7VPK/F+LSP)[>#G$U"Z"UXN#E(JC.K;=7480-V9NQ`"W!I[.K._2/L\^_71)`?[JZ/KL^OSK[C*ZN[Q_N?ON" MT7T_V`9OHF,K>[YGRWNRKW/JZ6'>P547SK?=7,MVX9OH[:P4X.(0*&\F)2!- M$6U;L?[R$>8?'P:DF'('1W;-QNKLYH'"L>%;Z.T1%6-$B<4C1!*/,A?#^57R MADVG-'MON*AJ^H8\*Z5CXG$8%^*H0'A7)VQ`6C8-W+%MU?'U5N'BS,C6Y,(4 M!5?7_\!@OKF[NAQNG33,6CD8&'-;WIW^KJDGAW<74QT`KRA^%XI9,DV#?S@V M?'?S<@!X=Q(4E!VF\57Q84**L7)HH-=LE:YN'B@;'SZ'`Y]#[SM80]A18K<, M(*RJU`<"_%.]S/IKEN9#,4S[DD^.IY+UON#N9!-AMHWP&E990Z(&8%$M`Q95 M[R@S%_T"BG7XVX(\E`3T;RAF36/1]ZW;/JM<72H1C^VZ$QKZCF_"&LY@#?6. M27)0KTQ7MI)0U9%C=")]M0UO@JY\C3CZ#<`>HFOH8R_260Z<82T3%D_OZU@< MU*O5A*UTE!`[*V!JRM M#6NK]_TJ$3;4GH;Z"0IP$_12M)D4M7*W;V6H;=_,=]K[+KSSZ5D6K*W>"1#\ M3"C;VOLHJ>[P!+5EXW$;/HG7T32DNRB/LK>(?GJ7YJ",=<'-70 MW-"+*`P'OH(+7^%(8F6\O'!@VP=L)]%7#+?E2'W,25=P\YCC2?-%E-!7@FG; MZ>$M5T$?`-WMJKK>R7<*!>/`LA])F(R/$V5*FXN<2HBL;(^*#@-Q_<\T^^,J MNF70B//B0-AAF#D,CR0(QL.'6G.9@Z*`M$%Q M@M>5MIH6O7(ULD+TMFOBW0Z^Z[$3B0XNCZ_^7*)?OY\8?N_^/L[G)P?MG^])6R"0DCA,82:M4OB\R MR?#&#"YT>E!@TS7T=IO+8UKV/B2-\J`Z,MH.C8JQ$8$DJHQ.[OK7-[H3!',< M4A5(V0]_.%50VV MXT^*]4*58@I&[H'=N5RK?FTMY)_%1'"_0[F0;1>2;1#Z2$ M[D7Z$L8)!K.\7(J^R67(AK?G^-CX'#2,X>%6TB<$++.*/?H:D@ MJ.\7S]%RLXINGD9*[T/XN(I.;<^3=_=M6EK'28SL=2L$;.)Y#-?UF",6@L*& MWN*I@GW9PJV`AZ"8@VQZD^V4=#Y!??+/,".5Y;]$+X]1=NHXKKQ*83M3C9/F M'JH+8=QM9OB&!Q>*X=T'U]3[OBL'];)%H9^$@#5!OT.CP=M9[2P9YO'B+%E> M@'.)8KM2=\*U)=9$&DC55#O4V*6H[T6"(WJ6J7?^RTC.U.T@0\C;V1R:@BUT M$%J&F0W#5#\:G&XP&GM2HB_'*8:U$,O0$>VY/_>IR>!I_A##1!PJ"9Q,0VMP M%Y&5BU=Q:9'M&6@@I)_)[?JMB;9.2Y&]CM9[?QTJLF6.Z/DFR_!/-6!:2LYX MW61,)93"S-:EL'<(UYA!%0_FS3H6X1O"F+JM<`!U.SMA)16:C3#AML<+*\G[ MG%XRU+&3=0\!&60.^YSLU*MWV9:QK"G>NP81&=QO7E["[+TJ30/J'2S2E^@A M_-Y4UM5U;(EW85HG'GLA1H"C[:68]DYT\2&KPF*ER_1.NQ9G1O:V(4Q1D9WZ M+9//3F^NYCJ0'CU.0_\#:!8L,V>\]`[!WL`-TI4 MNCA=.TB7`6]5VELIO'D4^+;;W+9!P=CL22R]4YN%>3F`^NXD*(`."/>8IA+S MY=-3M"`!E9*2NW`=G:?).DXV^-!_\QIE]*B>G_J&(>\"+S\=(V_8C."WO'+# M/X9C>SYY$L$R?'@20>][ZR,YDRTMX\@+RNZH(D5D!/IP'QL#;0>1+DERKJ;I M*TGURVO<8WCXB\X\CSV@HW=L?P172DRIX?151"@&$5IC$<*-!7VRS13LNHK/ MUI\B_(GAO;P-.<+O-,:@L@W%0B1$H`SI&KE"W6(G-KCAVP:I#HE5K$FK0WJ. MWNY?>4P?4&@G(#\H&Z,GZ*V/;"LT-8]4MCF-4['!'=MW`"4&H$1OE[0LE@]C MSHZFN]W.1;MCGZ!PC=CP:*L%]CJ)2?_G.'S$XZ_?/Z79;_C;9NLP3O!0MVD> M4Y."^>%/#=/PY7E1>,D8)\@CF"W$E7^(F36#HXRC=\K10(YD"]LPLH*R&WI* M,U1VI-)1=BT#K;)E18JMJZNLU,Q6[B'(&Y0S9N#H'5`:RI(2DW,@<7LRDZZ? MHPQM2LFI&)>OQ4!B<'$W`?"%/XD/YGJOWQ>*A+,G>?0;2%6Q+R98=3U#1E6Y"M#/> M@&AW4FY@2(61X:"2LB,=BT3M[%!#B?]?J\<5UJ#NS-`W-C`);]+WK"FH)`&V M+`IS*DIOI?2%Q4AT2UL6`H@W,=&TH"]A$GZ-7O"VF=]B#K8)-)XYIVG1VSJ4 M(%*/81Y303%,)B;D-VWCC!,%`>**3:2UBVE8<_?4LJR9YD$O3@[XX;M,%QLR M'(6.\%;!1TY0:89(N\&I/+W?W-48CS6;IJV'Y1@^/*3E.7HGX'!R(-MBX2,C M^')V??;KY9?+ZX=_NT>WG\^NI\+A-@V"?.RF;$D^($Z4/"-`70L4MUWH$EJP MA'KGR_"RH!B,;70T*,7!B3']']S3&HXU[TGW&MJPAGJ?[GA94.(=X22FKB&G MQN$P@U$9$'M-QKV5RA'^ M+4>O>(Q3,9S>17C7WRS6FRQ.OIXER[MH11Z3.B.!**AM5E@0MFO**R?$3<8X MV(_@MI`"_B$,?V8;],6+.7MOR-);3X]E3;8Y,9*^X.[R_N'NM_.'W^ZNKG\= M;/#V4M&8I^WXGKRPZ1"2)`L2WR)P"U7C<.YL-H=O##G=WQ*%WRW?H84\G?GQ_P.S=PU\CU]-X")^-1]@XX%:$[%1YV-T,V%GI\1V0T*+&23UGT80`J)==_.`;! M[*@*P3T:*5!@SDS0MW"UU?7TW@4GY%+)+C@=O=6R$;LBRK;4=S$!W&Z_9/Z7 MURC)V3/$=)\F).6T(-)CF$?+V_"=^G^V9U=L.$O;(\?1-DXJIUZ70C['CNO/ M+!=*B=@F8$+O>VI2^)6]HEH&=F<%NV]-XHCO7^SJ;#':UD5U^ MFH.*SX?5%BQ&+3U$=-P3J!WX@:H%5(P]PD\T%9"E6,H_A(C7#.B1`T.U+Q?> M#K?A<;^YWE?;)'&LQ+"60WOS7GTC&%4_^Q9F2V+9TQ>7+$?BFV?5F<;)53?1 MYX?J(R"@#<#/,N0IKB_A]_AE\\+JQ%N6 M)\_*VYEJ;))')]7;O(YJ,\.P#;9\D`SCZNVWX*!>?II;'PD!:S+Z%8&MXJVJ MYC/R1`'+(_GX7E/.(!WPKLN\,3EX:C_?2#*G\OY-OEIUE^#8*0QW[C.T0+J/ MJ[?S03+GZOSZ,LC?\?97SRT[YYOJ',3[WW#`0;!?#7KQII>Q-KX^A7%&[N!$ M9WF^>:$PRR^_OT8+;/5=Q&_Q,DJ64(_$]1UYS]-+IW^D=CG`\I9J1_[ MG#CH7YIM?WD5:C;?MHC_D2`>GCGQ]/8A'6I)U$1O#\-<4&J?]SA:+350/Y_2 M["F*UQN\9N3NA=]4JK?E9HAL>C34)MVK)5695*>FU37A,J6G=U4GU4MQE(91 M.S]@$:&/W1;11V81L7:[9[AF@VAK#U4FUU4=\=V8_$L=^GK7 MS5*]%,=KR[0S%1R!QN"\V_J7RMA?+K4Z`VJ_>7H7UE"]%/PZ8]S=7\5\P1WB MPNIX*MO14M$H+(="Z^=PC>*OBNJE M4'+*4L>/$K\SF5X_-27/S_PG55/-IR\IDWK@8X2'&>90>]K3N\*#^L50=P)3 MR590JI55_$2C_6ML7:7,M_/S>Q1F^=\T.)S](UWA84A-9^(39TE(-'5!7BD7 M=8QH>+SC77"IY[P6(CQZ`1SCV&?^3;V32@^]-$?IRN;G3XG1M26'/=C'*-)? M-1Y/`L`/HAK5N,U;B"![/+S'XS,_J]Y)SP=?F^-UK`MPN;7RWK9Z[`2]Z*K# MXJ04J:;"N\>CPX`1_758ZX*KU&$%$7B/9P!F/E_-$\D/O#0_@GG7P=^!S#N@ M2'_5>+3FW;&JQH.8=P419'.W04#@2J#F10(.OC8_C'G7Q663>8>MNX.KL+LX M_^-3%D57"5[<*%\7J=,2"\A*IU\CA<6YO%+T5//_D;94:LVN298\]QDWV6>9[@E._\3Y:E'$]6DM+OP"`V&(K4TZ5X)C-MN,_ M4?(\_XH::=`U]LL=5IJ6UPBU4HF1_!)0#U*W+\YED3 M6XG&RFE_=27(E9K:LRQR:^W1+31+!W`+1,'E__:D-Q?^-/0VO:M'TW. M.5<5Y.H'QUI3(K:^YKE>K42K.7RU31_0OS#DY0.A=[:BGSM:-FMHDAZ:Y-&I MXQL2WYGAHF$<2(?R63Y-P]=_;NE]*!%A0[9*%:`E*-NV/RG`VDN%OQ1UK"'\ M:XJ;K[]W:K@SU[).+Q0U M63X2D\-:IQTG``+<%)AO[^+,-4\6Z"-=MFKOF3\H_HZJ)LQ`"^8Z3?ZU"5?Q M4QS1`V)A)'GFO.D-Z):.EC8GC;AJ6[-4X?Y&)"-/BXJ M@FHK1)I)PA]?Y>A#X*^VRW)#P+!> M^;=K[5Q8.[WW7SX&^'$XKLHN%S7!7?2*QR*NV+*(&RV#^RW*(O0U"Q-R^DHW MZSQ>EM7>EM%3G.!?/T8)_FF-7O'HHI5P"ZQ]I16#$ M\DP?ED[OK)E.NE6AK6GR*MZ&19$:3^[,5WN#M>@Z3)9Q\O4JSS?1\@;4ZLU3 MYE:WDSOX]3$G!XFR#N4W/9WAXJ( M1V5(!&,B-BBZ>=IU+9"!#RO`HYX#.6X)YGW:0W0&6L\38T7OL\#DO*HZ-DQ- M.'U](]F0LPRSISK( MH63(ZQP32L#\3RO[@A][>J*E9Y1?\MRA[3*?-]AY,=G!3%_1^27Z= M:,/FR%ME])TMES'`Y2+.%ZLT)P\(G3WFZRQVTZ/*_.CW@H*I M\],GD3*]+LW]*+IKNMMQ?-#V9Y;G`[;!7>4?HQ-#[G(HB?`=@+'@GU'\]1F; M2Q_.L(D7?HW0K\1\0A?D_<+M75^URN?R>Y0MXCS*KY+;"*-O61#):*0D$@K+ MVX#TU<\F#[S0P4@FA8=5/).LZ%3J:`@Q[LRU(7;C'^,13>7BZ&YHC>9P@O?C MBQ-D20NZ2A!0@PIRT`^B$24_-/\GU(B3&V@#1<*9@4@(B^9+.`^3J``+X67Q@OSQ)5H_I\MTE7Y]GR2BQ[^ M+"^_O\89'4%(YJW93-VA=SS%A]6J4E9\*B4[!7%$VFR0-KVS]/1;+-T/S9-S M/.$AND(;PL2A"G6:'ZNGU`AJCME_Z>"&%==-!S/ONMX7]_5;K*,XID_.=O`0 M92]Q0LS6XU5^BL[Q?VF_IB773/VY<"/6/_)*:,H7ZUC\`)-S/M`O\`1TD#-] M1@I2Q-D/["(HUI;44'8UK!C;3K$V&K=C"25HT.ULGH,7V71\SV,1S!_T"7'1 M-3BB(W3]FJ5Y3E_BDGS M;,-G=21_[%`D!_='X=?NYR.@30YK7/2[ELC#[$WU3714%9I[J\,V5^*9IKUDZAI M2'B$[5CP7.A15O2;?@GX=0VDS-ROPVQ]&"N%DZ6@6K+S`[I9K%-2#=`X0432 M]-$:QE]:8YKUDZPU;,`7O/XY^[&O+O(N@:C6N$P.%"SG9&A/9UQ$"_I\`;(. MK37NTM7J4YJ1/Y)WC)UC.-=4:-9&>W2NHP0%4IT/&\>F"8!CF1D_=OQ+9!F. MZ*C3QXNL\P[ZGW>;Y_.@XAL[J?N`W!_[3IK8 M0AR%MU:(I;(R\L\Y&3/_V\'TQYY;N:@=<9O%"QKGF.M[AX&3"VU4C.!22U`Z MW11XC@,6N#\#G/[8%\-&K`A3E.3[4XHYKZKSFE27>O]H^DN61ZP/MQZP-N(?_# M^+&OD8U;F&/TEHNSJ:T/O8L5UGX,,7OXO)H_1]$:T>Y'5VQSH#C/_M**DR[C M8;0B>5\08G+&G^:FD/"R_!`QV5XVCR,BVRE,QE\Z:=)E/)Q.8L>3/\T5`N%E M^0&BK;U,*HZUYCV<]+T#5TM@L`^8ZSLI,Y*UF.R%YU9C$Q/BV7.:J#Z?,4@? M^24$!;?!ZYHJHY;UAU^Y!W5SDNJ;$%2>)[F&#J7WIS0!1U8D)(WI4+ M4L-R$8[\YH2*]=$C>JJ`4VG/???1WE"2OD>@YO,#EH*?F)T#Z[+QBS^9-A,F MQ;-G/H"8>:&/_`*$D@72WA*<@LMI;<'&-W1TLP8'"[*>]N"?1(M.;Q,*DT)L M@3G(#ZV^YYE'?AM#S0H=AUTX":_R'@+J([^SM&Q=I`YX`6,Z3@ZLRD8M^61: M3(0*S_;8_@]5_,PCOVPA>VVTMP!',CBM\<=1E/^@=M\0>=73Y/NA5>3TAIX( M%6179_YRJ%IH'OG=">F++/Z[R?!,M+^CSV#`]I32G?]SS M2I)K<*9KR[/.A`D:J4&F6(!2$0P9S(B<]'YG M0R!2G;1*>IWYB,2UX6UEX=&*!W8-P`E4US,USPN=CDL.J9WD9>3)*!X<"5L\ M1\O-*KIY:M[8JT2<+=;Q&_[@#^'C*GJ(OJ\_XA'^P/:B94GT8HPF<*0@REB@ M4BZG&-QQH#")S4PDS:^T2&)9^CXKA^Z@&)=<(VG;@T\0'7V[P183H-_I%(C, M@>@DH@42)D2WG!/Z#R3^]?/T!(/CS<"%%QYM9LQIGB@MBV7 M,'NG6J`BZZ6DCQ?KZE&\2B;)MH8S/+9#7N!W=02[$A^8FY38Z<5]TH7K$OU1 M$SD^PQ0S"37/+U;`_B$L@HEY:+4.]D[>>^9!.1NJ3"?%5IA"-I39#3^:4N&R M)\9,Y&,1@6(U#E2P-C5/OE7!_\'LC*DY";:U-ZIZ0E`I1%\)47?1:YJMX^3K MV6.^SL+%^M3V92:\MLPZ4DZY>2D%KJT'?2^8OISAZN;:_1[T4=TF]N;^@+*-&RR'17L.9XR=#=0,"W0 M^5AL`WUC;\]P(<1@P*5R2_,$O:$\J18$7L("UA&5/=&V*S8%!QN!(M"18]EI M)1UU&ZR_-SQ&;SY@DF)X87HR8_ M-2S;E6<%M4\\3@"$&"IPW]7)=%V]U7\_\;+U?"\%`;0@CH!M&U0T$D/LS6N4 MA41,KI)%^A)]3G/R91U?WEW;AAG'892/A0*;G*!LB6+:].]B:+W-TN5FLT]';T=1,N>Z_NG#TH_CH66E+V85G0JBF[;1,B MAW!OWV*G4[T]83V4*U%IW304$!/<1RL^Y;W3TE7RE&8OU(?\\9W]D7J03VVI M%]3$"9HL$#-\!1J"+=R#D:L5D,]NP0'4UOM<-!F/"F.QHPC=#;C67&B5P4YH M,C1K`:'5D:ZTRN"?XR2Z6DQ(%D(.":7UI?#RV^=(:>QN>`:&MN05U M8>SCFP89"VL^ MNK9`;FI/-W>F@+1;I)B$#G#^32]'Y6;*\S+(T.T^S+%K` MM8\R:Q!/+&O'%"%DG,2-8KD0,J%!'->QY[-3T[5JWHHO1PRW^&&:VG/=1/>)NNX@5FJA+" MD5?SNGW:J1R`O>S4G7VU+H9O^#/(N7?!UM6\I*8P+^J7_T1GY^R6W)'&X88!U4^F@J4 M-K4FM7Q\>NL(=X,5U'N;X&="-BZY*0EH2W16J->!2:.=']LP-43@EJA>",YA MS1Q8,[T/6/Q,\$-PF2XVY+A!]_CIH+A/T910_%C[ZG;3+=8N)'Z<&HF]-.T` M\6/#BOFP8BZLF-ZID_Q,*-&%/)0P`'Z4"4`17:@,@2VZL+YFQFP&:S:'-=,[ M#9"?":6ZD(>B*:%X\\0&N8L^ MQ4F8+.)P=97DZXQN//F.?PYV$`=O'+)0+TC,.$D8S7DA':(#V1@U79F MUS0\P*G>9?/4+L21AM>;N9DRP/YY:`T(F;$X+#Y8G1R9:IJ@$)+:-541/\>X M=9B?X$^ICAH6X4A549V3R?-\1FB@(BQ_^?TU6JRCY47\%B^C9'D7KJ-3W[7E MO0K`2\5TFD&,UR8I[QS!=35_%$"0$Y7RUD].R^LNY'%FZ(**/HATDBP1TC/6 M-)*(SKRQSA&(T]LVP)%B@Q'V@TA(,V?*<[G$:0Q**7F/HY7@X\I=4S]$V0N& MC$3/;-_L\L2BF3<><:`]76>N=Q27DX-#;@A;,OHW`M)6$K"5ZWV%P!;2\[0G MU3#,40[Q=4OOO)F!'!U MP30@U34.H>=WZ9`G&'W\\HC(WABN-3^>DSP7+X?<#YH(ZM\9MKTF/B2TX$7Y M=G%@^1#:0O;&H.K-!/7&`D9ZYP&/YNW@VPH/E4%%9MCN0FYNA,G[O^5HD;Z\ MI`G*R>NMXX7I+L[_^)1%T56"^8WR-3N%SN05ZN2E8GI!XN.U2XP:1W`=S5\F M$^3D$%M,.SFM&PSI@D@?5'2::'_IA(FRW44#D>#:61I'H%H-,B]=ELVC=^&4 MD9P=;%?AIS$@33\\$7F)"WG)ALO+Q_2.CO M*GG=K/&?\>KC7JQ\["[!14[CS%)0&D06^1,)E;K5K0FFM*E=TV6WJ_2N>JEX M)90I""7L5$W/QW=44SF#4I#OG\,LP@1&2W*DBY*<4G-&TIN_TI2$C^_;)K?A M._G5V;^F?$& M`SK;ATH<__4NC'I-#GVBKT.=07`HO(TCNA0M]%XU?Q>,C' M='!53ET7`.SH-VI'OV(MO4GBM9B.O0RS!-OU.2:@8"%>G/JSN25-W35..4[U M<')1:('&YG/Z*HU-7Z7Q9CYYE<;5O':/$!^*9$6$IH#^$271&IL2B_0E0C^O MTCS_&\5R3GI/`.9M<2O/EA?&[IQ:`KC;N>H$>:72U\RRZ$NQGF'`]]#[>#&$ M'27!@P&$]>->\/%X/HA(\48<'/BU0WMW-X<]/NL9,_@<>MM>XLS(/O8*4Q04 M/3#I['@ MT^@=/1O&T$%4/A=I`6LE4>VW@46)XC^(&/0J__V.CCTSX<.8\&'T+J$TA!W5 M&P`'38U;0"$/0S>!JV0!5TW#U3G-W*/CYF?K=18_;N@KW0_I>9K@XTR.O^'- MTRU&?Y1ET?)^35]',6Q?GGB,I&Z<^$R_-(5\C1W9MQV]X[K3,"A;!B>A,JB, M@F`8D,T<50^_'D.2:P3AV M9/+:D`>)U;;>6;H3)XU@O!$Q[)\#P##"H;#"J] MZ[U-PI_L#70*(@,\"+IB)[G/]"17CL3>!*%;:F4PYOA0)'52ML/CD+K:=BMC=&C2LS:V1<7M'(L8T[<9$2WNO#)]3XB3L2A/EM<%YF#-CDVH#(9//!& M=V@9'+'9E6.1^+P#W]Z#;Z_WO;*I6-1L^^LDMB.$,/%^N)>)=+TAE8O9['`2 MO=FL\W68+$GIP/(5X5-C/C/D77`>2-4XN9QN*0KI'#RB;]J0.Z-YX;%I&)2] M/TY"95!+?(9QRN@&A-2C#%K2F1U%(ZI\G MXE#3G7*/S)UP8VW;Y`P\#DT6F`JD4C+B?PCQK679CQZ8A+#8BUQZGT4GYI1? MG$=EZD]+=7"[VN1_1U49AVT6$:BAD%16P>*^*$.64^R_-T]M]!)+#PH^^\HD MMIT:"1(JQ'JG2':,1#\Q>W!$;Y_L2,X$C-H40WM"@>.FL73^?"NVSI!MG55O M3X[2[0B32%B-+A9IF[.'1-3MB&VT2)$N;K9[9*MY''8A"ISM)N1):EYM>!+^ M#KFU"=*Z]>Q,+&=G613>/-U%X>H2#[".;K/T-P?;% M=F?>S(7UUMLZXF5!B6^/DY@2O\]1N/S7)LS(E.@I7-!*48(`IF]@?4JS^W`5 MG>5_8)U]F\6+Z-3T3*^IL&++$_=MXXR$)#]U)29;N[@S@Y0[)FNH]Z&9EP7I MNI2/C@#:(=P0D98(FB+:=FHT;LL7:0G'+7E]>"17@$S3\2Q83>J9MWV]HY?" MO/`C=)DN:!T06C]D,J2V$:84LG.M$5L[K;5UF<-2VG0IW1DLI=YQ/5%6%)W! M!,D*&#A?Q<%Y$3VNMS5V:$5;PW+EU4NNSS<.OCST;Q^)K[6U''+EGBRF!8NI M]P&*DP/9VSX?&0%I5BF'-Z@:\NY4M(3J_2LV;I M46->*J;$L@BOS0CO&,%R-3*2$*4*A".N",8B MRA=93#_:S5.5&$HE!HUI*!*0;DJF%!)1GIL%I6<4P[?P0+#?TPQK9W9,V\D@ M[@X@3$/HK(M7*4[;%U;(/>8(+ZLJ"5-@E&DG83W&6<\HEF,:\&5=^+)ZGZ-' M\Z;6@!,GL&[25<8@GO8=BP[LO3&"]2E<1&&D6 MCDH/HN2(6XY\#1^^QC%9:;V<'&!;Z:.IOH4\X1XHI%TF!K6"G4$9J'LT?J6' MY?ALT>>PZ'H7TA3B0ZTF[R:FKK5)>W0V'LE9]*\-MJ#>;YZ@_'B\8+7+3SU/ MX@/QO%1,BG0!7EN0WSX"5D"N!<$7SX#/IG=IS9&<'4+="]+8H/Z+$8BA\\K& M0*\PR#@SIQ];*G8(7>2H;P=I'\%R[#E\QQE\1[UK8F@]T#;':3$%[?`5^@^9A'BJ>!J8+=\`B%MV?? M%!W6L$\-`0[CF,),`W@[\([)1V5] M>Y2R+;9"2O$>>'`1$MC=:F-8+C%KR.>#4(9Q3'$D8[2<$@E1UJ MC"A]CI/H:AV]D(1(9;[V9PVU+C[3-9!O8!Q3<%F`IT-80=S4U2V@-(D^K&-\8)C6%.H$ M$&>I&ITP7R]?P_D)'*9Q(!IB'E,<5X`G?M"/*VT0FGE*46#II%!QI;C@GQ]CG$V\UC"MBVLZ#6[FFE M([A?/$?+S8J"^'.)VCWC)T>_TQ$$G4:?XN_1\OPYS+Y&YRG4/;TCXDVU9]/! MMT7?MXTS#ID"U!7X;.U"=`NK0C2'**"I=V!5D!/9:!4C)Z#-$;1'10=$>TR- M4#XK_%`(K5G%XXD.\V=0[X"G(B2J+6(RLX`QPB6W>@ANA"!W6:S^9SN_8>CO\ M^HF7;3/T4A#LVK-3`$]*7%,V\&I&PFXSWW)-MG3@#K+U=L!Q4*_$&.BGHP+` MI3``V?V++Q%Y;N+4LN;R4E9WIAJ'P!ZJ"P3N-C,,VYG!VH%CQM$[OL=!O6SE MUT]"P)J@WZ&1X-G].EU'M^$[.?7?Q]_9/-B>FS<]/-EB;3:-,0Y>G%253Y>Q1S40Z\>=IO:TU#I> M.@>6#MP;KMZ;KQ`?JHXZ(D35<0GMIT0EG\](-2AK9F!3D_)<9MU*]*.\:'Z2_B.[!-$X#-0@]YD\5=\1E\1 M+P`^JJ^)S9IOP>$+/%G3,=0XY(K16`"XJQ?QWAY0<69460;"E$T,85I+ M@;X'85NN/-=E.]SAZ*)>M3+NG#^B?!ST( M`I5``-+XL\G+)Z],-`',VBC>`5HAJ7C%V%X#OC5/[\L2O;0K`5L'`075^&"OLM>L70?OJ657:])U;7LS#W#C82:,*TE_OIZNI[M,\M'[R.[("?2 ML2E$3E!ICG:.[KC'T$V9%Q1\YW@]`%P[W7.M,]@]<[T/^(*<*#GCB]$4W$=X M)9:H%3I//Z^?D8A;KTDO_^:1=#S6XQ_31JLR%\RP1P1\B;D M9Y)<\A@N_GC(PB0/%V09KJ/UQS3]XQ_A:A.=&JYI-X6NIK&->4@8)SX#F2Q$ MB+.[71R(P5\^USN)=3A3LHVH)NF'`EF M/BY*(#KNM!;B0#F!N4DKP#O)H/Z3KJ-(=/:2H&(#:[72((5?4A!'%Y[744QIJ7DRAS\+4$*3`SO7. M(1['F!(?YR@2F4BL*B*Q3M&Z$(D$B\0W*A(#KL,)PXK3_ZFG3-3]H2(?9@X> M!AL2<^=Z9SJ/8TR5MW04E<%=TS6[]4X5BJUPT&;/88X>HRC![=^BG'A4XV0K M27`++\SS:"UZN>X\BY8Q>3&2'IC!FC,E9A#4YQLG2CST%S+3T-8R?0_>QZ0U M,VU?[Y,`)P>R#24^,@)HAHIV@PX"NU,5AV73D^?';YIQ2HRV\=",TJ*VJ^G# MDY2N"]YP.O4\0]4CYCVDC,/W2*X'O4\&.RNK MW0U!]IG>,C$%>TIL_@D(K9>2B\JWQE0]%U@"[?#/`QY"O,8]_W=JN09[X@KR ML&9Z'Z7',R=[)QI-X:#G_`0+'L1)=/.T9]W1(\G-MN0=MEQL1]X!@8N&<0(U ME,VR=@)?_YEC@TGL0SU^4^^SQ0BN9,O.<-("TI6?W,,QX=N!PC/U-N;&L*7$B!M!8"DS"]K[I/1*32DJ'],L2[_A MH3['+_&:.L0>TK/%@LR4WT6+*'ZC]2K)U>6FE(L6]^V(J::7D^$\=DD/[ZCT M>B;[MF"8FWK;<-,S>XA]:13%('HW#=M5.2RBXYY`&)&$&(NQT7;P`X@G7\3Q MN,63:W,3^O[@AF)IU:;>@9GIF3W81CB*[-KV^%B,EN.?PSQ:DOK?T2J&V$Q8 MB&=6CGN"7B<\H`G#F#,2>MRR6H^8C@8"E"#V(>/#U/O"W_3,JHJL3DYY<+F" M&R99](KGIZ7,2:P5:IUB.0Y7J_0;B9\NWT@I?YJDT"6^HN5+&Q@Z3U>K$"LU M\AB9:9L2"YIV3CZ]G'8RUB6)U8XSQV-*%U))++WO)@YAYQ"6:0]-[:Z2;4V\6C$<0[?#B[-67K?49R2S<-N'$*TMCLS MM@.B[8@(#WDR:>A*`)K#W1=ZBYS@#M3Y?2$@ZR($(#E"!>$WO+&YW;@^[`^Y`W/X#Z@I?=%RRG9/*2K82#-`6Z3 MDPSL=`$%+V@YB]7-G*)?50O(7Q MBA:)@4Z3>"!>7N(U6;L][O#99:[8'=%(B0PQYF6Y6W9;1IDYI@6H@.P#Z_C2 M/81X.XPERD]@ES^C&(78G!.;G#T84^CKT$6L.&W0EE&(A>/"IX4,!>OX,D/$ MF#N@O2E`9LW*9!L9N>4WO6FYR3(\5AD'.`]?\5_6[P1DGKR*'"*D2!`L?J8[ M):MUF)GC,J4)"0C6\>6'B#%WD"U+A,*./0N&J>2!%`.-EZ[+[Z\QC88E%]@" M)8<8VU:;X+M'P?2RU,]BEPC5>L]\S1_$$.#B$$+13$H[^K?MT87PK1$A/"BS MSPX'>2Y[;+^WC344/O4ZAN4ZYJEE63/K^#(@^)@ZF/W%15Y0D84E;K8UP;;% M-,?+QZU6C>@<8O\ZD.B([E/;$8@>A&JQ M,\A>LX\O3Y"?,1WVHVX2N_>@UPA_CV6\F'#WJ=8/.%O?T@DNDR4]Y%M*=Z`6 M2J87)7Z6N\2I=929[QZ?^[N'FT/L.MTDM>\U.\4L4+A&T!5=BE9O'X0=9;N. M/N+"M?NTCN+.W)E!?5)':+9Q/ON"J6DF)B$R4++?[S7BI^1)^CU\V M+XT!2%MMU+6-E.GE1H#I+L%I'V;FF"Q[##*E[>-+7A=C[A"[D!"%[9L2&T9* MU+4?:,HV)9VDBVM;:AO&`_.[>-+21?B M[1`;EPB![?M6,4KAM-L>KQ3(E;)M2Q^YXMJT6D_18\^K6H8MKUAM?;[I9*2-_B9)*)ZCGSD.6VM()[:/ M)Z6[BP65^T4''?O;PK"'I3N^L70%+QFCG=JZ6%BB$!Q864C/M8_'/=S)@W+= MVT5-]I:LWJ&LW`6J_Q`DY4)2/L$3_VL1XO$]I=IZ^O*YB4N#GU+!F$D\` M/"2,@_9`)@NT\W4W;`^N?!@0Y7+TSD<;SI1LK3V8LH#UK+X=QSK32Z3;[C)E M1(JRUTU&:CL"7W=R$Q@>/3/`F>CHG2(V@BLEN\9P^DI9V;Z;M4C?HB2D==_H M,-/D8?9?RE)WPU.CFV@[`B0V!"E!;<`+:?`YY_H*T02<21>D\336"XBPRV=C MW;276(C3]RBZBR@J\5PY_9)DUK=2SJ?'`= MO<\:@IPHV3O$:`H>LO`-LQ8F2[3M@4VJ?)T//'KT`D+*:>-`X*X=*EI[.*[I MP.+/8/'U/D<(\2'[Z"!"3%`TKN)Y()*QO?1*S*4O*3F94Z$X2Y9?HO5SNL2" MD^1/6$X9*:9G>DWU:UM*.HF,/1+#X[@H@2TR#-4U-GP9$[Z,OL;,1-Q)%X+1 M)`;E$`C&8'H>CX)@&%2.HU1D.,N@Z2XS]:)GXM^,J3-ZW]42GAWM;#,/%A#-9_#NNO=YJ;&"/2X2U"34!; MHYWFLL`LQ6=_(##7K/&V'B3!W;8M`];=AW77.XM-E!4E=K8@40S78]STQ47N M3^GNO*>&;5GR*E^W33L.T`+,%(CNZ&+,]+Z*UD>Z;!7<,W]0_)UFY^RTF!JB MCODC8=2I^0];^]"3B]YF0R_M'##U`:9)])4\"3!,M?;1$9R'^?/`JBX[`YXE MR[N(O&ZP)'KY*J'9`O3G4\/Q/7EI[9Q4C(/O<%8+,'./X.IN$0MR(EL?BY$3 M[%K#+/)/G]P@K<@5*>A#_RE9'N9_'GF8#Y4'JJ?TMJE%6>&7B+TR'6M6" M9`4/Z3I_;T=E,+<,$/7+@C=[\.L_4$X.VD*O@8KL33WWN^M?%#(-;@1JP%+E$; M`E>>WB=``2Y$$7N9#+2S^6F:#J]GBT6V"5=GR__\M(3N$\]WC@V:'[-XMPCU2VB-M M3FO05Y_SD"X=B!Q$3)X6PO65>9\$/B@4=S-=>]=27V.:AW1^+`[/4>6@8W(X MGH>O\3I<77Y_C9)EC-5QE/^:I=_6SQ?1`K>-[@@;])LW7=MIP277H.,0.I3N M8M_GZV^:CF'/Z>)K?E5G$#^RK>(A1`6L$ZKV0M`-L7Z(=I0*=#Y;0#^@UPQ< M@6_@PS?0^Y+.('Z4F+1#*"O1'E71_A70_O,2.OZM?#]6*N0YC0[],%^__HZ],0YD.)62)"$4/M M"Z!V(C.$$Q*+$`!Y MB^KIC(C/:?*5W)2YB![79\F2V4&?HS"/;AY7\5?*;\[*#6'8>(;$JK8BM(QU M#HYC>WNO46B*[>ELL$W,FV9\:3&)`A/N#-Z06106@>87&B MI>.@RD`GB`VE1,H<*5F%^HN94TLQ%!N(GM/`(-#\#L\HOCADJ\P['YB[-8:^ MH!2G%16CM"I&BR%B=!VM28[[;9:^Q.<+R19XMEC';_1M MX/,TP;_8X-^Q/^))3PW+-.650!U'W#@YFWQA"KD;/;`WL^AYTC#TCCU,RZB2 M0]&D),/ED:]10OY.ZA%C;*&T;"UXQ;0@X2I9I"]1RT&D*6>GY<#4.^`X\1E" M;WFAM.A+?8=YN[_<`0-?[_UH`#=*L"Y.5U!VP:Z%=V'A]:YS.H`;52X"<=)ZXP_IO@1,YS80P!1?_$$?&:C7O^CO2SZ(WC?] M^)F0?6+GIJ2BP:'I!"&(OP^[5A*%]!:L39.DBBI;Y)XRMNZAX M`.WFZ3.6L;PH/']JV+[CRJNFP4/#.($9RF99PH"OOS.S]+:!A/B0+1,BQ`1% M8SB<_KQMC]*GO]'GIO+M>U-294"*`TD_&:@==OGZ.[,9=0,Z<]?0.\`QB!\E M!]XAE`7D72G<=)E^2TA^]6KGU0_1JU=O4;)I,Y2;'EMKL8E:!QJ'9!'ZMO>D MVOJ0@Y7E08*ZWJFCW#S(UMR\A`2LX03&.\1I93KG=G) MS8,2S2%@]O//S"G?%RCLJ M/2/9CF=D(>X9&0JD87$?+65B=T<8]+'T378>RHZ*?6(@;75WX<^?02XZ/8:" M>P5)*,C"Q;I28[TH7FWX\A)$6Z<=)QL"W)27LUJ[T&./WBG2_<3+/CSV4A!` MYF6UGN/0^M#G:8;M(CQ,65[=]*3Y\/8F&XO+'LJW:-QK2$J.V*>FX\]9D1Y+ M;Z\&'P-*CH]#AWSY M^K*7A@HD![X+41@.5/7F=]AJ8=B^WSS2#%[RJW"58Z/0<8Q+18J4N-:QJ-XDE9!%V0L(I1##U/$&E8Z.X35'1'K+]\R9'SR(K& MDM.>.-L_B.48I/8=_9IZF];#F5)BW`PF+Z#R`IX6X?$%D])XR"C0^%<=%5"WPWM#7]F^3YLQ?`&F>Z/60BPH2#Y@Y>6H&B+6..A MCP5U?W5.QYUZ.-8#,ZV+9Y,W\-AFA?<%V%#57A&@*:I<-E1X/]Z0\:[ M>;I-\YC>Q;E-M7&,R4\/ M&4%=[\LN,`3);2H'0=M1U(J>_*K31R)ZW76I^06>6#^%&Z"7$2M;?W/."YT.^D]1B+;G?NSW$27:VC%PH/ M1>9;"P72T-_!(X<(;'N3YR8,^$3,G7=$5ID04P<4AF[*]B2"=&4F&>V,?B?= M$>T_1D;N]M\\4O;PS81"T,Y$][M-[LQACPN!(M(^XY>7":6H[J*D^8V:*?&J M[/D9F7CE>ER&+*UG,.>PWID%/.2K-\>;"=F#:#8$HO>+*`GQ1_B49M$BS`OG ME>TY\@*VS7..0RDO'P5,6]H;GN'J;3AW$RY;?7;.'A1_/4'%WP>Z-^\7S]%R M0UYBZ3B5Y@_AXRHZM>=>TY7[J:#*3`MJ_D$,UY^QLPPH%,TO98SF M3;YHC",P*`8@/I1NAV:.?J?CB$H5A!PNTIYC7?.:B7CM]>$H(R9@6-A.&7O<6+J"%DV>33:`FE-@XR%F!\ M=&V1UM2>AJ$]6#%XMD_SJNTB;,C''CV>]8O#DL MG@N+IWQ=C[LV8Z05Y0YK7@!7D1#:DQ<@):,"N=N)JM7"KO_B, M?\*_+'Z%_P?;!!'^S?\/4$L#!!0````(`+9P3D3,)ZD([C8``"V,`P`5`!P` M8F%S:2TR,#$S,3(S,5]P&UL550)``,':?Y2!VG^4G5X"P`!!"4.```$ M.0$``.Q=6W/BR))^WXC]#ZS/RYP'8\1-,#&]9[&-9XBUP0'NF;-/&[)4V-H1 M*HXD:'M^_6;IA@`)2E*E)-0]#],V%LK,+R]5E965]+>XFDZN&[2BFIAC4)%^N3'KUC__\]W_[Y3^NK^\L MHCA$:[Q^-G[734=Y(]?7_I_6%M4V*OR-FHUV2^I>M]K74J?Q7PU)^EEJ-49/ MWI.&;O[Y,_O?JV*3!C!CVC_#C_J7JW?'6?]\<_/MV[H/G6KT;[X_AHXS,WGN_==QGI>%P>./^-7ST@`'_ M07BI=///I\>%^DY6RK5N,EA4`M^R]9]M]\-'JBJ.BV7DZU&N.C>AM(E/L-^N M@\>NV4?74ONZ(S4_;"U@\4B8>")7`'*CX<%L48/,R;+!_OTZGR1!S/Y\`'FQJZQO1\JQA,WL4[(8X-C+AO?;?(\LL5^_YUH!S&Y]_<3U3U-7S0 M^5R#]=CZ:FT`9#=HC#TK%C&==^+HJF)P<[DN@,V%`_]?`7/V;'FGV.\/!OW& MBZ--U67!+,[6Q'*-V1Z9\-!J;9%W^(*^)1,($2OR2&U^[JFBZH98`>[)J\-% M7Q-,EZH;!A&@,C8=W?FN?2S\1:O$,,Y6/#6-L2-B=3Q6*!:$M2 M`0284;"Q<1J+1B,.6$A574V%DSBN5BP$!E(89:68+-<.%1U)\'NY`5F+OSC MGZT*5DH\+^&(.++MSN\5FM5*LS]G2 M_?/,!7*D`KLP.4O'L$UM6@RB*1S#5D4'S`5Y8U$J[<35%CSW.68CE;9$SX&. MV4FC)-&C*@NC_F+,G<%O=;JQC<\)A`IWS7:\>`MGU;M5'%_@I6M=59>"5^I" M^$\S?/A2B/:5,\N6%!RZBY>"V4OC4"Y_Z.N*.5$I<&GHBK=<94%QX_B_L`6K MZGUG9NW-L^F];FS`2.+^F'9=8%&5ONJ4S<:?C3 MS+7H?`4P,R=;:FQA/O:HFV`I=Q;1="<56Y9!5<&,[4T4PS%\[],LH[AE4TL1 MK=&#J7T:?E9KTC^>+L;W[*?%['%R/WJ!7VY'CZ/IW;BQ^&T\?ED$9)DD@G+0G@3DPR'P#0B4.'<;BV6.1Z\`KJ(ZS6Z[ MTY3:37D?T.A.PU*Q7]V<^\:^?E.4M;L]<4,,QPX^<:&_;DE^]OYO_L=<#.Q+ M9["=!6H%"LHL7K/7[_=*D8M+GJC)C:Q`MJ5%5SDTY]!TN%!+(Y:['<;^NVJL M+9U:$(7`YJ\:&QNXI^X:8[>_H%CJD3WO[\CX3]RLW>V):_5=-P["*3S!2)$E M`8:T1T^=B>]S7^80RR;NDUQV\=5\U0V#:#`:$!-6G:8V<]Z)%2#0ECNM.)./ MCR%GWE:^ME-(ZRN\73>%CVP;PN0A8'VICQ<`XBAFCV1LFXSM/L$_XW]MP`0, M-@*/G#L8]#YA\'-GOLW^H(L7JKE8$&/M7-H*S#LU-#6(:F(13!E=ZAHD@DV$ M3Y"^*4D#Q.@0)56"RR1*ZJNV4S_5AALC.R,'R:7!`%'',31+4?8YV7VM=^NF M]6>+K!5=&W^P9#,)YCM25^[C:3V69@E:/R^[K_5>W;1^$J?A!&I*[KBJ^FLJ*6H_]%-+:GR';RV5Z,/]=N2K+I#VD@*&N:PTW MD>Y[`S758)75&;2[:`802[-(O9\7^G)F[UF6EH<`(:[,1"TF86G5DY%Y133! MA'5C5"K?Y.3JFURZ!>.=H=BV7]!Y3U>*;L+TRW.T/LHNSQ&][+:W(*P@?_0< MX..^](FL7HG5[+6\_004(4X0%F*E/$H)3)43A!+7Q!R:?-255]W0'9#D<%G? M:?7QIL#)=/,7A?@U:;NRAP'>F!U/4X@MIE'-X89?,@1U3=&`Y-8&7GT$6K,G M]_&6ZXEDRS2!\T#4-4ESM[$=NH))K+9E*Y90=+G7P[.!!**E60`'"'5-[OC& M']D9W1E_%V]O,)%LV5'@-!!U3>,\LM/A00UXN$/:[@XQYS/')$M3_EGYZYJU MN5/6.EN$$<4FLU=#?_.Z.X3;D'UO58E417>*=GF#`3",])>37DD[!IS%"B5EAK&PC9G+2VVIC5?W4MYRYB@A>$9V MWWP'U3??=-G!B-@CTTLMO5,#9+79QKOS&04.,9!Q?AZER\DOI=RS MIZN5[K@]$MR.H::CFV_$5`&4I@P`X$VND@E7)%9R0A..H;VJ6T;:,=1O$N%V MRX'AH8]8!+%'*T<51_">:-7#Z$.W@7VY`/8/R0JQY'.*V(WM',)7NW8C%('E M^R?P(^.]CU=!=$RO'(W%BEOB2BV?JI"FUKBJ.B'&?B5?3,UI#?(O(G'*,O36 M-2T1XA9I]?9,;=W%>;?TDB7\&'>"`[&NE$K4HUAX%#,K,V1Q`W!^]A'.,4]6 M9U9&\G.K3+94*F;%7+VUXY[LX6*@W:MX&$NW3-PO"?;:U$C=_@`OE19#45"4 MXD\-1AH4G)2^!N-_8G*`FA&A9:F#-\,[I%::ND^)7==YRDC3=(_O9T77)J:_ MI]3L8;862B!:FN(Y0*CKCLF<-2(UB396+%,WW^R1JFY6&X.U[[PG2UW5G:;4 M;_7P-EO/,U":6:3$IJZ[)Q&QO::,\==+30DL`%Z4CV9/'B"&CG3,E!=2LH-V M.5L.PC=G4581&#MM<;M&W3?;+S1%ZC_!!BJ;KG2Q-UQL_[5V+^?=`LB-0 M!-VWF;HC^X_SWC_.>Y>?AORQ3_UCG[HTFWO\L4_]8Y]:A*HXLN[NM4GV:..\ M`[Q_$8UUR&UAMFD\1;SPS?<46-0U';\/P93"+"[2Q4`)+_MPAGHEC"$) MC;JFY/K,&C^:*LM2MY`BCM*7#)P@U+5?Q)'X_E1)ECIX^[()1,O7 M_;'PE]-H(:?>H[,B&3/W<8IR^1:0`(-O!L.ZF<'(,.@WMN7S0*U[NGEUEAOC M^/:\L(?:$/&L7RI6BC_6D14HWW):%[BE^>/,PH\S"S4]LY!_M[['MUN_>(%_ MGL;3ET5C]M"X&RU^:SP\SO[(>5EZ2)BU.U3L]P<(3CDN3=?^;V-[9YA?*`0S M"A;N7IFZ*SU[H8S,LT6W.KSS]O.KS9ILSM:$W5!OOHU41]]Z1R5"?V@A=A]& M8#C[!LP]`5N!F.!ZCZF-O#M$W%^;@TYWB%CJDTA82-PKQ"YV)4)<*-9UV\:= M?=XJKI^OV'TSGN12?]C"R];&$[T\V^$`K[X[/@"?#8S'S$O9_70R7O;N%.G+ MLR%N(.NZ<82)=J]=_VG`KS#'921GYD(QR&RY=W-D>&TDS(+[7KDK#B9\7%3> M/7?@A)-[OU+ZFZ)29:ZTY0'B*=NSQ"O MO''%S#VYT:SK7A"(;K'6H/?$^S<"I'_`,401AD*\K0%^/B[/S+)A7-N=)S]O MP;J.PH\3E%%:8@X6"%?JWD&R6%BJGQ+(.LIG"!@X=B(X*G,*>[R_TI2D=D0,/&)7"_.T.D@9L2R M<55E(TN/:GV3/LGCO7_O+1OL9;QMU[/TRS(DCI7V*:2^GYS.\26Y;-AO]8HU MF0,6JFTUI_"J:VKF&(C#NW49#!V\K<7S#%38:$YB5==ZXBEQXM*D,4F?7;>8 M[G"(-Q5*SU#VU,4>> M_-%KBET`$%<$B80K;B/)&%6__B*KD>1`$V44+C*$`A&5$,U^`-LZ4'YW.,`\ MEYI`MVS_B"M0XD"H^AF7K*UGCP>0A"LM6;B0$&<6*5@IVXCX!F(N'.N;5DG` M=[=W&8-O#S,WG)ZA'''7MX8':D4##/RL;1@9$J38NNTAX@8C)QN8_I1.WV%4 MSH)??;?A\ MZ(5^5/6SE5MBO5(!Z91356>`K%2T'Z$44N]5WS6E3KO?PY1K1PO3)U)I+O") M9"2J/X*48/E%+H+S6CZB&<7<6():Y%K]K%WN$^[A&=O(<6_$9EFG*`NQKG2B M1<)1#IN\F)`E9N>#9Q)49,#*.^4MU*0XP:M!Y"D45LZ\8_4S[-D\=;Q<$A6` M''^H[XKY1N8`[_G8:3DKTSJR`U34)S84B MTHT^.6<$B4=PCC7Y3$!=VF%=0[,_\.XW1)$O#2?%.<31;499`:M^\CS;-4=< M*$JM2_>($8RFEO4)`Z?7&[0_Z';P)./BH3@GV`EYV@M.@70Q%99KUY4!%\L1 M[052;;T`1;*J>8&4TPND"RH7];Q@;*;8^!%U\!.GY6@1AWEQIN`"<:UKZ>F# MHGL]NW=YSMGR#_!"Q5V6]!'7<2=)"[&:0AL4<"-Y,1MO8G)Y/!E.E&51P=MN MG+3NJ`D?;.`S_X]NL5"G70D@XI@K>T?F:!TI$.O+R;6D6UKFR`P7:8$HE23\ MM)+,HU<%((IVQ52VD7X'XBS6EY,W%^**/+L)15H@2ETZ/ZTD\^@6[HJ0#3[ M4,6J9NTYV1)S0Q;$VNHJL<&IFE*_/!S)\A4?*WP-2H4RA2Z4>2=JZ`HTAU=L<$"M$(L]FNR>$KFN"TDV M_YHM@\#ZC MZ3U"J1Q%)XE:URQ3N`_EMUN,9%SZB$O)1++E1'8N%.I:5#$G(.M&=386:X;V MKEAOK)%9;]C#4W\;I@?PXIM$[%8E,($Q-L'?S6#]9-2>KW$%OO'9`KQ&;C^B6?$#JPV`IG.G-T M0O9]E+6+B-L-O"5+:I%(B_(GW72%#R"#&?O^6U@1K_/Y1)QW=I:#[?Z[6P^` M:4ON(:?2"I&DG+A:EJH"ZZ]=$BWIDC))DCIX)=28=[VEGI_Q0!#HOW8IMH2F M(%@%)F7/RY+%#31\`?FUE,MO=K5!PAXWP#%;@N7'GSG-#:S/F.QXMPHG$*V&[F,0"+1? MOR0@&R:GU*3[&;$PQ]!MM?!:7YTF7N*\@0^0P"@J7$^:S2C^(/K;.WC`:`L8 MO)'I9O5*K-G2=0Y[MG%L1S$U5J4;GC'LR7BKT;33`+ZM4N(-VR2+7M1AU#B`"%=8@X9YLB4'=YKTA`KW! M`*\!WDG:9=D`/R!UK53]E9B`F@$`C+25;NH,,=8@/<2@U4>\R^0,];+,(@TH MEU,5FG'3.1$VW)WG3-4F?)*P'609+V%R1*\@,T[>/(\5_'**7<7E:1^H!;,_ M\VX#Q$WU\\523!L@9)";FON;X2D@[+019I:DSJ"%%PAQF!9C>`AY;Y[`QCM^99?G)MB-@&"9=O`1D2FXN MP[JXL*SKDH.OGQ5.@1A^:[#TY6+\>.QJQRJ;QT0\%R^UY,9U8]=,C_TROGT) M>#U[FOWX#MX4A]'9EV/Z^,&$&N^:]GB:V1="^^][`>EOX>,_FS+F\8$$HD)\ MC5_QYV M8YC[EIB7I'?($R^-W`_O']_M[YLVX]`U6*GMFRO[A.N=.=S/?_L+?+/9EEHQ M?$5=SB9J\XUN;S2B>]X&/QPZ&7RT]UHQ7I4-V=#)XL4LT;$X=#,"CC7&]8.A MP"RL&V^ZN@KG."EYA] M3J&V!QAS%>-_B&(]P"=VL]WJ"5;<`84JJ2Y9^!(SL*F5YQE@($$?17T1&M53 M8#P`)383X%#ABZ6PK,+B<_5*C:8DBU+;WGNKH*HD04L\Y<]3T.=*.B=O[@:C MZ4R5%<3V@:C8&/?Z*BCKC-@E'M_GUMD=O,52C`FL53[^FWP"]Z)<*_;]U=%: MLN`E'KGGJ9YW=Y$B8W$XE>J)YW:[!]T@UAWP_48M9GL= MH4ZW]_8J:.VTT&4>?>J?,9L=0U$YD//$JJ-/3DC*/"?K%W?SR3/K4LM:UK[\-F[1KR'T63>^'WT^'7,PMK#9#J:WDU&CXW)=/$R_^HV[^:.;^%&<40O M$Y,U18KI))$BIH7OW7&^,Z)VJU?`35TQE+-'H+BW[FQU*'?QJMQ/DA82&M(I MZZC&X!PDW[7W=@^]=S+]'3QT-I^,^;V4M3XQ0;'Z8>%OJM;WWCL^8W:WVT/$ MJ_-.$,[NCS$OC0P=TJ"+5T)QBK2@[Q^B/ACXZ=[ MXBBZ8?-?9Q'Q3/^[/QQT7YJY\NT)YGD63"Q8WZ;!`&^5$DNS`BZ9",$%^R*? M\O^@UI\3\]FB*K%=T66\`^7Q1"N@_F00ZEJ.&XK^P$ZZO1/-;9W-1)?PJKKC MB59`_\D@U/6@'P]>2$T6,8;?<0+!),I%V;/<1UT^>"H_ET>V7OI^@BXMQ#!,(1W MD4.45`5BV*'`%WQ31_Z,5.=X!1RYR+'Q/)XW%K^-YN,4:^#@?&W01"OS&OBP M&]?N_(7^P]?&,D+]I"O"!/M_AT8!L)")0U9VLS?`\W%13&:/"3DY&*WHQG2:_1;B-K\0%H7$ M&C2;"@^MB-;&!8>Q#&;+"FSOZ4K134"X?:;D2K1![HAG]T;_,/038:?GF[U> M_US=6(YV`U%2B-YQ0B=A[X`DJ:M]E&Y!V`;+Z#FP<[?2+1"BU3Y7LYFGK6`B MX7(5R8E(M8_@G9U0HNA4_&Q_H;X3;6.0V3+GJ/*BO!JDV95E&<^BA?):S+KB MV/K1`*]V'!0]*RIPS$:::9^S+6S7%#2=C--,M6-W3H%O/^-?,/K0`0,O-U!% MZSS%]_=DL)SZ"\-I\ M\-UGH7>Q)/:&$]:AVFL:Y^(5*1?L=Q'+S3)R55(*6P2&%USFD]_O3Q5`9_'U ML-XRIY/7J]QR9Z;AZ_T#ND=VV9'Q:K!XV2BO*BL34!>&JW8ER3,(PS)I`6Y9@I-'5WV>@Z0 M[]@=NZU^XHZQZY"9MX9=U\Q_AJ%.'AI6BHT,@WY33)7<^]H'0B/;)L[=NV*^ MD8GI;P=*\K"--[BF9:<\3\X%W.64EZ;;2'W4E5?=8-TWJ/45(+'`U4QVT0&U M=2:/[<]#``9IB!?[>=DHSWHR`77!8\+I7,1R250GO,4"8)@K#ID3E9HJ@.0A M[SP0C=TNQ$[4;]B4=N_AYE#J(J8M\C-8GJD)1O>"%_H9C/".FHYN;G3SS;\5 M"%P3T)#PCGCQ\U$UDSJ'U06?!,J]PI1:AQ/:I]%T]/_M75MSZKBR_BN\[=D/ M.X6Y\T@2L@YU"*2`S-1Y=$`DWHO8C&TRR;\_DN_&,I9LM2T;7E9E02*UOKZH MU>IN_9J23A;_6K=>YA/V?CW/JJZ^NTU%7@YJ_IX\9^-$.S%1W\1.Z?Z=,DQ^ ME_1LP/!\1`BCN==LA(D]_;&#YRL-T[)JO,47C\*,SG5D-27=7AXVKZO9XA>S M?JP0Z>VRM4]FHH$9AW;$1IGHNQ4ZD%*4";%[[KV7S_+>H`/79XF9C/SZECD% M-5;1'P_A'/@\)`E1ZP)N4ZS$)X0U";#*O MFO#^ASQ2L=P_&)8=O4SH]\JX466F2!:#4!3,&I^XBOL$G7-[L-XL'_[W/_>3 M]?2Q];!\?IDNUGSM+ITT8OPAVI%T%Z1;Q3I;AL01'H8#>H)"V&HY=^G.E"_J M3[S9(+F"`U.:8K3E-Q_,\]Y'YPVE?S0T$<\%?LA?3: MG60J5YK=:?U!F@2VG"Z!K8EEG3X=6*P\!8QTTQ0^=!B.7KB>\1_5W)&-Q\G> MZ_8!DU&C,Q7P2`*IC4(S(:4^WJ'Z_B.326.*6G2%-PNI*U03B=!,MQ&65'OE/K(,>3$,3K\8 MBP<@@85-72X.UC@*7)X>3+^/:(L/\X_:E[9#^LY'L0_7Q0R<_NO2@TP.UO@. MMGP]^-,XX&%(=CO!T3N98CA'8[CBF/(6.#<(/-3P?`I8[AFTG"$UT,%X'DF_U,#$NT*3X:Y M1YI-7IDD50%C6I512K$#-#WUD.>R&%*?QQ4JE&I:<"%T',>`]9IE+>.ZE(*5 MGQ5&AVNN'('+.&[7)'1T81DWY:#Q,U".8?^ZE*-(NF`U>@"5GTG'CZ3^+AW6 M^RW.%;(M6]5WFOX^PYL4VI$/M!W)%`BUABC:7;?=ZXXH`'&=,WEG ME*C%8U4_B.C<)LOLR\V[KF>!WJP6\U0**$[?IY_%@_""4 M/&\JHS:&_O=) M/6A[#3E&P=-NTMJ.UMXD);A`'T6(?&:!ZLL;PT*:FA/M0^16>[2[<,_G16?* M+W,I+`6E6*#K=1EN7Q[3%RF-$9/@').&I308W>H'I3X'@]0/5E?9*^(&B;GQ M6NN/]>GS4S5_6L:^Y3CX+=?#;WE-\G[$72QY,\4"[?XL1>^:KMS!OP4:;RU? MI-LA;^';:VR;<`O?WL*W-R_[YF5+[F7?+@UNEP:WS!C!^6L,SL/Y"VOL' MZE M.`2YIP"Y42V4(T)S=<;G%_Y%VYKI+P@+U>Z7:5B64^8!7*HLEN)J[0>G-(JR M*5F<"]I8U#=GL"$F/T4L.`Y!A5!$S#.Z=$5#2&^_E,#/N MUF%'N)NHM&74!Z"C0)7@DSW6[4E=:\AEF72'FH3:U\C4ZZ2HV/734]Z=89\KH; MM!#\ZDZZ2HWZG[HGW:F^*\^:7?3`G"\?51L%W=:27>5 M2@[V_M&.V,5!1UZUII!<4ZF&YIW\Q^ZJQ#[+^Y#RQ%TG3UAV`&OD"4,>KFE\ MJ_D)NFC;P"Y/TT"G5TSAAH#N*'$\RN_Y!Y*/(FO/OZC3Z/=>=-BPP<#?XQ%^ M$URZ@%GSA0D48KQ$RPYKFS]._.5WX,6]@1.UV%&82+#3Y6/X8&<2L@'MC@U. M9/,36SOQ%<27&J=^%=U:E78_L;5.?SU/%YO6;/&T7#T[NRK[9HK>"4-F^MXP M/YTINZ?3:92.5+@]S7N`OKK'`7S&%&(](Z#UJI],9#R,L/!A+R M2V#X^/ONOR?+)C,M]W^1!X^Q>W0W'BA=N)5=G!MD;V!DGR^V[.`$`=:NTNE+ MN47D#K#R0%B*(R%6`=S`UW+O#D^\=6\^ZT[I]@9P/E_ZQ.6+?O+=*#94/+'' M)YK:>487A6)I?R!S8>C&$9%T1X(>]EN0_R:OTFNWX2JW+D\N@7!PH!.$D)71 M4$Z[6#A/O8`\N M+]36)RP>#X:.ISCA63QU-G3K'N'YD/M[&_4;6<^:[K!VIF,LD65/]%U\E.G? M)_SU,[(_#/S-%W*#!%A>E#8@3B6NI'PE')\K855\\_1\(+^>&[9ZR*_GB0N3 M4APXL?VPF9=$N=?-X^;5PET_B\I#!N>*7H2LD?FE;9%_/`J?*1]SO+=.'03P MFH-RL9BUBJ;Z#B^FL3MM;#%/Y1!RF3?]FK:$#Z4296?,&=LZ-N\B90 M;E/I>PA!\%(9]`'K=,ZFD^&2ZR("P5&VTY=4WB_<:Q5/`&;)4LJ1^YO(?"B8 M]]N8I"4^IRR2K-/O`+:,ST=550[K:;KS60S=11_^=1Z M64W_G"U?U_/_:\W6ZU>G%&#Q.%VX10&+]7(^>\2__MAZFBTFBX?99-X*_G[- M;"16V"1[&_%R_V*B+\TX68&#%),XS5],TS`?#,REEE"5>D/ M>MU*%RS6QA3B=?!V>UX$K]C6=(%M#;]G(L3H%'1FKLSTA/MU8FQ]]T*4P2WH M#5/0K.BFW8-,O"I`FCR621C`-3[[%[=4XW-#]329K5I_3N:O4V*G0O,S6ZPW MJ]><]B=(N%SN`\,RTSR(L2S`ZK855I]V'V]0OS2PB=]>RD$W$>:ZI;]I! MLS5D/2.53+-;ZBNT/9FD5P;^A86AF_Y_[S'X8B*C51/:2=K59C,%'?M2H:=*EK($NY[+]C/VFHHNLOU MP*[HTJ>5TT9AM>O"E?A`4B[8.\J4DC+,490;,2.$NV.5@4U)BQ85$#T9QX:_#N'[OM M7I)&Q?6(W?Z<;!YW?_X MN]:/*U_$+N#)2O`%:%,+<(XN[\+.MONJ&V\6,K_(5CO3CR<;?VU@Q_.@>3%2CRQ1[IQ##7&3M==@O M9J59OY],A/RLC)5J(W*^A[O>9J5"K#*6)DJTHP\KV#6^F^(6/)+^L[71[E'[ MTG9(WWE8].`:Q+!2T4#!RP*[QE&\W(+WIW'`X))-TD6C-X(K,6*GH\'"EPYX MC3N3Y1:_#3(_L0IVJA$Z,GN#1>TJYW^X=C7I@')!FG?6R1:-S6R0-CC%YJ4T_;;R:-X/'[CUB-+XPQE_1:,D# M9B.FZ6[D!1AAVDI?F+E>0IS84%E!K4^=:NZ:I')OD1,>35;D4)KPG9PX,EWF MU>3N`=H*U"F5@<^QDU,VRV2LW*U.P^V&EM(40\7MX=KOC<`DEI,8L0)8WFU< M=KZ8[YIFN6NO_F:SP!W&<6\:^13S\ MDQW\E[!GVW*[?6!P6J3C1PM[ZRW'X6_9!I[H<,(^>^KO_#M'0F#8700/XXP2 M)]1]E,`C<[EWB'3_9FE&_VIC>-31OBR:5CA531T+<#">0T7X!,(0T$V_.'7^ MN,`"V2'RDR^,CI,8:V"P/[VG13Z,`U80RYGP3NEVW,PXF(ZN?-0(,5J(^0.IQ%I[PF_JZKV5&'O_R>#SRG"20)7+14J)J)&)'^4%K M;GR'"N7=N#WJEJL25/ M'A!MR.0MOPM!@Z^IJ34I^`F&$UZ[Z6\@R^2DIE0E232\+0)=$&.6 M74TXF]92,4E#)&SE$(#=[P_A$F<*$B>A2GD1JH'+X3C`#*Q;5-[.]E^<$?'T%G.)>:+3XT3 MZ[E3E-X8+@I8D#JYQ5(D]#7>>XMG$@R3#8`>I_>;UA\+PT:M%_6'0)GG?O\1 MO=ED#&^(HC?Q9+@PP6,>)`LIW1Z<14^9-/_&-3?T=U+900;&5`]&<*T(HU,) MT65F#O@ZFKK8&BLI561R))Q/]?4+Z]@>[N'%0B-9`5A&Q42&#M+!AU-0DO3/- M\57%0^!9W2'R7M.0UK$VI4-7]H@R<#USI;7)/BIF(-0MFGR2MI=WPT%I9Z5P M5AE$@8Z!Q_]AL_G_B*RMJ1W=+/H_55,CIW'B93E5&1B/#MQM#`\E,L@).U:> M[(R:+3M1IWRZWY-'`+Y0Z)>3CU>D/OQ9T[7/TR?QOLKR.#A)DT&Z"J#I1TS: M39.W)^T;[1X^5/,=/1AND'A%\'/"8!LG3R6L MP-L8&RS6&C:E"V3_99CVAP]&E]JD+X7%C,-6P_$\:_8%H'$1L(F)U.5^A=3# MU'D&\=OO5M/IP:7)L9!0BGPG^P7Q@N,+N_SQ%>Y4-[<1 MPI-A$E`FUF_ROH2I;=UH`ZT^,&6'2QNG&@XSKHJZ\PNL_`/B?0XTA< MKSOH@S$LF*9\%E%76.$=&XO#[S_(N]XB'6]?AD-^'WNQ8`RB3ED^LS)7'C"N M+R/CR%K#%,:P/J#;AU,M^IS"6,>R'+HU3+"Z3AO90OU$_IM,W4%9OE,X*X#J MT7TI.N_HRZ\Y`TLX%W$RD+J.2++R6OOVVL;AL^Z(5D"3]V,<< MP'K1`ME]P?F/><_)MIDZ;?Y->FMJ[II.BKR\\-G9VD?EI16P>+6"58M@O M#"5$H#A`]\6+=7722%LF!FPGZN`8R@)9Y8L74727:-_K%MVMT)=Q^-+T]Q:) M:3F]>O'FJ=EY"_""\4)W7K=&MVCS<=P.TW.5]^^Q$?R_>R M.D/`-\PI,PJQ+RQL"-X3R%AVY3J5GVD@I\O<3*/2'U4^WW50`%.QD_,!"%P: M&X+JSXN+OHX2T'E-RY1O&>2E99#+GS@!F4%^-QP"-F3A(D4&Z>%`J[&Y@]%] MP]]KGM5O#!H[$EMY>A<;0% ML"O=QDCX:U0END?;DOQ6*MH1W" M.:P(XU3RR$<>;!I;[^ME1025SMB3T_!43X9)GO`\:*J^)0FI;<#3-@L)U4@/ M-SCU*904L?&<3$(0-5@U+#>RET:*/$:'":SZ5&0*$!^WJ5/L99=.KP_7(9&) M!GD$YC(\OJ0TO`':K7)7<.5NX^2%ICK3[Z-F.G`_.C"0"'BY=N6,`GFLRB5H MFEI40,,A>EL[\5K23O6=@P><6>&@1!Z188&JJ64*3>H+D&3_KK;:^GK7UMQ+M^I9HWPKM)&/(K="NSM4_XV3USVJZWJQ>'S:OJ]GB M5^N/]>GS4S5_2/W/"A&CL25/Z.COK0G)",6KS5,/%!O)FX%TJ(Q\Z@]?M$(H M-NB#8=D3?8<_0^:7IXU>&C2,$;D\>7Y7>(/_X@PPKPBBWW5[>H*L)W5:,=K( MRZJ@XRT+&I5K*[N8.NLF=[X[3PLT9`7[.D8!SL0RDY%?=-?;#[0['?"P.BU)S85B0<&)/0@+?U+W`KB+NI,WY+\(>=G M8N"&<$\Q,%)1OD(DFMSGP2NXXRZ_%ZJXEO?9W8L*G!BIZ%X.+C3HN%1V5(O/ M;%3->"I>%::-L#0=T]%&^T2D&Y>F.\#=(QWM-=OOS=4=`(9,LF87PG6.V&;0 MK(P#%;FU.WOQ($>F8H%=ZDJF?Y^TH_/8K?'E:9Z%5>\9V1_&SGFE!V\?D8YR M0XY&J#QCER23B=-=[O4W-6]M^GD\&#\(8=M-F(!7X"U>&2EPDITV:V5BP8"" M_&>>?!*PM#]0_*SGF^AX,W;GBB.S4OO@K8[AKK=1I MJW)8F'`(/)5.7T)/96Y8UE(G#[(M]^%>YTGR>-#E*<-,'ZHJ)65=76"J93^` M0T9D%05":2N]E(-?4767ME/EGD2(1Z5G7UW>E*;;T<5+UHLM/9<$%"`2G]ICE8*?8X99C\ MRK9`]H-J?;R8^"B$5W+_\VJAW4Q?8FYAQ(-D+PU99&/4]!/^S/O2T$F*>P>P MKV$W@_SX-+9OV9DC0,*/ MT^_MX;1S(S+QZ([E;`T<]Z5\H\OA"_%`$!2^-^P$BX_W6X1VUA.&=86.7L+D M*CAO%9RW"D[Q:[U5<$HH^DTO:GOX4,UW9)'[T3[<>V&T*O!]R>+.)?6&KT[SJ;WBO`0SJ)?G%J>/'MFA!IDRV[E M%7G+*ZIO#58U.BE51U649_2?0QR.X(U=LJ@)>*@99VR+?#$6>KJ>I M;DK@C#J(&.6[#&A@53-7(;31,;&;]M.@.X.GA;#)`R4K>!*>OLP%5()D@\7G5H5%,T5JY;>'$ M1"KQ)M3#U"(+QU;EB$S[YZ[?!RSM2YM5@M,D"R`5%D&4EV`?=RH7)V(*EOL7 MP]*<._/I07.J1-#..6N7%$9A)DH"21*`9B!H77(SU!Q!NY5<\9=<2>K&!3?D M3E*-M<+#.2ED%EJ?\#$4?T8^4@^60KH_`[X,S4Z(!+8A)VJU::V2-Y*YWB)= MQ8OR?*U!"1',Z)3RA+`R$0D\<2D+,7VJ7W7KB+;:7D,[WS,>#MJ`EV\ITXIA M+)N4AM=J#!C(?3KPE_!DF&BK6GZ0H3?LC\%Y&)]3D&8R2^4Y$],1D)N#E\LH M2VMU*<&6FXE$C`L` M`00E#@``!#D!``#M75]SXC@2?[^J^PXZ7B[[0(`D,[M)36;/$)AQ+?\*DYF] MIRTA"U"MD;R23))O?Y)LP-B&F(QG\=[Z);'E;KF[]7-WJRV+#S\_KSRPQEP0 M1N]KK[W`, M)7;![`5\(53"!:[7HTL^9VZ`U#5&P56S=5-O7M5;U^`_H-6Z:S6!-0@IGX5[ M)]`2KR"0D"^P',(5%CY$ZD9+*?V[1N/IZ>ER!@6AZ!*Q54-U=MVZNFXI03V\ MPE3V&%\]X#D,/'E?^R.`'ID3[-:`THR*.\WY>E_O$NN62\84B;5XW M"-5V0'A#3X-5-K4K>4.^^+BA*#`G:,O`:`X>1NL)/F6E/::GZXU0K<:O@[YC M#%A3]@3`6!12RB24:DQ-VZ;5]PF=LZA)-7J$_GZG_RB;X`F>@V?3PIF'CUA! M7VX@Z*'`,[?H[SJH13TL.9[?U[2EZQL;_Z8X+I4V&Q*MZGU-D)7OX4T;Y"AU M[TC5UNWM;<-0-12R?,PEP:*QD7UK)]UPG'U#FJ+<5W+7[EX3B@YP5R* MX6]L+@_.L)?34HKV;VPIGV.AG.`I3Z)B^;\PF)9PJH0'^N!Q8A]R\\9.'49= M3`5VU8%@'G%UX&I#3_MS9XFQ%#5`W,A4",W$J>)MA=N(MWOD/S:;5Z`.'#5* M)F*IX\YH^-`=.MT'?>2,^O:#-54G;:MO#3M=X'SN=J?.AT:RH^0]`J70B'XT MQPF7'#%'%,<8]WU3?KXD]/)S;A_O_"P*QYBKU`0?9HM:-[#XOF@90R6-7&)) ME-T3T/&+Q<[U6[`#+O8D_*'"4JFPM!U/,9IWH%CV//:T[X$$0_-BXS MD007@XAXQ>+KYBWX&HV[$VMJ*P)@#37E8#SI?E9L]I,KHVH?L`2$B\> M7ESJ%^HB;IH_AN!(.@EPH>4`D2`_@(M(EBI4G!$<`G'B:\U&\W:@+F*ADY*V MHE.)RCBF>1PQ;`9GK-!I4RL+,DYG8H]ULJ$SC^GG+F@_.O:PZX2Y1]MR;).3 MJ`S$4?F)24LJ*)W3STSPFGEK0A?JCEC-E#AVB9L$3,^R M)^"+U7_L:K?2LX?6L&-;?36O<::31S,'JJ!24JBDO8Q!3+%>IM5,AZDGA,]4I:0H]LE4D?*[?Y''`12A;A9VS8<>F:Z49XV0/(05'HYLD-NSA%S7^ MHXG=K:).&88^'6$*CB[-FW1TB8&@BB)E@,.F/C_&W%E"CN-P\'Q1:,!HF7>) M"3S$2NQ@W)T`Y[,UZ5:(*`\BAI#KMSOKC%*;1@AU"\7(3?,ZRVMDH@1<;&6K M9K^EQ,X$(Z924X_`L"2G7PX&,CK113D4\HQXG&O*'H@72.QF7(S0A3 M1](U_XI'9:H>A=H!QH/4#2D%@-`22@<@`!VDJO)<2 M[ZEIE\:F+';2E3>&5A.M$@!DFVVGD5$P+([-MRHHE``*VE=,X7,"!`4GV.\/ M.(>I]6LU[2[%Z&?D+[+@>??[@QFT@4&5.IP?$`-(X2)+$)PT]),$RZ^E5-9ZKD&WZJAK\4PW^D!,<+K[_]E'80>YBHJF[E M0TJTZMVL<%L3%@COQ18B,$OVTVOWMR^,=XOXXXAB/D%H7N@7:"KH9((J6HH? MK7K[8H\>G?Y_@>TXC^&R_:P%_+NWRKNE_!7Z_M+H2Q5'-A@L>L'"]T5A568I M!1RW8=,)5BO(7T;SO58+J=!%Y$M&+!6,PZ+#Z6WZQ4$BG$9BZA<#>X*"C:15 MF"T;LM(.J^!J[O&TO'(T9X>#(QDR`VD^>%1!+OE1@4`%EW93;L29CCJ_U-M6 M&)L&8Q6EJF\&2@B*[5)-2R5%*_-Q2D856*#Y&A9<"+Y*ORP\!!IPH<4$1DX0 M$[2*/:7%U9&J@$"%EP6NTF6!PUBJ*@3EA\\V.S:71^9Q/YP;"R288,4[J-Q1 M;2]/-B*#4.8J32X_UE+YLD!%3^U/`%*5/)\;)'BAZS[9G_:+@C]$>)<"1O>3 M*??8P]YH,JA2YI)!(2/V%/UAPKN,7"8-BBJZ5!2]$JZ/`ZC"B)%0N-# M([E!;-2ROY&LV4:6K'S&):"9&_4>VC`WW..WSY#I[`B+/JMO^.JZJ=ZZJE^W M+M6M-UM`GBK&%G8GBK'A>Y,8IC^!T>6"K1LN)F:WX7JS5=?[#1^0(Y-'']1W MS"=*$>SIRY,K<)-@Q:]W=O-'[VEL9Y!(AS#D-&+P-+Z!H+>3(>8FS1\9M0,8=B9A0+1'T!H9];CDS&!O:DV+1\LSS:SJ(@@4Q? M;W]N-E9'`=<>]45W?G7*<.TQ;L_JNV[>*A`+J.0O)\,GSK^)]OC?(_KV),=[35O)+FO64)@*7J,.]## MEOB=T,58N8;8MYN_'2:AQ/-TZG)?DSS0&R;K7>?O9N'FLO5Q MF#LU.S2'05%[\&`F))&!UNP39X%_7PNIB<2K&@CW6& M-3O226D.K3PHA/555T.I'.#5#/.X#EE7DQ)#)12'2!:G@?D5@#N7K2"A>75H M']4A>;5T.NC-G':[8Z@G@2+B0V\,7_3Y`+KQ9R=23$0$E&Z%&W_@K=F=UY M/[8-7$_O8*P>F3;C2E"S1]R*2"/GE%G(I#AB@A$F:RUQ3,=OZJ6$%N@P)9)4 MAYTJ$+ZB>P[^P4^\]WFT8B5@_;,WBLAH793W6?D!?I7UO96-9J4 MZ+!JKS*^DA0CX_4+NETZ/"?8]B$Q+S#M,GUA*HUH+U&Q@:Y`BK/L--_]> M]C:"_@D&CX%'5WF>?1+]5,\Y!J`(8?[J`S(*I/DY6Y4V_9FF/^VVKQOYM$)F M(39.:Q)^9:@;B(OW%K+N;ZIQP'JG=UBT7:*)KI9.Y+#+E$GH]0F4?1G*)><>\N8R7)5XC/']I M/ER\$KX#5*?_`U!+`0(>`Q0````(`+9P3D2,FG&P]E4``';3`P`1`!@````` M``$```"D@0````!B87-I+3(P,3,Q,C,Q+GAM;%54!0`#!VG^4G5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`+9P3D36[B,0O@\``/'#```5`!@```````$` M``"D@4%6``!B87-I+3(P,3,Q,C,Q7V-A;"YX;6Q55`4``P=I_E)U>`L``00E M#@``!#D!``!02P$"'@,4````"`"V<$Y$V/T9QD,B```K1`(`%0`8```````! M````I(%.9@``8F%S:2TR,#$S,3(S,5]D968N>&UL550%``,':?Y2=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`MG!.1"!RNE>Y?@```Q0````(`+9P3D3,)ZD([C8``"V,`P`5`!@````` M``$```"D@>@'`0!B87-I+3(P,3,Q,C,Q7W!R92YX;6Q55`4``P=I_E)U>`L` M`00E#@``!#D!``!02P$"'@,4````"`"V<$Y$J0HOV&P+``#F>@``$0`8```` M```!````I($E/P$`8F%S:2TR,#$S,3(S,2YX`L``00E >#@``!#D!``!02P4&``````8`!@`:`@``W$H!```` ` end XML 28 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION
3 Months Ended
Dec. 31, 2013
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION [Abstract]  
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION
  1. DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION

 

Bioanalytical Systems, Inc. and its subsidiaries ("We," the "Company" or "BASi") engage in contract laboratory research services and other services related to pharmaceutical development. We also manufacture scientific instruments for life sciences research, which we sell with related software for use in industrial, governmental and academic laboratories. Our customers are located throughout the world.

 

We have prepared the accompanying unaudited interim condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles ("GAAP"), and therefore should be read in conjunction with our audited consolidated financial statements, and the notes thereto, included in the Company's annual report on Form 10-K for the year ended September 30, 2013. In the opinion of management, the condensed consolidated financial statements for the three months ended December 31, 2013 and 2012 include all adjustments which are necessary for a fair presentation of the results of the interim periods and of our financial position at December 31, 2013. The results of operations for the three months ended December 31, 2013 are not necessarily indicative of the results for the year ending September 30, 2014.

XML 29 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Narrative) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options outstanding that were granted outside of the plan 155  
Employee Stock Option [Member]
   
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock-based compensation expense $ 47 $ 74
XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME (LOSS) PER SHARE (Narrative) (Details)
3 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Warrant [Member]
   
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares not considered in computing diluted earnings per share 1,126,500 1,376,500
Series A Preferred Stock [Member]
   
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares not considered in computing diluted earnings per share 660,902  
XML 31 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 32 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION
3 Months Ended
Dec. 31, 2013
STOCK-BASED COMPENSATION [Abstract]  
STOCK-BASED COMPENSATON
  2. STOCK-BASED COMPENSATION

 

The 2008 Stock Option Plan ("the Plan") is used to promote our long-term interests by providing a means of attracting and retaining officers, directors and key employees and aligning their interests with those of our shareholders. The Plan is described more fully in Note 9 in the Notes to the Consolidated Financial Statements in our Form 10-K for the year ended September 30, 2013. All options granted under the Plan had an exercise price equal to the market value of the underlying common shares on the date of grant. We expense the estimated fair value of stock options over the vesting periods of the grants. We recognize expense for awards subject to graded vesting using the straight-line attribution method, reduced for estimated forfeitures. Forfeitures are revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates and an adjustment is recognized at that time. The Compensation Committee may also issue non-qualified stock option grants with vesting periods different from the 2008 Plan. As of December 31, 2013, there are 155 shares outstanding that were granted outside of the Plan. The assumptions used are detailed in Note 9 to the Consolidated Financial Statements in our Form 10-K for the year ended September 30, 2013. Stock based compensation expense for the three months ended December 31, 2013 and 2012 was $47 and $74, respectively.

 

A summary of our stock option activity for the three months ended December 31, 2013 is as follows (in thousands except for share prices):

 

    Options
(shares)
    Weighted-
Average
Exercise Price
    Weighted-
Average
Grant Date
Fair Value
 
                   
Outstanding - October 1, 2013     479     $ 1.77     $ 1.35  
Exercised     -       -       -  
Granted     -       -       -  
Terminated     (40 )     2.29          
Outstanding - December 31, 2013     439     $ 1.72     $ 1.32  
XML 33 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Dec. 31, 2013
Sep. 30, 2013
Allowance for doubtful accounts $ 87 $ 87
Common stock, no par value      
Common stock, shares authorized 19,000,000 19,000,000
Common stock, shares issued 7,885,229 7,703,891
Common stock, shares outstanding 7,885,229 7,703,891
Series A Preferred Stock [Member]
   
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, no par value      
Preferred stock, shares issued 1,185 1,335
Preferred stock, shares outstanding 1,185 1,335
Preferred stock, stated value per share $ 1,000 $ 1,000
XML 34 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME (LOSS) PER SHARE (Tables)
3 Months Ended
Dec. 31, 2013
INCOME (LOSS) PER SHARE [Abstract]  
Reconciliation of Computation of Basic Loss Per Share to Diluted Net Loss Per Share

The following table reconciles our computation of basic income (loss) per share to diluted income (loss) per share:

 

    Three Months Ended
December 31,
 
    2013     2012  
             
Basic net income (loss) per share:                
Net income (loss) applicable to common shareholders   $ (662 )   $ 256  
Weighted average common shares outstanding     7,735       7,639  
Basic net income (loss) per share   $ (0.09 )   $ 0.03  
                 
Diluted net income (loss) per share:                
Diluted net income (loss) applicable to common shareholders   $ (662 )   $ 256  
                 
Weighted average common shares outstanding     7,735       7,639  
Plus:  Incremental shares from assumed conversions                
Series A preferred shares     -       767  
Diluted weighted average common shares outstanding     7,735       8,406  
                 
Diluted net income (loss) per share   $ (0.09 )   $ 0.03  
XML 35 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
3 Months Ended
Dec. 31, 2013
Feb. 11, 2014
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 31, 2013  
Document Fiscal Year Focus 2014  
Document Fiscal Period Focus Q1  
Trading Symbol BASi  
Entity Registrant Name BIOANALYTICAL SYSTEMS INC  
Entity Central Index Key 0000720154  
Current Fiscal Year End Date --09-30  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   7,965,387
XML 36 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES (Tables)
3 Months Ended
Dec. 31, 2013
INVENTORIES [Abstract]  
Summary of Inventories

Inventories consisted of the following:

 

    December 31,
2013
    September 30,
2013
 
             
Raw materials   $ 1,281     $ 1,157  
Work in progress     235       322  
Finished goods     323       259  
    $ 1,839     $ 1,738  
Obsolescence reserve     (388 )     (359 )
    $ 1,451     $ 1,379  
XML 37 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Dec. 31, 2012
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) [Abstract]    
Service revenue $ 4,916 $ 4,670
Product revenue 1,304 1,133
Total revenue 6,220 5,803
Cost of service revenue 3,323 3,382
Cost of product revenue 752 566
Total cost of revenue 4,075 3,948
Gross profit 2,145 1,855
Operating expenses:    
Selling 437 370
Research and development 143 85
General and administrative 1,103 1,098
Total operating expenses 1,683 1,553
Operating income 462 302
Interest expense (164) (165)
Change in fair value of warrant liability - (increase) decrease (961) 117
Other income 1 2
Income (loss) before income taxes (662) 256
Income taxes      
Net income (loss) (662) 256
Other comprehensive income (loss):    
Foreign currency translation adjustment (26) 8
Comprehensive income (loss) $ (688) $ 264
Basic net income (loss) per share $ (0.09) $ 0.03
Diluted net income (loss) per share $ (0.09) $ 0.03
Weighted common shares outstanding:    
Basic 7,735 7,639
Diluted 7,735 8,406
XML 38 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
DEBT
3 Months Ended
Dec. 31, 2013
DEBT [Abstract]  
DEBT
  7. DEBT

 

Mortgages and note payable

 

We have a term loan from Regions Bank ("Regions") aggregating approximately $5,205 at December 31, 2013, which is secured by mortgages on our facilities in West Lafayette and Evansville, Indiana.

 

On November 9, 2012, we executed a sixth amendment with Regions which we further modified on December 21, 2012. In the sixth amendment, Regions agreed to extend the term loan and mortgage loan maturity dates to October 31, 2013. The unpaid principal on the notes was incorporated into a replacement note payable for $5,786 bearing interest at LIBOR plus 400 basis points (minimum of 6.0%) with monthly principal payments of approximately $47 plus interest. The replacement note payable is secured by real estate at our West Lafayette and Evansville, Indiana locations. At September 30, 2013, the replacement note payable had a balance of $5,254.

 

On October 31, 2013, we executed a seventh amendment with Regions to extend the note payable maturity date to October 31, 2014.

  

Regions requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00 and a total liabilities to tangible net worth ratio of not greater than 2.10 to 1.00. Failure to comply with those covenants in future quarters would be a default under the Regions loans, requiring us to negotiate with Regions regarding loan modifications or waivers. If we are unable to obtain such modifications or waivers, Regions could accelerate the maturity of the loans and cause a cross default with our other lender.

 

The Regions loan agreements both contain cross-default provisions with each other and with the revolving line of credit with Entrepreneur Growth Capital LLC ("EGC") described below.

 

The replacement note payable with Regions matures in the first quarter of fiscal 2015. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. We have listed for sale our 7.25 acres and 120,000 square foot facility at 2701 Kent Avenue, West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations. We enlisted a new realtor in the third fiscal quarter of 2013 and changed the asking price to $10,800. We performed an impairment analysis on the building when we listed it for sale, but noted no impairment necessary. As of December 31, 2013, the net book value of the facility and land was $9,126.

 

We may be unsuccessful in renegotiating the terms of the debt or those terms may be unfavorable to us. For these reasons, if we are unsuccessful at refinancing our long-term debt, our operating results and financial condition could be adversely affected.

 

Revolving Line of Credit

 

At December 31, 2013, we had a $3,000 revolving line of credit agreement ("Credit Agreement") with EGC. Pursuant to the terms of the Credit Agreement, the line of credit would have automatically renewed on January 31, 2014 unless either party gave a 60-day notice of intent to terminate or withdraw. On October 30, 2013, we informed EGC of our intent not to renew the line of credit on January 31, 2014. On January 31, 2014, we paid off the remaining balance on this line of credit.

 

At December 31, 2013, borrowings under the Credit Agreement bear interest at an annual rate equal to Citibank's Prime Rate plus five percent (5%), or 8.25% as of December 31, 2013, with minimum monthly interest of $15. Interest is paid monthly. The line of credit also carries an annual facilities fee of 2% and a 0.2% collateral monitoring fee. Borrowings under the Credit Agreement are secured by a blanket lien on our personal property, including certain eligible accounts receivable, inventory, and intellectual property assets, a second mortgage on our West Lafayette and Evansville real estate and all common stock of our U.S. subsidiaries and 65% of the common stock of our non-United States subsidiary. Borrowings are calculated based on 75% of eligible accounts receivable. Under the Credit Agreement, as amended, the Company has agreed to restrict advances to subsidiaries, limit additional indebtedness and capital expenditures and maintain a minimum tangible net worth of at least $8,000. The Credit Agreement also contains cross-default provisions with the Regions loan and any future EGC loans. At December 31, 2013, we had available borrowing capacity of $1,845 on this line, of which $168 was outstanding. At September 30, 2013, we had $1,415 outstanding on this line.

 

At December 31, 2013, we were not in compliance with the minimum tangible net worth covenant requirement mainly due to the increase in the warrant liability. On January 29, 2014, EGC waived our breach with this covenant.

 

We are actively pursuing alternatives to replace this line of credit. We are focused on growing our revenues and improving our cash flow from operations in fiscal 2014 to reduce our reliance on our line of credit.

XML 39 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
INCOME TAXES
3 Months Ended
Dec. 31, 2013
INCOME TAXES [Abstract]  
INCOME TAXES
  6. INCOME TAXES

 

We use the asset and liability method of accounting for income taxes.  We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates in income in the period that includes the enactment date. We record valuation allowances based on a determination of the expected realization of tax assets.

 

We recognize the tax benefit from an uncertain tax position only if it is more likely than not to be sustained upon examination based on the technical merits of the position. We measure the amount of the accrual for which an exposure exists as the largest amount of benefit determined on a cumulative probability basis that we believe is more likely than not to be realized upon ultimate settlement of the position.

 

At December 31, 2013 and September 30, 2013, we had a $16 liability for uncertain income tax positions. The difference between the federal statutory rate of 34% and our effective rate of 0% is due to changes in our valuation allowance on our net deferred tax assets.

 

We record interest and penalties accrued in relation to uncertain income tax positions as a component of income tax expense. Any changes in the liability for uncertain tax positions would impact our effective tax rate. We do not expect the total amount of unrecognized tax benefits to significantly change in the next twelve months.

 

We file income tax returns in the U.S., several U.S. States, and the United Kingdom. We remain subject to examination by taxing authorities in the jurisdictions in which we have filed returns for years after 2008.

XML 40 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) (Employee Stock Option [Member], USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Employee Stock Option [Member]
 
Options (shares)  
Outstanding - October 1, 2013 479
Exercised   
Granted   
Terminated (40)
Outstanding - December 31, 2013 439
Weighted-Average Exercise Price  
Outstanding - October 1, 2013 $ 1.77
Exercised   
Granted   
Terminated $ 2.29
Outstanding - December 31, 2013 $ 1.72
Weighted-Average Grant Date Fair Value  
Outstanding - October 1, 2013 $ 1.35
Exercised   
Granted   
Terminated   
Outstanding - December 31, 2013 $ 1.32
XML 41 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION (Tables)
3 Months Ended
Dec. 31, 2013
SEGMENT INFORMATION [Abstract]  
Operating Segments
    Three Months Ended
December 31,
 
    2013     2012  
             
Revenue:                
Service   $ 4,916     $ 4,670  
Product     1,304       1,133  
    $ 6,220     $ 5,803  
                 
Operating income:                
Service   $ 424     $ 199  
Product     38       103  
    $ 462     $ 302  
                 
Interest Expense     (164 )     (165 )
Change in fair value of warrant liability - (increase) decrease     (961 )     117  
Other income     1       2  
                 
Income (loss) before income taxes   $ (662 )   $ 256  
XML 42 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
MANAGEMENT'S PLAN
3 Months Ended
Dec. 31, 2013
MANAGEMENT'S PLAN [Abstract]  
MANAGEMENT'S PLAN
10. MANAGEMENT'S PLAN

 

Our long-term strategic objective is to maximize the Company's intrinsic value per share.   However, in response to our financial performance through the second quarter of fiscal 2012, we began to operate the business in a manner designed to place more emphasis on cash flow generation. Thus, our short-term tactical objective is to maximize free cash flow from operating activities.

 

During the first fiscal quarter of 2014, revenues improved 7.2% as did gross margin by 15.6% and operating income by 53.0% from the first fiscal quarter of 2013. We also generated $976 in cash from operations, maintained strict controls on expenditures and paid down our line of credit $1.2 million while meeting all of our other obligations.

 

We negotiated an amendment to our loans with Regions Bank, extending the maturity date to October 2014. We intend to refinance the amounts in lieu of making balloon payments for the remaining principal balances or sell the building in West Lafayette, Indiana. We listed for sale our headquarters facility in West Lafayette, Indiana with the intent to leaseback 80% of that square footage in which to continue our laboratory and manufacturing operations.

 

For the remainder of fiscal 2014, we will focus on growing our revenues and continue initiatives to control costs and improve productivity to further reduce our break-even point and achieve our financial objectives. We expect to see improvement in the volume of new bookings in fiscal 2014 along with the continued improvements in gross profit margins. We have debt service and lease obligations of approximately $1.7 million in fiscal 2014. Based on our expected revenue, the impact of the cost reductions implemented and restructuring activities during fiscal 2012, we project that we will have the liquidity required to meet our fiscal 2014 operations and debt obligations. Though our current line of credit expired on January 31, 2014, we were able to pay off the remaining balance while continuing to meet all other debt obligations and working capital requirements. Although management believes our cash flow from operations will generate sufficient cash flow for our debt obligations, working capital requirements and capital expenditures, we are pursuing alternatives to replace this line of credit.

XML 43 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING
3 Months Ended
Dec. 31, 2013
RESTRUCTURING [Abstract]  
RESTRUCTURING
8. RESTRUCTURING

 

In March 2012, we announced a plan to restructure our bioanalytical laboratory operations. We consolidated our laboratory in McMinnville, Oregon into our 120,000 square foot headquarters facility in West Lafayette, Indiana. This plan was implemented to reduce operating costs and strengthen our ability to meet clients' needs by improving laboratory utilization. In the fourth fiscal quarter of 2012, we decided to initiate closure of our facility and bioanalytical laboratory in Warwickshire, United Kingdom after careful evaluation of its financial performance and analysis of our strategic alternatives. We will continue to sell our products globally while further consolidating delivery of our CRO services into our Indiana locations. As part of the overall evaluation of our business, personnel reductions in the Selling, R&D and General and Administrative functions were also implemented at both of our Indiana locations during the second half of fiscal 2012. In total, 74 employees were terminated as part of the restructuring activities in fiscal 2012.

 

We reserved for lease payments at the cease use date and have considered free rent, sublease rentals and the number of days it would take to restore the space to its original condition prior to our improvements. In the first quarter of fiscal 2013, we began amortizing into general and administrative expense, equally through the cease use date, the estimated rent income of $200 when the reserve was originally established. We have been unsuccessful at subleasing the facility. Based on these, we have $898 reserved for UK lease related costs.

 

The following table sets forth the rollforward of the restructuring activity for the three months ended December 31, 2013.

 

    Balance,
September 30,
2013
    Total
Charges
    Cash
Payments
    Other     Balance,
December 31,
2013
 
One-time termination benefits   $ -     $ -     $ -     $ -     $ -  
Lease related costs     877       -       -       21       898  
Equipment moving costs and method transfers     -       -       -       -       -  
Travel and relocation costs     -       -       -       -       -  
Loss on sale of equipment     (16 )     -       -       8       (8 )
Other costs     117       -       -       -       117  
Total   $ 978     $ -     $ -     $ 29     $ 1,007  

 

Other costs include legal and professional fees and other costs incurred in connection with transitioning services from sites being closed as well as costs incurred to remove improvements previously made to the UK facility. Other activity in the reserve rollforward primarily reflects a receivable for settlement of the capital lease in the UK.

XML 44 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE OF FINANCIAL INSTRUMENTS
3 Months Ended
Dec. 31, 2013
FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]  
FAIR VALUE OF FINANCIAL INSTRUMENTS
9. FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The provisions of the Fair Value Measurements and Disclosure Topic defines fair value, establishes a consistent framework for measuring fair value and provides the disclosure requirements about fair value measurements. This Topic also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's judgment about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:

 

  Level 1 - Valuations based on quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.
     
  Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
     
  Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

 

In May 2011, we issued Class A and B Warrants that are measured at fair value on a recurring basis. We recorded these warrants as a liability determining the fair value at inception on May 11, 2011. Subsequent quarterly fair value measurements, using the Black Scholes model which is considered a level 2 measurement, are calculated with fair value changes charged to the statement of operations and comprehensive income (loss). Class B Warrants expired in May 2012 and the liability was reduced to zero. The assumptions used to compute the fair value of the warrants at December 31, 2013 and September 30, 2013:

 

    December 31, 2013     September 30, 2013  
    Warrant A     Warrant A  
             
Risk-free interest rate     0.52 %     0.51 %
Dividend yield     0.00 %     0.00 %
Volatility of the Company's common stock     72.83 %     71.15 %
Expected life of the options (years)     2.35       2.6  
                 
Fair value per unit   $ 1.396     $ 0.444  

 

The carrying amounts for cash and cash equivalents, accounts receivable, inventories, prepaid expenses and other assets, accounts payable and other accruals approximate their fair values because of their nature and respective duration. The fair value of the revolving credit facility and certain long-term debt is equal to their carrying values due to the variable nature of their interest rates. Our long-term fixed rate debt was initiated in February 2011 and renewed on October 31, 2013.

XML 45 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCK-BASED COMPENSATION (Tables)
3 Months Ended
Dec. 31, 2013
STOCK-BASED COMPENSATION [Abstract]  
Summary of Stock Option Activity

A summary of our stock option activity for the three months ended December 31, 2013 is as follows (in thousands except for share prices):

 

    Options
(shares)
    Weighted-
Average
Exercise Price
    Weighted-
Average
Grant Date
Fair Value
 
                   
Outstanding - October 1, 2013     479     $ 1.77     $ 1.35  
Exercised     -       -       -  
Granted     -       -       -  
Terminated     (40 )     2.29          
Outstanding - December 31, 2013     439     $ 1.72     $ 1.32  
XML 46 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8
MANAGEMENT'S PLAN (Details) (USD $)
3 Months Ended
Dec. 31, 2013
Dec. 31, 2012
MANAGEMENT'S PLAN [Abstract]    
Revenue growth (decline), percent 7.20%  
Gross margin growth (decline), percent 15.60%  
Operating income growth (decline), percent 53.00%  
Cash generated from operations $ 1,036,000 $ 717,000
Net paydown on line of credit (1,200,000)  
Debt and lease obligations, current $ 1,700,000  
XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
3 Months Ended
Dec. 31, 2013
FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]  
Summary of Assumptions Used to Compute Fair Value of Warrants

The assumptions used to compute the fair value of the warrants at December 31, 2013 and September 30, 2013:

 

    December 31, 2013     September 30, 2013  
    Warrant A     Warrant A  
             
Risk-free interest rate     0.52 %     0.51 %
Dividend yield     0.00 %     0.00 %
Volatility of the Company's common stock     72.83 %     71.15 %
Expected life of the options (years)     2.35       2.6  
                 
Fair value per unit   $ 1.396     $ 0.444  
XML 48 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
INVENTORIES (Details) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Sep. 30, 2013
INVENTORIES [Abstract]    
Raw materials $ 1,281 $ 1,157
Work in process 235 322
Finished goods 323 259
Gross inventories 1,839 1,738
Obsolescence reserve (388) (359)
Inventories $ 1,451 $ 1,379
XML 49 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Operating activities:    
Net income (loss) $ (662) $ 256
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 402 473
Change in fair value of warrant liability - increase (decrease) 961 (117)
Employee stock compensation expense 47 74
Loss on sale of property and equipment    2
Changes in operating assets and liabilities:    
Accounts receivable 939 1,387
Inventories (72) (47)
Income tax accruals (14)   
Prepaid expenses and other assets (145) 74
Accounts payable (345) 82
Accrued expenses (151) (782)
Customer advances 76 (685)
Net cash provided by operating activities 1,036 717
Investing activities:    
Capital expenditures (51) (10)
Net cash used by investing activities (51) (10)
Financing activities:    
Payments of long-term debt (49) (166)
Payments of debt issuance costs (60) (15)
Payments on revolving line of credit (7,619) (6,118)
Borrowings on revolving line of credit 6,372 5,636
Payments on capital lease obligations (66) (100)
Net cash used by financing activities (1,422) (763)
Effect of exchange rate changes (26) 5
Net decrease in cash and cash equivalents (463) (51)
Cash and cash equivalents at beginning of period 1,304 721
Cash and cash equivalents at end of period 841 670
Supplemental disclosure of non-cash financing activities:    
Preferred stock dividends paid in common shares $ (18) $ (20)
XML 50 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION
3 Months Ended
Dec. 31, 2013
SEGMENT INFORMATION [Abstract]  
SEGMENT INFORMATION
  5. SEGMENT INFORMATION

 

We operate in two principal segments - research services and research products. Our Services segment provides research and development support on a contract basis directly to pharmaceutical companies. Our Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Our accounting policies in these segments are the same as those described in the summary of significant accounting policies found in Note 2 to Consolidated Financial Statements in our annual report on Form 10-K for the year ended September 30, 2013.

 

    Three Months Ended
December 31,
 
    2013     2012  
             
Revenue:                
Service   $ 4,916     $ 4,670  
Product     1,304       1,133  
    $ 6,220     $ 5,803  
                 
Operating income:                
Service   $ 424     $ 199  
Product     38       103  
    $ 462     $ 302  
                 
Interest Expense     (164 )     (165 )
Change in fair value of warrant liability - (increase) decrease     (961 )     117  
Other income     1       2  
                 
Income (loss) before income taxes   $ (662 )   $ 256  
XML 51 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Dec. 31, 2013
segments
Dec. 31, 2012
Segment Reporting Information [Line Items]    
Number of segments 2  
Revenue: $ 6,220 $ 5,803
Operating income: 462 302
Interest expense (164) (165)
Change in fair value of warrant liability - (increase) decrease (961) 117
Other income 1 2
Income (loss) before income taxes (662) 256
Service [Member]
   
Segment Reporting Information [Line Items]    
Revenue: 4,916 4,670
Operating income: 424 199
Product [Member]
   
Segment Reporting Information [Line Items]    
Revenue: 1,304 1,133
Operating income: $ 38 $ 103
XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 50 184 1 false 19 0 false 8 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.basinc.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.basinc.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.basinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Sheet http://www.basinc.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.basinc.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 101 - Disclosure - DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION Sheet http://www.basinc.com/role/DescriptionOfBusinessAndBasisOfPresentation DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION false false R7.htm 102 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.basinc.com/role/StockbasedCompensation STOCK-BASED COMPENSATION false false R8.htm 103 - Disclosure - INCOME (LOSS) PER SHARE Sheet http://www.basinc.com/role/IncomeLossPerShare INCOME (LOSS) PER SHARE false false R9.htm 104 - Disclosure - INVENTORIES Sheet http://www.basinc.com/role/Inventories INVENTORIES false false R10.htm 105 - Disclosure - SEGMENT INFORMATION Sheet http://www.basinc.com/role/SegmentInformation SEGMENT INFORMATION false false R11.htm 106 - Disclosure - INCOME TAXES Sheet http://www.basinc.com/role/IncomeTaxes INCOME TAXES false false R12.htm 107 - Disclosure - DEBT Sheet http://www.basinc.com/role/Debt DEBT false false R13.htm 108 - Disclosure - RESTRUCTURING Sheet http://www.basinc.com/role/Restructuring RESTRUCTURING false false R14.htm 109 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://www.basinc.com/role/FairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS false false R15.htm 110 - Disclosure - MANAGEMENT'S PLAN Sheet http://www.basinc.com/role/ManagementsPlan MANAGEMENT'S PLAN false false R16.htm 302 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.basinc.com/role/StockbasedCompensationTables STOCK-BASED COMPENSATION (Tables) false false R17.htm 303 - Disclosure - INCOME (LOSS) PER SHARE (Tables) Sheet http://www.basinc.com/role/IncomeLossPerShareTables INCOME (LOSS) PER SHARE (Tables) false false R18.htm 304 - Disclosure - INVENTORIES (Tables) Sheet http://www.basinc.com/role/InventoriesTables INVENTORIES (Tables) false false R19.htm 305 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.basinc.com/role/SegmentInformationTables SEGMENT INFORMATION (Tables) false false R20.htm 308 - Disclosure - RESTRUCTURING (Tables) Sheet http://www.basinc.com/role/RestructuringTables RESTRUCTURING (Tables) false false R21.htm 309 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://www.basinc.com/role/FairValueOfFinancialInstrumentsTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) false false R22.htm 40201 - Disclosure - STOCK-BASED COMPENSATION (Narrative) (Details) Sheet http://www.basinc.com/role/StockbasedCompensationNarrativeDetails STOCK-BASED COMPENSATION (Narrative) (Details) false false R23.htm 40202 - Disclosure - STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) Sheet http://www.basinc.com/role/StockbasedCompensationSummaryOfStockOptionActivityDetails STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) false false R24.htm 40301 - Disclosure - INCOME (LOSS) PER SHARE (Narrative) (Details) Sheet http://www.basinc.com/role/IncomeLossPerShareNarrativeDetails INCOME (LOSS) PER SHARE (Narrative) (Details) false false R25.htm 40302 - Disclosure - INCOME (LOSS) PER SHARE (Reconciliation of Computation of Basic Income or Loss Per Share to Diluted Income or Loss Per Share) (Details) Sheet http://www.basinc.com/role/IncomeLossPerShareReconciliationOfComputationOfBasicIncomeOrLossPerShareToDilutedIncomeOrLossPerShareDetails INCOME (LOSS) PER SHARE (Reconciliation of Computation of Basic Income or Loss Per Share to Diluted Income or Loss Per Share) (Details) false false R26.htm 40401 - Disclosure - INVENTORIES (Details) Sheet http://www.basinc.com/role/InventoriesDetails INVENTORIES (Details) false false R27.htm 40501 - Disclosure - SEGMENT INFORMATION (Details) Sheet http://www.basinc.com/role/SegmentInformationDetails SEGMENT INFORMATION (Details) false false R28.htm 40601 - Disclosure - INCOME TAXES (Details) Sheet http://www.basinc.com/role/IncomeTaxesDetails INCOME TAXES (Details) false false R29.htm 40701 - Disclosure - DEBT (Note Payable) (Details) Sheet http://www.basinc.com/role/DebtNotePayableDetails DEBT (Note Payable) (Details) false false R30.htm 40702 - Disclosure - DEBT (Revolving Line of Credit) (Details) Sheet http://www.basinc.com/role/DebtRevolvingLineOfCreditDetails DEBT (Revolving Line of Credit) (Details) false false R31.htm 40801 - Disclosure - RESTRUCTURING (Narrative) (Details) Sheet http://www.basinc.com/role/RestructuringNarrativeDetails RESTRUCTURING (Narrative) (Details) false false R32.htm 40902 - Disclosure - RESTRUCTURING (Summary of Restructuring Activity) (Details) Sheet http://www.basinc.com/role/RestructuringSummaryOfRestructuringActivityDetails RESTRUCTURING (Summary of Restructuring Activity) (Details) false false R33.htm 41001 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://www.basinc.com/role/FairValueOfFinancialInstrumentsDetails FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) false false R34.htm 41101 - Disclosure - MANAGEMENT'S PLAN (Details) Sheet http://www.basinc.com/role/ManagementsPlanDetails MANAGEMENT'S PLAN (Details) false false All Reports Book All Reports 'Monetary' elements on report '41101 - Disclosure - MANAGEMENT'S PLAN (Details)' had a mix of different decimal attribute values. Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Sep. 30, 2012' Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) Process Flow-Through: 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS basi-20131231.xml basi-20131231.xsd basi-20131231_cal.xml basi-20131231_def.xml basi-20131231_lab.xml basi-20131231_pre.xml true true XML 53 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
RESTRUCTURING (Tables)
3 Months Ended
Dec. 31, 2013
RESTRUCTURING [Abstract]  
Summary of Restructuring Activity

The following table sets forth the rollforward of the restructuring activity for the three months ended December 31, 2013.

 

    Balance,
September 30,
2013
    Total
Charges
    Cash
Payments
    Other     Balance,
December 31,
2013
 
One-time termination benefits   $ -     $ -     $ -     $ -     $ -  
Lease related costs     877       -       -       21       898  
Equipment moving costs and method transfers     -       -       -       -       -  
Travel and relocation costs     -       -       -       -       -  
Loss on sale of equipment     (16 )     -       -       8       (8 )
Other costs     117       -       -       -       117  
Total   $ 978     $ -     $ -     $ 29     $ 1,007